id	disease name	name	alias	HGNC_alias	geneid	hgnc_name	genecode_id	species	noncode id	strand	length	loc	strong experimental evidence	weak experimental evidence	direct evidence	high-throughput associations	methods	sample	regulated	function description	pubmed id	year	title	ICD-10 	DO-ID	sourse	organ
1	Graves Disease	TCONS_00012608	NA	NA	NA	NA	NA	NA	NA	NA	688	chr15:40,038,278-40,075,839	1	0	1	0	qRT-PCR,lncRNA microarray	CD4+ T cell	down-regulated	The differential expression of AK021954, AB075506, HMlincRNA1474 and TCONS_00012608 in GD CD4+ T cells suggested that these lncRNAs may participate in the pathogenesis of GD and might serve as novel biomarkers of GD and potential targets for GD treatment.	33112836	2020	lncRNA:mRNA expression profile in CD4+ T cells from patients with Graves’ disease	E05.002	12361	pubmed	Thyroid
2	Graves Disease	AK021954	NA	NA	NA	NA	NA	NA	NA	NA	1873	chr7:108300190-108302063	1	0	1	0	qRT-PCR,lncRNA microarray	CD4+ T cell	up-regulated	The differential expression of AK021954, AB075506, HMlincRNA1474 and TCONS_00012608 in GD CD4+ T cells suggested that these lncRNAs may participate in the pathogenesis of GD and might serve as novel biomarkers of GD and potential targets for GD treatment.	33112836	2020	lncRNA:mRNA expression profile in CD4+ T cells from patients with Graves’ disease	E05.002	12361	pubmed	Thyroid
3	Graves Disease	TCONS_00022357-XLOC_010919	NA	NA	NA	NA	NA	NA	NA	NA	42807	chrX:15,560,138-15,602,945	1	0	1	0	qRT-PCR,lncRNA microarray,Flow cytometry analysis	CD19+ B cells	up-regulated	The lncRNAs TCONS_00022357-XLOC_010919 were predicted to regulate TCL1 family AKT coactivator A (TCL1A). TCL1A are highly involved in B-cell proliferation. 	32432440	2020	Microarray profile of B cells from Graves' disease patients reveals biomarkers of proliferation	E05.002	12361	pubmed	Thyroid
4	Graves Disease	n335641	NA	NA	NA	NA	NA	NA	NA	-	434	chr14:95,710,058-95,710,492	1	0	1	0	qRT-PCR,lncRNA microarray,Flow cytometry analysis	CD19+ B cells	up-regulated	The lncRNA n335641 were predicted to regulate TCL1 family AKT coactivator A (TCL1A). TCL1A are highly involved in B-cell proliferation. 	32432440	2020	Microarray profile of B cells from Graves' disease patients reveals biomarkers of proliferation	E05.002	12361	pubmed	Thyroid
5	Graves Disease	n337845	NA	NA	NA	NA	NA	NA	NA	-	1100	chrX:124,375,902-124,377,002	1	0	1	0	qRT-PCR,lncRNA microarray,Flow cytometry analysis	CD19+ B cells	down-regulated	The lncRNA n337845 was predicted to regulate SH2 domain containing 1A (SH2D1A).SH2D1A are highly involved in B-cell proliferation. 	32432440	2020	Microarray profile of B cells from Graves' disease patients reveals biomarkers of proliferation	E05.002	12361	pubmed	Thyroid
6	Subclinical hypothyroidism	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	NA	NA	30815	NA	NA	NA	+	33512	chr11:65,416,582-65,450,093(GRCh38/hg38)	1	0	1	0	qRT-PCR, western blotting, and immunofluorescence	primary endothelial cells (ECs) and HUVECs	down-regulated	In conclusion, dysregulation of the NEAT1/miR-126/TRAF7 axis is responsible for impaired endothelial functions in SCH. Targeting this axis might become a promising treatment strategy or improving endothelial functions in SCH.	33677813	2021	Long non-coding RNA NEAT1 regulates endothelial functions in subclinical hypothyroidism through miR-126/TRAF7 pathway	NA	NA	pubmed	Thyroid
7	Hashimotos thyroiditis	NONHSAT079547.2	TCONS_00023825	NA	NA	NA	NA	NA	NA	-	4266	chr20:36,045,509-36,050,975	1	0	1	0	qRT-PCR, western blotting, and immunofluorescence	CD4+ T cells	up-regulated	NONHSAT079547.2 was significantly upregulated in HT patients and was positively correlated with serum thyroid peroxidase antibody level. Further studies confirmed that NONHSAT079547.2 could promote cell growth and control IL-17 expression and secretion via the NONHSAT079547.2/miR-4716-5p/IL-17 axis.	32229697	2020	LncRNA profile in Hashimoto's thyroiditis and potential function of NONHSAT079547.2	E04.954	12176	pubmed	Thyroid
8	Graves Disease	Heg	Heart Development Protein With EGF Like Domains 1	NA	NA	29227	NA	NA	NA	+	1909	chr12:67,989,444-68,021,327	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	up-regulated	Heg is negatively related to TRAb in untreated patients with GD and to CD14 mRNA in treated patients and controls. 	33125100	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	E05.002	12361	pubmed	Thyroid
9	Autoimmune thyroid disease	ENST00000566575	TCONS_00025288	NA	NA	NA	NA	NA	NA	-	1078	chr22:41,922,022-41,923,100	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	up-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
10	Autoimmune thyroid disease	TCONS_00029808	NA	NA	NA	NA	ENST00000511222.1	NA	NA	+	455	chr4:55,053,059-55,092,534	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	up-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
11	Autoimmune thyroid disease	NR_046687	TCONS_00026267	NA	NA	NA	ENST00000491676.1	NA	NA	+	503	chr3:183,548,734-183,552,326	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	up-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
12	Autoimmune thyroid disease	ENST00000604086	NA	NA	NA	NA	NA	NA	NA	+	840	chr10:11,679,674-11,680,514	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	up-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
13	Autoimmune thyroid disease	ENST00000609178	lnc-SYCE3-1-2_dup1	NA	NA	NA	ENST00000604086.1	NA	NA	-	602	chr22:50,542,304-50,544,984	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	up-regulated	These data suggest that IFNG-AS1 expression could reflect disease severity of HT to some extent.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
14	Autoimmune thyroid disease	NR_038446	NA	NA	NA	NA	ENST00000500989.2	NA	NA	-	5335	chr8:125,941,131-125,951,197	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	up-regulated	treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
15	Autoimmune thyroid disease	NR_110783	TCONS_00017466	NA	NA	NA	ENST00000580867.1	NA	NA	-	764	chr18:14,969,605-14,970,468	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	down-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
16	Autoimmune thyroid disease	ENST00000443123	TCONS_00020814	NA	NA	NA	NA	NA	NA	-	860	chr2：107254690-107365873（hg38)	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	down-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
17	Autoimmune thyroid disease	T001580	TCONS_00000097	NA	NA	NA	NA	NA	NA	+	437	chr1:24,040,852-24,086,799	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	down-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
18	Autoimmune thyroid disease	ENST00000528497	TCONS_00005637	NA	NA	NA	NA	NA	NA	+	762	chr11：134950707-134951568（hg38）	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	down-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
19	Autoimmune thyroid disease	ENST00000606457	lnc-SLC25A32-3:9	NA	NA	NA	NA	NA	NA	-	354	chr8：103481265-103481619（hg38）	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	down-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
20	Autoimmune thyroid disease	ENST00000580937	TCONS_00017505	NA	NA	NA	NA	NA	NA	-	433	chr18：31496644-31497195（hg38）	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	down-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
21	Autoimmune thyroid disease	ENST00000511064	TCONS_00029849	NA	NA	NA	NA	NA	NA	+	573	chr21:45,972,812-45,974,954	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	down-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
22	Autoimmune thyroid disease	NR_109931	TCONS_00024859	NA	NA	NA	NA	NA	NA	+	1225	chr21:45,972,812-45,974,954	1	0	1	0	LncRNA and mRNA microarray，analysisqRT-PCR,lncRNA microarray	 Thyroid para‐carcinoma specimens	down-regulated	The data may supply novel insight of mechanism, diagnostic marker, and new treatment target for patients with AITD.	32916160	2020	Dysregulation of non-coding RNAs in autoimmune thyroid disease	NA	7188	pubmed	Thyroid
23	Autoimmune thyroid disease	ATP6V1G2-DDX39B	lnc-ATP6V1G2-DDX39B-2-1_d	NA	NA	NA	NA	NA	NA	NA	16631 	chr6:31,502,311-31,506,937	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
24	Autoimmune thyroid disease	ATXN8OS	ENST00000414504.5	NA	NA	NA	ENST00000414504.5	NA	NA	NA	92821 	chr13:70,107,212-70,139,753	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
25	Autoimmune thyroid disease	BCAR4	NA	NA	NA	NA	ENST00000574028.1	NA	NA	NA	5119 	chr16:11,819,947-11,828,828	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
26	Autoimmune thyroid disease	BOK-AS1	TCONS_00021085	NA	NA	NA	NA	NA	NA	NA	15852 	chr2:241,544,385-241,559,143	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
27	Autoimmune thyroid disease	BPESC1	TCONS_00027846	NA	NA	NA	NA	NA	NA	NA	20988 	chr3:139,104,184-139,125,171	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
28	Autoimmune thyroid disease	BX118339	 NONHSAT108037	NA	NA	NA	NA	NA	NA	NA	NA	chr6:21,485,895-21,524,049	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
29	Autoimmune thyroid disease	CASC2	Cancer Susceptibility 2	NA	NA	NA	NA	NA	NA	+	170235 	chr10:118,045,862-118,216,096	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
30	Autoimmune thyroid disease	CBR3-AS1	NONHSAG032772.2	CBR3 Antisense RNA 1	NA	NA	NA	NA	NA	-	145856 bases	chr21:36,130,371-36,276,226(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
31	Autoimmune thyroid disease	CDKN2B-AS1	CDKN2B Antisense RNA 1	NA	NA	NA	NA	NA	NA	+	244984 bases	chr9:21,984,139-22,249,122	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
32	Autoimmune thyroid disease	CECR3	Cat Eye Syndrome Chromosome Region, Candidate 3 	NA	NA	NA	NA	NA	NA	-	9877	chr22:17,256,858-17,266,734(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
33	Autoimmune thyroid disease	CECR9	NA	NA	NA	NA	NA	NA	NA	-	1584	chr3:237,441-239,024	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
34	Autoimmune thyroid disease	CHL1-AS2	CHL1 Antisense RNA 2	NA	NA	NA	NA	NA	NA	-	87636	chr3:109,707-197,342(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
35	Autoimmune thyroid disease	CRNDE	NA	NA	NA	NA	NA	NA	NA	-	10024	chr16:54,845,188-54,930,942(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
36	Autoimmune thyroid disease	DAOA-AS1	NA	NA	NA	30243	NA	NA	NA	-	48000	chr13:105,457,683-105,505,682(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
37	Autoimmune thyroid disease	DAPK1	Death Associated Protein Kinase 1	NA	NA	2674	NA	NA	NA	+	211407	chr9:87,497,228-87,708,634(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
38	Autoimmune thyroid disease	DGCR5	NA	NA	NA	16757	NA	NA	NA	+	60745	chr22:18,968,903-19,031,605(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
39	Autoimmune thyroid disease	DISC2	NA	NA	NA	2889	NA	NA	NA	-	3892	chr1:231,809,944-231,847,876(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
40	Autoimmune thyroid disease	DLEU1	NA	NA	NA	13747	NA	NA	NA	+	446475	chr13:50,082,168-50,906,856(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
41	Autoimmune thyroid disease	DLEU2	NA	NA	NA	13748	NA	NA	NA	-	142993	chr13:49,912,705-50,125,720(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
42	Autoimmune thyroid disease	DMPK	DM1 Protein Kinase	NA	NA	2933	NA	NA	NA	-	12782	chr19:45,769,709-45,782,552(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
43	Autoimmune thyroid disease	DNM3OS	DNM3 Opposite Strand/Antisense RNA	NA	NA	41228	NA	NA	NA	-	7957	chr1:172,128,631-172,145,146(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
44	Autoimmune thyroid disease	DSCAM-AS1	DSCAM Antisense RNA 1	NA	NA	40197	NA	NA	NA	+	2276 	chr21:40,382,898-40,385,359(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
45	Autoimmune thyroid disease	EPB41L4A-AS1	EPB41L4A Antisense RNA 1	NA	NA	30749	NA	NA	NA	+	4369	chr5:112,160,450-112,164,818(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
46	Autoimmune thyroid disease	ESRG	Embryonic Stem Cell Related	NA	NA	39079	NA	NA	NA	-	20553	chr3:54,619,661-54,640,213(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
47	Autoimmune thyroid disease	FMR1-AS1	FMR1 Antisense RNA 1 	NA	NA	39081	NA	NA	NA	-	17556	chrX:147,904,603-147,922,158(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
48	Autoimmune thyroid disease	GAS5	Growth Arrest Specific 5	NA	NA	16355	NA	NA	NA	-	17723	chr1:173,851,284-173,869,006(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
49	Autoimmune thyroid disease	GDNF-AS1	GDNF Antisense RNA 1 	NA	NA	43592	NA	NA	NA	+	142240	chr5:37,811,588-37,953,827(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
50	Autoimmune thyroid disease	GS-AS1	GNAS Antisense RNA 1	NA	NA	24872	NA	NA	NA	-	32112 	chr20:58,818,792-58,850,903(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
51	Autoimmune thyroid disease	H19	H19 Imprinted Maternally Expressed Transcript	NA	NA	4713	NA	NA	NA	-	6582 	chr11:1,995,129-2,001,710(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
52	Autoimmune thyroid disease	HAR1A	Highly Accelerated Region 1A 	NA	NA	33117	NA	NA	NA	+	3097 	chr20:63,101,291-63,104,387(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
53	Autoimmune thyroid disease	HAR1B	Highly Accelerated Region 1B	NA	NA	33118	NA	NA	NA	-	11826 	chr20:63,090,806-63,102,631(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
54	Autoimmune thyroid disease	HCP5	HLA Complex P5	NA	NA	21659	NA	NA	NA	+	78236 	chr6:31,400,701-31,478,936(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
55	Autoimmune thyroid disease	HOTAIR	HOX Transcript Antisense RNA	NA	NA	33510	NA	NA	NA	-	12651	chr12:53,962,307-53,974,957(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
56	Autoimmune thyroid disease	HTT-AS	HTT Antisense RNA	NA	NA	37118	NA	NA	NA	-	25940 	chr4:3,048,599-3,074,538(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
57	Autoimmune thyroid disease	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	NA	NA	34232	NA	NA	NA	+	1638 	chr6:8,435,567-9,294,133(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
58	Autoimmune thyroid disease	HYMAI	Hydatidiform Mole Associated And Imprinted	NA	NA	5326	NA	NA	NA	-	3815 	chr6:143,942,624-144,064,540	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
59	Autoimmune thyroid disease	IFNG-AS1	IFNG Antisense RNA 1	NA	NA	43910	NA	NA	NA	+	246137 	chr12:67,989,381-68,235,517(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
60	Autoimmune thyroid disease	IGF2-AS	IGF2 Antisense RNA	NA	NA	14062	NA	NA	NA	+	8166 	chr11:2,140,501-2,148,666(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
61	Autoimmune thyroid disease	IPW	Imprinted In Prader-Willi Syndrome	NA	NA	6109	NA	NA	NA	NA	5933	chr15:25,116,544-25,122,476(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
62	Autoimmune thyroid disease	KCNQ1DN	KCNQ1 Downstream Neighbor	NA	NA	13335	NA	NA	NA	+	7459	chr11:2,869,535-2,876,993(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
63	Autoimmune thyroid disease	KCNQ1OT1	KCNQ1 Opposite Strand/Antisense Transcript 1	NA	NA	6295	NA	NA	NA	-	102886	KCNQ1 Opposite Strand/Antisense Transcript 1 	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
64	Autoimmune thyroid disease	LINC00032	Long Intergenic Non-Protein Coding RNA 32	NA	NA	16506	NA	NA	NA	-	37110 	chr9:27,235,683-27,284,869	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
65	Autoimmune thyroid disease	LINC00271	Long Intergenic Non-Protein Coding RNA 271	NA	NA	32526	NA	NA	NA	NA	316641 	chr6:135,497,350-135,813,990	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
66	Autoimmune thyroid disease	LINC00312	Long Intergenic Non-Protein Coding RNA 312	NA	NA	6662	NA	NA	NA	NA	2887 	chr3:8,571,781-8,574,668	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
67	Autoimmune thyroid disease	LINC00538	Long Intergenic Non-Protein Coding RNA 538	NA	NA	43655	NA	NA	NA	NA	1907 	chr1:213,924,748-213,926,654	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
68	Autoimmune thyroid disease	LINC00901	TCONS_00005428	NA	NA	40352	NA	NA	NA	+	21075 	chr3:116,911,324-116,932,398	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
69	Autoimmune thyroid disease	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	NA	NA	29665	NA	NA	NA	+	12820 	chr11:65,496,266-65,509,085	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
70	Autoimmune thyroid disease	MAP3K14	Mitogen-Activated Protein Kinase Kinase Kinase 14	NA	NA	6853	NA	NA	NA	-	53930 	chr17:45,263,119-45,317,048	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
71	Autoimmune thyroid disease	MEG3	Maternally Expressed 3	NA	NA	14575	NA	NA	NA	+	81623 	chr14:100,779,409-100,861,031	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
72	Autoimmune thyroid disease	MESTIT1	MEST Intronic Transcript 1, Antisense RNA	NA	NA	17991	NA	NA	NA	-	31820 	chr7:130,459,354-130,491,173	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
73	Autoimmune thyroid disease	MIAT	Myocardial Infarction Associated Transcript	NA	NA	33425	NA	NA	NA	+	30068 	chr22:26,646,411-26,676,478	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
74	Autoimmune thyroid disease	MIR100HG	Mir-100-Let-7a-2-Mir-125b-1 Cluster Host Gene	NA	NA	39522	NA	NA	NA	-	528519 	chr11:122,028,203-122,556,721	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
75	Autoimmune thyroid disease	MIR155HG	MIR155 Host Gene	NA	NA	35460	NA	NA	NA	+	22342 	chr21:25,560,398-25,582,739	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
76	Autoimmune thyroid disease	MIR17HG	MiR-17-92a-1 Cluster Host Gene	NA	NA	23564	NA	NA	NA	+	49412 	chr13:91,347,686-91,397,097	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
77	Autoimmune thyroid disease	MIR31HG	MIR31 Host Gene	NA	NA	37187	NA	NA	NA	-	152292 	chr9:21,439,475-21,591,766	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
78	Autoimmune thyroid disease	MKRN3-AS1	MKRN3 Antisense RNA 1	NA	NA	12910	NA	NA	NA	NA	NA	chr15:-(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
79	Autoimmune thyroid disease	MYCNOS	MYCN Opposite Strand	NA	NA	16911	NA	NA	NA	-	24084 	chr2:15,918,350-15,942,433	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
80	Autoimmune thyroid disease	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	NA	NA	30815	NA	NA	NA	+	33513 	chr11:65,416,581-65,450,093	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
81	Autoimmune thyroid disease	NRON	Non-Coding Repressor Of NFAT	NA	NA	37079	NA	NA	NA	-	3059 	chr9:126,407,773-126,410,831	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
82	Autoimmune thyroid disease	PCA3	Prostate Cancer Associated 3	NA	NA	8637	NA	NA	NA	+	171328 	chr9:76,691,980-76,863,307	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
83	Autoimmune thyroid disease	PCAT1	Prostate Cancer Associated Transcript 1	NA	NA	43022	NA	NA	NA	+	866589 	chr8:126,552,462-127,419,050	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
84	Autoimmune thyroid disease	PCGEM1	PCGEM1 Prostate-Specific Transcript	NA	NA	30145	NA	NA	NA	+	34945 	chr2:192,749,008-192,783,952	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
85	Autoimmune thyroid disease	PDZRN3-AS1	PDZRN3 Antisense RNA 1 	NA	NA	40814	NA	NA	NA	+	6701 	chr3:73,621,712-73,628,412	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
86	Autoimmune thyroid disease	PICSAR	P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA	NA	NA	19725	NA	NA	NA	-	5522 	chr21:44,999,207-45,004,728	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
87	Autoimmune thyroid disease	PINK1-AS	PINK1 Antisense RNA	NA	NA	38872	NA	NA	NA	-	9538 	chr1:20,642,656-20,652,193	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
88	Autoimmune thyroid disease	PISRT1	PISRT1 LncRNA	NA	NA	16671	NA	NA	NA	-	532 	chr3:139,232,991-139,233,522	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
89	Autoimmune thyroid disease	PPP3CB	Protein Phosphatase 3 Catalytic Subunit Beta 	NA	NA	9315	NA	NA	NA	-	59592 	chr10:73,436,433-73,496,024	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
90	Autoimmune thyroid disease	PRINS	Psoriasis Associated Non-Protein Coding RNA Induced By Stress	NA	NA	34235	NA	NA	NA	NA	NA	chr10:-(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
91	Autoimmune thyroid disease	PSORS1C3	Psoriasis Susceptibility 1 Candidate 3 	NA	NA	17203	NA	NA	NA	-	26270 	chr6:31,171,608-31,197,877	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
92	Autoimmune thyroid disease	PTCSC1	Papillary Thyroid Carcinoma Susceptibility Candidate 1	NA	NA	37127	NA	NA	NA	+	2810 	chr8:133,054,958-133,057,767	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
93	Autoimmune thyroid disease	PVT1	Pvt1 Oncogene	NA	NA	9709	NA	NA	NA	+	393690 	chr8:127,794,522-128,188,211	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
94	Autoimmune thyroid disease	RMST	Rhabdomyosarcoma 2 Associated Transcript 	NA	NA	29893	NA	NA	NA	+	413200 	chr12:97,430,633-97,843,832	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
95	Autoimmune thyroid disease	RN7SK	RNA Component Of 7SK Nuclear Ribonucleoprotein	NA	NA	10037	NA	NA	NA	+	349 	chr6:52,995,603-52,995,951	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
96	Autoimmune thyroid disease	RN7SL1	RNA Component Of Signal Recognition Particle 7SL1	NA	NA	10038	NA	NA	NA	+	302 	chr14:49,586,580-49,586,881	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
97	Autoimmune thyroid disease	RRP1B	Ribosomal RNA Processing 1B	NA	NA	23818	NA	NA	NA	+	36520 	chr21:43,659,560-43,696,079	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
98	Autoimmune thyroid disease	SCAANT1	SCA7/ATXN7 Antisense RNA 1	NA	NA	43718	NA	NA	NA	-	1761 	chr3:63,911,338-63,913,098	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
99	Autoimmune thyroid disease	SNHG11	Small Nucleolar RNA Host Gene 11	NA	NA	25046	NA	NA	NA	+	4598 	chr20:38,446,343-38,450,940	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
100	Autoimmune thyroid disease	SNHG3	Small Nucleolar RNA Host Gene 3	NA	NA	10118	NA	NA	NA	+	4951 	chr1:28,505,942-28,510,892	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
101	Autoimmune thyroid disease	SNHG4	Small Nucleolar RNA Host Gene 4	NA	NA	32964	NA	NA	NA	+	42374 	chr5:139,273,751-139,316,124	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
102	Autoimmune thyroid disease	SNHG5	Small Nucleolar RNA Host Gene 4	NA	NA	32964	NA	NA	NA	-	28757 	chr6:85,650,491-85,679,247	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
103	Autoimmune thyroid disease	SOX2OT	TCONS_00007597;TCONS_00020726	NA	NA	20209	ENSMUST00000197977.1	mouse	NONMMUT042524.2	-	2970	chr3:181,711,925-181,714,436	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
104	Autoimmune thyroid disease	SPRY4-IT1	SPRY4 Intronic Transcript 1	NA	NA	42394	NA	NA	NA	-	704 	chr5:142,317,619-142,318,322	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
105	Autoimmune thyroid disease	SRA1	Steroid Receptor RNA Activator 1	NA	NA	11281	NA	NA	NA	-	20913 	chr5:140,537,340-140,558,252	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
106	Autoimmune thyroid disease	TCL6	T Cell Leukemia/Lymphoma 6 	NA	NA	13463	NA	NA	NA	+	29336 	chr14:95,650,498-95,679,833	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
107	Autoimmune thyroid disease	TDRG1	Testis Development Related 1	NA	NA	43642	NA	NA	NA	+	101805 	chr6:40,285,786-40,387,590	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
108	Autoimmune thyroid disease	TERC	Telomerase RNA Component	NA	NA	11727	NA	NA	NA	-	599 	chr3:169,764,462-169,765,060	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
109	Autoimmune thyroid disease	TRAF3IP2-AS1	TRAF3IP2 Antisense RNA 1	NA	NA	40005	NA	NA	NA	+	119222 	chr6:111,483,074-111,602,295	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
110	Autoimmune thyroid disease	TUG1	aurine Up-Regulated 1	NA	NA	26066	NA	NA	NA	+	16069 	chr22:30,969,157-30,985,225	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
111	Autoimmune thyroid disease	TUSC7	Tumor Suppressor Candidate 7	NA	NA	27701	NA	NA	NA	+	80969 	chr3:116,642,614-116,723,582	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
112	Autoimmune thyroid disease	Ube3a-as	Ubiquitin Protein Ligase E3A	NA	NA	12496	NA	NA	NA	-	105654 	chr15:25,333,728-25,439,381	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
113	Autoimmune thyroid disease	WRAP53	WD Repeat Containing Antisense To TP53	NA	NA	25522	NA	NA	NA	+	9562 	chr19:15,828,205-15,837,766	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
114	Autoimmune thyroid disease	WT1-AS	WD Repeat Containing Antisense To TP53	NA	NA	18135	ENST00000395900.1	human	NONHSAG007984.3	+	26101 	chr11:32,434,075-32,460,175	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
115	Autoimmune thyroid disease	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
116	Autoimmune thyroid disease	ZFAS1	WD Repeat Containing Antisense To TP53	NA	NA	33101	ENST00000441722.4	human	NONHSAT080209.2	+	84394 	chr20:49,276,738-49,361,131	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	7188	LncRNADisease v2.0	Thyroid
117	Osteoporosis	KCNQ1OT1	KCNQ1 opposite strand/ antisense transcript 1	NA	NA	6295	NA	NA	NA	-	102886 	chr11:2,597,113-2,699,998	0	1	0	0	LRLSLDA-LNCSIM2	NA	up-regulated	NA	NA	NA	NA	M81.991	11476	LncRNADisease v2.0	Bone
118	Osteoporosis	TUG1	taurine up-regulated 1	NA	NA	26066	NA	NA	NA	+	16069	chr22:30,969,157-30,985,225	0	1	0	0	LRLSLDA-LNCSIM3	NA	upregulated	NA	NA	NA	NA	M81.991	11476	LncRNADisease v2.0	Bone
119	Osteoporosis	ROR	long intergenic nonprotein coding RNA, regulator of reprogramming	NA	NA	43022	NA	NA	NA	+	866589 	chr8:126,552,462-127,419,050	0	1	0	0	LRLSLDA-LNCSIM8	NA	upregulated	NA	NA	NA	NA	M81.991	11476	LncRNADisease v2.0	Bone
120	Osteoporosis	Linc02349	Long Intergenic Non-Protein Coding RNA 2349	NA	NA	53271	NA	NA	NA	+	1626 	chr15:61,729,765-61,731,390	0	1	0	0	LRLSLDA-LNCSIM10	NA	upregulated	NA	NA	NA	NA	M81.991	11476	LncRNADisease v2.0	Bone
121	Osteoporosis	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM12	NA	downregulated	NA	NA	NA	NA	M81.991	11476	LncRNADisease v2.0	Bone
122	Osteoporosis	MIR31HG	MIR31 host gene	NA	NA	37187	NA	NA	NA	-	152292 	chr9:21,439,475-21,591,766	0	1	0	0	LRLSLDA-LNCSIM14	NA	downregulated	NA	NA	NA	NA	M81.991	11476	LncRNADisease v2.0	Bone
123	Autoimmune thyroid disease	Ube3a-as	Ubiquitin Protein Ligase E3A	NA	NA	12496	NA	NA	NA	-	105654 	chr15:25,333,728-25,439,381	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Thyroid
124	Pseudohypoparathyroidism	AIRN	Antisense Of IGF2R Non-Protein Coding RNA	NA	NA	34515	NA	NA	NA	-	4375 	chr6:160,003,290-160,007,664	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	4184	LncRNADisease v2.0	Parathyroid
125	Pseudohypoparathyroidism	ATP6V1G2-DDX39B	ATP6V1G2-DDX39B Readthrough (NMD Candidate)	NA	NA	41999	NA	NA	NA	-	16631	chr6:31,530,218-31,546,848	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
126	Pseudohypoparathyroidism	ATXN8OS	ATXN8 Opposite Strand LncRNA	NA	NA	10561	NA	NA	NA	+	92821	chr13:70,078,918-70,171,738	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
127	Pseudohypoparathyroidism	BACE1-AS	BACE1 Antisense RNA	NA	NA	37125	NA	NA	NA	+	5119 	chr11:117,288,453-117,293,571	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
128	Pseudohypoparathyroidism	BCAR4	Breast Cancer Anti-Estrogen Resistance 4	NA	NA	22170	NA	NA	NA	-	10554 	chr16:11,818,292-11,828,845	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
129	Pseudohypoparathyroidism	BCYRN1	Brain Cytoplasmic RNA 1	NA	NA	1022	NA	NA	NA	+	18661 	chr2:47,325,857-47,344,517	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
130	Pseudohypoparathyroidism	BDNF-AS1	BDNF Antisense RNA	NA	NA	20608	NA	NA	NA	+	191419 	chr11:27,506,830-27,698,248	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
131	Pseudohypoparathyroidism	BOK-AS1	BOK Antisense RNA 1	NA	NA	35125	NA	NA	NA	-	15852 	chr2:241,543,822-241,559,673	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
132	Pseudohypoparathyroidism	BPESC1	Blepharophimosis, Epicanthus Inversus And Ptosis Candidate 1	NA	NA	13228	NA	NA	NA	+	20988 	chr3:139,104,184-139,125,171	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
133	Pseudohypoparathyroidism	C1QTNF9B-AS1	Pro-X-Gly Collagen Triple Helix Like Repeat Containing	NA	NA	39839	NA	NA	NA	+	8422 	chr13:23,888,842-23,897,263	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
134	Pseudohypoparathyroidism	CASC2	Cancer Susceptibility 2 	NA	NA	22933	NA	NA	NA	+	170235 	chr10:118,045,862-118,216,096	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
135	Pseudohypoparathyroidism	CBR3-AS1	CBR3 Antisense RNA 1	NA	NA	43664	NA	NA	NA	-	145856 	chr21:36,130,371-36,276,226	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
136	Pseudohypoparathyroidism	CDKN2B-AS1	CDKN2B Antisense RNA 1	NA	NA	34341	NA	NA	NA	+	244984 	chr9:21,994,139-22,239,122	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
137	Pseudohypoparathyroidism	CECR3	Cat Eye Syndrome Chromosome Region, Candidate 3	NA	NA	1841	NA	NA	NA	-	9877 	chr22:17,256,858-17,266,734	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
138	Pseudohypoparathyroidism	CECR9	Cat Eye Syndrome Chromosome Region, Candidate 9	NA	NA	1847	NA	NA	NA	+	200 	chr22:17,329,033-17,329,232	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
139	Pseudohypoparathyroidism	CHL1-AS2	CHL1 Antisense RNA 2	NA	NA	40147	NA	NA	NA	-	87636 	chr3:109,707-197,342	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
140	Pseudohypoparathyroidism	CRNDE	Colorectal Neoplasia Differentially Expressed 	NA	NA	37078	NA	NA	NA	-	85755 	chr16:54,845,188-54,930,942	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
141	Pseudohypoparathyroidism	DAOA-AS1	DAOA Antisense RNA 1	NA	NA	30243	NA	NA	NA	-	48000 	chr13:105,457,683-105,505,682	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
142	Pseudohypoparathyroidism	DAPK1	Death Associated Protein Kinase 1	NA	NA	2674	NA	NA	NA	+	211407 	chr9:87,497,228-87,708,634	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
143	Pseudohypoparathyroidism	DGCR5	DiGeorge Syndrome Critical Region Gene 5	NA	NA	16757	NA	NA	NA	+	62703 	chr22:18,968,903-19,031,605	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
144	Pseudohypoparathyroidism	DISC2	Disrupted In Schizophrenia 2 	NA	NA	2889	NA	NA	NA	-	37933 	chr1:231,809,944-231,847,876	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
145	Pseudohypoparathyroidism	DLEU1	Deleted In Lymphocytic Leukemia 1	NA	NA	13747	NA	NA	NA	+	824689 	chr13:50,082,168-50,906,856	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
146	Pseudohypoparathyroidism	DLEU2	Deleted In Lymphocytic Leukemia 2	NA	NA	13748	NA	NA	NA	-	213016 	chr13:49,912,705-50,125,720	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
147	Pseudohypoparathyroidism	DLG2-AS1	DLG2 Antisense RNA 1	NA	NA	37132	NA	NA	NA	NA	NA	chr11:-	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
148	Pseudohypoparathyroidism	DLX6-AS1	DLX6 Antisense RNA 1	NA	NA	37151	NA	NA	NA	-	63405 	chr7:96,950,684-97,014,088	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
149	Pseudohypoparathyroidism	DMPK	DM1 Protein Kinase	NA	NA	2933	NA	NA	NA	-	12844 	chr19:45,769,709-45,782,552	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
150	Pseudohypoparathyroidism	DNM3OS	DNM3 Opposite Strand/Antisense RNA 	NA	NA	41228	NA	NA	NA	-	16516 	chr1:172,128,631-172,145,146	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Parathyroid
151	Pseudohypoparathyroidism	DSCAM-AS1	DSCAM Antisense RNA 1	NA	NA	40197	NA	NA	NA	+	2462 	chr21:40,382,898-40,385,359	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
152	Pseudohypoparathyroidism	EPB41L4A-AS1	EPB41L4A Antisense RNA 1	NA	NA	30749	NA	NA	NA	+	4369 	chr5:112,160,450-112,164,818	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
153	Pseudohypoparathyroidism	ESRG	Embryonic Stem Cell Related	NA	NA	39079	NA	NA	NA	-	20553 	chr3:54,619,661-54,640,213	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
154	Pseudohypoparathyroidism	FMR1-AS1	FMR1 Antisense RNA 1	NA	NA	39081	NA	NA	NA	-	17556 	chrX:147,904,603-147,922,158	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
155	Pseudohypoparathyroidism	GAS5	Growth Arrest Specific 5	NA	NA	16355	NA	NA	NA	-	17723 	chr1:173,851,284-173,869,006	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
156	Pseudohypoparathyroidism	GDNF-AS1	GDNF Antisense RNA 1	NA	NA	43592	NA	NA	NA	+	142240 	chr5:37,811,588-37,953,827	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
157	Pseudohypoparathyroidism	GS-AS1	GNAS Antisense RNA 1	NA	NA	24872	NA	NA	NA	-	32112 	chr20:58,818,792-58,850,903	0	1	0	0	MSP//Southern blot	NA	NA	Deletion of the nespas causes pseudohypoparathyroidism Type Ib.	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
158	Pseudohypoparathyroidism	H19	H19 Imprinted Maternally Expressed Transcript	NA	NA	4713	NA	NA	NA	-	6582 	chr11:1,995,129-2,001,710	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
159	Pseudohypoparathyroidism	HAR1A	Highly Accelerated Region 1A 	NA	NA	33117	NA	NA	NA	+	3097 	chr20:63,101,291-63,104,387	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
160	Pseudohypoparathyroidism	HAR1B	Highly Accelerated Region 1B	NA	NA	33118	NA	NA	NA	-	11826 	chr20:63,090,806-63,102,631	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
161	Pseudohypoparathyroidism	HCP5	HLA Complex P5	NA	NA	21659	NA	NA	NA	+	78236 	chr6:31,400,701-31,478,936	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
162	Pseudohypoparathyroidism	HIF1A-AS1	HIF1A Antisense RNA 1	NA	NA	43014	NA	NA	NA	-	18209 	chr14:61,677,633-61,695,841	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
163	Pseudohypoparathyroidism	HOTAIR	HOX Transcript Antisense RNA	NA	NA	33510	NA	NA	NA	-	12651 	chr12:53,962,307-53,974,957	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
164	Pseudohypoparathyroidism	HTT-AS	HTT Antisense RNA	NA	NA	37118	NA	NA	NA	-	25940 	chr4:3,048,599-3,074,538	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
165	Pseudohypoparathyroidism	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	NA	NA	34232	NA	NA	NA	+	858567 	chr6:8,435,567-9,294,133	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
166	Pseudohypoparathyroidism	HYMAI	Hydatidiform Mole Associated And Imprinted	NA	NA	5326	NA	NA	NA	-	121917 	chr6:143,942,624-144,064,540	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
167	Pseudohypoparathyroidism	IFNG-AS1	IFNG Antisense RNA 1	NA	NA	43910	NA	NA	NA	+	246137 	chr12:67,989,381-68,235,517	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
168	Pseudohypoparathyroidism	IGF2-AS	IGF2 Antisense RNA	NA	NA	14062	NA	NA	NA	+	8166 	chr11:2,140,501-2,148,666	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
169	Pseudohypoparathyroidism	IPW	Imprinted In Prader-Willi Syndrome 	NA	NA	6109	NA	NA	NA	+	5933 	chr15:25,116,544-25,122,476	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
170	Pseudohypoparathyroidism	KCNQ1DN	KCNQ1 Downstream Neighbor	NA	NA	13335	NA	NA	NA	+	7459 	chr11:2,869,535-2,876,993	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
171	Pseudohypoparathyroidism	KCNQ1OT1	KCNQ1 Opposite Strand/Antisense Transcript 1	NA	NA	6295	NA	NA	NA	-	102886 	chr11:2,597,113-2,699,998	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
172	Pseudohypoparathyroidism	LINC00032	Long Intergenic Non-Protein Coding RNA 32	NA	NA	16506	NA	NA	NA	-	49187 	chr9:27,235,683-27,284,869	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
173	Pseudohypoparathyroidism	LINC00271	Long Intergenic Non-Protein Coding RNA 271	NA	NA	32526	NA	NA	NA	+	316641 	chr6:135,497,350-135,813,990	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
174	Pseudohypoparathyroidism	LINC00312	Long Intergenic Non-Protein Coding RNA 312	NA	NA	6662	NA	NA	NA	+	2888 	chr3:8,571,781-8,574,668	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
175	Pseudohypoparathyroidism	LINC00538	Long Intergenic Non-Protein Coding RNA 538	NA	NA	43655	NA	NA	NA	+	1907 	chr1:213,924,748-213,926,654	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
176	Pseudohypoparathyroidism	LINC00901	Long Intergenic Non-Protein Coding RNA 901	NA	NA	40352	NA	NA	NA	+	21075 	chr3:116,911,324-116,932,398	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
177	Pseudohypoparathyroidism	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	NA	NA	29665	NA	NA	NA	+	12820 	chr11:65,496,266-65,509,085	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
178	Pseudohypoparathyroidism	MAP3K14	Mitogen-Activated Protein Kinase Kinase Kinase 14	NA	NA	6853	NA	NA	NA	-	53930 	chr17:45,263,119-45,317,048	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
179	Pseudohypoparathyroidism	MEG3	Maternally Expressed 3	NA	NA	14575	NA	NA	NA	+	81623 	chr14:100,779,409-100,861,031	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
180	Pseudohypoparathyroidism	MESTIT1	MEST Intronic Transcript 1, Antisense RNA	NA	NA	17991	NA	NA	NA	-	31820 	chr7:130,459,354-130,491,173	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
181	Autoimmune thyroid disease	Ube3a-as	Ubiquitin Protein Ligase E3A	NA	NA	12496	NA	NA	NA	-	105654 	chr15:25,333,728-25,439,381	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Thyroid
182	Pseudohypoparathyroidism	MIAT	Myocardial Infarction Associated Transcript	NA	NA	33425	NA	NA	NA	+	30068	chr22:26,646,411-26,676,478	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
183	Pseudohypoparathyroidism	MIR100HG	Mir-100-Let-7a-2-Mir-125b-1 Cluster Host Gene 	NA	NA	39522	NA	NA	NA	-	528519	chr11:122,028,203-122,556,721	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
184	Pseudohypoparathyroidism	MIR155HG	MIR155 Host Gene	NA	NA	35460	NA	NA	NA	+	22342	chr21:25,560,398-25,582,739	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
185	Pseudohypoparathyroidism	MIR17HG	MiR-17-92a-1 Cluster Host Gene	NA	NA	23564	NA	NA	NA	+	49412	chr13:91,347,686-91,397,097	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
186	Pseudohypoparathyroidism	MIR31HG	MIR31 Host Gene	NA	NA	37187	NA	NA	NA	-	152292	chr9:21,439,475-21,591,766	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
187	Pseudohypoparathyroidism	MKRN3-AS1	MKRN3 Antisense RNA 1	NA	NA	12910	NA	NA	NA	NA 	NA 	chr15:-	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
188	Pseudohypoparathyroidism	MYCNOS	MYCN Opposite Strand	NA	NA	16911	NA	NA	NA	-	24084	chr2:15,918,350-15,942,433	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
189	Pseudohypoparathyroidism	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	NA	NA	30815	NA	NA	NA	+	33513	chr11:65,416,581-65,450,093	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
190	Pseudohypoparathyroidism	NRON	Non-Coding Repressor Of NFAT	NA	NA	37079	NA	NA	NA	-	3059	chr9:126,407,773-126,410,831	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
191	Pseudohypoparathyroidism	PCA3	Prostate Cancer Associated 3	NA	NA	8637	NA	NA	NA	+	171328	chr9:76,691,980-76,863,307	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
192	Pseudohypoparathyroidism	PCAT1	Prostate Cancer Associated Transcript 1	NA	NA	43022	NA	NA	NA	+	866589	chr8:126,552,462-127,419,050	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
193	Pseudohypoparathyroidism	PCGEM1	PCGEM1 Prostate-Specific Transcript	NA	NA	30145	NA	NA	NA	+	34945	chr2:192,749,008-192,783,952	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
194	Pseudohypoparathyroidism	PDZRN3-AS1	PDZRN3 Antisense RNA 1	NA	NA	40814	NA	NA	NA	+	6701	chr3:73,621,712-73,628,412	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
195	Pseudohypoparathyroidism	PICSAR	P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA	NA	NA	19725	NA	NA	NA	-	5522	chr21:44,999,207-45,004,728	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
196	Pseudohypoparathyroidism	PINK1-AS	PINK1 Antisense RNA	NA	NA	38872	NA	NA	NA	-	9538	chr1:20,642,656-20,652,193	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
197	Pseudohypoparathyroidism	PISRT1	PISRT1 LncRNA	NA	NA	16671	NA	NA	NA	-	532	chr3:139,232,991-139,233,522	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
198	Pseudohypoparathyroidism	PPP3CB	Protein Phosphatase 3 Catalytic Subunit Beta 	NA	NA	9315	NA	NA	NA	-	59592	chr10:73,436,433-73,496,024	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
199	Pseudohypoparathyroidism	PRINS	Psoriasis Associated Non-Protein Coding RNA Induced By Stress	NA	NA	34235	NA	NA	NA	NA	NA	chr10:-	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
200	Pseudohypoparathyroidism	PSORS1C3	Psoriasis Susceptibility 1 Candidate 3	NA	NA	17203	NA	NA	NA	-	26270	chr6:31,171,608-31,197,877	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
201	Pseudohypoparathyroidism	PTCSC1	Papillary Thyroid Carcinoma Susceptibility Candidate 1	NA	NA	37127	NA	NA	NA	+	2810	chr8:133,054,958-133,057,767	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
202	Pseudohypoparathyroidism	PVT1	Pvt1 Oncogene	NA	NA	9709	NA	NA	NA	+	393690	chr8:127,794,522-128,188,211	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
203	Pseudohypoparathyroidism	RMST	Rhabdomyosarcoma 2 Associated Transcript	NA	NA	29893	NA	NA	NA	+	413200	chr12:97,430,633-97,843,832	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
204	Pseudohypoparathyroidism	RN7SK	RNA Component Of 7SK Nuclear Ribonucleoprotein	NA	NA	10037	NA	NA	NA	+	349	chr6:52,995,603-52,995,951	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
205	Pseudohypoparathyroidism	RN7SL1	RNA Component Of Signal Recognition Particle 7SL1	NA	NA	10038	NA	NA	NA	+	302	chr14:49,586,580-49,586,881	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
206	Pseudohypoparathyroidism	RRP1B	Ribosomal RNA Processing 1B	NA	NA	23818	NA	NA	NA	+	36520	chr21:43,659,560-43,696,079	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
207	Pseudohypoparathyroidism	SCAANT1	SCA7/ATXN7 Antisense RNA 1	NA	NA	43718	NA	NA	NA	-	1761	chr3:63,911,338-63,913,098	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
208	Pseudohypoparathyroidism	SNHG11	Small Nucleolar RNA Host Gene 11	NA	NA	25046	NA	NA	NA	+	4598	chr20:38,446,343-38,450,940	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
209	Pseudohypoparathyroidism	SNHG3	Small Nucleolar RNA Host Gene 3 	NA	NA	10118	NA	NA	NA	+	4951	chr1:28,505,942-28,510,892	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
210	Pseudohypoparathyroidism	SNHG4	Small Nucleolar RNA Host Gene 4	NA	NA	32964	NA	NA	NA	+	42374	chr5:139,273,751-139,316,124	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
211	Pseudohypoparathyroidism	SNHG5	Small Nucleolar RNA Host Gene 5	NA	NA	21026	NA	NA	NA	-	28757	chr6:85,650,491-85,679,247	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
212	Pseudohypoparathyroidism	SOX2OT	TCONS_00007597;TCONS_00020726	NA	NA	20209	ENSMUST00000197977.1	mouse	NONMMUT042524.2	+	2970	chr3:181,711,925-181,714,436	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
213	Pseudohypoparathyroidism	SPRY4-IT1	SPRY4 Intronic Transcript 1	NA	NA	42394	NA	NA	NA	-	704	chr5:142,317,619-142,318,322	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
214	Pseudohypoparathyroidism	SRA1	Steroid Receptor RNA Activator 1	NA	NA	11281	NA	NA	NA	-	20913	chr5:140,537,340-140,558,252	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
215	Pseudohypoparathyroidism	TCL6	T Cell Leukemia/Lymphoma 6	NA	NA	13463	NA	NA	NA	+	29336 	chr14:95,650,498-95,679,833	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
216	Pseudohypoparathyroidism	TDRG1	Testis Development Related 1	NA	NA	43642	NA	NA	NA	+	101805 	chr6:40,285,786-40,387,590(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
217	Pseudohypoparathyroidism	TERC	Telomerase RNA Component 	NA	NA	11727	NA	NA	NA	-	599 	chr3:169,764,462-169,765,060	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
218	Pseudohypoparathyroidism	TRAF3IP2-AS1	TRAF3IP2 Antisense RNA 1	NA	NA	40005	NA	NA	NA	+	119222 	chr6:111,483,074-111,602,295	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
219	Pseudohypoparathyroidism	TUG1	Taurine Up-Regulated 1	NA	NA	26066	NA	NA	NA	+	16069 	chr22:30,969,157-30,985,225	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
220	Pseudohypoparathyroidism	TUSC7	Tumor Suppressor Candidate 7	NA	NA	27701	NA	NA	NA	+	80969 	chr3:116,642,614-116,723,582	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
221	Pseudohypoparathyroidism	Ube3a-as	Ubiquitin Protein Ligase E3A	NA	NA	12496	NA	NA	NA	+	105654 	chr15:25,333,728-25,439,381	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
222	Pseudohypoparathyroidism	UCA1	Urothelial Cancer Associated 1	NA	NA	37126	NA	NA	NA	+	9562 	chr19:15,828,205-15,837,766	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
223	Pseudohypoparathyroidism	WRAP53	WD Repeat Containing Antisense To TP53	NA	NA	25522	NA	NA	NA	+	17432 	chr17:7,686,071-7,703,502	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
224	Pseudohypoparathyroidism	WT1-AS	WT1 Antisense RNA	NA	NA	18135	ENST00000395900.1	human	NONHSAG007984.3	+	26101 	chr11:32,434,075-32,460,175	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
225	Pseudohypoparathyroidism	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
226	Pseudohypoparathyroidism	ZFAS1	WD Repeat Containing Antisense To TP53	NA	NA	33101	ENST00000441722.4	human	NONHSAT080209.2	+	84394 	chr20:49,276,738-49,361,131	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
227	Pseudohypoparathyroidism	ZFAT-AS1	ZFAT Antisense RNA 1	NA	NA	33992	NA	NA	NA	+	2740 	chr8:134,598,071-134,600,810	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	E20.102	4184	LncRNADisease v2.0	Parathyroid
228	Nonfunctioning pituitary adenomas	AIRN	Antisense Of IGF2R Non-Protein Coding RNA	NA	NA	34515	NA	NA	NA	-	4375	chr6:160,003,290-160,007,664	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
229	Nonfunctioning pituitary adenomas	ANTI-NOS2A	Nitric Oxide Synthase 2	NA	NA	7873	NA	NA	NA	-	43764 	chr17:27,756,766-27,800,529	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
230	Nonfunctioning pituitary adenomas	ATP6V1G2-DDX39B	ATP6V1G2-DDX39B Readthrough (NMD Candidate)	NA	NA	41999	NA	NA	NA	-	16631 	chr6:31,530,218-31,546,848	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
231	Nonfunctioning pituitary adenomas	ATXN8OS	ATXN8 Opposite Strand LncRNA	NA	NA	10561	NA	NA	NA	+	92821 	chr13:70,078,918-70,171,738	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
232	Nonfunctioning pituitary adenomas	BACE1-AS	BACE1 Antisense RNA	NA	NA	37125	NA	NA	NA	+	5119 	chr11:117,288,453-117,293,571	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
233	Nonfunctioning pituitary adenomas	BCAR4	Breast Cancer Anti-Estrogen Resistance 4	NA	NA	22170	NA	NA	NA	-	10554	chr16:11,818,292-11,828,845	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
234	Nonfunctioning pituitary adenomas	BCYRN1	Brain Cytoplasmic RNA 1	NA	NA	1022	NA	NA	NA	+	18661 	chr2:47,325,857-47,344,517	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
235	Nonfunctioning pituitary adenomas	BDNF-AS1	BDNF Antisense RNA	NA	NA	20608	NA	NA	NA	+	191419	chr11:27,506,830-27,698,248	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
236	Nonfunctioning pituitary adenomas	BOK-AS1	BOK Antisense RNA 1	NA	NA	35125	NA	NA	NA	-	15852 	chr2:241,543,822-241,559,673	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
237	Nonfunctioning pituitary adenomas	BPESC1	Blepharophimosis, Epicanthus Inversus And Ptosis Candidate 	NA	NA	13228	NA	NA	NA	+	20988 	chr3:139,104,184-139,125,171	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
238	Nonfunctioning pituitary adenomas	C15orf2	Nuclear Pore Associated Protein 1	NA	NA	1190	NA	NA	NA	+	7619 	chr15:24,675,775-24,683,393	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
239	Nonfunctioning pituitary adenomas	C1QTNF9B-AS1	Pro-X-Gly Collagen Triple Helix Like Repeat Containing	NA	NA	39839	NA	NA	NA	+	8422	chr13:23,888,842-23,897,263	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
240	Nonfunctioning pituitary adenomas	CASC2	Cancer Susceptibility 2 	NA	NA	22933	NA	NA	NA	+	170235 	chr10:118,045,862-118,216,096	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
241	Nonfunctioning pituitary adenomas	CBR3-AS1	CBR3 Antisense RNA 1	NA	NA	43664	NA	NA	NA	-	145856 	chr21:36,130,371-36,276,226	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
242	Pituitary adenoma	CCAT2	Colon Cancer Associated Transcript 2	NA	NA	47044	NA	NA	NA	+	1753	chr8:127,400,398-127,402,150	0	1	0	0	qRT-PCR//Gain- and Loss-of-function assays	NA	NA	NA	NA	NA	NA	NA	3829	LncRNADisease v2.0	Pituitary
243	Nonfunctioning pituitary adenomas	CDKN2B-AS1	CDKN2B Antisense RNA 1 	NA	NA	34341	NA	NA	NA	+	244984 	chr9:21,994,139-22,239,122	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
244	Nonfunctioning pituitary adenomas	CECR3	Cat Eye Syndrome Chromosome Region, Candidate 3	NA	NA	1841	NA	NA	NA	-	9877 	chr22:17,256,858-17,266,734	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
245	Nonfunctioning pituitary adenomas	CECR9	Cat Eye Syndrome Chromosome Region, Candidate 9	NA	NA	1847	NA	NA	NA	+	199 	chr22:17,329,033-17,329,232	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
246	Nonfunctioning pituitary adenomas	CHL1-AS2	CHL1 Antisense RNA 2	NA	NA	40147	NA	NA	NA	-	87636 	chr3:109,707-197,342	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
247	Nonfunctioning pituitary adenomas	CRNDE	Colorectal Neoplasia Differentially Expressed	NA	NA	37078	NA	NA	NA	-	85755 	chr16:54,845,188-54,930,942	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
248	Nonfunctioning pituitary adenomas	DAOA-AS1	DAOA Antisense RNA 1	NA	NA	30243	NA	NA	NA	-	48000 	chr13:105,457,683-105,505,682	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
249	Nonfunctioning pituitary adenomas	DAPK1	Death Associated Protein Kinase 1	NA	NA	2674	NA	NA	NA	+	211407 	chr9:87,497,228-87,708,634	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
250	Nonfunctioning pituitary adenomas	DGCR5	DiGeorge Syndrome Critical Region Gene 5	NA	NA	16757	NA	NA	NA	+	62703 	chr22:18,968,903-19,031,605	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
251	Nonfunctioning pituitary adenomas	DISC2	Disrupted In Schizophrenia 2	NA	NA	2889	NA	NA	NA	-	37933 	chr1:231,809,944-231,847,876	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
252	Nonfunctioning pituitary adenomas	DLEU1	Deleted In Lymphocytic Leukemia 1	NA	NA	13747	NA	NA	NA	-	824689 	chr13:50,082,168-50,906,856	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
253	Nonfunctioning pituitary adenomas	DLEU2	Deleted In Lymphocytic Leukemia 2	NA	NA	13748	NA	NA	NA	-	213016 	chr13:49,912,705-50,125,720	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
254	Nonfunctioning pituitary adenomas	DLG2-AS1	DLG2 Antisense RNA 1	NA	NA	37132	NA	NA	NA	NA	NA	chr11:-	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
255	Nonfunctioning pituitary adenomas	DLX6-AS1	DLX6 Antisense RNA 1	NA	NA	37151	NA	NA	NA	-	63405 	chr7:96,950,684-97,014,088	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
256	Nonfunctioning pituitary adenomas	DMPK	DM1 Protein Kinase	NA	NA	2933	NA	NA	NA	-	12844 	chr19:45,769,709-45,782,552	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
257	Nonfunctioning pituitary adenomas	DNM3OS	DNM3 Opposite Strand/Antisense RNA	NA	NA	41228	NA	NA	NA	-	16516 	chr1:172,128,631-172,145,146	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
258	Nonfunctioning pituitary adenomas	DSCAM-AS1	DSCAM Antisense RNA 1	NA	NA	40197	NA	NA	NA	+	2462	chr21:40,382,898-40,385,359	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
259	Nonfunctioning pituitary adenomas	EPB41L4A-AS1	EPB41L4A Antisense RNA 1	NA	NA	30749	NA	NA	NA	+	4369 	chr5:112,160,450-112,164,818	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
260	Nonfunctioning pituitary adenomas	ESRG	Embryonic Stem Cell Related	NA	NA	39079	NA	NA	NA	-	20553 	chr3:54,619,661-54,640,213	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
261	Nonfunctioning pituitary adenomas	FMR1-AS1	FMR1 Antisense RNA 1	NA	NA	39081	NA	NA	NA	-	17556 	chrX:147,904,603-147,922,158	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
262	Pituitary adenoma	GADD45G	Growth Arrest And DNA Damage Inducible Gamma	NA	NA	4097	NA	NA	NA	+	1547	chr9:89,605,009-89,606,555	0	1	0	0	qPCR	NA	NA	NA	NA	NA	NA	NA	3829	LncRNADisease v2.0	Pituitary
263	Nonfunctioning pituitary adenomas	GAS5	Growth Arrest Specific 5	NA	NA	16355	NA	NA	NA	-	17723 	chr1:173,851,284-173,869,006	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
264	Nonfunctioning pituitary adenomas	GDNF-AS1	GDNF Antisense RNA 1	NA	NA	43592	NA	NA	NA	+	142240 	chr5:37,811,588-37,953,827	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
265	Nonfunctioning pituitary adenomas	GS-AS1	GNAS Antisense RNA 1	NA	NA	24872	NA	NA	NA	-	32112 	chr20:58,818,792-58,850,903	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
266	Nonfunctioning pituitary adenomas	H19	H19 Imprinted Maternally Expressed Transcript	NA	NA	4713	NA	NA	NA	-	6582 	chr11:1,995,129-2,001,710	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
267	Nonfunctioning pituitary adenomas	HAR1A	Highly Accelerated Region 1A	NA	NA	33117	NA	NA	NA	+	3097 	chr20:63,101,291-63,104,387	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
268	Nonfunctioning pituitary adenomas	HAR1B	Highly Accelerated Region 1B	NA	NA	33118	NA	NA	NA	-	11826 	chr20:63,090,806-63,102,631	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
269	Nonfunctioning pituitary adenomas	HCP5	HLA Complex P5	NA	NA	21659	NA	NA	NA	+	78236 	chr6:31,400,701-31,478,936	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
270	Nonfunctioning pituitary adenomas	HIF1A-AS1	HIF1A Antisense RNA 1	NA	NA	43014	NA	NA	NA	-	18209 	chr14:61,677,633-61,695,841	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
271	Functionless pituitary adenoma	HOTAIR	HOX Transcript Antisense RNA	NA	NA	33510	NA	NA	NA	-	12651 	chr12:53,962,307-53,974,957	0	1	0	0	qPCR//Microarray	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
272	Nonfunctioning pituitary adenomas	HTT-AS	HTT Antisense RNA	NA	NA	37118	NA	NA	NA	NA	25940 	chr4:3,048,599-3,074,538	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
273	Nonfunctioning pituitary adenomas	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	NA	NA	34232	NA	NA	NA	+	858567 	chr6:8,435,567-9,294,133	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
274	Nonfunctioning pituitary adenomas	HYMAI	Hydatidiform Mole Associated And Imprinted	NA	NA	5326	NA	NA	NA	-	121917 	chr6:143,942,624-144,064,540	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
275	Nonfunctioning pituitary adenomas	IFNG-AS1	IFNG Antisense RNA 1	NA	NA	43910	NA	NA	NA	+	246137 	chr12:67,989,381-68,235,517	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
276	Nonfunctioning pituitary adenomas	IGF2-AS	IGF2 Antisense RNA	NA	NA	14062	NA	NA	NA	+	8166 	chr11:2,140,501-2,148,666	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
277	Nonfunctioning pituitary adenomas	IPW	Imprinted In Prader-Willi Syndrome	NA	NA	6109	NA	NA	NA	+	5933 	chr15:25,116,544-25,122,476	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
278	Nonfunctioning pituitary adenomas	KCNQ1DN	KCNQ1 Downstream Neighbor	NA	NA	13335	NA	NA	NA	+	7459 	chr11:2,869,535-2,876,993	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
279	Nonfunctioning pituitary adenomas	KCNQ1OT1	KCNQ1 Opposite Strand/Antisense Transcript 1	NA	NA	6295	NA	NA	NA	-	102886 	chr11:2,597,113-2,699,998	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
280	Nonfunctioning pituitary adenomas	LINC00032	Long Intergenic Non-Protein Coding RNA 32	NA	NA	16506	NA	NA	NA	-	49187 	chr9:27,235,683-27,284,869	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
281	Nonfunctioning pituitary adenomas	LINC00271	Long Intergenic Non-Protein Coding RNA 271	NA	NA	32526	NA	NA	NA	+	316641 	chr6:135,497,350-135,813,990	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
282	Nonfunctioning pituitary adenomas	LINC00312	Long Intergenic Non-Protein Coding RNA 312	NA	NA	6662	NA	NA	NA	+	2888 	chr3:8,571,781-8,574,668	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
283	Nonfunctioning pituitary adenomas	LINC00538	Long Intergenic Non-Protein Coding RNA 538	NA	NA	43655	NA	NA	NA	+	1907 	chr1:213,924,748-213,926,654	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
284	Nonfunctioning pituitary adenomas	LINC00901	Long Intergenic Non-Protein Coding RNA 901	NA	NA	40352	NA	NA	NA	+	21075 	chr3:116,911,324-116,932,398	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
285	Nonfunctioning pituitary adenomas	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	NA	NA	29665	NA	NA	NA	+	12820 	chr11:65,496,266-65,509,085	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
286	Nonfunctioning pituitary adenomas	MAP3K14	Mitogen-Activated Protein Kinase Kinase Kinase 14	NA	NA	6853	NA	NA	NA	-	53930 	chr17:45,263,119-45,317,048	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
287	Functionless pituitary adenoma	MEG3	Maternally Expressed 3	NA	NA	14575	NA	NA	NA	+	81623 	chr14:100,779,409-100,861,031	0	1	0	0	qPCR	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
288	Pituitary adenoma	MEG3	Maternally Expressed 3	NA	NA	14575	NA	NA	NA	+	81623 	chr14:100,779,409-100,861,031	0	1	0	0	qPCR//Microarray	NA	NA	NA	NA	NA	NA	NA	3829	LncRNADisease v2.0	Pituitary
289	Nonfunctioning pituitary adenomas	MESTIT1	MEST Intronic Transcript 1, Antisense RNA	NA	NA	17991	NA	NA	NA	-	31820 	chr7:130,459,354-130,491,173	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
290	Nonfunctioning pituitary adenomas	MIAT	Myocardial Infarction Associated Transcript	NA	NA	33425	NA	NA	NA	+	30068 	chr22:26,646,411-26,676,478	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
291	Pituitary adenoma	MIAT	Myocardial Infarction Associated Transcript	NA	NA	33425	NA	NA	NA	+	30068 	chr22:26,646,411-26,676,478	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	3829	LncRNADisease v2.0	Pituitary
292	Nonfunctioning pituitary adenomas	MIR100HG	Mir-100-Let-7a-2-Mir-125b-1 Cluster Host Gene 	NA	NA	39522	NA	NA	NA	-	528519 	chr11:122,028,203-122,556,721	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
293	Nonfunctioning pituitary adenomas	MIR155HG	MIR155 Host Gene	NA	NA	35460	NA	NA	NA	+	22342 	chr21:25,560,398-25,582,739	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
294	Nonfunctioning pituitary adenomas	MIR17HG	MiR-17-92a-1 Cluster Host Gene 	NA	NA	23564	NA	NA	NA	+	49412 	chr13:91,347,686-91,397,097	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
295	Nonfunctioning pituitary adenomas	MIR31HG	MIR31 Host Gene	NA	NA	37187	NA	NA	NA	-	152292 	chr9:21,439,475-21,591,766	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
296	Nonfunctioning pituitary adenomas	MKRN3-AS1	MKRN3 Antisense RNA 1	NA	NA	12910	NA	NA	NA	NA	NA	chr15:-	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
297	Nonfunctioning pituitary adenomas	MYCNOS	MYCN Opposite Strand	NA	NA	16911	NA	NA	NA	-	24084	chr2:15,918,350-15,942,433	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
298	Nonfunctioning pituitary adenomas	NEAT1	Nuclear Paraspeckle Assembly Transcript 1 	NA	NA	30815	NA	NA	NA	+	33513 	chr11:65,416,581-65,450,093	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
299	Nonfunctioning pituitary adenomas	NRON	Non-Coding Repressor Of NFAT	NA	NA	37079	NA	NA	NA	-	3059 	chr9:126,407,773-126,410,831	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
300	Nonfunctioning pituitary adenomas	PCA3	Prostate Cancer Associated 3	NA	NA	8637	NA	NA	NA	+	171328 	chr9:76,691,980-76,863,307	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
301	Nonfunctioning pituitary adenomas	PCAT1	Prostate Cancer Associated Transcript 1	NA	NA	43022	NA	NA	NA	+	866589 	chr8:126,552,462-127,419,050	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
302	Nonfunctioning pituitary adenomas	PCGEM1	PCGEM1 Prostate-Specific Transcript	NA	NA	30145	NA	NA	NA	+	34945 	chr2:192,749,008-192,783,952	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
303	Nonfunctioning pituitary adenomas	PDZRN3-AS1	PDZRN3 Antisense RNA 1	NA	NA	40814	NA	NA	NA	+	6701 	chr3:73,621,712-73,628,412	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
304	Nonfunctioning pituitary adenomas	PICSAR	P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA	NA	NA	19725	NA	NA	NA	-	5522 	chr21:44,999,207-45,004,728	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
305	Nonfunctioning pituitary adenomas	PINK1-AS	PINK1 Antisense RNA	NA	NA	38872	NA	NA	NA	-	9538 	chr1:20,642,656-20,652,193	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
306	Nonfunctioning pituitary adenomas	PISRT1	PISRT1 LncRNA	NA	NA	16671	NA	NA	NA	-	532 	chr3:139,232,991-139,233,522	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
307	Nonfunctioning pituitary adenomas	PPP3CB	Protein Phosphatase 3 Catalytic Subunit Beta	NA	NA	9315	NA	NA	NA	-	59592 	chr10:73,436,433-73,496,024	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
308	Nonfunctioning pituitary adenomas	PRINS	Psoriasis Associated Non-Protein Coding RNA Induced By Stress	NA	NA	34235	NA	NA	NA	NA	NA	chr10:-	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
309	Nonfunctioning pituitary adenomas	PSORS1C3	Psoriasis Susceptibility 1 Candidate 3	NA	NA	17203	NA	NA	NA	-	26270 	chr6:31,171,608-31,197,877	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
310	Nonfunctioning pituitary adenomas	PTCSC1	Papillary Thyroid Carcinoma Susceptibility Candidate 1	NA	NA	37127	NA	NA	NA	+	2810 	chr8:133,054,958-133,057,767	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
311	Nonfunctioning pituitary adenomas	PVT1	Pvt1 Oncogene	NA	NA	9709	NA	NA	NA	+	393690 	chr8:127,794,522-128,188,211	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
312	Nonfunctioning pituitary adenomas	RMST	Rhabdomyosarcoma 2 Associated Transcript	NA	NA	29893	NA	NA	NA	+	413200 	chr12:97,430,633-97,843,832	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
313	Nonfunctioning pituitary adenomas	RN7SK	RNA Component Of 7SK Nuclear Ribonucleoprotein	NA	NA	10037	NA	NA	NA	+	349 	chr6:52,995,603-52,995,951	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
314	Nonfunctioning pituitary adenomas	RN7SL1	RNA Component Of Signal Recognition Particle 7SL1	NA	NA	10038	NA	NA	NA	+	302 	chr14:49,586,580-49,586,881	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
315	Nonfunctioning pituitary adenomas	RRP1B	Ribosomal RNA Processing 1B	NA	NA	23818	NA	NA	NA	+	36520 	chr21:43,659,560-43,696,079	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
316	Nonfunctioning pituitary adenomas	SCAANT1	SCA7/ATXN7 Antisense RNA 1	NA	NA	43718	NA	NA	NA	-	1761 	chr3:63,911,338-63,913,098	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
317	Nonfunctioning pituitary adenomas	SNHG11	Small Nucleolar RNA Host Gene 11	NA	NA	25046	NA	NA	NA	+	4598 	chr20:38,446,343-38,450,940	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
318	Nonfunctioning pituitary adenomas	SNHG3	Small Nucleolar RNA Host Gene 3 	NA	NA	10118	NA	NA	NA	+	4951 	chr1:28,505,942-28,510,892	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
319	Nonfunctioning pituitary adenomas	SNHG4	Small Nucleolar RNA Host Gene 4 	NA	NA	32964	NA	NA	NA	+	42374 	chr5:139,273,751-139,316,124	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
320	Nonfunctioning pituitary adenomas	SNHG5	Small Nucleolar RNA Host Gene 5	NA	NA	21026	NA	NA	NA	-	28757 	chr6:85,650,491-85,679,247	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
321	Nonfunctioning pituitary adenomas	SOX2OT	TCONS_00007597;TCONS_00020726	NA	NA	20209	ENSMUST00000197977.1	mouse	NONMMUT042524.2	+	2970	chr3:181,711,925-181,714,436	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
322	Nonfunctioning pituitary adenomas	SPRY4-IT1	SPRY4 Intronic Transcript 1	NA	NA	42394	NA	NA	NA	-	704 	chr5:142,317,619-142,318,322	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
323	Nonfunctioning pituitary adenomas	SRA1	Steroid Receptor RNA Activator 1	NA	NA	11281	NA	NA	NA	-	20913 	chr5:140,537,340-140,558,252	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
324	Nonfunctioning pituitary adenomas	TCL6	T Cell Leukemia/Lymphoma 6	NA	NA	13463	NA	NA	NA	+	29336 	chr14:95,650,498-95,679,833	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
325	Nonfunctioning pituitary adenomas	TDRG1	Testis Development Related 1	NA	NA	43642	NA	NA	NA	+	101805 	chr6:40,285,786-40,387,590	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
326	Nonfunctioning pituitary adenomas	TERC	Telomerase RNA Component 	NA	NA	11727	NA	NA	NA	-	599 	chr3:169,764,462-169,765,060	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
327	Nonfunctioning pituitary adenomas	TRAF3IP2-AS1	TRAF3IP2 Antisense RNA 1	NA	NA	40005	NA	NA	NA	+	119222 	chr6:111,483,074-111,602,295	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
328	Nonfunctioning pituitary adenomas	TUG1	Taurine Up-Regulated 1 	NA	NA	26066	NA	NA	NA	+	16069 	chr22:30,969,157-30,985,225	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
329	Nonfunctioning pituitary adenomas	TUSC7	Tumor Suppressor Candidate 7	NA	NA	27701	NA	NA	NA	+	80969 	chr3:116,642,614-116,723,582	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
330	Nonfunctioning pituitary adenomas	UCA1	Urothelial Cancer Associated 1	NA	NA	37126	NA	NA	NA	+	9562 	chr19:15,828,205-15,837,766	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
331	Nonfunctioning pituitary adenomas	WRAP53	WD Repeat Containing Antisense To TP53	NA	NA	25522	NA	NA	NA	+	17432 	chr17:7,686,071-7,703,502	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
332	Nonfunctioning pituitary adenomas	WT1-AS	WT1 Antisense RNA 	NA	NA	18135	ENST00000395900.1	human	NONHSAG007984.3	+	26101 	chr11:32,434,075-32,460,175	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
333	Nonfunctioning pituitary adenomas	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
334	Nonfunctioning pituitary adenomas	ZFAS1	WD Repeat Containing Antisense To TP53	NA	NA	33101	ENST00000441722.4	human	NONHSAT080209.2	+	84394 	chr20:49,276,738-49,361,131	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
335	Nonfunctioning pituitary adenomas	ZFAT-AS1	ZFAT Antisense RNA 1 	NA	NA	33992	NA	NA	NA	+	2740 	chr8:134,598,071-134,600,810	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Pituitary
336	Klinefelters syndrome	AIRN	Antisense Of IGF2R Non-Protein Coding RNA 	NA	NA	34515	NA	NA	NA	-	4375 	chr6:160,003,290-160,007,664	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
337	Klinefelters syndrome	ATP6V1G2-DDX39B	ATP6V1G2-DDX39B Readthrough (NMD Candidate)	NA	NA	41999	NA	NA	NA	-	16631 	chr6:31,530,218-31,546,848	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
338	Klinefelters syndrome	ATXN8OS	ATXN8 Opposite Strand LncRNA	NA	NA	10561	NA	NA	NA	+	92821 	chr13:70,078,918-70,171,738	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
339	Klinefelters syndrome	BACE1-AS	BACE1 Antisense RNA 	NA	NA	37125	NA	NA	NA	+	5119 	chr11:117,288,453-117,293,571	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
340	Klinefelters syndrome	BCAR4	Breast Cancer Anti-Estrogen Resistance 4	NA	NA	22170	NA	NA	NA	-	10554 	chr16:11,818,292-11,828,845	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
341	Klinefelters syndrome	BCYRN1	Brain Cytoplasmic RNA 1	NA	NA	1022	NA	NA	NA	+	18661 	chr2:47,325,857-47,344,517	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
342	Klinefelters syndrome	BDNF-AS1	BDNF Antisense RNA	NA	NA	20608	NA	NA	NA	+	191419 	chr11:27,506,830-27,698,248	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
343	Klinefelters syndrome	BOK-AS1	BOK Antisense RNA 1	NA	NA	35125	NA	NA	NA	-	15852 	chr2:241,543,822-241,559,673	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
344	Klinefelters syndrome	BPESC1	Blepharophimosis, Epicanthus Inversus And Ptosis Candidate 1	NA	NA	13228	NA	NA	NA	+	20988 	chr3:139,104,184-139,125,171	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
345	Klinefelters syndrome	CASC2	Cancer Susceptibility 2	NA	NA	22933	NA	NA	NA	+	170235 	chr10:118,045,862-118,216,096	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
346	Klinefelters syndrome	CBR3-AS1	CBR3 Antisense RNA 1	NA	NA	43664	NA	NA	NA	-	145856	chr21:36,130,371-36,276,226	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
347	Klinefelters syndrome	CDKN2B-AS1	CDKN2B Antisense RNA 1	NA	NA	34341	NA	NA	NA	+	244984 	chr9:21,994,139-22,239,122	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
348	Klinefelters syndrome	CECR3	Cat Eye Syndrome Chromosome Region, Candidate 3	NA	NA	1841	NA	NA	NA	-	9877 	chr22:17,256,858-17,266,734	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
349	Klinefelters syndrome	CECR9	Cat Eye Syndrome Chromosome Region, Candidate 9	NA	NA	1847	NA	NA	NA	+	200 	chr22:17,329,033-17,329,232	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
350	Klinefelters syndrome	CHL1-AS2	CHL1 Antisense RNA 2	NA	NA	40147	NA	NA	NA	-	87636 	chr3:109,707-197,342	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
351	Klinefelters syndrome	CRNDE	Colorectal Neoplasia Differentially Expressed	NA	NA	37078	NA	NA	NA	-	85755 	chr16:54,845,188-54,930,942	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
352	Klinefelters syndrome	DAOA-AS1	DAOA Antisense RNA 1	NA	NA	30243	NA	NA	NA	-	48000 	chr13:105,457,683-105,505,682	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
353	Klinefelters syndrome	DAPK1	Death Associated Protein Kinase 1 	NA	NA	2674	NA	NA	NA	+	211407 	chr9:87,497,228-87,708,634	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
354	Klinefelters syndrome	DGCR5	DiGeorge Syndrome Critical Region Gene 5	NA	NA	16757	NA	NA	NA	+	62703 	chr22:18,968,903-19,031,605	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
355	Klinefelters syndrome	DISC2	Disrupted In Schizophrenia 2	NA	NA	2889	NA	NA	NA	-	37933 	chr1:231,809,944-231,847,876	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
356	Klinefelters syndrome	DLEU1	Deleted In Lymphocytic Leukemia 1	NA	NA	13747	NA	NA	NA	+	824689 	chr13:50,082,168-50,906,856	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
357	Klinefelters syndrome	DLEU2	Deleted In Lymphocytic Leukemia 2	NA	NA	13748	NA	NA	NA	-	213016 	chr13:49,912,705-50,125,720	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
358	Klinefelters syndrome	DLG2-AS1	DLG2 Antisense RNA 1 	NA	NA	37132	NA	NA	NA	NA	NA	chr11:-	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
359	Klinefelters syndrome	DLX6-AS1	DLX6 Antisense RNA 1	NA	NA	37151	NA	NA	NA	-	63405 	chr7:96,950,684-97,014,088	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
360	Klinefelters syndrome	DMPK	DM1 Protein Kinase	NA	NA	2933	NA	NA	NA	-	12844	chr19:45,769,709-45,782,552	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
361	Klinefelters syndrome	DNM3OS	DNM3 Opposite Strand/Antisense RNA	NA	NA	41228	NA	NA	NA	-	16516 	chr1:172,128,631-172,145,146	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
362	Klinefelters syndrome	DSCAM-AS1	DSCAM Antisense RNA 1	NA	NA	40197	NA	NA	NA	+	2462 	chr21:40,382,898-40,385,359	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
363	Klinefelters syndrome	EPB41L4A-AS1	EPB41L4A Antisense RNA 1 	NA	NA	30749	NA	NA	NA	+	4369 	chr5:112,160,450-112,164,818	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
364	Klinefelters syndrome	ESRG	Embryonic Stem Cell Related	NA	NA	39079	NA	NA	NA	-	20553	chr3:54,619,661-54,640,213	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
365	Klinefelters syndrome	FMR1-AS1	FMR1 Antisense RNA 1 	NA	NA	39081	NA	NA	NA	-	17556 	chrX:147,904,603-147,922,158	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
366	Klinefelters syndrome	GAS5	Growth Arrest Specific 5	NA	NA	16355	NA	NA	NA	-	17723 	chr1:173,851,284-173,869,006	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
367	Klinefelters syndrome	GDNF-AS1	GDNF Antisense RNA 1	NA	NA	43592	NA	NA	NA	+	142240 	chr5:37,811,588-37,953,827	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
368	Klinefelters syndrome	GS-AS1	GNAS Antisense RNA 1	NA	NA	24872	NA	NA	NA	-	32112 	chr20:58,818,792-58,850,903	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
369	Klinefelters syndrome	H19	H19 Imprinted Maternally Expressed Transcript	NA	NA	4713	NA	NA	NA	-	6582 	chr11:1,995,129-2,001,710	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
370	Klinefelters syndrome	HAR1A	Highly Accelerated Region 1A 	NA	NA	33117	NA	NA	NA	+	3097 	chr20:63,101,291-63,104,387	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
371	Klinefelters syndrome	HAR1B	Highly Accelerated Region 1B	NA	NA	33118	NA	NA	NA	-	11826 	chr20:63,090,806-63,102,631	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
372	Klinefelters syndrome	HCP5	HLA Complex P5	NA	NA	 21659	NA	NA	NA	+	78236 	chr6:31,400,701-31,478,936	0	1	0	0	LRLSLDA-LNCSIM2	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
373	Klinefelters syndrome	HIF1A-AS1	HIF1A Antisense RNA 1	NA	NA	43014	NA	NA	NA	-	18209 	chr14:61,677,633-61,695,841	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
374	Klinefelters syndrome	HOTAIR	HOX Transcript Antisense RNA	NA	NA	33510	NA	NA	NA	-	12651 	chr12:53,962,307-53,974,957	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
375	Klinefelters syndrome	HTT-AS	HTT Antisense RNA	NA	NA	37118	NA	NA	NA	-	25940 	chr4:3,048,599-3,074,538	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
376	Klinefelters syndrome	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	NA	NA	34232	NA	NA	NA	+	858567 	chr6:8,435,567-9,294,133	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
377	Klinefelters syndrome	HYMAI	Hydatidiform Mole Associated And Imprinted	NA	NA	5326	NA	NA	NA	-	121917 	chr6:143,942,624-144,064,540	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
378	Klinefelters syndrome	IFNG-AS1	IFNG Antisense RNA 1	NA	NA	43910	NA	NA	NA	+	246137 	chr12:67,989,381-68,235,517	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
379	Klinefelters syndrome	IGF2-AS	IGF2 Antisense RNA 	NA	NA	14062	NA	NA	NA	+	8166 	chr11:2,140,501-2,148,666	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
380	Klinefelters syndrome	IPW	Imprinted In Prader-Willi Syndrome	NA	NA	6109	NA	NA	NA	+	5933 	chr15:25,116,544-25,122,476	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
381	Klinefelters syndrome	KCNQ1DN	KCNQ1 Downstream Neighbor	NA	NA	13335	NA	NA	NA	+	7459 	chr11:2,869,535-2,876,993	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
382	Klinefelters syndrome	KCNQ1OT1	KCNQ1 Opposite Strand/Antisense Transcript 1	NA	NA	6295	NA	NA	NA	-	102886 	chr11:2,597,113-2,699,998	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
383	Klinefelters syndrome	LINC00032	Long Intergenic Non-Protein Coding RNA 32	NA	NA	16506	NA	NA	NA	-	49187 	chr9:27,235,683-27,284,869	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
384	Klinefelters syndrome	LINC00271	Long Intergenic Non-Protein Coding RNA 271	NA	NA	32526	NA	NA	NA	+	316641 	chr6:135,497,350-135,813,990	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
385	Klinefelters syndrome	LINC00312	Long Intergenic Non-Protein Coding RNA 312	NA	NA	6662	NA	NA	NA	+	2888 	chr3:8,571,781-8,574,668	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
386	Klinefelters syndrome	LINC00538	Long Intergenic Non-Protein Coding RNA 538	NA	NA	43655	NA	NA	NA	+	1907 	chr1:213,924,748-213,926,654	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
387	Klinefelters syndrome	LINC00901	Long Intergenic Non-Protein Coding RNA 901	NA	NA	40352	NA	NA	NA	+	21075 	chr3:116,911,324-116,932,398	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
388	Klinefelters syndrome	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	NA	NA	29665	NA	NA	NA	+	12820 	chr11:65,496,266-65,509,085	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
389	Klinefelters syndrome	MAP3K14	Mitogen-Activated Protein Kinase Kinase Kinase 14	NA	NA	6853	NA	NA	NA	-	53930 	chr17:45,263,119-45,317,048	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
390	Klinefelters syndrome	MEG3	Maternally Expressed 3	NA	NA	14575	NA	NA	NA	+	81623 	chr14:100,779,409-100,861,031	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
391	Klinefelters syndrome	MESTIT1	MEST Intronic Transcript 1, Antisense RNA	NA	NA	17991	NA	NA	NA	-	31820 	chr7:130,459,354-130,491,173	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
392	Klinefelters syndrome	MIAT	Myocardial Infarction Associated Transcript	NA	NA	33425	NA	NA	NA	+	30068 	chr22:26,646,411-26,676,478	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
393	Klinefelters syndrome	MIR100HG	Mir-100-Let-7a-2-Mir-125b-1 Cluster Host Gene	NA	NA	39522	NA	NA	NA	-	528519 	chr11:122,028,203-122,556,721	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
394	Klinefelters syndrome	MIR155HG	MIR155 Host Gene	NA	NA	35460	NA	NA	NA	+	22342 	chr21:25,560,398-25,582,739	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
395	Klinefelters syndrome	MIR17HG	MiR-17-92a-1 Cluster Host Gene	NA	NA	23564	NA	NA	NA	+	49412 	chr13:91,347,686-91,397,097	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
396	Klinefelters syndrome	MIR31HG	MIR31 Host Gene	NA	NA	37187	NA	NA	NA	-	152292 	chr9:21,439,475-21,591,766	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
397	Klinefelters syndrome	MKRN3-AS1	MKRN3 Antisense RNA 1	NA	NA	12910	NA	NA	NA	NA	NA	chr15:-	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
398	Klinefelters syndrome	MYCNOS	MYCN Opposite Strand	NA	NA	16911	NA	NA	NA	-	24084 	chr2:15,918,350-15,942,433	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
399	Klinefelters syndrome	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	NA	NA	30815	NA	NA	NA	+	33513 	chr11:65,416,581-65,450,093	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
400	Klinefelters syndrome	NRON	Non-Coding Repressor Of NFAT	NA	NA	37079	NA	NA	NA	-	3059	chr9:126,407,773-126,410,831	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
401	Klinefelters syndrome	PCA3	Prostate Cancer Associated 3	NA	NA	8637	NA	NA	NA	+	171328 	chr9:76,691,980-76,863,307	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
402	Klinefelters syndrome	PCAT1	Prostate Cancer Associated Transcript 1	NA	NA	43022	NA	NA	NA	+	866589 	chr8:126,552,462-127,419,050	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
403	Klinefelters syndrome	PCGEM1	PCGEM1 Prostate-Specific Transcript	NA	NA	30145	NA	NA	NA	+	34945 	chr2:192,749,008-192,783,952	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
404	Klinefelters syndrome	PDZRN3-AS1	PDZRN3 Antisense RNA 1	NA	NA	40814	NA	NA	NA	+	6701 	chr3:73,621,712-73,628,412	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
405	Klinefelters syndrome	PICSAR	P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA	NA	NA	19725	NA	NA	NA	-	5522 	chr21:44,999,207-45,004,728	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
406	Klinefelters syndrome	PINK1-AS	PINK1 Antisense RNA	NA	NA	38872	NA	NA	NA	-	9538 	chr1:20,642,656-20,652,193	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
407	Klinefelters syndrome	PISRT1	PISRT1 LncRNA	NA	NA	16671	NA	NA	NA	-	532 	chr3:139,232,991-139,233,522	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
408	Klinefelters syndrome	PPP3CB	Protein Phosphatase 3 Catalytic Subunit Beta	NA	NA	9315	NA	NA	NA	-	59592 	chr10:73,436,433-73,496,024	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
409	Klinefelters syndrome	PRINS	Psoriasis Associated Non-Protein Coding RNA Induced By Stress	NA	NA	34235	NA	NA	NA	NA	NA	chr10:-	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
410	Klinefelters syndrome	PSORS1C3	Psoriasis Susceptibility 1 Candidate 3	NA	NA	17203	NA	NA	NA	-	26270 	chr6:31,171,608-31,197,877	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
411	Klinefelters syndrome	PTCSC1	Papillary Thyroid Carcinoma Susceptibility Candidate 1	NA	NA	37127	NA	NA	NA	+	2810 	chr8:133,054,958-133,057,767	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
412	Klinefelters syndrome	PVT1	Pvt1 Oncogene	NA	NA	 9709	NA	NA	NA	+	393690 	chr8:127,794,522-128,188,211	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
413	Klinefelters syndrome	RMST	Rhabdomyosarcoma 2 Associated Transcript	NA	NA	29893	NA	NA	NA	+	413200 	chr12:97,430,633-97,843,832	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
414	Klinefelters syndrome	RN7SK	RNA Component Of 7SK Nuclear Ribonucleoprotein	NA	NA	10037	NA	NA	NA	+	349 	chr6:52,995,603-52,995,951	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
415	Klinefelters syndrome	RN7SL1	RNA Component Of Signal Recognition Particle 7SL1	NA	NA	10038	NA	NA	NA	+	302 	chr14:49,586,580-49,586,881	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
416	Klinefelters syndrome	RRP1B	Ribosomal RNA Processing 1B	NA	NA	23818	NA	NA	NA	+	36520 	chr21:43,659,560-43,696,079	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
417	Klinefelters syndrome	SCAANT1	SCA7/ATXN7 Antisense RNA 1 	NA	NA	43718	NA	NA	NA	-	1761 	chr3:63,911,338-63,913,098	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
418	Klinefelters syndrome	SNHG11	Small Nucleolar RNA Host Gene 11	NA	NA	25046	NA	NA	NA	+	4598 	chr20:38,446,343-38,450,940	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
419	Klinefelters syndrome	SNHG3	Small Nucleolar RNA Host Gene 3	NA	NA	10118	NA	NA	NA	+	4951 	chr1:28,505,942-28,510,892	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
420	Klinefelters syndrome	SNHG4	Small Nucleolar RNA Host Gene 4	NA	NA	32964	NA	NA	NA	+	42374 	chr5:139,273,751-139,316,124	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
421	Klinefelters syndrome	SNHG5	Small Nucleolar RNA Host Gene 5	NA	NA	21026	NA	NA	NA	-	28757 	chr6:85,650,491-85,679,247	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
422	Klinefelters syndrome	SOX2OT	TCONS_00007597;TCONS_00020726	NA	NA	20209	ENSMUST00000197977.1	mouse	NONMMUT042524.2	+	2970	chr3:181,711,925-181,714,436	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
423	Klinefelters syndrome	SPRY4-IT1	SPRY4 Intronic Transcript 1	NA	NA	42394	NA	NA	NA	-	704 	chr5:142,317,619-142,318,322	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
424	Klinefelters syndrome	SRA1	Steroid Receptor RNA Activator 1	NA	NA	11281	NA	NA	NA	-	20913 	chr5:140,537,340-140,558,252	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
425	Klinefelters syndrome	TCL6	T Cell Leukemia/Lymphoma 6	NA	NA	13463	NA	NA	NA	+	29336 	chr14:95,650,498-95,679,833	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
426	Klinefelters syndrome	TDRG1	Testis Development Related 1	NA	NA	43642	NA	NA	NA	+	101805 	chr6:40,285,786-40,387,590	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
427	Klinefelters syndrome	TERC	Telomerase RNA Component 	NA	NA	11727	NA	NA	NA	-	599 	chr3:169,764,462-169,765,060	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
428	Klinefelters syndrome	TRAF3IP2-AS1	TRAF3IP2 Antisense RNA 1	NA	NA	40005	NA	NA	NA	+	119222 	chr6:111,483,074-111,602,295	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
429	Klinefelters syndrome	TUG1	Taurine Up-Regulated 1	NA	NA	26066	NA	NA	NA	+	16069 	chr22:30,969,157-30,985,225	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
430	Klinefelters syndrome	TUSC7	Tumor Suppressor Candidate 7	NA	NA	27701	NA	NA	NA	+	80969 	chr3:116,642,614-116,723,582	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
431	Klinefelters syndrome	UCA1	Urothelial Cancer Associated 1	NA	NA	37126	NA	NA	NA	+	9562 	chr19:15,828,205-15,837,766	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
432	Klinefelters syndrome	WRAP53	WD Repeat Containing Antisense To TP53	NA	NA	25522	NA	NA	NA	+	17432 	chr17:7,686,071-7,703,502	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
433	Klinefelters syndrome	WT1-AS	WT1 Antisense RNA	NA	NA	18135	ENST00000395900.1	human	NONHSAG007984.3	+	26101 	chr11:32,434,075-32,460,175	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
434	Klinefelters syndrome	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	0	1	0	0	Genotyping	NA	NA	NA	18854511	NA	NA	NA	NA	LncRNADisease v2.0	Testis
435	Klinefelters syndrome	ZFAS1	WD Repeat Containing Antisense To TP53	NA	NA	33101	ENST00000441722.4	human	NONHSAT080209.2	+	84394 	chr20:49,276,738-49,361,131	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
436	Klinefelters syndrome	ZFAT-AS1	ZFAT Antisense RNA 1	NA	NA	33992	NA	NA	NA	+	2740 	chr8:134,598,071-134,600,810	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	Testis
437	Obesity	AIRN	Antisense Of IGF2R Non-Protein Coding RNA	NA	NA	34515	NA	NA	NA	-	4375 	chr6:160,003,290-160,007,664	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
438	Obesity	ATP6V1G2-DDX39B	ATP6V1G2-DDX39B Readthrough (NMD Candidate)	NA	NA	41999	NA	NA	NA	-	16631	chr6:31,530,218-31,546,848	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
439	Obesity	ATXN8OS	ATXN8 Opposite Strand LncRNA	NA	NA	10561	NA	NA	NA	+	92821	chr13:70,078,918-70,171,738	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
440	Obesity	BACE1-AS	BACE1 Antisense RNA	NA	NA	37125	NA	NA	NA	+	5119	chr11:117,288,453-117,293,571	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
441	Obesity	BCAR4	Breast Cancer Anti-Estrogen Resistance 4	NA	NA	22170	NA	NA	NA	-	10554	chr16:11,818,292-11,828,845	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
442	Obesity	BCYRN1	Brain Cytoplasmic RNA 1	NA	NA	1022	NA	NA	NA	+	18661	chr2:47,325,857-47,344,517	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
443	Obesity	BDNF-AS1	BDNF Antisense RNA	NA	NA	20608	NA	NA	NA	+	191419	chr11:27,506,830-27,698,248	0	1	0	0	Genotyping	NA	Mutation	Association identified by GWAS (rs4074134,A118887G).	19079260	NA	NA	NA	NA	LncRNADisease v2.0	NA
444	Obesity	BPESC1	Blepharophimosis, Epicanthus Inversus And Ptosis Candidate 1	NA	NA	13228	NA	NA	NA	+	20988 	chr3:139,104,184-139,125,171	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
445	Obesity	CASC2	Cancer Susceptibility 2	NA	NA	22933	NA	NA	NA	+	170235	chr10:118,045,862-118,216,096	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
446	Obesity	CBR3-AS1	CBR3 Antisense RNA 1	NA	NA	43664	NA	NA	NA	-	145856 	chr21:36,130,371-36,276,226	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
447	Obesity	CDKN2B-AS1	CDKN2B Antisense RNA 1	NA	NA	34341	NA	NA	NA	+	244984 	chr9:21,994,139-22,239,122	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
448	Obesity	CECR3	Cat Eye Syndrome Chromosome Region, Candidate 3	NA	NA	1841	NA	NA	NA	-	9877 	chr22:17,256,858-17,266,734	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
449	Obesity	CECR9	Cat Eye Syndrome Chromosome Region, Candidate 9	NA	NA	1847	NA	NA	NA	+	200 	chr22:17,329,033-17,329,232	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
450	Obesity	CHL1-AS2	CHL1 Antisense RNA 2	NA	NA	40147	NA	NA	NA	-	87636 	chr3:109,707-197,342	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
451	Obesity	CRNDE	Colorectal Neoplasia Differentially Expressed	NA	NA	37078	NA	NA	NA	-	85755 	chr16:54,845,188-54,930,942	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
452	Obesity	DAOA-AS1	DAOA Antisense RNA 1	NA	NA	30243	NA	NA	NA	-	48000 	chr13:105,457,683-105,505,682	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
453	Obesity	DAPK1	Death Associated Protein Kinase 1 2 3 5	NA	NA	2674	NA	NA	NA	+	211407 	chr9:87,497,228-87,708,634	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
454	Obesity	DGCR5	DiGeorge Syndrome Critical Region Gene 5	NA	NA	16757	NA	NA	NA	+	62703 	chr22:18,968,903-19,031,605	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
455	Obesity	DISC2	Disrupted In Schizophrenia 2	NA	NA	2889	NA	NA	NA	-	37933 	chr1:231,809,944-231,847,876	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
456	Obesity	DLEU1	Deleted In Lymphocytic Leukemia 1	NA	NA	13747	NA	NA	NA	+	824689 	chr13:50,082,168-50,906,856	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
457	Obesity	DLEU2	Deleted In Lymphocytic Leukemia 2	NA	NA	13748	NA	NA	NA	-	213016 	chr13:49,912,705-50,125,720	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
458	Obesity	DLG2-AS1	DLG2 Antisense RNA 1	NA	NA	37132	NA	NA	NA	NA	NA	chr11:-(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
459	Obesity	DLX6-AS1	DLX6 Antisense RNA 1	NA	NA	37151	NA	NA	NA	-	63405 	chr7:96,950,684-97,014,088	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
460	Obesity	DMPK	DM1 Protein Kinase 2 3 4 5	NA	NA	2933	NA	NA	NA	-	12844 	chr19:45,769,709-45,782,552	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
461	Obesity	DNM3OS	DNM3 Opposite Strand/Antisense RNA	NA	NA	41228	NA	NA	NA	-	16516 	chr1:172,128,631-172,145,146	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
462	Obesity	DSCAM-AS1	DSCAM Antisense RNA 1	NA	NA	40197	NA	NA	NA	+	2462 	chr21:40,382,898-40,385,359	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
463	Obesity	EPB41L4A-AS1	EPB41L4A Antisense RNA 1	NA	NA	30749	NA	NA	NA	+	4369 	chr5:112,160,450-112,164,818	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
464	Obesity	ESRG	Embryonic Stem Cell Related	NA	NA	39079	NA	NA	NA	-	20553 	chr3:54,619,661-54,640,213	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
465	Obesity	FMR1-AS1	FMR1 Antisense RNA 1	NA	NA	39081	NA	NA	NA	-	17556	chrX:147,904,603-147,922,158	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
466	Obesity	GAS5	Growth Arrest Specific 5	NA	NA	16355	NA	NA	NA	-	17723 	chr1:173,851,284-173,869,006	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
467	Obesity	GDNF-AS1	GDNF Antisense RNA 1	NA	NA	43592	NA	NA	NA	+	142240 	chr5:37,811,588-37,953,827	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
468	Obesity	GS-AS1	GNAS Antisense RNA 1	NA	NA	24872	NA	NA	NA	-	32112 	chr20:58,818,792-58,850,903	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
469	Obesity	H19	H19 Imprinted Maternally Expressed Transcript	NA	NA	4713	NA	NA	NA	-	6582 	chr11:1,995,129-2,001,710	0	1	0	0	RWRlncD	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
470	Obesity	HAR1A	Highly Accelerated Region 1A	NA	NA	33117	NA	NA	NA	+	3097 	chr20:63,101,291-63,104,387	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
471	Obesity	HAR1B	Highly Accelerated Region 1B	NA	NA	33118	NA	NA	NA	-	11826 	chr20:63,090,806-63,102,631	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
472	Obesity	HCP5	HLA Complex P5	NA	NA	21659	NA	NA	NA	+	78236 	chr6:31,400,701-31,478,936	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
473	Obesity	HIF1A-AS1	HIF1A Antisense RNA 1	NA	NA	43014	NA	NA	NA	-	18209 	chr14:61,677,633-61,695,841	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
474	Obesity	HOTAIR	HOX Transcript Antisense RNA	NA	NA	33510	NA	NA	NA	-	12651 	chr12:53,962,307-53,974,957	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
475	Obesity	HTT-AS	HTT Antisense RNA	NA	NA	37118	NA	NA	NA	-	25940 	chr4:3,048,599-3,074,538	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
476	Obesity	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	NA	NA	34232	NA	NA	NA	+	858567 	chr6:8,435,567-9,294,133	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
477	Obesity	HYMAI	Hydatidiform Mole Associated And Imprinted	NA	NA	5326	NA	NA	NA	-	121917	chr6:143,942,624-144,064,540	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
478	Obesity	IFNG-AS1	IFNG Antisense RNA 1	NA	NA	43910	NA	NA	NA	+	246137	chr12:67,989,381-68,235,517	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
479	Obesity	IGF2-AS	IGF2 Antisense RNA	NA	NA	14062	NA	NA	NA	+	8166 	chr11:2,140,501-2,148,666	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
480	Obesity	IPW	Imprinted In Prader-Willi Syndrome	NA	NA	6109	NA	NA	NA	+	5933 	chr15:25,116,544-25,122,476	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
481	Obesity	KCNQ1DN	KCNQ1 Downstream Neighbor	NA	NA	13335	NA	NA	NA	+	2075 	chr11:2,870,032-2,872,106	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
482	Obesity	KCNQ1OT1	KCNQ1 Opposite Strand/Antisense Transcript 1	NA	NA	6295	NA	NA	NA	-	102886 	chr11:2,597,113-2,699,998	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
483	Obesity	LINC00032	Long Intergenic Non-Protein Coding RNA 32	NA	NA	16506	NA	NA	NA	-	49187 	chr9:27,235,683-27,284,869	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
484	Macrosomia obesity macrocephaly ocular abnormalities	LINC00237	Long Intergenic Non-Protein Coding RNA 237	NA	NA	38166	NA	NA	NA	-	20953 	chr20:21,085,576-21,106,528	1	0	0	0	FISH//PCR	NA	Regulation	LINC00237 could play a role in the pathogenesis of this syndrome and could provide new insights into hyperphagia related obesity and intellectual disability	23034868	NA	NA	NA	NA	LncRNADisease v2.0	NA
485	Obesity	LINC00271	Long Intergenic Non-Protein Coding RNA 271	NA	NA	32526	NA	NA	NA	+	316641 	chr6:135,497,350-135,813,990	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
486	Obesity	LINC00312	Long Intergenic Non-Protein Coding RNA 312	NA	NA	6662	NA	NA	NA	+	2888 	chr3:8,571,781-8,574,668	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
487	Obesity	LINC00538	Long Intergenic Non-Protein Coding RNA 538	NA	NA	43655	NA	NA	NA	+	1907 	chr1:213,924,748-213,926,654	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
488	Obesity	LINC00901	Long Intergenic Non-Protein Coding RNA 901	NA	NA	40352	NA	NA	NA	+	21075 	chr3:116,911,324-116,932,398	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
489	Obesity	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	NA	NA	29665	NA	NA	NA	+	12820 	chr11:65,496,266-65,509,085	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
490	Obesity	MAP3K14	Mitogen-Activated Protein Kinase Kinase Kinase 14 2 3 4 5	NA	NA	6853	NA	NA	NA	-	53930 	chr17:45,263,119-45,317,048	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
491	Obesity	MEG3	Maternally Expressed 3	NA	NA	14575	NA	NA	NA	+	81623 	chr14:100,779,409-100,861,031	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
492	Obesity	MESTIT1	MEST Intronic Transcript 1, Antisense RNA	NA	NA	17991	NA	NA	NA	-	31820 	chr7:130,459,354-130,491,173	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
493	Obesity	MIAT	Myocardial Infarction Associated Transcript	NA	NA	33425	NA	NA	NA	+	30068 	chr22:26,646,411-26,676,478	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
494	Obesity	MIR100HG	Mir-100-Let-7a-2-Mir-125b-1 Cluster Host Gene	NA	NA	39522	NA	NA	NA	-	528519 	chr11:122,028,203-122,556,721	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
495	Obesity	MIR155HG	MIR155 Host Gene	NA	NA	35460	NA	NA	NA	+	22342 	chr21:25,560,398-25,582,739	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
496	Obesity	MIR17HG	MiR-17-92a-1 Cluster Host Gene	NA	NA	23564	NA	NA	NA	+	49412 	chr13:91,347,686-91,397,097	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
497	Obesity	MIR31HG	MIR31 Host Gene	NA	NA	37187	NA	NA	NA	-	152292 	chr9:21,439,475-21,591,766	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
498	Obesity	MKRN3-AS1	MKRN3 Antisense RNA 1	NA	NA	12910	NA	NA	NA	NA	NA	chr15:-(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
499	Obesity	MYCNOS	MYCN Opposite Strand	NA	NA	16911	NA	NA	NA	-	24084 	chr2:15,918,350-15,942,433	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
500	Obesity	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	NA	NA	30815	NA	NA	NA	+	33513 	chr11:65,416,581-65,450,093	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
501	Obesity	NRON	Non-Coding Repressor Of NFAT	NA	NA	37079	NA	NA	NA	-	3059	chr9:126,407,773-126,410,831	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
502	Obesity	PCA3	Prostate Cancer Associated 3	NA	NA	8637	NA	NA	NA	+	171328 	chr9:76,691,980-76,863,307	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
503	Obesity	PCAT1	Prostate Cancer Associated Transcript 1	NA	NA	43022	NA	NA	NA	+	866589 	chr8:126,552,462-127,419,050	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
504	Obesity	PCGEM1	PCGEM1 Prostate-Specific Transcript	NA	NA	30145	NA	NA	NA	+	34945 	chr2:192,749,008-192,783,952	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
505	Obesity	PDZRN3-AS1	PDZRN3 Antisense RNA 1	NA	NA	40814	NA	NA	NA	+	6701 	chr3:73,621,712-73,628,412	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
506	Obesity	PICSAR	P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA	NA	NA	19725	NA	NA	NA	-	5522 	chr21:44,999,207-45,004,728	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
507	Obesity	PINK1-AS	PINK1 Antisense RNA	NA	NA	38872	NA	NA	NA	-	9538 	chr1:20,642,656-20,652,193	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
508	Obesity	PISRT1	PISRT1 LncRNA	NA	NA	16671	NA	NA	NA	-	532 	chr3:139,232,991-139,233,522	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
509	Obesity	PPP3CB	Protein Phosphatase 3 Catalytic Subunit Beta	NA	NA	9315	NA	NA	NA	-	59592 	chr10:73,436,433-73,496,024	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
510	Obesity	PRINS	Psoriasis Associated Non-Protein Coding RNA Induced By Stress	NA	NA	34235	NA	NA	NA	NA	NA	chr10:-(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
511	Obesity	PSORS1C3	Psoriasis Susceptibility 1 Candidate 3	NA	NA	17203	NA	NA	NA	-	26270 	chr6:31,171,608-31,197,877	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
512	Obesity	PTCSC1	Papillary Thyroid Carcinoma Susceptibility Candidate 1	NA	NA	37127	NA	NA	NA	+	2810 	chr8:133,054,958-133,057,767	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
513	Obesity	PVT1	Pvt1 Oncogene	NA	NA	9709	NA	NA	NA	+	393690 	chr8:127,794,522-128,188,211	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
514	Obesity	RMST	Rhabdomyosarcoma 2 Associated Transcript	NA	NA	29893	NA	NA	NA	+	413200	chr12:97,430,633-97,843,832	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
515	Obesity	RN7SK	RNA Component Of 7SK Nuclear Ribonucleoprotein	NA	NA	10037	NA	NA	NA	+	338 	chr6:52,995,614-52,995,951	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
516	Obesity	RN7SL1	RNA Component Of Signal Recognition Particle 7SL1	NA	NA	10038	NA	NA	NA	+	304	chr14:49,586,578-49,586,881	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
517	Obesity	RRP1B	Ribosomal RNA Processing 1B 2 3 5	NA	NA	23818	NA	NA	NA	+	36520	chr21:43,659,560-43,696,079	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
518	Obesity	SCAANT1	SCA7/ATXN7 Antisense RNA 1	NA	NA	43718	NA	NA	NA	-	1761	chr3:63,911,338-63,913,098	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
519	Obesity	SNHG11	Small Nucleolar RNA Host Gene 11	NA	NA	25046	NA	NA	NA	+	4598 	chr20:38,446,343-38,450,940	0	1	0	0	RWRlncD	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
520	Obesity	SNHG3	Small Nucleolar RNA Host Gene 3	NA	NA	10118	NA	NA	NA	+	4951 	chr1:28,505,942-28,510,892	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
521	Obesity	SNHG4	Small Nucleolar RNA Host Gene 4	NA	NA	32964	NA	NA	NA	+	42374 	chr5:139,273,751-139,316,124	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
522	Obesity	SNHG5	Small Nucleolar RNA Host Gene 5	NA	NA	21026	NA	NA	NA	-	28757 	chr6:85,650,491-85,679,247	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
523	Obesity	SOX2OT	TCONS_00007597;TCONS_00020726	NA	NA	20209	ENSMUST00000197977.1	mouse	NONMMUT042524.2	+	2970	chr3:181,711,925-181,714,436	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
524	Obesity	SPRY4-IT1	SPRY4 Intronic Transcript 1	NA	NA	42394	NA	NA	NA	-	704 	chr5:142,317,619-142,318,322	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
525	Obesity	SRA1	Steroid Receptor RNA Activator 1 2 3 4 5	NA	NA	11281	NA	NA	NA	-	20913 	chr5:140,537,340-140,558,252	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
526	Obesity	TCL6	T Cell Leukemia/Lymphoma 6	NA	NA	13463	NA	NA	NA	+	29336 	chr14:95,650,498-95,679,833	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
527	Obesity	TDRG1	Testis Development Related 1	NA	NA	43642	NA	NA	NA	+	101805 	chr6:40,285,786-40,387,590	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
528	Obesity	TERC	Telomerase RNA Component 	NA	NA	11727	NA	NA	NA	-	599 	chr3:169,764,462-169,765,060	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
529	Obesity	TRAF3IP2-AS1	TRAF3IP2 Antisense RNA 1	NA	NA	40005	NA	NA	NA	+	119222 	chr6:111,483,074-111,602,295	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
530	Obesity	TUG1	Taurine Up-Regulated 1	NA	NA	26066	NA	NA	NA	+	16069 	chr22:30,969,157-30,985,225	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
531	Obesity	TUSC7	Tumor Suppressor Candidate 7	NA	NA	27701	NA	NA	NA	+	80969 	chr3:116,642,614-116,723,582	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
532	Obesity	UCA1	Urothelial Cancer Associated 1	NA	NA	37126	NA	NA	NA	+	9562 	chr19:15,828,205-15,837,766	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
533	Obesity	WRAP53	WD Repeat Containing Antisense To TP53	NA	NA	25522	NA	NA	NA	+	17432 	chr17:7,686,071-7,703,502	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
534	Obesity	WT1-AS	WT1 Antisense RNA	NA	NA	18135	ENST00000395900.1	human	NONHSAG007984.3	+	26101 	chr11:32,434,075-32,460,175	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
535	Obesity	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
536	Obesity	ZFAS1	WD Repeat Containing Antisense To TP53	NA	NA	33101	ENST00000441722.4	human	NONHSAT080209.2	+	84394 	chr20:49,276,738-49,361,131	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
537	Obesity	ZFAT-AS1	ZFAT Antisense RNA 1	NA	NA	33992	NA	NA	NA	+	2740 	chr8:134,598,071-134,600,690	0	1	0	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
538	Gout 	ENST00000566457	Novel Transcript, Overlapping To EGR3	NA	NA	NA	NA	NA	NA	-	4998 	chr8:22,679,012-22,684,009	1	0	0	0	lncRNA microarrays	NA	up-regulated	TCONS_00004393 and ENST00000566457 might be as candidate targets for the treatment of gout flare; ENST00000566457 and NR-026756 could effectively discriminate between the gout and the healthy control groups.	33600466	NA	NA	NA	NA	LncRNADisease v2.0	Joint
539	Type 2 diabetes mellitus	TCONS_00027491	NA	NA	NA	NA	NA	NA	NA	+	818	chr3:195710448-195711581	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 20 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
540	Type 2 diabetes mellitus	TCONS_00019755	NA	NA	NA	NA	NA	NA	NA	-	399	chr19:28960505-28964943	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 21 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
541	Type 2 diabetes mellitus	ENST00000529323	RRM1-AS1	NA	NA	40512	NA	NA	NA	-	346	chr11:4137115-4138257	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 22 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
542	Type 2 diabetes mellitus	TCONS_00000856	LINC01361	NA	NA	50595	NA	NA	NA	-	1523	chr1:82973881-82986208	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 24 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
543	Type 2 diabetes mellitus	ENST00000420452	MYCNOS	NA	NA	16911	NA	NA	NA	-	1454	chr2:15936264-15941723	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 25 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
544	Type 2 diabetes mellitus	TCONS_00004576	NA	NA	NA	NA	NA	NA	NA	+	1375	chr24:1180160-1181698	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 26 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
545	Type 2 diabetes mellitus	NR_027471	LOC440173	NA	NA	NA	NA	NA	NA	-	2016	chr9:87008450-87042126	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 27 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
546	Type 2 diabetes mellitus	ENST00000500180	LOC101927657	NA	NA	NA	NA	NA	NA	+	1422	chr8:126325494-126329535	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 28 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
547	Type 2 diabetes mellitus	ENST00000568384	TCONS_00026510	NA	NA	NA	NA	NA	NA	-	1946	chr3:134347287-134349233	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 29 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
548	Type 2 diabetes mellitus	ENST00000412228	TCONS_00000023	NA	NA	NA	NA	NA	NA	+	921	chr1:1891470-1892673	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 30 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
549	Type 2 diabetes mellitus	ENST00000563052	NA	NA	NA	NA	NA	NA	NA	-	679	chr16:27708425-27718776	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 31 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
550	Type 2 diabetes mellitus	ENST00000559786	NA	NA	NA	NA	NA	NA	NA	+	1988	chr19:42152535-42157523	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 32 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
551	Type 2 diabetes mellitus	ENST00000484046	TM4SF1-AS1	NA	NA	40587	NA	NA	NA	+	931	chr3:149377777-149386584	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 34 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
552	Type 2 diabetes mellitus	ENST00000554032	NA	NA	NA	NA	NA	NA	NA	NA	20641	chr14:70809841-70830482	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 35 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
553	Type 2 diabetes mellitus	ENST00000448433	TDRG1	NA	NA	43642	NA	NA	NA	+	1015	chr6:40378336-40379885	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 36 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
554	Type 2 diabetes mellitus	ENST00000434790	NA	NA	NA	NA	NA	NA	NA	-	388	chr2:88818273-88825207	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 37 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
555	Type 2 diabetes mellitus	TCONS_00018389	NA	NA	NA	NA	NA	NA	NA	+	424	chr19:24049450-24057965	1	0	1	0	RT-qPCR	NA	up-regulated	Expression of the top 38 upregulated lncRNAs in the three groups.	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
556	Type 2 diabetes mellitus	GHRLOS	NCRNA00068 GHRL-AS1	NA	NA	33885	NA	NA	NA	+	1765	chr3:10280951-10293449	1	0	1	0	RT-qPCR	NA	down-regulated	Expression of the top 26 downregulated lncRNAs in the three groups	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
557	Type 2 diabetes mellitus	AC022596.2	NA	NA	NA	NA	NA	NA	NA	+	3115	chr17:16,861,109-16,864,223	1	0	1	0	RT-qPCR	NA	down-regulated	Expression of the top 27 downregulated lncRNAs in the three groups	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
558	Type 2 diabetes mellitus	LINC00511	NA	NA	NA	43564	NA	NA	NA	-	2265	chr17:72598040-72640471	1	0	1	0	RT-qPCR	NA	down-regulated	Expression of the top 39 downregulated lncRNAs in the three groups	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	E11	9352	pubmed	NA
559	Type 2 diabetes mellitus	ENST00000588707	GTF3C2-AS1	NA	NA	40269	NA	NA	NA	+	607	chr2:27337222-27340824	1	0	1	0	RT-qPCR	NA	down-regulated	 Compared with the control group, the expression levels of the GCKR gene and  lncRNA ENST00000588707.1 and TCONS_00004187 in the T2DM group were significantly lower	31756311	2019	Association Between lncRNA and GCKR Gene in Type 2 Diabetes Mellitus	E11	9352	pubmed	NA
560	Type 2 diabetes mellitus	TCONS_00004187	NA	NA	NA	NA	NA	NA	NA	+	444	chr10:91103167-91112614	1	0	1	0	RT-qPCR	NA	down-regulated	 Compared with the control group, the expression levels of the GCKR gene and  lncRNA ENST00000588707.1 and TCONS_00004187 in the T3DM group were significantly lower	31756311	2019	Association Between lncRNA and GCKR Gene in Type 3 Diabetes Mellitus	E11	9352	pubmed	NA
561	Type 2 diabetes mellitus	MALAT1	LINC00047	NA	NA	29665	NA	NA	NA	+	12819	chr11:65496266-65509085	1	0	1	0	RT-qPCR	NA	down-regulated	Relative lncRNA-MALAT1 expression levels were 45% or 44% lower in the T2D group than in the control group for serum and serum exosomes respectively.	32783409	2020	Altered levels of MALAT1 and H19 derived from serum or serum exosomes associated with type-2 diabetes	E11	9352	pubmed	NA
562	Type 2 diabetes mellitus	AK139328	NA	NA	NA	NA	NA	NA	NA	+	3128	chr2:96525105-96528233	1	0	1	0	RT-qPCR	NA	up-regulated	The results of RT‐qPCR assay showed that lncRNA AK139328 was most up‐regulated in DM compared with other lncRNAs	30047214	2018	Knockdown of lncRNA AK139328 alleviates myocardial ischaemia/reperfusion injury in diabetic mice via modulating miR‐204‐3p and inhibiting autophagy	E11	9352	pubmed	NA
563	Type 2 diabetes mellitus	NONMMUT034373	NA	NA	NA	NA	NA	NA	NA	+	3114	chr:1929367459-29370573	1	0	1	0	RT-qPCR	NA	up-regulated	NA	31221822	2019	Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease	E11	9352	pubmed	NA
564	Type 2 diabetes mellitus	GAS5	NR_152521	NA	NA	16355	NA	NA	NA	-	4892	chr1:173863901-173868882	1	0	1	0	RT-qPCR	NA	down-regulated	GAS5 expression was decreased in HG-induced HK-2 cells	31849505	2019	lncRNA GAS5/miR-452-5p Reduces Oxidative Stress and Pyroptosis of High-Glucose-Stimulated Renal T ubular Cells	E11	9352	pubmed	NA
565	Type 2 diabetes mellitus	LINC-PINT	FLJ43663	NA	NA	26885	NA	NA	NA	-	3257	chr7:130944159-131109916	1	0	1	0	RT-qPCR	NA	down-regulated	A comparison was made in this study, where LINC-PINT did not experience significant downregulation level in  the majority of those suffering diabetes complications when in contrast to healthy controls, while LINC-PINT  expression was found in diabetics.	32346662	2020	Role of Long Non-Coding RNA (LncRNA) LINC-PINT Downregulation in Cardiomyopathy and Retinopathy Progression Among Patients with Type 2 Diabetes	E11	9352	pubmed	NA
566	Type 2 diabetes mellitus	AP001432.1	NA	NA	NA	NA	NA	NA	NA	+	16236	chr21:38,593,720-38,610,045	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
567	Type 2 diabetes mellitus	AC092134.1	NA	NA	NA	NA	NA	NA	NA	-	22088	chr16:77,741,468-77,763,555	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
568	Type 2 diabetes mellitus	ZNF295-AS1 	NA	NA	NA	23130	NA	NA	NA	+	45943	chr21:42,009,188-42,055,130	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
569	Type 2 diabetes mellitus	AL353898.3 	NA	NA	NA	NA	NA	NA	NA	NA	1755	chr1:54,033,126-54,034,880	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
570	Type 2 diabetes mellitus	LINC01230	lnc-DRMT2	NA	NA	49686	NA	NA	NA	+	3817	chr9:1,045,426-1,049,242	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
571	Type 2 diabetes mellitus	Z95114.3	NA	NA	NA	NA	NA	NA	NA	NA	1921	chr22:36,137,430-36,139,350	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
572	Type 2 diabetes mellitus	SI3-AS1 	MGC23284	NA	NA	28327	NA	NA	NA	+	23981	chr16:88,663,298-88,687,278	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
573	Type 2 diabetes mellitus	LINC02015 	NA	NA	NA	52850	NA	NA	NA	NA	100472	chr3:177,816,865-177,917,336	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
574	Type 2 diabetes mellitus	AC121247.1 	NA	NA	NA	NA	NA	NA	NA	NA	108	chr3:49,270,132-49,270,239	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
575	Type 2 diabetes mellitus	AL079343.1 	NA	NA	NA	NA	NA	NA	NA	NA	1771	chr14:26,592,747-26,594,517	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
576	Type 2 diabetes mellitus	AL355816.2	Lnc-DENND2D-1	NA	NA	NA	NA	NA	NA	-	647	chr1:111,184,415-111,185,061	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
577	Type 2 diabetes mellitus	FLG-AS1	NA	NA	NA	27913	NA	NA	NA	+	2857	chr1:152337067-152366692	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
578	Type 2 diabetes mellitus	LINC01239 	NA	NA	NA	49796	NA	NA	NA	+	2349	chr9：22646197-22824213	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
579	Type 2 diabetes mellitus	AC008147.2	NA	NA	NA	NA	NA	NA	NA	+	5784	chr12:50,185,580-50,191,363	1	0	1	0	RT-qPCR	NA	down-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
580	Type 2 diabetes mellitus	EMX2OS 	NCRNA00045	NA	NA	18511	NA	NA	NA	-	74268	chr10:117,470,801-117,545,068	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
581	Type 2 diabetes mellitus	AC017002.1 	NA	NA	NA	NA	NA	NA	NA	+	4819	chr2:111,607,700-111,612,518	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
582	Type 2 diabetes mellitus	AL031429.1 	NA	NA	NA	NA	NA	NA	NA	+	4115	chr1:70,947,379-70,951,493	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
583	Type 2 diabetes mellitus	LINC00968 	NA	NA	NA	48727	NA	NA	NA	-	2520	chr8:56518318-56559823	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
584	Type 2 diabetes mellitus	AL359091.4 	NA	NA	NA	NA	NA	NA	NA	NA	409	chr9:128,431,598-128,432,006	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
585	Type 2 diabetes mellitus	AP000892.3 	NA	NA	NA	NA	NA	NA	NA	NA	324	chr11:117,297,005-117,297,328	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
586	Type 2 diabetes mellitus	AC025580.2 	NA	NA	NA	NA	NA	NA	NA	+	7475	chr15:45430610-45556730	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
587	Type 2 diabetes mellitus	LINC01173 	NA	NA	NA	49545	NA	NA	NA	+	646	chr2:234682692-234723472	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
588	Type 2 diabetes mellitus	LINC01503 	lnc-PPP2R4-5	NA	NA	51184	NA	NA	NA	+	5853	chr9:129332299-129359711	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
589	Type 2 diabetes mellitus	AC079298.3 	NA	NA	NA	NA	NA	NA	NA	+	5919	chr4:154137221-154298819	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
590	Type 2 diabetes mellitus	AC124276.2 	Lnc-MICAL2-1	NA	NA	NA	NA	NA	NA	+	1570	chr11:12086890-12089761	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
591	Type 2 diabetes mellitus	LINC01705 	RP11-400N13.3	NA	NA	52493	NA	NA	NA	-	565	chr1:222041704-222064764	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
592	Type 2 diabetes mellitus	AP000879.1	Lnc-SHANK2-5	NA	NA	NA	NA	NA	NA	-	1634	chr11:70206128-70208988	1	0	1	0	RT-qPCR	NA	up-regulated	 The significant DElncRNAs in T2DM with obesity.	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	E11	9352	pubmed	NA
593	Type 2 diabetes mellitus	ENST00000588058.1	DAB1-AS1	NA	NA	49443	NA	NA	NA	+	755	chr1:57862454-57878465	1	0	1	0	RT-qPCR	NA	up-regulated	14 lncRNAs of these were upregulated in T2DM patients and 3 were downregulated.	28407663	2017	The Diagnostic Value of Whole Blood lncRNA ENST00000550337.1 for Pre-Diabetes and Type 2 Diabetes Mellitus	E11	9352	pubmed	NA
594	Type 2 diabetes mellitus	TCONS_00000886	NA	NA	NA	NA	NA	NA	NA	+	423	chr1:100264008-100266120	1	0	1	0	RT-qPCR	NA	up-regulated	15 lncRNAs of these were upregulated in T2DM patients and 3 were downregulated.	28407663	2017	The Diagnostic Value of Whole Blood lncRNA ENST00000550337.1 for Pre-Diabetes and Type 2 Diabetes Mellitus	E11	9352	pubmed	NA
595	Type 2 diabetes mellitus	TCONS_00007244	NA	NA	NA	NA	NA	NA	NA	+	565	chr12:22699858-22888043	1	0	1	0	RT-qPCR	NA	up-regulated	16 lncRNAs of these were upregulated in T2DM patients and 3 were downregulated.	28407663	2017	The Diagnostic Value of Whole Blood lncRNA ENST00000550337.1 for Pre-Diabetes and Type 2 Diabetes Mellitus	E11	9352	pubmed	NA
596	Type 2 diabetes mellitus	ENST00000550337.1	LINC02402 	NA	NA	53329	NA	NA	NA	-	1212	chr12:42615502-42646498	1	0	1	0	RT-qPCR	NA	up-regulated	17 lncRNAs of these were upregulated in T2DM patients and 3 were downregulated.	28407663	2017	The Diagnostic Value of Whole Blood lncRNA ENST00000550337.1 for Pre-Diabetes and Type 2 Diabetes Mellitus	E11	9352	pubmed	NA
597	Type 2 diabetes mellitus	ENST00000512246.1	HAND2-AS1	NA	NA	48872	NA	NA	NA	+	867	chr4:173530457-173541931	1	0	1	0	RT-qPCR	NA	up-regulated	18 lncRNAs of these were upregulated in T2DM patients and 3 were downregulated.	28407663	2017	The Diagnostic Value of Whole Blood lncRNA ENST00000550337.1 for Pre-Diabetes and Type 2 Diabetes Mellitus	E11	9352	pubmed	NA
598	Type 2 diabetes mellitus	ARAP1	NA	NA	NA	16925	NA	NA	NA	NA	108531	chr11:72,685,069-72,793,599	1	0	1	0	RT-qPCR	NA	up-regulated	We found increased expression of ARAP1‐AS2 and ARAP1 in HK‐2 cells under HG condition, and observed that the overexpression of ARAP1‐AS2 significantly increased the EMT process	31975379	2020	The effect of lncRNA‐ARAP1‐AS2/ARAP1 on high glucose‐induced cytoskeleton rearrangement and epithelial–mesenchymal transition in human renal tubular epithelial cells	E11	9352	pubmed	NA
599	Type 2 diabetes mellitus	ARAP1-AS2	NA	NA	NA	39994	NA	NA	NA	+	1826	chr11:72700473-72705608	1	0	1	0	RT-qPCR	NA	up-regulated	We found increased expression of ARAP1‐AS2 and ARAP1 in HK‐2 cells under HG condition, and observed that the overexpression of ARAP1‐AS3 significantly increased the EMT process	31975379	2020	The effect of lncRNA‐ARAP1‐AS2/ARAP2 on high glucose‐induced cytoskeleton rearrangement and epithelial–mesenchymal transition in human renal tubular epithelial cells	E11	9352	pubmed	NA
600	Type 2 diabetes mellitus	VIM-AS1	NA	NA	NA	44879	NA	NA	NA	-	2302	chr10:17159153-17202054	1	0	1	0	RT-qPCR	NA	down-regulated	Our results display that decreased levels of VIM‐AS1 and CTBP1‐AS2 in PBMC were associated with diabetes in Iranian population.	30506719	2019	Clinical significance of long noncoding RNA VIM‐AS1 and CTBP1‐AS2 expression in type 2 diabetes	E11	9352	pubmed	NA
601	Type 2 diabetes mellitus	CTBP1-AS2	CTBP1-DT	NA	NA	28307	NA	NA	NA	+	13310	chr4:1248916-1288291	1	0	1	0	RT-qPCR	NA	down-regulated	Our results display that decreased levels of VIM‐AS1 and CTBP1‐AS3 in PBMC were associated with diabetes in Iranian population.	30576019	2019	Clinical significance of long noncoding RNA VIM‐AS1 and CTBP1‐AS2 expression in type 2 diabetes	E11	9352	pubmed	NA
602	Type 2 diabetes mellitus	H19	LINC00008	NA	NA	4713	NA	NA	NA	-	3119	chr11:1995129-20001710	1	0	1	0	RT-qPCR	NA	down-regulated	H19 is highly expressed in skeletal muscle confirming previous reports	30201684	2018	H19 lncRNA promotes skeletal muscle insulin sensitivity in part by targeting AMPK  	E11	9352	pubmed	NA
603	Type 2 diabetes mellitus	MEG8	LINC00024	NA	NA	14574	NA	NA	NA	+	498	chr14:100894769-100906968	1	0	1	0	RT-qPCR	NA	up-regulated	MEG8 and miR-770-5p were upregulated in plasma of DM patients and were further upregulated in DN patients.	32765026	2020	lncRNA MEG8 Upregulates miR-770-5p Through Methylation and Promotes Cell Apoptosis in Diabetic Nephropathy	E11	9352	pubmed	NA
604	Type 2 diabetes mellitus	MIAT	LINC00066	NA	NA	33425	NA	NA	NA	+	2123	chr22:26792255-26794378	1	0	1	0	RT-qPCR	NA	up-regulated	 MALAT1 and MIAT were upregulated in CAD patients	32447981	2020	Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus	E11	9352	pubmed	NA
605	Type 2 diabetes mellitus	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	RT-qPCR	NA	up-regulated	 MALAT1 and MIAT were upregulated in CAD patients	32447981	2020	Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus	E11	9352	pubmed	NA
606	Type 2 diabetes mellitus	PRINS	Psoriasis Associated Non-Protein Coding RNA Induced By Stress	NA	NA	34235	NA	NA	NA	+	2192	chr10:24247124-24256046	1	0	1	0	RT-qPCR	NA	up-regulated	Expression level of PRINS increases in patients with diabetes	30936994	2019	LncRNA PRINS is involved in the development of nephropathy in patients with diabetes via interaction with Smad7	E11	9352	pubmed	NA
607	Type 2 diabetes mellitus	MEG3	LINC00023	NA	NA	14575	NA	NA	NA	+	23054	chr14:100779409-100861029	1	0	1	0	RT-qPCR	NA	up-regulated	Meg3 expression is decreased in type 1 and type 2 diabetic mice. 	273335687	2016	Long non-coding RNA-mediated  regulation of glucose homeostasis and diabetes	E11	9352	pubmed	NA
608	Type 2 diabetes mellitus	SRA	SLIRP	NA	NA	20495	NA	NA	NA	+	787	chr14:77696590-77697377	1	0	1	0	RT-qPCR	NA	up-regulated	 In mature  adipocytes, SRA increases insulin receptor  transcription and expression and leads to  increased insulin signaling	273335687	2016	Long non-coding RNA-mediated  regulation of glucose homeostasis and diabetes	E11	9352	pubmed	NA
609	Type 2 diabetes mellitus	NEAT1	LINC00084	NA	NA	30815	NA	NA	NA	+	22744	chr11:65422796-65445540	1	0	1	0	RT-qPCR	NA	up-regulated	After transfection of miR181b mimics into HL7720 cells, we found that miR-181b level increased  while NEAT1 level decreased	28643459	2017	Construction of competitive endogenous RNA network reveals regulatory role of long non-coding RNAs in type 2 diabetes mellitus	E11	9352	pubmed	NA
610	Type 2 diabetes mellitus	PVT1	LINC00079	NA	NA	9709	NA	NA	NA	+	11748	chr8:127794532-128101257	1	0	1	0	RT-qPCR	NA	down-regulated	 SP1 and lncRNA PVT1 were up-regulated in the high glucose-administrated HLE B-3	31755246	2019	SP1-mediated lncRNA PVT1 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract via  miR-214-3p/MMP2 axis	E11	9352	pubmed	NA
611	Type 2 diabetes mellitus	ENST00000364558	RN7SKP71	NA	NA	45795	NA	NA	NA	+	318	chr12:112267076-112267394	1	0	1	0	RT-qPCR	NA	up-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
612	Type 2 diabetes mellitus	ENST00000608916	AC073529.1	NA	NA	NA	NA	NA	NA	-	567	chrX:11038538-11111141	1	0	1	0	RT-qPCR	NA	up-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
613	Type 2 diabetes mellitus	ENST00000425189	DBH-AS1	NA	NA	24155	NA	NA	NA	-	2139	chr9:133654586-133657314	1	0	1	0	RT-qPCR	NA	up-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
614	Type 2 diabetes mellitus	ENST00000499762	A2M-AS1	NA	NA	27057	NA	NA	NA	+	2187	chr12:9065177-9068056	1	0	1	0	RT-qPCR	NA	up-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
615	Type 2 diabetes mellitus	ENST00000565382	AC040169.1	NA	NA	NA	NA	NA	NA	+	521	chr16:84117050-84117571	1	0	1	0	RT-qPCR	NA	down-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
616	Type 2 diabetes mellitus	ENST00000424044	FLVCR1-DT	NA	NA	39077	NA	NA	NA	-	3096	chr1:212852108-212858089	1	0	1	0	RT-qPCR	NA	down-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
617	Type 2 diabetes mellitus	ENST00000432511	LINC01136	NA	NA	49452	NA	NA	NA	-	2741	chr1:203298757-203305325	1	0	1	0	RT-qPCR	NA	down-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
618	Type 2 diabetes mellitus	ENST00000602845	NCBP2-AS2	NA	NA	25121	NA	NA	NA	NA	870	chr3:196,942,674-196,943,543	1	0	1	0	RT-qPCR	NA	down-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
619	Type 2 diabetes mellitus	ENST00000436373	LINC02573	NA	NA	53730	NA	NA	NA	-	866	chr21:20256751-20258821	1	0	1	0	RT-qPCR	NA	down-regulated	For validation purposes, we selected four upregulated and five downregulated lncRNAs to identify the differentially expressed lncRNAs by qRT-PCR	32148491	2020	The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults	E11	9352	pubmed	NA
620	Type 2 diabetes mellitus	CASC15	LINC00340	NA	NA	28245	NA	NA	NA	+	341	chr6:22260423-22317798	1	0	1	0	RT-qPCR	NA	up-regulated	Upregulation of CASC15 distinguished DCRF patients from healthy controls and diabetic patients	32053576	2020	Long Non-Coding RNA (LncRNA) CASC15 Is Upregulated in Diabetes-Induced Chronic Renal Failure and Regulates Podocyte Apoptosis	E11	9352	pubmed	NA
621	Type 2 diabetes mellitus	LINC01370	HI-LNC25	NA	NA	 50608	NA	NA	NA	+	17501	chr20:40003981-40043890	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulation of the trans-acting islet-specific lncRNA LINC01370 in mature β cells triggers the downregulation of the GLIS3 (GLIS family zinc finger 3) gene 	32674342	2020	Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases	E11	9352	pubmed	NA
622	Type 2 diabetes mellitus	PLUT	PDX1-AS1	NA	NA	 43698	NA	NA	NA	-	2060	chr13:27829758-27921405	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulation of PLUT correlated with reduced expression of PDX1 at both mRNA and protein levels in primary islet cells.	32674342	2020	Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases	E11	9352	pubmed	NA
623	Type 2 diabetes mellitus	TUG1	LINC00080	NA	NA	26066	NA	NA	NA	+	8448	chr22:30969157-30979394	1	0	1	0	RT-qPCR	NA	down-regulated	 TUG1 was highly expressed in pancreatic tissue compared with other organ tissues	32674342	2020	Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases	E11	9352	pubmed	NA
624	Type 2 diabetes mellitus	LY86-AS1	FLJ33708	NA	NA	 26593	NA	NA	NA	-	8900	chr6:6346103-6622826	1	0	1	0	RT-qPCR	NA	down-regulated	 List of lncRNAs whose expression has been down-regulated in T2DM	33155514	2020	Non-coding RNAs and type 2 diabetes mellitus	E11	9352	pubmed	NA
625	Type 2 diabetes mellitus	CASC2	NA	NA	NA	 22933	NA	NA	NA	+	13277	chr10:118045861-118210153	1	0	1	0	RT-qPCR	NA	down-regulated	 List of lncRNAs whose expression has been down-regulated in T2DM	33155514	2020	Non-coding RNAs and type 2 diabetes mellitus	E11	9352	pubmed	NA
626	Type 2 diabetes mellitus	HOTAIR	HOXC11-AS1	NA	NA	33510	NA	NA	NA	-	3610	chr12:53962307-53974957	1	0	1	0	RT-qPCR	NA	up-regulated	 List of lncRNAs whose expression has been down-regulated in T2DM	33155514	2020	Non-coding RNAs and type 5 diabetes mellitus	E11	9352	pubmed	NA
627	Type 2 diabetes mellitus	PAX8-AS1 	NA	NA	NA	 49271	NA	NA	NA	+	17853	chr2:113211515-113276581	1	0	1	0	RT-qPCR	NA	up-regulated	 List of lncRNAs whose expression has been down-regulated in T2DM	33155514	2020	Non-coding RNAs and type 6 diabetes mellitus	E11	9352	pubmed	NA
628	Type 2 diabetes mellitus	MT1P3 	MTL4 	NA	NA	 16120	NA	NA	NA	+	12651	chr20:35,218,009-35,218,185	1	0	1	0	RT-qPCR	NA	up-regulated	 List of lncRNAs whose expression has been down-regulated in T2DM	33155514	2020	Non-coding RNAs and type 8 diabetes mellitus	E11	9352	pubmed	NA
629	Type 2 diabetes mellitus	CDKN2B-AS1	NCRNA00089	NA	NA	 34341	NA	NA	NA	+	126307	chr9:21,994,139-22,239,122	1	0	1	0	RT-qPCR	NA	up-regulated	Compared to control subjects, expression levels of lncRNAs in PBMCs from type 2 diabetes patients showed significantly (p < 0.05) increased levels of HOTAIR, MEG3, LET, MALAT1, MIAT, CDKN2BAS1/ANRIL, XIST, PANDA, GAS5, Linc-p21, ENST00000550337.1, PLUTO, and NBR2.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes	E11	9352	pubmed	NA
630	Type 2 diabetes mellitus	NBR2	NCRNA00192	NA	NA	 20691	NA	NA	NA	+	3795	chr17:43125582-43153670	1	0	1	0	RT-qPCR	NA	up-regulated	Compared to control subjects, expression levels of lncRNAs in PBMCs from type 2 diabetes patients showed significantly (p < 0.05) increased levels of HOTAIR, MEG3, LET, MALAT1, MIAT, CDKN2BAS1/ANRIL, XIST, PANDA, GAS5, Linc-p21, ENST00000550337.1, PLUTO, and NBR2.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes	E11	9352	pubmed	NA
631	Type 2 diabetes mellitus	RNCR3	MIR124-1HG	NA	NA	 27231	NA	NA	NA	-	13886	chr8:9886104-9907034	1	0	1	0	RT-qPCR	NA	up-regulated	Compared to control subjects, expression levels of lncRNAs in PBMCs from type 2 diabetes patients showed significantly (p < 0.05) increased levels of HOTAIR, MEG3, LET, MALAT1, MIAT, CDKN2BAS1/ANRIL, XIST, PANDA, GAS5, Linc-p21, ENST00000550337.1, PLUTO, and NBR2.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes	E11	9352	pubmed	NA
632	Type 2 diabetes mellitus	GM4419	SNHG6	NA	NA	 32965	NA	NA	NA	-	3791	chr8:66921683-66926398	1	0	1	0	RT-qPCR	NA	up-regulated	Compared to control subjects, expression levels of lncRNAs in PBMCs from type 2 diabetes patients showed significantly (p < 0.05) increased levels of HOTAIR, MEG3, LET, MALAT1, MIAT, CDKN2BAS1/ANRIL, XIST, PANDA, GAS5, Linc-p21, ENST00000550337.1, PLUTO, and NBR2.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes	E11	9352	pubmed	NA
633	Type 2 diabetes mellitus	SALR1	XLOC_023166	NA	NA	 49001	NA	NA	NA	+	2585	chr14:60639215-60727514	1	0	1	0	RT-qPCR	NA	down-regulated	Compared to control subjects, expression levels of lncRNAs in PBMCs from type 2 diabetes patients showed significantly (p < 0.05) increased levels of HOTAIR, MEG3, LET, MALAT1, MIAT, CDKN2BAS1/ANRIL, XIST, PANDA, GAS5, Linc-p21, ENST00000550337.1, PLUTO, and NBR2.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes	E11	9352	pubmed	NA
634	Type 2 diabetes mellitus	THRIL	TCONS_00020260	NA	NA	 49503	NA	NA	NA	-	4866	chr12:125025442-125031199	1	0	1	0	RT-qPCR	NA	down-regulated	Compared to control subjects, expression levels of lncRNAs in PBMCs from type 2 diabetes patients showed significantly (p < 0.05) increased levels of HOTAIR, MEG3, LET, MALAT1, MIAT, CDKN2BAS1/ANRIL, XIST, PANDA, GAS5, Linc-p21, ENST00000550337.1, PLUTO, and NBR2.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes	E11	9352	pubmed	NA
635	Type 2 diabetes mellitus	NKILA	HSALNG0131196	NA	NA	 51599	NA	NA	NA	+	8105	chr20:57710182-57718287	1	0	1	0	RT-qPCR	NA	up-regulated	 Among patients with T2DM, higher expression of lncRNA NKILA was associated with hypertension (p=0.001), smoking (p<0.0001), and alcoholism (p<0.0001)	33436407	2020	Circulating long non- coding RNAs NKILA, NEAT1, MALAT1, and MIAT expression and their association in type 2 diabetes mellitus	E11	9352	pubmed	NA
636	Type 2 diabetes mellitus	MIR143HG	CARMN	NA	NA	 42872	NA	NA	NA	+	26262	chr5:149,406,688-149,432,949	1	0	1	0	RT-qPCR	NA	down-regulated	 Main features of dysregulated lncRNA-related studies in T2DM patients	33274206	2020	Research Status of Differentially Expressed Noncoding RNAs in Type 2 Diabetes Patients	E11	9352	pubmed	NA
637	Type 2 diabetes mellitus	ENST00000550337.1	LINC02402	NA	NA	 53329	NA	NA	NA	-	170776	chr12:42,614,702-42,785,477	1	0	1	0	RT-qPCR	NA	down-regulated	 Main features of dysregulated lncRNA-related studies in T2DM patients	33274206	2020	Research Status of Differentially Expressed Noncoding RNAs in Type 2 Diabetes Patients	E11	9352	pubmed	NA
638	Type 2 diabetes mellitus	ENSG00000273338	Lnc-FUBP1-3	NA	NA	NA	NA	NA	NA	-	20764	chr1:77,983,791-78,004,554	1	0	1	0	RT-qPCR	NA	down-regulated	 Main features of dysregulated lncRNA-related studies in T2DM patients	33299893	2020	A Genome-Wide Analysis of Long Noncoding RNAs in Circulating Leukocytes and Their Differential Expression in Type 1 Diabetes Patients	E10	9744	pubmed	NA
639	Type 2 diabetes mellitus	ENSG00000270069	MIR222HG	NA	NA	 49555	NA	NA	NA	-	26038	chrX:45,745,210-45,771,247	1	0	1	0	RT-qPCR	NA	down-regulated	 Main features of dysregulated lncRNA-related studies in T2DM patients	33299893	2020	A Genome-Wide Analysis of Long Noncoding RNAs in Circulating Leukocytes and Their Differential Expression in Type 1 Diabetes Patients	E10	9744	pubmed	NA
640	Type 2 diabetes mellitus	ENSG00000269902	Lnc-CXorf36-46	NA	NA	NA	NA	NA	NA	-	529	chrX:45,764,771-45,765,299	1	0	1	0	RT-qPCR	NA	down-regulated	 Main features of dysregulated lncRNA-related studies in T2DM patients	33299893	2020	A Genome-Wide Analysis of Long Noncoding RNAs in Circulating Leukocytes and Their Differential Expression in Type 1 Diabetes Patients	E10	9744	pubmed	NA
641	Type 2 diabetes mellitus	ENSG00000267174	HSALNG0124011	NA	NA	NA	NA	NA	NA	-	23913	chr19:11,300,529-11,324,441	1	0	1	0	RT-qPCR	NA	up-regulated	 Main features of dysregulated lncRNA-related studies in T2DM patients	33299893	2020	A Genome-Wide Analysis of Long Noncoding RNAs in Circulating Leukocytes and Their Differential Expression in Type 1 Diabetes Patients	E10	9744	pubmed	NA
642	Type 2 diabetes mellitus	LINC-P21	TRP53COR1	NA	NA	 43652	NA	NA	NA	NA	NA	chr6:-(GRCh38/hg38)	1	0	1	0	RT-qPCR	NA	up-regulated	Serum expression of LINC-P21 was elevated in T2DM patients, which was correlated with fasting blood glucose levels and disease diagnosis. 	33007789	2020	Elevated Circulating LINC-P21 Serves as a Diagnostic Biomarker of Type 2 Diabetes Mellitus and Regulates Pancreatic β-cell Function by Sponging miR-766-3p to Upregulate NR3C2	E11	9352	pubmed	NA
643	Type 2 diabetes mellitus	SNHG17	NA	NA	NA	48600	NA	human	NONHSAT079656.2	-	20304	chr20:38,415,106-38,435,409	1	0	1	0	RT-qPCR	NA	down-regulated	SNHG17 was downregulated in GDM patients compared to normal pregnant  females. Low plasma expression levels of SNHG17 were closely correlated with the high  incidence rate of GDM (GDM-free curve). 	33654419	2021	lncRNA SNHG17 is Downregulated in Gestational Diabetes Mellitus (GDM) and Has Predictive Values	E11	9352	pubmed	NA
644	Type 2 diabetes mellitus	AK077216	NA	NA	NA	 42354	NA	NA	NA	-	153941	chr10:31,166,834-31,320,774	1	0	1	0	RT-qPCR	NA	down-regulated	It was observed that AK077216 was signifi‐cantly downregulated only in DR patients but not in DB patients comparing to Control	31391356	2019	LncRNA AK077216 is downregulated in diabetic retinopathy and inhibited the apoptosis of retinal pigment epithelial cells by downregulating miR-383	E11	9352	pubmed	NA
645	Type 2 diabetes mellitus	ZEB1‑AS1	STAT1	NA	NA	 11362	NA	NA	NA	-	112501	chr2:190,908,460-191,020,960	1	0	1	0	RT-qPCR	NA	up-regulated	 The expression of SNHG5 was increased and TGR5 was decreased with high-glucose and high-fat culture.	32242546	2019	Long Non-Coding RNA (lncRNA) SNHG5 Participates in Vertical Sleeve Gastrectomy for Type II Diabetes Mellitus by Regulating TGR5	E11	9352	pubmed	NA
646	Type 2 diabetes mellitus	Lnc13	PRPF31	NA	NA	 15446	NA	NA	NA	+	16310	chr19:54,115,410-54,131,719	1	0	1	0	RT-qPCR	NA	up-regulated	Up-regulation of Lnc13 in pancreatic β-cells increased activation of the proinflammatory STAT1 pathway, which correlated with increased production of chemokines in an allele-specific manner	32284404	2019	The T1D-associated lncRNA Lnc13 modulates human pancreatic β cell inflammation by allele-specific stabilization of STAT1 mRNA	E11	9352	pubmed	NA
647	Type 2 diabetes mellitus	RP11	STF-1 	NA	NA	 6107	NA	NA	NA	+	6332	chr13:27,919,982-27,926,313	1	0	1	0	RT-qPCR	NA	up-regulated	Overexpression of RP11 significantly enhanced adipocyte differentiation and  increased the mRNA and protein expression levels of adipogenesis makers, such as  PPAR-γ, SREBP1c, and FASN by qPCR/western blot.	33475530	2019	High expression of an NA long noncoding RNA RP11-290L1.3 from GDM macrosomia and its effect on preadipocyte differentiation	E11	9352	pubmed	NA
648	Type 2 diabetes mellitus	PDX1	NA	NA	NA	 48498	NA	NA	NA	-	259714	chr5:91,054,834-91,314,547	1	0	1	0	RT-qPCR	NA	down-regulated	Both PLUTO and PDX1 are downregulated in islets from donors with type 2 dia- betes or impaired glucose tolerance	28041957	2017	Human Pancreatic b Cell lncRNAs Control Cell-Specific Regulatory Networks	E11	9352	pubmed	NA
649	Type 2 diabetes mellitus	LUCAT1	MYO1GUT	NA	NA	 27797	NA	NA	NA	-	22250	chr7:44,977,833-45,000,082	1	0	1	0	RT-qPCR	NA	up-regulated	 The expression of LUCAT1 was significantly upregulated in HG-treated AC16 car- diomyocytes.	31646588	2019	Knockdown of long non-coding RNA LUCAT1 reverses high glucose-induced cardiomyocyte injury via targeting CYP11B2	E11	9352	pubmed	NA
650	Type 2 diabetes mellitus	ENST00000526456	HSALNG0082459	NA	NA	NA	NA	NA	NA	+	1256	chr11:6,621,324-6,622,579	1	0	1	0	RT-qPCR	NA	up-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
651	Type 2 diabetes mellitus	ENST00000523459	NA	NA	NA	NA	NA	NA	NA	-	37593	chr8:42,233,674-42,271,266	1	0	1	0	RT-qPCR	NA	up-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
652	Type 2 diabetes mellitus	ENST00000453798	NA	NA	NA	NA	NA	NA	NA	+	1917	chr7:1,267,352-1,269,268	1	0	1	0	RT-qPCR	NA	up-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
653	Type 2 diabetes mellitus	ENST00000563895	ULK4P3	NA	NA	 15777	NA	NA	NA	+	28038	chr15:30,103,720-30,131,757	1	0	1	0	RT-qPCR	NA	up-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
654	Type 2 diabetes mellitus	ENST00000567688	NA	NA	NA	NA	NA	NA	NA	-	54377	chr16:29,053,732-29,108,108	1	0	1	0	RT-qPCR	NA	up-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
655	Type 2 diabetes mellitus	ENST00000558749	NA	NA	NA	NA	NA	NA	NA	-	11243	chr15:59,348,647-59,359,889	1	0	1	0	RT-qPCR	NA	up-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
656	Type 2 diabetes mellitus	ENST00000552367	NA	NA	NA	NA	NA	NA	NA	+	885	chr12:76,030,494-76,031,378	1	0	1	0	RT-qPCR	NA	up-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
657	Type 2 diabetes mellitus	ENST00000514791	NA	NA	NA	NA	NA	NA	NA	-	89358	chr5:67,800,739-67,890,096	1	0	1	0	RT-qPCR	NA	up-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
658	Type 2 diabetes mellitus	ENST00000551844	Lnc-CDK17-1	NA	NA	NA	NA	NA	NA	-	1178	chr12:96,222,796-96,223,973	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
659	Type 2 diabetes mellitus	ENST00000575838	NA	NA	NA	NA	NA	NA	NA	+	16031	chr16:69,726,533-69,742,563	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
660	Type 2 diabetes mellitus	ENST00000438858	NA	NA	NA	NA	NA	NA	NA	-	59263	chr22:23,658,094-23,717,356	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
661	Type 2 diabetes mellitus	ENST00000507274	AC138409.2	NA	NA	NA	NA	NA	NA	-	80099	chr5:34,164,698-34,244,796	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
662	Type 2 diabetes mellitus	ENST00000428999	LINC01522	NA	NA	51224	NA	NA	NA	-	38582	chr20:47,951,546-47,990,12	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
663	Type 2 diabetes mellitus	ENST00000506058	AC008948.1	NA	NA	NA	NA	NA	NA	+	6874	chr5:102,140,001-102,146,874	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
664	Type 2 diabetes mellitus	ENST00000453039	NA	NA	NA	NA	NA	NA	NA	+	9774	chr2:206,112,597-206,122,370	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
665	Type 2 diabetes mellitus	ENST00000572491	AC091062.1	NA	NA	NA	NA	NA	NA	-	4461	chr17:50,840,056-50,844,516	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
666	Type 2 diabetes mellitus	ENST00000444346	LINC01983	NA	NA	52813	NA	NA	NA	-	35053	chr3:195,825,695-195,860,747	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
667	Type 2 diabetes mellitus	ENST00000551846	NA	NA	NA	NA	NA	NA	NA	-	22554	chr12:56,019,253-56,041,806	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
668	Type 2 diabetes mellitus	ENST00000531210	LINC02741	NA	NA	 54258	NA	NA	NA	-	231248	chr11:41,485,704-41,716,951	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
669	Type 2 diabetes mellitus	ENST00000455455	CEACAM22P	NA	NA	 38029	NA	NA	NA	-	83764	chr19:44,537,058-44,620,821	1	0	1	0	RT-qPCR	NA	down-regulated	NA	25997527	2015	Microarray Expression Profile Analysis of Long Non-Coding RNAs in Umbilical Cord Plasma Reveals their Potential Role in Gestational Diabetes-Induced Macrosomia	E11	9352	pubmed	NA
670	Type 2 diabetes mellitus	TUR	HI-LNC78	NA	NA	 44088	NA	NA	NA	+	49407	chr14:95,876,257-95,925,663	1	0	1	0	RT-qPCR	NA	up-regulated	TUNAR is Enriched in Human Islets and is Upregulated in T2D	33682459	2020	The long noncoding RNA TUNAR modulates Wnt signaling and regulates human β-cell proliferation  	E11	9352	pubmed	NA
671	Type 2 diabetes mellitus	NR_024582	JPX	NA	NA	 37191	NA	NA	NA	+	126651	chrX:73,944,182-74,070,832	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 2 Diabetes	E11	9352	pubmed	NA
672	Type 2 diabetes mellitus	NR_026956	LINC00663	NA	NA	 28609	NA	NA	NA	-	20053	chr19:19,756,371-19,776,423	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 3 Diabetes	E11	9352	pubmed	NA
673	Type 2 diabetes mellitus	NR_028138	ATP2B1-AS1	NA	NA	 27883	NA	NA	NA	+	4773	chr12:89,708,954-89,713,726	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 4 Diabetes	E11	9352	pubmed	NA
674	Type 2 diabetes mellitus	NR_027012	LINC00293	NA	NA	 39078	NA	NA	NA	+	265796	chr8:46,641,514-46,907,309	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 5 Diabetes	E11	9352	pubmed	NA
675	Type 2 diabetes mellitus	NR_034127	LOC100132356	NA	NA	NA	NA	NA	NA	-	1785	chr5:43,065,187-43,066,971	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 6 Diabetes	E11	9352	pubmed	NA
676	Type 2 diabetes mellitus	NR_040005	LINC00960	NA	NA	 48710	NA	NA	NA	+	69788	chr3:75,672,261-75,742,048	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 7 Diabetes	E11	9352	pubmed	NA
677	Type 2 diabetes mellitus	NR_024065	LINC00312	NA	NA	 6662	NA	NA	NA	+	2888	chr3:8,571,781-8,574,668	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 8 Diabetes	E11	9352	pubmed	NA
678	Type 2 diabetes mellitus	NR_033998	CNN3-DT	NA	NA	 54176	NA	NA	NA	+	52265	chr1:94,926,360-94,978,624	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 9 Diabetes	E11	9352	pubmed	NA
679	Type 2 diabetes mellitus	ENSG00000230844	ZNF674-AS1	NA	NA	 44266	NA	NA	NA	+	14461	chrX:46,545,221-46,559,681	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 14 Diabetes	E11	9352	pubmed	NA
680	Type 2 diabetes mellitus	ENSG00000228839	PIK3IP1-DT	NA	NA	 41072	NA	NA	NA	+	47572	chr22:31,291,101-31,338,672	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 15 Diabetes	E11	9352	pubmed	NA
681	Type 2 diabetes mellitus	ENSG00000213753	CENPBD1P1	NA	NA	 28421	NA	NA	NA	+	31721	chr19:58,573,503-58,605,223	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 16 Diabetes	E11	9352	pubmed	NA
682	Type 2 diabetes mellitus	ENSG00000179859	RNF227	NA	NA	 27571	NA	NA	NA	-	2995	chr17:7,913,324-7,916,318	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 17 Diabetes	E11	9352	pubmed	NA
683	Type 2 diabetes mellitus	ENSG00000245694	CRNDE	NA	NA	 37078	NA	NA	NA	-	85755	chr16:54,845,188-54,930,942	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 18 Diabetes	E11	9352	pubmed	NA
684	Type 2 diabetes mellitus	ENSG00000227388	NA	NA	NA	NA	NA	NA	NA	+	28349	chr9:35,762,174-35,790,522	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 20 Diabetes	E11	9352	pubmed	NA
685	Type 2 diabetes mellitus	ENSG00000171658	NMRAL2P	NA	NA	 52332	NA	NA	NA	+	20935	chr3:185,959,943-185,980,877	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 22 Diabetes	E11	9352	pubmed	NA
686	Type 2 diabetes mellitus	ENSG00000235947	EGOT	NA	NA	 37129	NA	NA	NA	-	11442	chr3:4,740,216-4,751,657	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 23 Diabetes	E11	9352	pubmed	NA
687	Type 2 diabetes mellitus	ENSG00000241163	LINC00877	NA	NA	 27706	NA	NA	NA	-	475981	chr3:71,897,127-72,373,107	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 25 Diabetes	E11	9352	pubmed	NA
688	Type 2 diabetes mellitus	ENSG00000226383	LINC01876	NA	NA	 52695	NA	NA	NA	-	271002	chr2:155,984,033-156,255,034	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 26 Diabetes	E11	9352	pubmed	NA
689	Type 2 diabetes mellitus	ENSG00000230002	ALMS1-IT1	NA	NA	 41305	NA	NA	NA	+	4253	chr2:73,455,232-73,459,484	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 27 Diabetes	E11	9352	pubmed	NA
690	Type 2 diabetes mellitus	ENSG00000224818	AC096677.2	NA	NA	NA	NA	NA	NA	-	881	chr1:201,464,267-201,465,147	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 28 Diabetes	E11	9352	pubmed	NA
691	Type 2 diabetes mellitus	ENSG00000186056	MATN1-AS1	NA	NA	 40364	NA	NA	NA	+	8736	chr1:30,718,093-30,726,828	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 29 Diabetes	E11	9352	pubmed	NA
692	Type 2 diabetes mellitus	ENSG00000244020	MT1HL1	NA	NA	 31864	NA	NA	NA	-	339	chr1:237,004,103-237,004,441	1	0	1	0	RT-qPCR	NA	down-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 30 Diabetes	E11	9352	pubmed	NA
693	Type 2 diabetes mellitus	NR_023925	LINC00470	NA	NA	 1225	NA	NA	NA	-	159705	chr18:1,248,640-1,408,344	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 31 Diabetes	E11	9352	pubmed	NA
694	Type 2 diabetes mellitus	NR_026646	PWRN1	NA	NA	 33235	NA	NA	NA	+	721539	chr15:24,101,827-24,823,365	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 32 Diabetes	E11	9352	pubmed	NA
695	Type 2 diabetes mellitus	NR_002717	ATXN8OS	NA	NA	 10561	NA	NA	NA	+	92821	chr13:70,078,918-70,171,738	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 34 Diabetes	E11	9352	pubmed	NA
696	Type 2 diabetes mellitus	NR_026928	N4BP2L2-IT2	NA	NA	 25038	NA	NA	NA	-	4891	chr13:32,504,505-32,509,395	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 35 Diabetes	E11	9352	pubmed	NA
697	Type 2 diabetes mellitus	NR_026932	PDCD4-AS1	NA	NA	 27425	NA	NA	NA	-	18998	chr10:110,868,742-110,887,739	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 36 Diabetes	E11	9352	pubmed	NA
698	Type 2 diabetes mellitus	NR_028390	PACRG-AS1	NA	NA	 27772	NA	NA	NA	-	17624	chr6:163,306,907-163,324,530	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 38 Diabetes	E11	9352	pubmed	NA
699	Type 2 diabetes mellitus	NR_027117	LOC285847	NA	NA	NA	NA	NA	NA	-	10186	chr6:35,726,762-35,736,947	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 39 Diabetes	E11	9352	pubmed	NA
700	Type 2 diabetes mellitus	NR_024606	LBX2-AS1	NA	NA	 25136	NA	NA	NA	+	6973	chr2:74,498,093-74,505,065	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 41 Diabetes	E11	9352	pubmed	NA
701	Type 2 diabetes mellitus	NR_024124	ATP1A1-AS1	NA	NA	 28262	NA	NA	NA	-	42865	chr1:116,378,437-116,421,301	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 42 Diabetes	E11	9352	pubmed	NA
702	Type 2 diabetes mellitus	NR_033887	LINC01141	NA	NA	 49455	NA	NA	NA	-	71435	chr1:20,359,800-20,431,234	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 43 Diabetes	E11	9352	pubmed	NA
703	Type 2 diabetes mellitus	ENSG00000260386	LDC1P	NA	NA	 49677	NA	NA	NA	+	9564	chr1:31,500,085-31,509,648	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 46 Diabetes	E11	9352	pubmed	NA
704	Type 2 diabetes mellitus	ENSG00000233482	AC093579.1	NA	NA	NA	NA	NA	NA	+	510	chr1:94,145,110-94,145,619	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 47 Diabetes	E11	9352	pubmed	NA
705	Type 2 diabetes mellitus	ENSG00000226906	TTTY4	NA	NA	 16481	NA	NA	NA	+	36831	chrY:22,936,454-22,973,284	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 52 Diabetes	E11	9352	pubmed	NA
706	Type 2 diabetes mellitus	ENSG00000215560	TTTY5	NA	NA	 16482	NA	NA	NA	-	2080	chrY:22,296,797-22,298,876	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 53 Diabetes	E11	9352	pubmed	NA
707	Type 2 diabetes mellitus	ENSG00000234405	Z69733.1	NA	NA	NA	NA	NA	NA	+	49315	chrX:103,468,605-103,517,919	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 54 Diabetes	E11	9352	pubmed	NA
708	Type 2 diabetes mellitus	ENSG00000234883	MIR155HG	NA	NA	 35460	NA	NA	NA	+	22342	chr21:25,560,398-25,582,739	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 55 Diabetes	E11	9352	pubmed	NA
709	Type 2 diabetes mellitus	ENSG00000237282	LINC00851	NA	NA	 43424	NA	NA	NA	+	3626	chr20:18,378,063-18,381,688	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 56 Diabetes	E11	9352	pubmed	NA
710	Type 2 diabetes mellitus	ENSG00000214049	UCA1	NA	NA	 37126	NA	NA	NA	+	9562	chr19:15,828,205-15,837,766	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 57 Diabetes	E11	9352	pubmed	NA
711	Type 2 diabetes mellitus	ENSG00000268658	LINC00664	NA	NA	 44319	NA	NA	NA	+	30432	chr19:21,474,857-21,505,288	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 58 Diabetes	E11	9352	pubmed	NA
712	Type 2 diabetes mellitus	ENSG00000227274	MYOCD-AS1	NA	NA	 40750	NA	NA	NA	-	48301	chr17:12,671,861-12,720,161	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 59 Diabetes	E11	9352	pubmed	NA
713	Type 2 diabetes mellitus	ENSG00000249383	LINC02071	NA	NA	 52917	NA	NA	NA	-	22558	chr17:51,312,608-51,335,165	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 60 Diabetes	E11	9352	pubmed	NA
714	Type 2 diabetes mellitus	ENSG00000247324	NA	NA	NA	NA	NA	NA	NA	+	3666	chr16:71,462,277-71,465,942	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 61 Diabetes	E11	9352	pubmed	NA
715	Type 2 diabetes mellitus	ENSG00000245750	DRAIC	NA	NA	 32382	NA	NA	NA	+	380200	chr15:69,462,921-69,843,120	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 62 Diabetes	E11	9352	pubmed	NA
716	Type 2 diabetes mellitus	ENSG00000251533	LINC00605	NA	NA	 43928	NA	NA	NA	-	3475	chr14:103,186,995-103,190,469	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 63 Diabetes	E11	9352	pubmed	NA
717	Type 2 diabetes mellitus	ENSG00000233208	LINC00642	NA	NA	 44293	NA	NA	NA	+	39188	chr14:90,451,576-90,490,763	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 64 Diabetes	E11	9352	pubmed	NA
718	Type 2 diabetes mellitus	ENSG00000226722	LINC00424	NA	NA	 42815	NA	NA	NA	-	5494	chr13:21,872,763-21,878,256	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 65 Diabetes	E11	9352	pubmed	NA
719	Type 2 diabetes mellitus	ENSG00000236036	LINC00445	NA	NA	 42782	NA	NA	NA	+	6235	chr13:35,697,487-35,703,721	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 66 Diabetes	E11	9352	pubmed	NA
720	Type 2 diabetes mellitus	ENSG00000261057	LINC00555	NA	NA	 43699	NA	NA	NA	-	443	chr13:102,589,371-102,589,813	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 67 Diabetes	E11	9352	pubmed	NA
721	Type 2 diabetes mellitus	ENSG00000226900	NA	NA	NA	NA	NA	NA	NA	-	9974	chr10:132,508,394-132,518,367	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 68 Diabetes	E11	9352	pubmed	NA
722	Type 2 diabetes mellitus	ENSG00000225768	LINC02620	NA	NA	 54097	NA	NA	NA	-	5503	chr10:104,474,874-104,480,376	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 69 Diabetes	E11	9352	pubmed	NA
723	Type 2 diabetes mellitus	ENSG00000224596	ZMIZ1-AS1	NA	NA	 27433	NA	NA	NA	-	198259	chr10:78,871,271-79,069,529	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 70 Diabetes	E11	9352	pubmed	NA
724	Type 2 diabetes mellitus	ENSG00000235387	SPAAR	NA	NA	 27244	NA	NA	NA	+	27664	chr9:35,909,490-35,937,153	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 71 Diabetes	E11	9352	pubmed	NA
725	Type 2 diabetes mellitus	ENSG00000227619	AL391056.1	NA	NA	NA	NA	NA	NA	+	31976	chr9:129,575,116-129,607,091	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 72 Diabetes	E11	9352	pubmed	NA
726	Type 2 diabetes mellitus	ENSG00000235659	AL391987.4	NA	NA	NA	NA	NA	NA	-	4007	chr9:61,865,330-61,869,336	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 73 Diabetes	E11	9352	pubmed	NA
727	Type 2 diabetes mellitus	ENSG00000254129	AC108449.1	NA	NA	NA	NA	NA	NA	+	30158	chr8:29,110,573-29,140,730	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 74 Diabetes	E11	9352	pubmed	NA
728	Type 2 diabetes mellitus	ENSG00000226869	LHFPL3-AS1	NA	NA	NA	NA	NA	NA	-	65513	chr7:104,738,596-104,804,108	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 75 Diabetes	E11	9352	pubmed	NA
729	Type 2 diabetes mellitus	ENSG00000179406	LINC00174	NA	NA	 27788	NA	NA	NA	-	117966	chr7:66,375,601-66,493,566	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 76 Diabetes	E11	9352	pubmed	NA
730	Type 2 diabetes mellitus	ENSG00000228775	WEE2-AS1	NA	NA	 48669	NA	NA	NA	-	35007	chr7:141,703,341-141,738,347	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 77 Diabetes	E11	9352	pubmed	NA
731	Type 2 diabetes mellitus	ENSG00000188185	LINC00265	NA	NA	 28019	NA	NA	NA	+	101375	chr7:39,699,885-39,801,259	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 78 Diabetes	E11	9352	pubmed	NA
732	Type 2 diabetes mellitus	ENSG00000244158	CALHM6-AS1	NA	NA	 40971	NA	NA	NA	-	5449	chr6:116,460,738-116,466,186	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 80 Diabetes	E11	9352	pubmed	NA
733	Type 2 diabetes mellitus	ENSG00000230910	AL391807.1	NA	NA	NA	NA	NA	NA	-	7287	chr6:68,627,879-68,635,165	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 81 Diabetes	E11	9352	pubmed	NA
734	Type 2 diabetes mellitus	ENSG00000226249	LOC105378044	NA	NA	NA	NA	NA	NA	-	5350	chr6:147,738,071-147,743,420	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 82 Diabetes	E11	9352	pubmed	NA
735	Type 2 diabetes mellitus	ENSG00000246214	LOC101929524	NA	NA	NA	NA	NA	NA	+	655981	chr5:16,615,925-16,681,905	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 83 Diabetes	E11	9352	pubmed	NA
736	Type 2 diabetes mellitus	ENSG00000253955	LOC285593	NA	NA	NA	NA	NA	NA	+	6798	chr5:173,578,275-173,585,072	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 84 Diabetes	E11	9352	pubmed	NA
737	Type 2 diabetes mellitus	ENSG00000249001	AC093895.1	NA	NA	NA	NA	NA	NA	-	191188	chr4:87,542,769-87,733,956	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 85 Diabetes	E11	9352	pubmed	NA
738	Type 2 diabetes mellitus	ENSG00000248339	LINC02504	NA	NA	 53493	NA	NA	NA	-	208157	chr4:171,090,111-171,298,267	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 86 Diabetes	E11	9352	pubmed	NA
739	Type 2 diabetes mellitus	ENSG00000240024	LINC00888	NA	NA	 48575	NA	NA	NA	+	8440	chr3:183,447,585-183,456,024	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 87 Diabetes	E11	9352	pubmed	NA
740	Type 2 diabetes mellitus	ENSG00000239508	PLCH1-AS1	NA	NA	 41231	NA	NA	NA	+	8572	chr3:155,449,183-155,457,754	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 88 Diabetes	E11	9352	pubmed	NA
741	Type 2 diabetes mellitus	ENSG00000244161	FLNB-AS1	NA	NA	 40239	NA	NA	NA	-	9699	chr3:58,162,546-58,172,244	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 89 Diabetes	E11	9352	pubmed	NA
742	Type 2 diabetes mellitus	ENSG00000239513	LINC01210 	NA	NA	 49642	NA	NA	NA	+	9572	chr3:137,771,319-137,780,890	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 90 Diabetes	E11	9352	pubmed	NA
743	Type 2 diabetes mellitus	ENSG00000189223	PAX8-AS1	NA	NA	 49271	NA	NA	NA	+	65161	chr2:113,211,421-113,276,581	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 91 Diabetes	E11	9352	pubmed	NA
744	Type 2 diabetes mellitus	ENSG00000228203	GRASLND	NA	NA	 30963	NA	NA	NA	-	6981	chr2:6,911,754-6,918,734	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 92 Diabetes	E11	9352	pubmed	NA
745	Type 2 diabetes mellitus	ENSG00000178836	LOC100286922	NA	NA	NA	NA	NA	NA	-	1041	chr2:233,754,305-233,755,345	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 93 Diabetes	E11	9352	pubmed	NA
746	Type 2 diabetes mellitus	ENSG00000203643	NA	NA	NA	NA	NA	NA	NA	-	4152	chr2:11,720,083-11,724,234	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 94 Diabetes	E11	9352	pubmed	NA
747	Type 2 diabetes mellitus	ENSG00000233729	NCKAP5-AS1	NA	NA	 41246	NA	NA	NA	+	20386	chr2:132,912,532-132,932,917	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 95 Diabetes	E11	9352	pubmed	NA
748	Type 2 diabetes mellitus	ENSG00000237638	LINC02245	NA	NA	 53134	NA	NA	NA	-	154911	chr2:64,901,305-65,056,215	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 96 Diabetes	E11	9352	pubmed	NA
749	Type 2 diabetes mellitus	ENSG00000232931	LINC00342	NA	NA	 42470	NA	NA	NA	-	28518	chr2:95,807,051-95,835,568	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 97 Diabetes	E11	9352	pubmed	NA
750	Type 2 diabetes mellitus	ENSG00000224699	LAMTOR5-AS1	NA	NA	 40823	NA	NA	NA	+	96785	chr1:110,347,115-110,443,899	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 98 Diabetes	E11	9352	pubmed	NA
751	Type 2 diabetes mellitus	ENSG00000224702	LMX1A-AS2	NA	NA	 40343	NA	NA	NA	+	9361	chr1:165,204,047-165,213,407	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 99 Diabetes	E11	9352	pubmed	NA
752	Type 2 diabetes mellitus	ENSG00000237463	LRRC52-AS1	NA	NA	 54044	NA	NA	NA	-	105604	chr1:165,476,552-165,582,155	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 100 Diabetes	E11	9352	pubmed	NA
753	Type 2 diabetes mellitus	ENSG00000237058	MMEL1-AS1	NA	NA	 40695	NA	NA	NA	+	8206	chr1:2,628,689-2,636,894	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 101 Diabetes	E11	9352	pubmed	NA
754	Type 2 diabetes mellitus	ENSG00000203288	TDRKH-AS1	NA	NA	 40578	NA	NA	NA	+	3654	chr1:151,790,749-151,794,402	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 102 Diabetes	E11	9352	pubmed	NA
755	Type 2 diabetes mellitus	ENSG00000233184	NA	NA	NA	NA	NA	NA	NA	+	64670	chr1:101,025,844-101,090,513	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 103 Diabetes	E11	9352	pubmed	NA
756	Type 2 diabetes mellitus	ENSG00000233410	LINC01222	NA	NA	 49672	NA	NA	NA	-	28451	chr1:198,992,588-199,021,038	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 104 Diabetes	E11	9352	pubmed	NA
757	Type 2 diabetes mellitus	ENSG00000231814	LINC00210	NA	NA	 37458	NA	NA	NA	+	27907	chr1:217,892,899-217,920,805	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 105 Diabetes	E11	9352	pubmed	NA
758	Type 2 diabetes mellitus	ENSG00000228127	LINC01649	NA	NA	 52436	NA	NA	NA	+	27191	chr1:115,904,855-115,932,045	1	0	1	0	RT-qPCR	NA	up-regulated	Differentially expressed lncRNAs between diabetic and non-diabetic lymph	28214888	2017	Analysis of Long Non-Coding RNA Expression of Lymphatic Endothelial Cells in Response to Type 106 Diabetes	E11	9352	pubmed	NA
759	Type 2 diabetes mellitus	HOTTIP	HOXA13-AS1	NA	NA	 37461	NA	NA	NA	+	9184	chr7:27,198,574-27,207,757	1	0	1	0	RT-qPCR	NA	up-regulated	HOTTIP was upregulated in normal islet tissues of C57BL/6J mice but downreg- ulated in islet tissues of diabetic mice. 	30070332	2018	Downregulation of HOTTIP regulates insulin secretion and cell cycle in islet β cells via inhibiting MEK/ERK pathway	E11	9352	pubmed	NA
760	Type 2 diabetes mellitus	EPB41L4A-AS1	TIGA1	NA	NA	 30749	NA	NA	NA	+	4369	chr5:112,160,450-112,164,818	1	0	1	0	RT-qPCR	NA	down-regulated	EPB41L4A-AS1 showed very low expression, which was significantly negatively  correlated with levels of inflammatory factors in PBMCs of T2DM patients and PBMCs  treated with LPS. 	33505165	2020	Downregulation of lncRNA EPB41L4A-AS1 Mediates Activation of MYD88-Dependent NF-κB Pathway in Diabetes-Related Inflammation	E11	9352	pubmed	NA
761	Type 2 diabetes mellitus	LINC01619	NA	NA	NA	27409	NA	NA	NA	-	168730	chr12:91,974,185-92,142,914	1	0	1	0	RT-qPCR	NA	down-regulated	LINC01619 downregulation contributes to proteinuria and declined renal function in DN  patients   	29334763	2017	Long non-coding RNA LINC01619 regulates miR-27a/FOXO1 and endoplasmic reticulum stress-mediated podocyte injury in diabetic nephropathy 	E11	9352	pubmed	NA
762	Type 2 diabetes mellitus	HI-LNC12	LINC01574	NA	NA	 51388	NA	NA	NA	+	8391	chr5:176,743,058-176,751,448	1	0	1	0	RT-qPCR	NA	down-regulated	Involves in β-cell development and insulin secretion	33478141	2020	Long Non-Coding RNAs (lncRNAs) in Cardiovascular Disease Complication of Type 2 Diabetes	E11	9352	pubmed	NA
763	Type 2 diabetes mellitus	 SNHG7	HSALNG0075291	NA	NA	 28254	NA	NA	NA	-	8192	chr9:136,720,113-136,728,304	1	0	1	0	RT-qPCR	NA	down-regulated	SNHG7 suppresses HG-induced cell proliferation and angiogenesis	31056258	2019	Long noncoding RNA SNHG7 inhibits high glucose-induced human retinal endothelial cells angiogenesis by regulating miR-543/SIRT1 axis	E11	9352	pubmed	NA
764	Type 2 diabetes mellitus	ENST00000421257	MIR646HG	NA	NA	 27659	NA	NA	NA	+	566093	chr20:60,087,826-60,653,918	1	0	1	0	RT-qPCR	NA	up-regulated	Most differentially expressed long non-coding RNAs (lncRNAs) in human umbilical vein endothelial cells (HUVECs) cultured in elevated vs. normal glucose conditions.	27434139	2015	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs	E11	9352	pubmed	NA
765	Type 2 diabetes mellitus	ENST00000547721 	AC011611.4	NA	NA	NA	NA	NA	NA	+	1241	chr12:76,032,657-76,033,897	1	0	1	0	RT-qPCR	NA	up-regulated	Most differentially expressed long non-coding RNAs (lncRNAs) in human umbilical vein endothelial cells (HUVECs) cultured in elevated vs. normal glucose conditions.	27434139	2015	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs	E11	9352	pubmed	NA
766	Type 2 diabetes mellitus	ENST00000565041 	AC005606.2	NA	NA	NA	NA	NA	NA	-	5602	chr16:1,984,876-1,990,477	1	0	1	0	RT-qPCR	NA	up-regulated	Most differentially expressed long non-coding RNAs (lncRNAs) in human umbilical vein endothelial cells (HUVECs) cultured in elevated vs. normal glucose conditions.	27434139	2015	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs	E11	9352	pubmed	NA
767	Type 2 diabetes mellitus	ENST00000421891	HDAC2-AS2	NA	NA	 43590	NA	NA	NA	+	571877	chr6:113,968,844-114,540,720	1	0	1	0	RT-qPCR	NA	up-regulated	Most differentially expressed long non-coding RNAs (lncRNAs) in human umbilical vein endothelial cells (HUVECs) cultured in elevated vs. normal glucose conditions.	27434139	2015	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs	E11	9352	pubmed	NA
768	Type 2 diabetes mellitus	NR_024091	ZFP91-CNTF	NA	NA	 33441	NA	NA	NA	+	46620	chr11:58,579,114-58,625,733	1	0	1	0	RT-qPCR	NA	up-regulated	Most differentially expressed long non-coding RNAs (lncRNAs) in human umbilical vein endothelial cells (HUVECs) cultured in elevated vs. normal glucose conditions.	27434139	2015	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs	E11	9352	pubmed	NA
769	Type 2 diabetes mellitus	ENST00000559989	CSPG4P12	NA	NA	 48362	NA	NA	NA	+	22472	chr15:85,191,434-85,213,905	1	0	1	0	RT-qPCR	NA	down-regulated	Most differentially expressed long non-coding RNAs (lncRNAs) in human umbilical vein endothelial cells (HUVECs) cultured in elevated vs. normal glucose conditions.	27434139	2015	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs	E11	9352	pubmed	NA
770	Type 2 diabetes mellitus	ENST00000538550	AP000721.2	NA	NA	NA	NA	NA	NA	+	67685	chr11:64,035,969-64,103,653	1	0	1	0	RT-qPCR	NA	down-regulated	Most differentially expressed long non-coding RNAs (lncRNAs) in human umbilical vein endothelial cells (HUVECs) cultured in elevated vs. normal glucose conditions.	27434139	2015	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs	E11	9352	pubmed	NA
771	Type 2 diabetes mellitus	ENST00000432411 	AP001619.1	NA	NA	NA	NA	NA	NA	-	2860	chr21:41,874,755-41,877,614	1	0	1	0	RT-qPCR	NA	down-regulated	Most differentially expressed long non-coding RNAs (lncRNAs) in human umbilical vein endothelial cells (HUVECs) cultured in elevated vs. normal glucose conditions.	27434139	2015	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs	E11	9352	pubmed	NA
772	Type 2 diabetes mellitus	ENSG00000276116 	FUT8-AS1	NA	NA	NA	NA	NA	NA	-	8097	chr14:65,405,867-65,413,963	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
773	Type 2 diabetes mellitus	ENSG00000261320	AC009061.1	NA	NA	NA	NA	NA	NA	-	7492	chr16:67,423,973-67,431,464	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
774	Type 2 diabetes mellitus	ENSG00000214248	AC010336.1	NA	NA	NA	NA	NA	NA	-	4740	chr19:7,898,803-7,903,542	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
775	Type 2 diabetes mellitus	ENSG00000250208	FZD10-AS1	NA	NA	 48632	NA	NA	NA	-	41101	chr12:130,121,265-130,162,365	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
776	Type 2 diabetes mellitus	ENSG00000273471	AC112229.4	NA	NA	NA	NA	NA	NA	-	86666	chr2:110,386,410-110,473,075	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
777	Type 2 diabetes mellitus	ENSG00000279196	AC135048.4	NA	NA	NA	NA	NA	NA	-	3641	chr16:30,984,630-30,988,270	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
778	Type 2 diabetes mellitus	ENSG00000274269	AL031665.1	NA	NA	NA	NA	NA	NA	+	22071	chr20:1,184,966-1,207,036	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
779	Type 2 diabetes mellitus	ENSG00000245008	LOC101929538	NA	NA	NA	NA	NA	NA	-	72672	chr11:128,614,251-128,686,922	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
780	Type 2 diabetes mellitus	ENSG00000244300	GATA2-AS1	NA	NA	51108	NA	NA	NA	+	14579	chr3:128,488,629-128,503,207	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
781	Type 2 diabetes mellitus	ENSG00000280311	AC131212.4	NA	NA	NA	NA	NA	NA	-	975	chr12:132,621,999-132,622,973	1	0	1	0	RT-qPCR	NA	down-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
782	Type 2 diabetes mellitus	ENSG00000225434	LINC01504	NA	NA	51185	NA	NA	NA	+	58523	chr9:72,305,016-72,363,538	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
783	Type 2 diabetes mellitus	ENSG00000231426	FILNC1	NA	NA	53755	NA	NA	NA	+	199754	chr6:139,677,638-139,877,391	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
784	Type 2 diabetes mellitus	ENSG00000260585	AL359851.1	NA	NA	NA	NA	NA	NA	+	5525	chrX:121,871,868-121,877,392	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
785	Type 2 diabetes mellitus	ENSG00000233098	CCDC144NL-AS1	NA	NA	51340	NA	NA	NA	+	133845	chr17:20,868,432-21,002,276	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
786	Type 2 diabetes mellitus	ENSG00000262202	AC007952.4	NA	NA	NA	NA	NA	NA	-	49291	chr17:19,063,346-19,112,636	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
787	Type 2 diabetes mellitus	ENSG00000259702	AC024337.1	NA	NA	NA	NA	NA	NA	-	126556	chr15:95,938,041-96,064,596	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
788	Type 2 diabetes mellitus	ENSG00000267270	PARD6G-AS1	NA	NA	 44109	NA	NA	NA	+	32172	chr18:80,147,668-80,179,839	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
789	Type 2 diabetes mellitus	ENSG00000282057	AC092807.3	NA	NA	NA	NA	NA	NA	-	95971	chr1:85,482,280-85,578,250	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
790	Type 2 diabetes mellitus	ENSG00000276850	AC245041.2	NA	NA	NA	NA	NA	NA	-	89680	chr10:47,908,063-47,997,742	1	0	1	0	RT-qPCR	NA	up-regulated	Top 10 up- and down-regulated differentially expressed lncRNAs in gestational diabetes mellitus.	33618585	2020	Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing	E11	9352	pubmed	NA
791	Type 2 diabetes mellitus	IGF2-AS	NA	NA	NA	 14062	NA	NA	NA	+	8166	chr11:2,140,501-2,148,666	1	0	1	0	RT-qPCR	NA	up-regulated	IGF2AS was upregulated, whereas IGF2 was downregulated, in diabetic GK mMVE cells. IGF2AS inhibition augmented proliferation and invasion in GK mMVE cells.	28570978	2017	Inhibition of long noncoding RNA IGF2AS promotes angiogenesis in type 2 diabetes	E11	9352	pubmed	NA
792	Type 2 diabetes mellitus	HCG18	NA	NA	NA	 31337	NA	NA	NA	-	93344	chr6:30,234,039-30,327,382	1	0	1	0	RT-qPCR	NA	up-regulated	LncRNA HCG18 is highly expressed in DPN model  and HG‑induced macrophages	32996080	2020	Long non‑coding RNA HCG18 promotes M1 macrophage polarization through regulating the miR‑146a/TRAF6 axis, facilitating the progression of diabetic peripheral neuropathy	E11	9352	pubmed	NA
793	Type 2 diabetes mellitus	CRNDE	LINC00180	NA	NA	37078	NA	NA	NA	-	85755	chr16:54,845,188-54,930,942	1	0	1	0	RT-qPCR	NA	up-regulated	 CRNDE knockdown decreases endothelial cell proliferation, migration, and capillary  tube formation.	31863035	2019	Transcriptome analysis-identified long noncoding RnA cRnDe in maintaining endothelial cell proliferation, migration, and tube formation	E11	9352	pubmed	NA
794	Type 2 diabetes mellitus	NONHSAT180405.1	Lnc-RPS16-1	NA	NA	NA	NA	NA	NA	-	2727	chr19:39,433,222-39,435,948	1	0	1	0	RT-qPCR	NA	up-regulated	Dozens of lncRNAs with high degree may play important roles in high-glucose-induced HUVEC damage,	32689997	2020	Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells	E11	9352	pubmed	NA
795	Type 2 diabetes mellitus	NONHSAT086922.2	Lnc-PMM1-1	NA	NA	NA	NA	NA	NA	-	1627	chr22:41,598,029-41,599,655	1	0	1	0	RT-qPCR	NA	up-regulated	Dozens of lncRNAs with high degree may play important roles in high-glucose-induced HUVEC damage,	32689997	2020	Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells	E11	9352	pubmed	NA
796	Type 2 diabetes mellitus	NONHSAT094345.2	Lnc-SMCO1-2	NA	NA	NA	NA	NA	NA	-	1964	chr3:196,468,939-196,470,902	1	0	1	0	RT-qPCR	NA	up-regulated	Dozens of lncRNAs with high degree may play important roles in high-glucose-induced HUVEC damage,	32689997	2020	Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells	E11	9352	pubmed	NA
797	Type 2 diabetes mellitus	NONHSAT056661.2	Lnc-CCDC57-6	NA	NA	NA	NA	NA	NA	-	8749	chr17:82,242,666-82,251,414	1	0	1	0	RT-qPCR	NA	down-regulated	Dozens of lncRNAs with high degree may play important roles in high-glucose-induced HUVEC damage,	32689997	2020	Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells	E11	9352	pubmed	NA
798	Type 2 diabetes mellitus	NONHSAT204850.1	Lnc-IL17B-2 	NA	NA	NA	NA	NA	NA	-	20245	chr5:149,493,385-149,513,629	1	0	1	0	RT-qPCR	NA	down-regulated	Dozens of lncRNAs with high degree may play important roles in high-glucose-induced HUVEC damage,	32689997	2020	Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells	E11	9352	pubmed	NA
799	Type 2 diabetes mellitus	NONHSAT217441.1	Lnc-KLF10-2	NA	NA	NA	NA	NA	NA	-	5191	chr8:102,648,774-102,653,964	1	0	1	0	RT-qPCR	NA	down-regulated	Dozens of lncRNAs with high degree may play important roles in high-glucose-induced HUVEC damage,	32689997	2020	Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells	E11	9352	pubmed	NA
800	Type 2 diabetes mellitus	BANCR	LINC00586	NA	NA	43877	NA	NA	NA	-	14464	chr9:69,296,677-69,311,140	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulation of lncRNA BANCR participates in the development of retinopathy among diabetic patients	31007747	2019	Downregulation of lncRNA BANCR participates in the development of retinopathy among diabetic patients	E11	9352	pubmed	NA
801	Type 2 diabetes mellitus	MIR503HG	H19X	NA	NA	 28258	NA	NA	NA	-	9653	chrX:134,540,008-134,549,660	1	0	1	0	RT-qPCR	NA	up-regulated	In the presence of high  glucose, the expression levels of lncRNA MIR503HG and miR-503 were up-regulated in  HK-2 cells cultured in high glucose.	33262626	2020	LncRNA MIR503HG Promotes High-Glucose- Induced Proximal Tubular Cell Apoptosis by Targeting miR-503-5p/Bcl-2 Pathway	E11	9352	pubmed	NA
802	Type 2 diabetes mellitus	UCA1	LINC00178	NA	NA	37126	NA	NA	NA	+	9562	chr19:15,828,205-15,837,766	1	0	1	0	RT-qPCR	NA	down-regulated	Results showed that compared with non-T2DM patients, UCA1 was markedly  downregulated, while miR-582-5p was upregu-lated in VSMCs and serum exosomes of T2DM  patients. 	33378036	2020	LncRNA UCA1 stimulates the repair of hyperglycemic vascular smooth muscle cells through targeting miR-582-5p	E11	9352	pubmed	NA
803	Osteoporosis	HOTAIRM1	HOXA-AS1	NA	NA	 37117	NA	NA	NA	+	4619	chr7:27,095,647-27,100,265	1	0	1	0	RT-qPCR	NA	down-regulated	HOTAIRM1 is downregulated in human and mouse OP	33404645	2020	HOTAIRM1 promotes osteogenic differentiation and alleviates osteoclast differentiation by inactivating the NF-κB pathway	M81.991	11476	pubmed	Bone
804	Osteoporosis	PVT1	LINC00079	NA	NA	 9709	NA	NA	NA	+	11748	chr8:127794532-128101257	1	0	1	0	RT-qPCR	NA	up-regulated	Higher levels of lncRNA score and PVT1 expression were associated with increased serum calcium level after water ingestion and PC risk 	33910638	2021	Role of LncRNA score and PVT1 in primary hyperparathyroidism-- a preliminary study	E21.005	11476	pubmed	Bone
805	Osteoporosis	SNHG14	LNCAT	NA	NA	37462	NA	NA	NA	+	596729	chr15:24,823,608-25,420,336	NA	0	1	0	RT-qPCR	NA	down-regulated	The expression of SNHG14 in the hBMSCs isolated from the patients with OP was much lower than that in the control group	33928771	2020	LncRNA SNHG14 promotes osteogenic differentitation of hunman marrow-derived mesenchymal stem cells via regulating miR-185-5p/WISP2 axis	M81.991	11476	pubmed	Bone
806	Osteoporosis	MALAT1	LINC00047	NA	NA	29665	NA	NA	NA	+	12819	chr11:65496266-65509085	1	0	1	0	RT-qPCR	NA	down-regulated	The results showed that the expression of MALAT1 in OP was much lower than that in the NC 	29741283	2018	Long noncoding RNA MALAT1 promotes osterix expression to regulate osteogenic differentiation by targeting miRNA-143 in human bone marrow-derived mesenchymal stem cells	M81.992	11476	pubmed	Bone
807	Osteoporosis	GAS5	NR_152521	NA	NA	16355	NA	NA	NA	-	4892	chr1:173863901-173868882	1	0	1	0	RT-qPCR	NA	up-regulated	GAS5 Expression Level Is Significantly Upregulated in Serum from OP Patients with Fragility Fractures	32967315	2020	Circulating Long Non-Coding RNA GAS5 Is Overexpressed in Serum from Osteoporotic Patients and Is Associated with Increased Risk of Bone Fragility	M81.994	11476	pubmed	Bone
808	Osteoporosis	FTX	LINC00182	NA	NA	 37190	NA	NA	NA	-	353140	chrX:73,940,435-74,293,574	1	0	1	0	RT-qPCR	NA	down-regulated	FTX was suppressed in OP samples and serums, however, miR-137 was greatly elevated. 	32660465	2020	Down-regulation of FTX promotes the differentiation of osteoclasts in osteoporosis through the Notch1 signaling pathway by targeting miR-137	M81.995	11476	pubmed	Bone
809	Osteoporosis	LINC01535	HSALNG0125829	NA	NA	 51282	NA	NA	NA	+	278697	chr19:37,251,461-37,530,157	1	0	1	0	RT-qPCR	NA	down-regulated	Silencing of LINC01535 inhibits the osteogenic differentiation and proliferation of hBMSCs.	33174047	2020	lncRNA LINC01535 upregulates BMP2 expression levels to promote osteogenic differentiation via sponging miR‑3619‑5p	M81.996	11476	pubmed	Bone
810	Osteoporosis	SNHG1	LINC00057	NA	NA	32688	NA	human	NONHSAG008552.3	-	4139	chr11:62,851,873-62,856,011	1	0	1	0	RT-qPCR	NA	down-regulated	During the process of osteogenic differentiation, the expression of miR‑101 and the osteogenesis‑related genes were upregulated, whereas SNHG1 and DKK1 were downregulated in a time‑dependent manner	32901867	2020	lncRNA SNHG1 attenuates osteogenic differentiation via the  miR‑101/DKK1 axis in bone marrow mesenchymal stem cells	M81.997	11476	pubmed	Bone
811	Osteoporosis	DANCR	ANCR	NA	NA	28964	NA	NA	NA	+	11367	chr4:52,712,257-52,723,623	1	0	1	0	RT-qPCR	NA	up-regulated	DANCR was upregulated in blood MNCs from patients with osteoporosis.	25660720	2014	Long non-coding RNA-DANCR in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis	M81.998	11476	pubmed	Bone
812	Osteoporosis	HCG18	NA	NA	NA	31337	NA	NA	NA	-	93344	chr6:30,234,039-30,327,382	1	0	1	0	RT-qPCR	NA	up-regulated	The expression of HCG18 was increased in BMSCs of OP patients, while the expression of miR-30a-5p was decreased. The expression of HCG18 and miR-30a-5p was negatively correlated in BMSCs.	33176682	2020	Long noncoding RNA HCG18 inhibits the differentiation of human bone marrow-derived mesenchymal stem cells in osteoporosis by targeting miR-30a-5p/NOTCH1 axis	M81.999	11476	pubmed	Bone
813	Osteoporosis	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	RT-qPCR	NA	up-regulated	The results indicated that the expression level of lncRNA XIST in the serum and peripheral blood monocytes of patients with OP was significantly increased compared with that in normal subjects 	30651866	2018	Long non‑coding RNA XIST promotes osteoporosis through inhibiting bone marrow mesenchymal stem cell differentiation	M81.1000	11476	pubmed	Bone
814	Osteoporosis	SNHG5	LINC00044	NA	NA	21026	NA	NA	NA	-	28757	chr6:85,650,491-85,679,247	1	0	1	0	RT-qPCR	NA	down-regulated	 Knockdown of SNHG5 obstructed osteogenic differentiation and promoted apoptosis of hBMSCs	33111341	2020	SNHG5/miR‐582‐5p/RUNX3 feedback loop regulates osteogenic differentiation and apoptosis of bone marrow mesenchymal stem cells	M81.1001	11476	pubmed	Bone
815	Osteoporosis	SNHG14	LNCAT 	NA	NA	37462	NA	NA	NA	+	596729	chr15:24,823,608-25,420,336	1	0	1	0	RT-qPCR	NA	up-regulated	We found that the expression of SNHG14 was enhanced, while the expression of miR-2861 was suppressed in serum and hMSCs from patients with osteoporosis	32770994	2020	SNHG14 induces osteogenic differentiation of human stromal (mesenchymal) stem cells in vitro by downregulating miR-2861	M81.1002	11476	pubmed	Bone
816	Osteoporosis	MEG3	LINC00023	NA	NA	14575	NA	NA	NA	+	23054	chr14:100779409-100861029	1	0	1	0	RT-qPCR	NA	up-regulated	The expressions of MEG3 and miR-133a-3p in BMSCs from PMOP were increased, and there was a positive correlation between MEG3 and miR-133a-3p expression in BMSCs	28320084	2017	LncRNA MEG3 inhibited osteogenic differentiation of bone marrowmesenchymal stem cells from postmenopausal osteoporosis by targeting miR-133a-3p	M81.1003	11476	pubmed	Bone
817	Osteoporosis	TERC	Telomerase RNA Component 	NA	NA	11727	NA	NA	NA	-	599 	chr3:169,764,462-169,765,060	1	0	1	0	RT-qPCR	NA	down-regulated	The downregulated TERC and up-regulated miRNA-217 were identified in the serum of the OP patients. 	32016954	2020	LncRNA TERC alleviates the progression of osteoporosis by absorbing miRNA-217 to upregulate RUNX2	M81.1005	11476	pubmed	Bone
818	Osteoporosis	H19	LINC00008	NA	NA	4713	NA	NA	NA	-	3119	chr11:1995129-20001710	1	0	1	0	RT-qPCR	NA	up-regulated	LncRNA H19 expression were significantly higher in the plasma of osteoporosis patients relative to healthy participants 	33207859	2020	An emerging potential therapeutic target osteoporosis:LncRNA H19/miR-29a-3p axis	M81.1006	11476	pubmed	Bone
819	Osteoporosis	CRNDE	ENSG00000245694	NA	NA	37078	NA	NA	NA	-	85755	chr16:54,845,188-54,930,942	1	0	1	0	RT-qPCR	NA	up-regulated	We found that the CRNDE was highly expressed in the osteoclast from patients with OP, compared with OH. 	30280760	2018	CRNDE impacts the proliferation of osteoclast by estrogen deficiency in postmenopausal osteoporosis	M81.1008	11476	pubmed	Bone
820	Osteoporosis	GAS5	NR_152521	NA	NA	16355	NA	NA	NA	-	4892	chr1:173863901-173868882	1	0	1	0	RT-qPCR	NA	down-regulated	GAS5 decreased in osteoporosis and positively correlated with thr osteoblast differentiation	33006314	2020	Manuscripy title:GAS5 protects against osteoporosis by targeting UPF1/SMAD7 axis in osteoblast differentiation	M81.1009	11476	pubmed	Bone
821	Osteoporosis	ENSG00000250696	LOC105377267	NA	NA	NA	NA	NA	NA	+	35109	chr4:69,181,659-69,216,767	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1010	11476	pubmed	Bone
822	Osteoporosis	ENSG00000258084	Lnc-NAV3-2	NA	NA	NA	NA	NA	NA	+	271667	chr12:78,223,398-78,495,064	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1011	11476	pubmed	Bone
823	Osteoporosis	ENSG00000237636	ANKRD26P3	NA	NA	39689	NA	NA	NA	-	82177	chr13:19,262,797-19,344,973	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1013	11476	pubmed	Bone
824	Osteoporosis	ENSG00000100181	TPTEP1	NA	NA	43648	NA	NA	NA	+	96856	chr22:16,601,887-16,698,742	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1014	11476	pubmed	Bone
825	Osteoporosis	ENSG00000231131	LNCAROD	NA	NA	50913	NA	NA	NA	-	333963	chr10:52,421,545-52,755,507	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1015	11476	pubmed	Bone
826	Osteoporosis	ENSG00000251002	LOC105370401	NA	NA	NA	NA	NA	NA	-	287416	chr14:22,197,196-22,484,611	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1017	11476	pubmed	Bone
827	Osteoporosis	ENSG00000260947	Lnc-PRSS3-2 	NA	NA	NA	NA	NA	NA	+	3669	chr9:33,697,458-33,701,126	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1018	11476	pubmed	Bone
828	Osteoporosis	ENSG00000253516	HMGB1P41	NA	NA	39188	NA	NA	NA	-	502	chr8:80,812,080-80,812,581	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1019	11476	pubmed	Bone
829	Osteoporosis	ENSG00000242810	MRPL42P6	NA	NA	44533	NA	NA	NA	-	371	chr3:151,475,804-151,476,174	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1020	11476	pubmed	Bone
830	Osteoporosis	ENSG00000272168	CASC15	NA	NA	28245	NA	NA	NA	+	990271	chr6:21,664,185-22,654,455	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1021	11476	pubmed	Bone
831	Osteoporosis	ENSG00000249363	AC011411.1	NA	NA	NA	NA	NA	NA	-	990	chr5:145,728,360-145,729,349	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1024	11476	pubmed	Bone
832	Osteoporosis	ENSG00000270061	AC068790.5	NA	NA	NA	NA	NA	NA	-	356	chr12:123,969,989-123,970,344	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1025	11476	pubmed	Bone
833	Osteoporosis	ENSG00000232555	AC104088.1	NA	NA	NA	NA	NA	NA	+	233057	chr2:172,137,345-172,370,401	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1026	11476	pubmed	Bone
834	Osteoporosis	ENSG00000215386	MIR99AHG	NA	NA	1274	NA	NA	NA	+	717250	chr21:15,928,246-16,645,495	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1027	11476	pubmed	Bone
835	Osteoporosis	ENSG00000260802	SERTM2	NA	NA	48576	NA	NA	NA	+	10755	chrX:111,511,645-111,522,399	1	0	1	0	RT-qPCR	NA	up-regulated	Top 20 upregulated and 20 downregulated lncRNAs in patients with PMOP compared to controls.	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1029	11476	pubmed	Bone
836	Osteoporosis	ENSG00000234026	Lnc-PDLIM1-1	NA	NA	NA	NA	NA	NA	-	62324	chr10:95,168,822-95,231,145	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1030	11476	pubmed	Bone
837	Osteoporosis	ENSG00000263823	AC009831.1	NA	NA	NA	NA	NA	NA	+	2410	chr18:31,941,855-31,944,264	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1031	11476	pubmed	Bone
838	Osteoporosis	ENSG00000236972	FABP5P1	NA	NA	31059	NA	NA	NA	-	675	chr13:73,100,371-73,101,045	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1032	11476	pubmed	Bone
839	Osteoporosis	ENSG00000230438	SERPINB9P1	NA	NA	28590	NA	NA	NA	-	30178	chr6:2,851,230-2,881,407	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1033	11476	pubmed	Bone
840	Osteoporosis	ENSG00000213820	RPL13P2	NA	NA	16342	NA	NA	NA	+	720	chr20:46,099,475-46,100,194	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1034	11476	pubmed	Bone
841	Osteoporosis	ENSG00000226721	EEF1DP2	NA	NA	33523	NA	NA	NA	-	976	chr9:92,836,766-92,837,741	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1035	11476	pubmed	Bone
842	Osteoporosis	ENSG00000255723	AC108516.2	NA	NA	NA	NA	NA	NA	-	57246	chr4:87,317,169-87,374,414	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1036	11476	pubmed	Bone
843	Osteoporosis	ENSG00000257366	Lnc-ABCC6-2	NA	NA	NA	NA	NA	NA	-	1460	chr16:16,308,541-16,310,000	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1037	11476	pubmed	Bone
844	Osteoporosis	ENSG00000263874	LINC00672	NA	NA	44353	NA	NA	NA	+	4218	chr17:38,925,167-38,929,384	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1038	11476	pubmed	Bone
845	Osteoporosis	ENSG00000204620	AC115618.1	NA	NA	NA	NA	NA	NA	-	7772	chrX:48,567,089-48,574,860	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1039	11476	pubmed	Bone
846	Osteoporosis	ENSG00000270137	AF230666.2	NA	NA	NA	NA	NA	NA	+	726	chr8:132,826,178-132,826,903	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1040	11476	pubmed	Bone
847	Osteoporosis	ENSG00000204283	LINC01973	NA	NA	52800	NA	NA	NA	-	17965	chr17:77,876,138-77,894,102	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1041	11476	pubmed	Bone
848	Osteoporosis	ENSG00000206356	LOC100652833	NA	NA	NA	NA	NA	NA	-	3152	chr5:99,522,311-99,525,462	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1042	11476	pubmed	Bone
849	Osteoporosis	ENSG00000182487	NCF1B	NA	NA	32522	NA	NA	NA	+	15322	chr7:73,220,624-73,235,945	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1044	11476	pubmed	Bone
850	Osteoporosis	ENSG00000248693	LINC02100	NA	NA	52955	NA	NA	NA	-	231346	chr5:18,514,857-18,746,202	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1045	11476	pubmed	Bone
851	Osteoporosis	ENSG00000255468	LOC102724064	NA	NA	NA	NA	NA	NA	+	17653	chr11:66,347,170-66,364,804	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1046	11476	pubmed	Bone
852	Osteoporosis	ENSG00000263731	AC145207.5	NA	NA	NA	NA	NA	NA	-	9190	chr17:81,878,420-81,887,609	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1047	11476	pubmed	Bone
853	Osteoporosis	ENSG00000260176	AC141586.2	NA	NA	NA	NA	NA	NA	-	1132	chr16:2,644,083-2,645,214	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1048	11476	pubmed	Bone
854	Osteoporosis	ENSG00000249526	AC008667.1	NA	NA	NA	NA	NA	NA	+	65379	chr5:139,684,644-139,750,022	1	0	1	0	RT-qPCR	NA	down-regulated	Downregulated lncRNAs 	32742382	2020	Investigation of long non‑coding RNA expression profiles in patients with post‑menopausal osteoporosis by RNA sequencing	M81.1049	11476	pubmed	Bone
855	Osteoporosis	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	RT-qPCR	NA	up-regulated	XIST was up-regulated while miR-758-3p was down-regulated in IA mouse  and cells models.	33336851	2020	Iron accumulation regulates osteoblast apoptosis through lncRNA  XIST/miR-758-3p/caspase 3 axis leading to osteoporosis 	M81.1050	11476	pubmed	Bone
856	Osteoporosis	AWPPH	MIR4435-2HG	NA	NA	35163	NA	NA	NA	-	517362	chr2:111,006,015-111,523,376	1	0	1	0	RT-qPCR	NA	down-regulated	LncRNA AWPPH is downregulated in osteoporosis and regulates type I collagen α1 and α2 ratio	32552067	2020	LncRNA AWPPH is downregulated in osteoporosis and regulates type I collagen α1 and α2 ratio	M81.1052	11476	pubmed	Bone
857	Osteoporosis	GAS5	NR_152521	NA	NA	16355	NA	NA	NA	-	4892	chr1:173863901-173868882	1	0	1	0	RT-qPCR	NA	up-regulated	The resultsshowed that GAS5 was upregulated, while miR-21 was downregulated in plasma of osteoporosis patients. 	32764903	2020	lncRNA GAS5 Is Upregulated in Osteoporosis and Downregulates miR-21 to Promote Apoptosis of Osteoclasts	M81.1054	11476	pubmed	Bone
858	Osteoporosis	KCNQ1OT1	LIT1	NA	NA	6295	NA	NA	NA	-	102886	chr11:2,597,113-2,699,998	1	0	1	0	RT-qPCR	NA	up-regulated	KCNQ1OT1 was significantly up-regulated during the process of osteogenic induction  while miR-214 was contrarily down-regulated.	30703347	2019	LncRNA KCNQ1OT1 promoted BMP2 expression to regulate osteogenic differentiation by sponging miRNA-214	M81.1055	11476	pubmed	Bone
859	Osteoporosis	LOXL1-AS1	NA	NA	NA	44169	NA	NA	NA	-	48514	chr15:73,898,711-73,947,224	1	0	1	0	RT-qPCR	NA	up-regulated	The abnormal high expression of LOXL1-AS1 was found in patients. 	32651705	2019	LncRNA LOXL1‑AS1 controls osteogenic and adipocytic differentiation of bone marrow mesenchymal stem cells in postmenopausal osteoporosis through regulating the miR‑196a‑5p/Hmga2 axis	M81.1056	11476	pubmed	Bone
860	Osteoporosis	TUG1	LINC00080	NA	NA	26066	NA	NA	NA	+	8448	chr22:30969157-30979394	1	0	1	0	RT-qPCR	NA	up-regulated	We found that plasma lncRNA TUG1 was upregulated in osteoporosis patients than in healthy participants.	31815638	2019	LncRNA TUG1 was upregulated in osteoporosis and regulates the proliferation and apoptosis of osteoclasts	M81.1057	11476	pubmed	Bone
861	Osteoporosis	H19	LINC00008	NA	NA	4713	NA	NA	NA	-	3119	chr11:1995129-20001710	1	0	1	0	RT-qPCR	NA	down-regulated	Long noncoding RNA MIRG induces osteoclastogenesis and bone resorption in osteoporosis through negative regulation of miR-1897	31918667	2020	MicroRNA-19b-3p promotes cell proliferation and osteogenic differentiation of BMSCs by interacting with lncRNA H19	M81.1061	11476	pubmed	Bone
862	Osteoporosis	TUG1	LINC00080	NA	NA	26066	NA	NA	NA	+	8448	chr22:30969157-30979394	1	0	1	0	RT-qPCR	NA	up-regulated	LncRNA TUG1 was upregulated in osteoporosis and regulates the proliferation and apoptosis of osteoclasts	33046099	2020	Retraction Note: LncRNA TUG1 was upregulated in osteoporosis and regulates the proliferation and apoptosis of osteoclasts	M81.1062	11476	pubmed	Bone
863	Osteoporosis	BCAR4	HSALNG0109621	NA	NA	22170	NA	NA	NA	-	10554	chr16:11,818,292-11,828,845	1	0	1	0	RT-qPCR	NA	down-regulated	BCAR4 was markedly down-regulated compared with controls, indicating the involvement of BCAR4 in osteogenic differentiation of BMSCs	32572903	2020	Silence of lncRNA BCAR4 alleviates  the deterioration of osteoporosis	M81.1063	11476	pubmed	Bone
864	Osteoporosis	MCF2L-AS1	NA	NA	NA	39825	NA	NA	NA	-	1947	chr13:112,967,201-112,969,147	1	0	1	0	RT-qPCR	NA	down-regulated	MCF2L-AS1 expression is up-regulated after osteogenic induction of BMSCs	32255731	2020	The lncRNA MCF2L-AS1 controls osteogenic differentiation by regulating miR-33a	M81.1064	11476	pubmed	Bone
865	Diabetic peripheral neuropathy	BC168687	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr1:151,540,357-151,582,911	0	1	0	1	NA	NA	up-regulated	lncRNAs are essential regulators of gene expression. In addition to the articles mentioned, more lncRNAs will be found to be involved in the pathogenesis of DPN. At the same time, they have recently been characterized as important modulators of neuronal functions. As shown above, some specific lncRNAs participate in the pathophysiological processes of DPN. This review provides a better understanding of the emerging roles of lncRNAs in DPN	32431526	2020	Advances with Long Non-Coding RNAs in Diabetic Peripheral Neuropathy	NA	NA	pubmed	Peripheral nerve
866	Diabetic cardiomyopathy	H19	NA	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	0	1	0	1	NA	NA	NA	In summary, current data indicate that LncRNAs are a vital regulator of DCM and act as the promising diagnostic and therapeutic targets for DCM.	30342478	2018	Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy	NA	NA	pubmed	Heart
867	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	0	1	0	1	NA	NA	up-regulated	our study demonstrates that MALAT1 is significantly upregulated in cardiac tissue of diabetic rats, and its knockdown is associated with an improvement in left ventricular function, partly through the attenuation of cardiomyocyte apoptosis. Therefore, inhibition of MALAT1 may serve as a novel therapeutic strategy for diabetes-related cardiac dysfunction.	26512840	2016	Down-regulation of lncRNA MALAT1 reduces cardiomyocyte apoptosis and improves left ventricular function in diabetic rats	NA	NA	pubmed	Heart
868	Patent ductus arteriosus	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	0	1	0	1	NA	NA	up-regulated	The plethora of studies covered in this review highlight the importance of ncRNAs in CLI from mice to human subjects. Accumulating studies reveal that the failure of therapeutic delivery of angiogenic growth factors in CLI is not likely related to growth factor deficiency, but rather due to impaired downstream angiogenic signaling pathways, an effect potentially overcome through the use of miRNAs or lncRNAS	31893949	2020	Noncoding RNAs in Critical Limb Ischemia	NA	NA	pubmed	Heart
869	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	0	1	0	1	NA	NA	down-regulated	This review provides a comprehensive update on pre-clinical and clinical studies that might develop therapeutic strategies to limit/prevent DMCM.	33551838	2021	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy	NA	NA	pubmed	Heart
870	Diabetic cardiomyopathy	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	Mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Cell culture and treatments,CCK-8 assay,Cell apoptosis analysis,RT-qPCR analysis,Western blot analysis,Dual-luciferase reporter assay,RNA immunoprecipitation (RIP) assay	AC16 human cardiomyocyte-like cells (Davidson et al., 2005), purchased from the American Type Culture Collection	up-regulated	this study demonstrated that GAS5 knockdown alleviated HG-induced inflammation in AC16 cells partly by inhibiting miR-21-5p-mediated TLR4/NF-κB signaling, indicating that GAS5 could act as a potential lncRNA-based therapeutic target for patients with DCM in the future	31865425	2020	Knockdown of long noncoding RNA GAS5 protects human cardiomyocyte-like AC16 cells against high glucose-induced inflammation by inhibiting miR-21-5p-mediated TLR4/NF-κB signaling	NA	NA	pubmed	Heart
871	Diabetic cardiomyopathy	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	Mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Animal model,Cardiomyocyte HG model,CCK-8 detection cell activity,Cell transfection,Real-time quantitative polymerase chain reaction,Flow cytometry,Lactate dehydrogenase,TUNEL detection,ELISA detection of low-density lipoprotein, TNF-ɑ, IL-1β, IL-6, SOD, and MDA levels in cell supernatants and mouse serum	AC16 cells	up-regulated	We confirmed for the first time that the down-regulation of GAS5 could reverse CYP11B2 via the miR-138 axis to reverse HG-induced cardiomyocyte injury. This research might provide a new direction for explaining the developmental mechanism of DCM and potential targets for the treatment of myocardial injury	33682891	2021	Long-chain noncoding RNA-GAS5/hsa-miR-138-5p attenuates high glucose-induced cardiomyocyte damage by targeting CYP11B2	NA	NA	pubmed	Heart
872	Diabetic cardiomyopathy	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	Mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Cell isolation and treatment,Cell transfection,Animal model,Echocardiographic examination,Histological analysis,Western blot,QRT‑PCR,Luciferase reporter assay,RNA immunoprecipitation (RIP) assay,Apoptosis analysis	Primary mouse cardiomyocytes were isolated from the hearts of 3-day-old neonatal male C57BL/6 mice as previously described	up-regulated	Our study showed that GAS5 promotes DCM progression by regulating miR-26a/b-5p, suggesting that GAS5 might be a potential therapeutic target for DCM.	34091757	2021	Silencing lncRNA GAS5 alleviates apoptosis and fibrosis in diabetic cardiomyopathy by targeting miR-26a/b-5p	NA	NA	pubmed	Heart
873	Diabetic cardiomyopathy	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	Mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Cell culture and treatment,RNA isolation and quantitative real‐time polymerase chain reaction,Cell transfection,Chromatin immunoprecipitation,Luciferase reporter assay,Terminal deoxynucleotidyl transferase dUTP nick‐end labeling assay,JC‐1 assay,Flow cytometer assay,Western blot,Subcellular fraction,Fluorescence in situ hybridization,RNA pull‐down	Newborn rat cardiomyocyte (NRC) and newborn mouse cardiomyocyte (NMC) were isolated from the 1‐ to 2‐day old Sprague‐Dawley rat	up-regulated	Tcf3‐activated lncRNA Gas5 regulates NMC apoptosis in diabetic cardiomyopathy	32003049	2020	Tcf3-activated lncRNA Gas5 regulates newborn mouse cardiomyocyte apoptosis in diabetic cardiomyopathy	NA	NA	pubmed	Heart
874	Diabetic cardiomyopathy	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	Mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Animal model and treatment,Echocardiographic study,Cell culture and treatment,Cell transfection,QRT-PCR,Hematoxylin-eosin (HE)staining,Western blot (WB),Enzyme-linked immunosorbent assay (ELISA),Casepare-1 activity detection,LDH-release assay,Luciferase reporter assay	Cardiac muscle cell line HL-1 was obtained from ATCC	down-regulated	In summary, our study demonstrates that lncRNA GAS5 is down-regulated in the heart tissues of DCM mice and may act as a ceRNA to enhance AHR expression by sponging miR-34b-3p,which consequently represses NLRP3 inflammasome activation-mediated pyroptosis to improve DCM. Our data provide a novel lncRNA GAS5 that could be a valuable target for DCM treatment	33092444	2020	LncRNA GAS5 inhibits NLRP3 inflammasome activation-mediated pyroptosis in diabetic cardiomyopathy by targeting miR-34b-3p/AHR	NA	NA	pubmed	Heart
875	Diabetic cardiomyopathy	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	Mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Ethics statement,Cell culture,Vector construction and adeno-associated virus (AAV-9A) packaging,Establishment of diabetic rats,Reverse transcription-qPCR,Hematoxylin and eosin (H&E) staining,Masson staining,Western blot,Luciferase reporter assay,Transfection of sip27,	H9C2 cells [H9c2 (2–1); The Cell Bank of Type Culture Collection of Chinese Academy of Sciences] were cultured in DMEM	up-regulated	GAS5 reversed the histopathological changes induced by DCM and enhanced cardiomyocyte autophagy to ameliorate myocardial function. The mechanism underlying the effect of GAS5 in the diabetic myocardium may be attributed to a GAS5/miR-221-3p/p27 competing endogenous network and cardiomyocyte autophagy. Thus, GAS5 may promote cardiomyocyte autophagy via regulating the miR-221-3p/p27 axis to protect myocardial function in DCM.	33313941	2021	GAS5 regulates diabetic cardiomyopathy via miR‑221‑3p/p27 axis‑associated autophagy	NA	NA	pubmed	Heart
876	Diabetic cardiomyopathy	H19	NA	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Animal model and treatment,Cardiomyocyte culture,Echocardiographic study,Inflammatory cytokines detection,Oxidative stress measurement,TUNEL staining,Annexin V-FITC/PI staining,Luciferase reporter assay,Real-time PCR,	The hearts were surgically removed from 1–2 days old rats and washed instantly in cold D-Hanks solution	down-regulated	these data revealed a novel function of H19/miR-675/VDAC1 pathway in the regulation of high glucose-mediated apoptosis, which may provide valuable insights for understanding the pathogenic role of lncRNA H19 in the development of DCM	27796346	2016	lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy	NA	NA	pubmed	Heart
877	Diabetic cardiomyopathy	H19	NA	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Animal model and treatment,Cardiomyocyte culture,Hemodynamic study,Transmission electron microscopy (TEM),Chromatin immunoprecipitation (ChIP),RNA-binding protein immunoprecipitation (RIP),Real-time PCR,Western blotting	Neonatal ventricular myocytes were isolated from 1-2 days old rats as previously described	down-regulated	In conclusion, our study suggested that H19 could inhibit autophagy in cardiomyocytes by epigenetically silencing of DIRAS3, which might provide novel insights into understanding the molecular mechanisms of diabetic cardiomyopathy.	27903964	2017	LncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy	NA	NA	pubmed	Heart
878	Diabetic cardiomyopathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	Serum samples of patients,Animal model and treatment,Cell culture and transfection,Echocardiography,HE and Masson’s trichrome staining,Total RNA isolation and quantitative real-time RT-PCR (qRT-PCR),Protein extraction and western blot analysis,Immunofluorescence staining,Immunohistochemical analysis,Luciferase assay	The primary cardiac fibroblasts were extracted from hearts of one- to 3-day-old neonatal C57BL/6 mice. The isolation and culture methods were described previously	up-regulated	 Kcnq1ot1/miR-214-3p/caspase-1/TGF-尾1 signal pathway presents a new mechanism of DCM progression and could potentially be a novel therapeutic target	30250027	2018	Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy	NA	NA	pubmed	Heart
879	Diabetic cardiomyopathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	Ethics statement,Animals and establishment of the diabetic model,Echocardiography,Hematoxylin and eosin (HE) staining and Masson’s trichrome staining,Immunohistochemical analysis,Cell culture and transfection,RNA isolation and quantitative real-time RT-PCR (qRT-PCR),Protein extraction and western blot analysis,Immunofluorescence staining,TUNEL staining,Fluorescence measurement of [Ca2+]i in cardiomyocytes	AC16 human myocardial cells were obtained from the Shanghai Institute for Biological Sciences	up-regulated	our results indicate that the lncRNA Kcnq1ot1 is upregulated in DCM and that silencing Kcnq1ot1 inhibits pyroptosis by influencing miR-214-3p and caspase-1. We are the first to clarify that Kcnq1ot1 could be a new therapeutic target for DCM.	30355944	2018	LncRNA KCNQ1OT1 Mediates Pyroptosis in Diabetic Cardiomyopathy	NA	NA	pubmed	Heart
880	Diabetic corneal endothelial keratopathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	Study participants,Donor corneal tissue samples,Animal models,Measurement and analysis of corneal endothelial cell density in vivo,Cell culture and treatment,Cell proliferation assay,LDH Quantification,RNA interference and transfection assay,Immunohistochemical analysis and immunofluorescence staining,Quantitative real-time RT-PCR (qRT-PCR),Western blot analysis,Luciferase assay	The human corneal endothelial cell (HCEC) line HCEC-B4G12	up-regulated	Therefore, the KCNQ1OT1/miR-214/caspase-1 signaling pathway represents a new mechanism of diabetic corneal endothelial keratopathy progression, and KCNQ1OT1 could potentially be a novel therapeutic target.	31693400	2020	Long noncoding RNA KCNQ1OT1 induces pyroptosis in diabetic corneal endothelial keratopathy	NA	NA	pubmed	Eye
881	Diabetic retinopathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	Cell culture and treatment,Cell transfection and transfection,Measurement of cell viability,Assessment of cell death,Assessment of lactate dehydrogenase (LDH) cytotoxicity,Enzyme-linked immunosorbent assay (ELISA),Luciferase reporter assay,RNA Immunoprecipitation (RIP),Quantitative RT-PCR,Western blot analysis	Mouse podocyte cell line, MPC5, derived from kidney	 	Kcnq1ot1 is highly expressed in sC5b-9-injured podocytes, and it 357 promotes podocyte pyroptosis through activating NLRP3 inflammasome and 358 subsequent downstream inflammatory responses. Meanwhile, Kcnq1ot1 mediates 359 sC5b-9-induced miR-486a-3p inhibition	33296289	2021	Long noncoding RNA Kcnq1ot1 promotes sC5b-9-induced podocyte pyroptosis by inhibiting miR-486a-3p and upregulating NLRP3	NA	NA	pubmed	Eye
882	Diabetic cardiomyopathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	Cell culture and treatment,Plasmid construction and transfection,Luciferase reporter gene assay,RNA immunoprecipitation (RIP) assay,Cell apoptosis assay,Cell counting kit 8 (CCK8) assay,The establishment of a mouse model of DCM,Haematoxylin and eosin (HE) staining and Masson’s trichrome staining,TUNEL staining,Immunohistochemical analysis,Quantitative real‑time PCR (qPCR),Enzyme‑linked immunosorbent assay (ELISA),Western blotting	Human cardiomyocytes (HCMs) were obtained from PromoCell and maintained in cardiac myocyte growth medium	up-regulated	our fnding suggested that KCNQ1OT1 and its downstream target gene miR-181a-5p/PDCD4 modulated the infammatory response and apoptosis by modulating PDCD4 in DCM, presenting new insights into the mechanisms of apoptosis in the occurrence and development of DCM and suggesting the therapeutic potential of targeting apoptosis-related pathways in DCM. Further studies are warranted to confrm the preliminary fndings in our study.	33907874	2021	Long non-coding RNA KCNQ1OT1 increases the expression of PDCD4 by targeting miR-181a-5p, contributing to cardiomyocyte apoptosis in diabetic cardiomyopathy	NA	NA	pubmed	Heart
883	Diabetic cardiomyopathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	Microarray analysis,Experimental animals,Induction of diabetes,Neonatal rat cardiomyocytes (NCMs) isolation and culture,Cell transfection,Ex vivo hypoxia-reoxygenation injury in cardiomyocytes,Myocardial ischemia reperfusion injury (MI/R) in rats,QRT-PCR,Construction of adenovirus vector,Lactate dehydrogenase (LDH) assay,Assays for superoxide dismutase (SOD),Determination of serum myocardial enzyme content,Determination of cardiac function, Measurement of myocardial infarct size,Western blotting analysis,Mitochondrial membrane potential measurement,Assessment of ATP content,Evaluation of fluorescent LC3 puncta,Determination of myocardial apoptosis,Immunohistochemical staining,MTT assays	Neonatal rat cardiomyocytes (NCMs) isolation and culture	up-regulated	LncRNANeat1 was significantly upregulated in I/R treated diabetic myocardial tissues. In diabetic rats, Neat1 exacerbated H/R injury ex vivo and I/R injury in vivo by activating autophagic flux, which suggested that Neat1 inhibition induced autophagic flux arrest and alleviated reperfusion injuries in diabetic rats	30205319	2018	Long non-coding RNA nuclear-enriched abundant transcript 1 inhibition blunts myocardial ischemia reperfusion injury via autophagic flux arrest and apoptosis in streptozotocin-induced diabetic rats	NA	NA	pubmed	Heart
884	Diabetic cardiomyopathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	Isolation and culture of mouse cardiomyocytes,cell treatment,Cell transfection,Luciferase reporter assay, In vivo experiments,Cardiac hemodynamic parameters,Histological examination,TUNEL staining,Quantitative RT-PCR analysis,Western blot	Isolation and culture of mouse cardiomyocytes	up-regulated	In conclusion, we initiated an exploratory analysis on the expression of lncRNA Neat1 in process of cardioprotective effect of Catalpol in DCM and determined its downstream mechanism of miR-140-5p/HDAC4	31078585	2019	Catalpol attenuates cardiomyocyte apoptosis in diabetic cardiomyopathy via Neat1/miR-140-5p/HDAC4 axis	NA	NA	pubmed	Heart
885	Diabetic cardiomyopathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	Subjects and ethical statement,RNA extraction and quantitative reverse transcription (qRT)-PCR,Western blotting,Preparation of dendrobium mixture,Cell culture,Flow cytometry and MTT assay,Plasmid construction and dual luciferase reporter assays,Construction of DCM model rats,Hematoxylin and eosin staining	H9c2 rat cardiomyocytes were obtained from the China Center for Type Culture Collection	up-regulated	Dendrobium mixture and Met upregulated the expression of NEAT1 in DCM, thereby inhibiting apoptosis of myocardial cells.	34231706	2021	Combination of Dendrobium Mixture and Metformin Curbs the Development and Progression of Diabetic Cardiomyopathy by Targeting the lncRNA NEAT1	NA	NA	pubmed	Heart
886	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	The diabetic rat model was induced with a single intraperitoneal injection of streptozotocin,Diabeti c rats were intracoronary injected with lentivirus of MALAT1 shRNA (DM + MALAT1-shRNA) or scramble shRNA (DM + ScrshRNA), and were then kept for 12 weeks together with the normal rats (Control) and the diabetic rats without lentivirus injection (DM), Cardiac structure and function were evaluated by two-dimensional echocardiography performed as previously described;Total RNA was isolated from the cardiac tissue using TRIZOL reagent. RNA was reverse transcribed using SuperScript First Strand cDNA System;	Total RNA was isolated from the cardiac tissue using TRIZOL reagent	up-regulated	our study demonstrates that MALAT1 is significantly upregulated in cardiac tissue of diabetic rats, and its knockdown is associated with an improvement in left ventricular systolic function, partly through the attenuation of diabetes-induced myocardial inflammation.	26476026	2016	Involvement of long noncoding RNA MALAT1 in the pathogenesis of diabetic cardiomyopathy	NA	NA	pubmed	Heart
887	Diabetic atherosclerosis	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Ethics statement, preparation of DA model and experimental grouping,Detection of ET-1 and IL-1β contents,Culture of macrophages and HG-OxLDL induction,Detection of cell viability and cell pyroptosis ,Overexpression and knockdown of MALAT1,Quantitative PCR,Western blotting,	Bone marrow-derived macrophages (BMDMs) were derived by harvesting marrow from male Sprague-Dawley rats (6 months old)	up-regulated	ow-dose SA can abate the pyroptosis of macrophages by downregulation of lncRNA-MALAT1 in rats with DA	29095793	2018	Low-dose Sinapic Acid Abates the Pyroptosis of Macrophages by Downregulation of lncRNA-MALAT1 in Rats With Diabetic Atherosclerosis	NA	NA	pubmed	Blood vessel
888	Diabetic gastroparesis(DGP)	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Animals and ethics statement,Gastric emptying test,Tissue specimens,Cell culture,RNA extraction and Real-time PCR analyses,RNA interference and cell transfection,Western blot assay,CCK8 assay,Migration assay	full-thickness gastric samples were collected from the adjacent normal region (at least5cm away from gastric cancer lesions) of the stomach	up-regulated	MALAT1 may be involved in the development of DGP by promoting phenotypetransition and affecting cellular processes of SMCs	29317209	2018	LncRNA MALAT1 is up-regulated in diabetic gastroparesis and involved in high-glucose-induced cellular processes in human gastric smooth muscle cells	NA	NA	pubmed	Stomach
889	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Cell lines, treatments, and RNA interference,Animal care and treatment,RNA extraction and qRT,Gene expression by qPCR,Chromatin immunoprecipitation (ChIP),	Mouse HL-1 cells and rat H9C2 differentiated into cardiomyocytes	up-regulated	these data suggest that Sildenafil counteracts the increase of MALAT1 occurring in cardiomyocytes as a consequence of elevated glucose levels in vitro	29691810	2018	Sildenafil normalizes MALAT1 level in diabetic cardiomyopathy	NA	NA	pubmed	Heart
890	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Animal model establishment,Cardiomyocyte isolation and viral infection,Quantitative real-time PCR,Western blot,Hematoxylin-eosin staining,TdT mediated X-dUTP nicked labeling (TUNEL) assay,Dual-luciferase assay	Cardiomyocyte isolation and viral infection	up-regulated	our findings reveal that Malat1 knockdown attenuates high glucose-induced cardiomyocyte apoptosis via releasing miR-181a-5p, and this mechanism may provide us with new diagnosis target of DCM	31353329	2020	Inhibition of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 attenuates high glucose-induced cardiomyocyte apoptosis via regulation of miR-181a-5p	NA	NA	pubmed	Heart
891	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	 Animals and mouse model of diabetes, Echocardiography, Transmission electron microscopy,Immunohistochemical staining, Histopathological analysis,Real-time RT-PCR,Western blot,Isolation and culture of CFs,Transfection and treatment of CFs,Immunofluorescence assay,Luciferase reporter assay	 	up-regulated	Melatonin alleviates cardiac fibrosis by inhibiting lncR-MATAL1/miR-141-mediated NLRP3 inflammasome activation and TGF-β1/Smads signaling in diabetic mice, and it might be considered a new therapeutic molecule for preventing and treating DCM	32067273	2020	Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy	NA	NA	pubmed	Heart
892	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Ethics statement,Isolation and culture of neonatal mouse cardiac fibroblasts (CFs),Cell transfection,RNA-Fluorescence in situ hybridization (FISH),Fractionation of nuclear and cytoplasmic RNA,Reverse transcription quantitative polymerase chain reaction (RT-qPCR),Immunocytochemical staining,Enzyme-linked immunosorbent assay (ELISA),3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay,Flow cytometry,Transwell assay,Western blot analysis,Animal experiment,Assessment of cardiac function,Pathological observation,Immunohistochemical staining	Isolation and culture of neonatal mouse cardiac fibroblasts (CFs)	up-regulated	the present study provided evidence that silencing MALAT1 could reduce inflammation and collagen accumulation in high-glucose CFs and DCM mice via the Hippo/YAP pathway	32069074	2020	LncRNA MALAT1 regulates diabetic cardiac fibroblasts through the Hippo-YAP signaling pathway	NA	NA	pubmed	Heart
893	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Animal treatment,Cell culture and treatment, RNA isolation and quantitation,Western blot analysis,Dual-luciferase reporter assay,RNA immunoprecipitation (RIP) assay,Northern blot assay,Chromatin immunoprecipitation (ChIP) assay,Evaluation of cardiac function,Histological analysis,Flow cytometric analysis,Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining,Statistical analysis	Cardiac tissues of 1-day-old newborn C57BL/Ks mice were subjected to primary culture to obtain mouse cardiomyocytes	up-regulated	MALAT1 may improve cardiac function and suppress cardiomyocyte apoptosis by impairing EZH2-mediated transcriptional inhibition of miR-22 and inducing miR-22-targeted inhibition of ABCA1 (summarized in Fig. 6). Hence, the role of MALAT1 via EZH2/miR-22/ABCA1 in cardiac function and cardiomyocyte apoptosis may help improve the existing understanding of the underlying mechanisms associated with myocardial injury in diabetic cardiomyopathy, with the potential of serving as a diagnostic and prognostic marker for the disease in the future.	33097254	2021	MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabetic cardiomyopathy	NA	NA	pubmed	Heart
894	Diabetic cardiomyopathy	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Cell culture and groups,Reverse transcription-quantitative PCR (RT-qPCR) RT-qPCR,Cell transfection and grouping,Dual luciferase reporter assay,Detection of pyroptosis by TUNEL staining,Immunofluorescence staining,Western blotting,Verification experiment	Rat cardiomyocytes (H9C2; The Cell Bank of Type Culture Collection of The Chinese Academy of Sciences) 	up-regulated	Collectively, the present study provided novel insight for the diagnosis and targeted therapy of DCM. The results suggested that it might be possible to prevent the damage caused by HG-induced pyroptosis in the early stages, thereby preventing the occurrence and development of DCM	33576445	2021	lncRNA‑MALAT1 promotes high glucose‑induced H9C2 cardiomyocyte pyroptosis by downregulating miR‑141‑3p expression	NA	NA	pubmed	Heart
895	Diabetic cardiomyopathy	HOTAIR	TCONS_00007755	NA	NA	33510	ENST00000439545.1	human	NONHSAT028509.2	-	2337	chr12:53,962,308-53,974,956	1	0	1	0	Animal and model,Echocardiography and hemodynamic evaluations,Histological analysis, immunohistochemistry,and TUNEL staining,Detection of total superoxide dismutase activity, nicotinamide adenine dinucleotide phosphate oxidase activity,Detection of reactive oxygen species and cell viability,Cell culture and treatment,Real‐time polymerase chain reaction,Western blot analysis,Luciferase reporter assay,RNA‐binding protein immunoprecipitation assay	H9c2 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China)	down-regulated	 Furthermore, the protective effects of HOTAIR on DCM was abolished in SIRT1 deficiency mice in vivo. HOTAIR protected against DCM via activation of the SIRT1 expression by sponging miR-34a	30216438	2019	LncRNA HOTAIR functions as a competing endogenous RNA to upregulate SIRT1 by sponging miR-34a in diabetic cardiomyopathy	NA	NA	pubmed	Heart
896	Diabetic cardiomyopathy	HOTAIR	TCONS_00007755	NA	NA	33510	ENST00000439545.1	human	NONHSAT028509.2	-	2337	chr12:53,962,308-53,974,956	1	0	1	0	Subjects,Specimen collection,Cell line and cell culture,Cell transfection,MTT assay,RT-qPCR,Western blot analysis	Human cardiomyocyte cell line AC16 was purchased from EMD Millipore (Billerica, MA, USA)	down-regulated	HOTAIR expression was specifically downregulated in patients with diabetic cardiomyopathy. Serum HOTAIR may serve as a promising biomarker for diabetic cardiomyopathy. High glucose treatment inhibited HOTAIR expression and Akt phosphorylation. HOTAIR overexpression promoted Akt phosphorylation and improved AC16 cell viability. PI3K/Akt inhibitor treatment reduced this enhancing effect of HOTAIR overexpression on AC16 cell viability. These results suggest that lncRNA HOTAIR may improve diabetic cardiomyopathy by improving the viability of cardiomyocytes through activation of the PI3K/Akt pathway	30542437	2018	LncRNA HOTAIR improves diabetic cardiomyopathy by increasing viability of cardiomyocytes through activation of the PI3K/Akt pathway	NA	NA	pubmed	Heart
897	Diabetic cardiomyopathy	DACH1	NA	NA	NA	2663	NA	human	NONHSAT166910.1	-	255	chr13:71,437,966-71,867,204	1	0	1	0	Animals,Mouse model of diabetic cardiomyopathy,Blood glucose and lipid measurement,Echocardiography,Histological analysis,Transmission electron microscopy,TUNEL assay,Culture of NMVCs and treatments,Transfection of plasmids or siRNAs to cells,Quantitative real-time PCR,Western blot analysis,Determination of mitochondrial ROS and total ROS production,Mitochondrial membrane potential measurement,Mitochondrial morphology assessment in cardiomyocytes,RNA pull-down assay,RNA immunoprecipitation assay,Ubiquitination of SIRT3,	Cardiomyocytes or heart tissue	up-regulated	we clarify the role of lncDACH1 in regulation of oxidative stress damage, apoptosis, and cardiac function in DCM hearts. Knockdown of lncDACH1 attenuates mitochondrial oxidative stress and cell apoptosis,alleviates cardiomyocyte damage and improves cardiac function in DCM mice via reducing ubiquitination-mediated degradation of SIRT3	34668131	2021	LncDACH1 promotes mitochondrial oxidative stress of cardiomyocytes by interacting with sirtuin3 and aggravates diabetic cardiomyopathy	NA	NA	pubmed	Heart
898	Vascular complication	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr14:100,779,410-100,829,185	1	0	1	0	Research subjects,Biochemical measures,Quantitative real‑time PCR (qRT‑PCR),	PBMCs were extracted from EDTA tubes of whole blood by using Ficoll density gradient separation method and were stored at − 80 °C	up-regulated	levels of MEG3 in PBMCs were signifcantly higher in diabetic patients with vascular complications than diabetic patients with no vascular complications and in healthy control group. Our fndings indicated that MEG3 upregulation may serve as a prognostic factor in diabetic patients and novel therapeutic strategy for diabetes-related vascular complications	32594338	2020	Upregulation of long non-coding RNA MEG3 in type 2 diabetes mellitus complicated with vascular disease: a case-control study	NA	NA	pubmed	Blood vessel
899	Diabetic gastroparesis(DGP)	OIP5-AS1	TCONS_00011868	NA	NA	43563	ENST00000500949.5	human	NONHSAT041920.2	+	8865	chr15:41,284,032-41,309,737	1	0	1	0	Patients and Blood Samples,Cell Culture and High Glucose (HG, 30 mM)-Treated H9c2 Cells,Cell Transfection, Quantitative Real Time Polymerase Chain Reaction(qRT-PCR), Western Blot,Bioinformatics-Based Prediction and Analyses,Dual-Luciferase Reporter Assay, MTT Assay,Reactive Oxygen Species (ROS) Measurement,Detection of Oxidative Stress Measurement	Rat myocardial cell line H9c2 was obtained from the American Type Culture Collection	down-regulated	OIP5-AS1 overexpression enhanced viability and attenuated oxidative stress of cardiomyocyte via regulating miR-34a/SIRT1 axis in DCM, providing a new therapeutic target for DCM	33380310	2020	Long noncoding RNA OIP5-AS1 overexpression promotes viability and inhibits high glucose-induced oxidative stress of cardiomyocytes by targeting microRNA-34a/SIRT1 axis in diabetic cardiomyopathy	NA	NA	pubmed	Stomach
900	Diabetic gastroparesis(DGP)	DAPK2	NA	NA	NA	NA	NA	human	NONHSAT171683.1	-	554	chr15:63,907,923-64,046,322	1	0	1	0	Animal model and treatmen,Cardiomyocyte culture and treatment,Echocardiographic study,Histological analysis,TUNEL staining,Annexin V-FITC /PI staining,Luciferase reporter assay,RNA-binding protein immunoprecipitation,Real-time PCR,Western blotting,	The dissociated cells were preplated at 37 °C for 1 h to separate cardiomyocytes by adherence of cardiac fibroblasts	up-regulated	our study demonstrates that lncRNA MIAT is upregulated in the myocardium of diabetic rats and may act as a ceRNA to increase DAPK2 expression by sponging miR-22-3p, which consequently contributes to cardiomyocyte apoptosis involved in the pathogenesis of DCM	28703801	2017	lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy	NA	NA	pubmed	Stomach
901	Diabetic gastroparesis(DGP)	Smad3	TCONS_00013049	NA	NA	6769	NA	human	NONHSAT046837.2	+	1784	chr15:67,065,602-67,195,169	1	0	1	0	Mouse neonatal cardiac fibroblasts (CFs) isolation and culture,Animals,Cardiac ultrasound,Real‐time quantitative PCR,Western blotting analysis,AAV construct,Assessment of cardiac fibrosis,RNA pull‐down,RIP assay,ChIP assay,Luciferase reporter gene assay,	The hearts of C57BL/6 mice, 1–3 days old, were minced and put into 0.25% trypsin. Mixed cell suspensions were centrifuged and resuspended in Dulbecco modified Eagle's medium supplemented with 10% FBS, 100 U·mL−1 penicillin, and 100 μg·mL−1 streptomycin	up-regulated	The expression of Crnde was governed by Smad3. However, Crnde also inhibited the transcriptional activation of Smad3 on target genes, thereby inhibiting the differentiation of myofibroblasts from CFs during DCM‐induced cardiac fibrosis. All in all, our findings offer some new views into the clinical development of anti‐cardiac fibrosis strategies	30748104	2019	Long noncoding RNA Crnde attenuates cardiac fibrosis via Smad3-Crnde negative feedback in diabetic cardiomyopathy	NA	NA	pubmed	Stomach
902	Coronary artery disease	STAT3	TCONS_00015840	NA	NA	11364	ENST00000597755.2	human	NONHSAT053703.2	-	1496	chr17:42,315,559-42,388,414	1	0	1	0	Biochemical analysis,Gene expression analysis,In Silico Analysis	PBMCs were isolated from whole blood samples using Ficoll-Paque꽓 Lymphodex (InnoTrain, Sweden) according to the manufacturer's instructions	up-regulated	Our results shed further light to the inflammatory aspects of CAD and T2DM with emphasis to JAK/STAT pathway and the regulatory role of long non-coding RNAs in the physiopathology of these diseases	29398326	2018	The role of lnc-DC long non-coding RNA and SOCS1 in the regulation of STAT3 in coronary artery disease and type 2 diabetes mellitus	NA	NA	pubmed	Heart
903	Diabetic peripheral neuropathy	Smad4	NA	NA	NA	6770	NA	human	NONHSAT059302.2	+	4647	chr18:51,029,614-51,085,045	0	1	0	1	Reagents,Animals,Measurement of Nerve Conduction Velocity,Selection of Differentially Expressed (DE) lncRNAs,Identification of DE lncRNAs Bound to miR-146a-5p,Identification of mRNAs Targeted by miR-146a-5p,Quantitative Real-Time PCR Analysis,	extracted total RNA from the sciatic nerve of T2DM and DPN rats using the TRIzol method based on the manufacturer’s product manual	up-regulated	our findings imply that lncRNAs functioning as ceRNAs may participate in the pathogenesis of DPN by regulating inflammation	32110074	2020	Long Non‑Coding RNAs Regulate Inflammation in Diabetic Peripheral Neuropathy by Acting as ceRNAs Targeting miR-146a-5p	NA	NA	pubmed	Peripheral nerve
904	Diabetic gastroparesis(DGP)	TINCR	NA	NA	NA	14607	NA	human	NONHSAT239707.1	-	1115	chr19:5,558,167-5,568,034	1	0	1	0	Subjects and specimens,Real-time quantitative PCR,Cell line, cell culture and cell transfection,Cell apoptosis assay	Human cardiomyocyte cell line AC16 was provided by EMD Millipore	down-regulated	the specific downregulation of TINCR is likely involved in thepathogenesis of diabetic cardiomyopathy possibly through the inhibition ofcardiomyocytes. Our study provided a novel therapeutic target and diagnostic markerfor diabetic cardiomyopathy	30453794	2019	LncRNA TINCR is downregulated in diabetic cardiomyopathy and relates to cardiomyocyte apoptosis	NA	NA	pubmed	Stomach
905	Diabetic gastroparesis(DGP)	Daw1	NA	NA	NA	26383	NA	NA	NA	NA	NA	chr2:227,871,631-227,924,344	1	0	1	0	Animals,Measurements of blood glucose and insulin,LV hemodynamic measurement,Transthoracic echocardiography,RNA extraction,Microarray and bioinformatics analysis,LncRNA-mRNA correlation analysis,qRT-PCR reaction analysis of lncRNAs and mRNAs	Myocardial tissues were immersed immediately into liquid nitrogen, and total RNAs were isolated using Triazol Reagent (Invitrogen, Carlsbad, CA, USA), as described5	up-regulated	the results of our investigation indicate that db/db mice at 20 weeks of age develop early DCM. Among aberrant expression of the 754 lncRNAs that are associated with the pathogenesis of early DCM	31653946	2019	Genome-wide differential expression profiling of lncRNAs and mRNAs associated with early diabetic cardiomyopathy	NA	NA	pubmed	Stomach
906	Diabetic gastroparesis(DGP)	NORAD	TCONS_00023526	NA	NA	44311	ENST00000565493.1	human	NONHSAT079548.2	-	5373	chr20:36,045,618-36,051,018	1	0	1	0	Cell Culture and Transfection,5-Ethynyl-2’-Deoxyuridine (EdU) Assay,Apoptosis Determination,Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR),Cell Counting Kit-8 (CCK-8) Assay,Dual-Luciferase Reporter Gene Assay,	Human cardiomyocyte cell line AC16 was purchased from American Type Culture Collection	up-regulated	NORAD is upregulated under high-level glucose treatment. Overexpression of NORAD protects DCM development via miRNA-150-5p/ZEB1 axis.	33215445	2020	NORAD regulates proliferation and apoptosis in cardiomyocytes under high-glucose treatment through miRNA-150-5p/ZEB1 axis	NA	NA	pubmed	Stomach
907	Diabetic gastroparesis(DGP)	NORAD	TCONS_00023526	NA	NA	44311	ENST00000565493.1	human	NONHSAT079548.2	-	5373	chr20:36,045,618-36,051,018	1	0	1	0	Ethics statement,Animal treatment and grouping,Echocardiography,Detection of serum biochemical indexes,Hematoxylin and eosin (HE) staining and Masson staining,Enzyme‑linked immunosorbent assay (ELISA),Cell transfection,Dual‑luciferase reporter gene assay,RNA immunoprecipitation (RIP) assay,RNA pull‑down,RT‑qPCR,Western blot analysis,	As previously described [22], primary cardiomyocytes were  extracted from C57BL/6 mice (Changzhou Cavens) within 3 days after birth	down-regulated	Our findings highlight a novel approach based on NORAD down-regulation for DCM treatment. Our future endeavors will aim to explore the underlying downstream pathways and other targets of miR-125a-3p and to identify reliable therapeutic targets for DCM. In this paper, we mainly verify this mechanism in vivo, and further experiments will be carried out to verify this mechanism in vitro	34591118	2021	NORAD lentivirus shRNA mitigates fibrosis and inflammatory responses in diabetic cardiomyopathy via the ceRNA network of NORAD/miR-125a-3p/Fyn	NA	NA	pubmed	Stomach
908	Diabetic gastroparesis(DGP)	ZFAS1	WD Repeat Containing Antisense To TP53	NA	NA	33101	ENST00000441722.4	human	NONHSAT080209.2	+	946	chr20:49,278,642-49,299,600	1	0	1	0	Ethics and animal experiments,Primary culture of neonatal cardiomyocytes and cell transfection,Microarray‐based gene expression data analysis,Dual‐luciferase reporter assay,Quantitative reverse‐transcription‐polymerase chain reaction (qRT‐PCR),RNA pull‐down assay,Immunofluorescence staining,Histology and immunohistochemistry,Masson staining,Monobromobimane (MBB) staining,JC‐1 staining,Western blotting,Echocardiography	 	down-regulated	all these findings strongly suggest that ZFAS1 simulation promotes ferroptosis in DbCM. Further, lncRNA‐ZFAS1 was recognized to act as a ceRNA to sponge miR‐150‐5p and could downregulate CCND2. Most importantly, ZFAS1 inhibition suppressed cardiomyocyte ferroptosis and attenuated DbCM progression. Targeting lncRNA‐ZFAS1 will enable further development of novel treatments for DbCM	34609043	2021	Inhibition of the long non-coding RNA ZFAS1 attenuates ferroptosis by sponging miR-150-5p and activates CCND2 against diabetic cardiomyopathy	NA	NA	pubmed	Stomach
909	Diabetic gastroparesis(DGP)	NKILA	HE-BI-PMEPA1-2	NA	NA	51599	NA	human	NONHSAT243526.1	+	8101	chr20:57,710,156-57,712,780	1	0	1	0	Subjects and specimens,Follow-up,Reverse transcription-quantitative polymerase chain reaction (RT-qPCR),Cells and cell transfection,Cell apoptosis assay,	Primary human cardiomyocyte cells (T4037; Applied Biological Materials)	up-regulated	the present study demonstrated that lncRNA NKILA was upregulated specifically in diabetic patients who developed DC, and lncRNA NKILA overexpression may contribute to the progression of DC by promoting cardiomyocyte apoptosis.	31316617	2019	LncRNA NKILA was upregulated in diabetic cardiomyopathy with early prediction values	NA	NA	pubmed	Stomach
910	Diabetic gastroparesis(DGP)	MIAT	NA	NA	NA	33425	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,646,452-26,669,655	1	0	1	0	Patients Statement,Establishment of Diabetic Mice Model,Echocardiography,Transmission Electron Microscopy,Hematoxylin and Eosin (H&E) and Masson Staining,Immunohistochemistry,Cell Culture and Transfection,RNA Isolation and Quantitative Real-Time -PCR (qRT-PCR),Western Blotting,Luciferase Assay,	Primary cardiomyocytes and fibroblasts were extracted from C57BL/6 mice within 3 days of birth	up-regulated	our study first reported that HG-induced lncRNA-MIAT is a major reason for DCM. By sponging miR-214-3p, lncRNA-MIAT enhanced the production of IL-17. The emerging IL-17 together with proinflammatory cytokines promotes heart inflammation, eventually leading to cardiac fibrosis and onset of DCM. Our study also shed light on a potential strategy by which targeting lncRNA-MIAT improves heart function and reverse cardiac fibrosis	32351959	2020	LncRNA-MIAT-Mediated miR-214-3p Silencing Is Responsible for IL-17 Production and Cardiac Fibrosis in Diabetic Cardiomyopathy	NA	NA	pubmed	Stomach
911	Coronary artery disease	MIAT	NA	NA	NA	33425	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,646,452-26,669,655	1	0	1	0	The extraction of total RNA was done using the GeneAll Hybrid-RTM RNA purification kit (Gene all Biotechnology Co. Ltd, Seoul, Korea) from all samples. The extracted RNA samples’ quality and quantity were evaluated by Nanodrop instrument (Thermo Fisher Scientific). DNase I was used to eliminating residual DNA from RNA samples. 	the sample of human	up-regulated	MALAT1 and MIAT were upregulated in CAD patients,MALAT1 gene had the highest diagnostic power for discrimination of CAD patients from controls	32447981	2020	Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus	NA	NA	pubmed	Heart
912	Coronary artery disease	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Cell Culture and Transfection,Cell Treatment,RNA Extraction and qRT-PCR (Quantitative Real-Time Polymerase Chain Reaction),Cell Counting Kit-8 (CCK-8) Assay,Western Blot,Cell Cycle,Transwell Assay Detection	Primary human umbilical vein endothelial cel- ls (HUVECs) were isolated from umbilical vein and cultured in ECM (endothelial cell medium)	up-regulated	We found that overexpressed TUG1 stimulates proliferation and migration of endothelial cells via Wnt pathway, thereby promoting the occurrence and progression of diabetic atherosclerosis	30402858	2018	TUG1 promotes diabetic atherosclerosis by regulating proliferation of endothelial cells via Wnt pathway	NA	NA	pubmed	Heart
913	Diabetic cardiomyopathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Animals and treatments,TUG1 knockdown in vivo mediated by lentivirus,Echocardiography and hemodynamics,Biochemical examinations,Masson’s trichrome staining,Wheat germ agglutinin (WGA) staining,Cell culture and treatment,Dual-luciferase assay,Immunofluorescence,Western blotting,Real-time quantitative PCR (RT-qPCR)	Cardiomyocytes (CM) and non-cardiomyocytes (Non-CM) were isolated from mice	up-regulated	our data demonstrate that TUG1 was upregulated in DCM and inhibition of TUG1 protects against DCM-induced diastolic dysfunction by regulating miR-499-5p. The results suggest that TUG1 might be a potential therapeutic target to alleviate DCM.	32269707	2020	Inhibition of long non-coding RNA TUG1 protects against diabetic cardiomyopathy induced diastolic dysfunction by regulating miR-499-5p	NA	NA	pubmed	Heart
914	Coronary artery disease	FAL1/FALEC	TCONS_00000403	NA	NA	43713	ENST00000416894.1	human	NONHSAT006301.2	+	571	chr1:150,515,757-150,518,032	1	0	1	0	Patients,Cell Culture and Transfection,RNA Extraction and Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR),Cell Counting Kit-8 (CCK-8) Assay,Western Blot,Cell Cycle Detection,Transwell Assay	Human HUVECs were obtained from ATCC	up-regulated	We demonstrated that highly expressed FAL1 can promote proliferation and migration of endothelial cells through activating PTEN/AKT signaling pathway	30338819	2018	FAL1 regulates endothelial cell proliferation in diabetic arteriosclerosis through PTEN/AKT pathway	NA	NA	pubmed	Heart
915	Diabetic cardiomyopathy	LUCAT1	NA	NA	NA	48498	ENST00000511918.4	human	NONHSAT102745.2	-	890	chr5:91,285,160-91,314,516	1	0	1	0	Cell Culture,RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction,Cell Transfection,Cell Counting kit-8 (CCK-8) and Lactate Dehydrogenase (LDH) Assay,Cell Apoptosis,Western Blot Analysis (RT-qPCR)	AC16 cells	up-regulated	We first demonstrated that knockdown of LUCAT1 could reverse HG-induced cardiomyocyte injury by down-regulating CYP11B2. Our findings might offer a new direction for interpreting the mechanism of DCM development.	 31646588	2019	Knockdown of long non-coding RNA LUCAT1 reverses high glucose-induced cardiomyocyte injury via targeting CYP11B2	NA	NA	pubmed	Heart
916	Diabetic cardiomyopathy	LUCAT1	NA	NA	NA	48498	ENST00000511918.4	human	NONHSAT102745.2	-	890	chr5:91,285,160-91,314,516	1	0	1	0	Cell Culture,RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction(RT-qPCR),Cell Transfection,Cell Counting kit-8 (CCK-8) and Lactate Dehydrogenase (LDH) Assay,Cell Apoptosis,Western Blot Analysism	Human adult ventricular cardiomyocyte cell line (AC16) was bought from American Type Culture Collection (ATCC)	up-regulated	he expression of LUCAT1 was significantly upregulated in HG-treated AC16 cardiomyocytes. Moreover, knockdown of LUCAT1 could reverse cardiomyocyte injury and apoptosis through downregulating CYP11B2	31646588	2019	Knockdown of long non-coding RNA LUCAT1 reverses high glucose-induced cardiomyocyte injury via targeting CYP11B2	NA	NA	pubmed	Heart
917	Diabetic cardiomyopathy	HRAT17	NA	NA	NA	NA	ENST00000451962.4	human	NONHSAT122807.2	-	707	chr7:112,953,284-112,995,671	1	0	1	0	DCM model,RNA isolation and quality check,Array hybridization and data analysis,Microarray data validation,Gene ontology and pathway enrichment analysis in DCM,LncRNA classification and subgroup analysis,LncRNA-mRNA co-expression network,	CMs derived from hiPSCs	 	CMs but also allow us to manipulate in vitro the nongenetic components involved in the disease pathogenesis.This model will enable us to direct the external environment, opening the possibility to study the changing molecular pathways and gene expression as a function ofepigenetic modifications. These epigenetic modificationsare understood to play a profound role in disease progression and pathogenesis	30482051	2019	Microarray analysis of long non-coding RNA and mRNA expression profiles in diabetic cardiomyopathy using human induced pluripotent stem cell-derived cardiomyocytes	NA	NA	pubmed	Heart
918	Diabetic cardiomyopathy	LINC-PINT	NA	NA	NA	26885	NA	human	NONHSAT123383.2	-	2021	chr7:130,945,610-131,107,979	1	0	1	0	Study participants,Follow-up study,Human specimens and cell lines,Real-time quantitative polymerase chain reaction (RT-qPCR),Cell transfection,MTT assay,	AC16 cells were purchased from EMD Millipore	down-regulated	LINC-PINT is downregulated in diabetes patients and overexpression of LINC-PINT may inhibit the progression of cardiomyopathy and retinopathy among patients with T2D. Therefore, lncRNAs may reconstruct the specificity and sensitivity that cardiomyopathy and retinopathy cells have, and thereby are considered as new targets for the treatment of T2D diabetes complications. Furthermore, lncRNAs may even cure T2D diabetes.	31711064	2019	Role of Long Non-Coding RNA (LncRNA) LINC-PINT Downregulation in Cardiomyopathy and Retinopathy Progression Among Patients with Type 2 Diabetes	NA	NA	pubmed	Heart
919	Diabetic peripheral neuropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	Diabetes Rat Model Construction,RNA Extraction and Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR),Western Blot,Determination of Mechanical Withdrawal Threshold (MWT),Determination of Thermal Withdrawal Latency (TWL),Determination of Sensory Nerve Conduction Velocity (SNCV),TUNEL (Terminal DexynucleotidylTransferase (TdT)-Mediated dUTP Nick end Labeling),Isolation of DRG Non-Neurons,	Isolation of DRG Non-Neurons	down-regulated	PVT1 was lowly expressed in diabetic rats, resulting in decreased mechanical withdrawal threshold, thermal withdrawal latency and sensory nerve conduction velocity. PVT1 protects diabetic peripheral neuropathy via inhibiting the PI3K/AKT pathway	30402856	2018	PVT1 protects diabetic peripheral neuropathy via PI3K/AKT pathway	NA	NA	pubmed	Peripheral nerve
920	Diabetic cardiomyopathy	NRON	NA	NA	NA	37079	NA	human	NONHSAT134764.2	-	370	chr9:126,408,041-126,408,410	0	1	0	1	NA	NA	up-regulated	NA	33754582	2021	Dysregulation of lncRNA NRON in diabetic cardiomyopathy protects against high glucoseinduced cardiomyocyte injury and inflammation	NA	NA	pubmed	Heart
921	Acute myocardial infarction	ANRIL	NA	NA	NA	34341	ENST00000428597.4	human	NONHSAT130421.2	+	3837	chr9:21,802,636-22,049,597	1	0	1	0	Patients,Animals,Induction of T2DM mice,Establishment of the MI mouse model,Groups,Echocardiography,Triphenyltetrazolium chloride (TTC) staining,Haematoxylin-eosin (HE) staining,Masson staining,TUNEL staining,Western blot analysis,Reverse transcription-quantitative polymerase chain reaction (RT-qPCR),	LncRNA ANRIL was upregulated in patients with T2DM-MI,Effects of lncRNA ANRIL on myocardial pathology and fibrosis in the T2DM-MI mice	up-regulated	ANRIL was upregulated in peripheral venous blood from patients with T2DM-MI and in myocardial tissues from the established T2DM-MI model mice. Furthermore, ANRIL overexpression caused cardiac dysfunction and increased the heart/body weight rate and infarct size in the T2DM-MI mice. Moreover, ANRIL overexpression caused myocardial fibrosis and myocardial cell apoptosis, and it increased the expression of the myocardial fibrosis-related proteins TGF-β1, collagen I and collagen III in the T2DM-MI mice	31469688	2019	Expression and function of lncRNA ANRIL in a mouse model of acute myocardial infarction combined with type 2 diabetes mellitus	NA	NA	pubmed	Heart
922	Diabetic cardiomyopathy	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	0	1	0	1	Identification of DCM-related genes,miRNA-mRNA and lncRNA-miRNA interactions,Construction of the ceRNA background network,Signaling pathway enrichment analysis,Construction of a DCM-related ceRNA network (DCMCN),Analysis of the DCMCN	NA	up-regulated	Finally, a functional lncRNA XIST was identified in the network and the main miRNAs (miR-424-5p and miR-497-5p) that are regulated by XIST were further screened to obtain the ceRNA regulatory network of DCM	31173240	2019	Construction and analysis of a lncRNA‑miRNA‑mRNA network based on competitive endogenous RNA reveals functional lncRNAs in diabetic cardiomyopathy	NA	NA	pubmed	Heart
923	Diabetic peripheral neuropathy	TUBA4B	NA	NA	NA	18637	NA	Mouse	NA	NA	NA	chr1:75,192,290-75,193,605	0	1	0	1	Data acquisition,Statistical analysis,Visualization	NA	up-regulated	The findings from this analysis show how dynamic the epigenetic mechanisms are in DPN, ranging from hypomethylation and hypermethylation, to histone modifications.	30607320	2018	lncRNA-based study of epigenetic regulations in diabetic peripheral neuropathy	NA	NA	pubmed	Peripheral nerve
924	Diabetic peripheral neuropathy	HCG18	NA	NA	NA	31337	ENST00000412685.5	human	NONHSAT108616.2	-	6820	chr6:30,287,397-30,289,372	1	0	1	0	Macrophage grouping, polarization and transfection,Construction of DPN model,Quantitative reverse transcription PCR (qRT‑PCR),Enzyme‑linked immunosorbent assay (ELISA),Flow cytometry analysis,Dual luciferase reporter (DLR) assay,Western blot analysis,	We procured the mouse leukemia cells of monocyte macrophage (Raw264.7) from Chuanqiu Biotech, Ltd (Shanghai, China).	up-regulated	The present study demonstrates that the HCG18/miR-146a/ TRAF6 axis is essential in DPN progression, pointing to HCG18 might act as a potential therapeutic target for DPN in clinic	32996080	2021	Long non-coding RNA HCG18 promotes M1 macrophage polarization through regulating the miR-146a/TRAF6 axis, facilitating the progression of diabetic peripheral neuropathy	NA	NA	pubmed	Peripheral nerve
925	Diabetic peripheral neuropathy	KCNA2-AS	NA	NA	NA	6220	NA	human	NONHSAT227007.1	-	907	chr1:110,593,580-110,607,429	0	1	0	1	NA	NA	NA	These studies suggested that specific regulation of lncRNAs or their downstream targets might provide novel therapeutic avenues for this refractory disease	30362191	2019	Emerging roles of long non-coding RNAs in neuropathic pain	NA	NA	pubmed	Peripheral nerve
926	Dilated cardiomyopathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	Cell culture and treatment,Cell transfection,3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay,Cell viability assay,Lactate dehydrogenase (LDH) release assay,qRT-PCR,Flow cytometry assay,Western blot analysis,Caspase3 activity detection,Dual-luciferase reporter assay,Statistical analysis 	adult ventricular cardiomyocyte cell line	up-regulated 	PVT1 silencing mitigated high glucose-induced cardiomyocyte death through reducing CASP10 expression via sponging miR-23a-3p.	33049089	2021	Long noncoding RNA PVT1 facilitates high glucose-induced cardiomyocyte death through the miR-23a-3p/CASP10 axis	NA	NA	pubmed	Heart
927	Diabetic foot	H19	NA	NA	NA	4713	NA	NA	NA	-	1558	chr11:1,995,176-1,997,875	1	0	1	0	Ethics Statement,Sample Collection,Isolation, Culture, and Identification of Fibroblasts,Establishment of a Mouse Model with DFU,H&E Staining,Immunohistochemistry,RNA Isolation and Quantitation,Western Blot Analysis,TUNEL Assay,solation, Culture, and Osteogenic, Adipogenic, and Chondrogenic Differentiation of MSCs,Isolation and Identification of MSC-exo,Dual-Luciferase Reporter Gene Assay,Plasmid Transfection,Coculture of MSCs or Exosomes and Fibroblasts,EdU Cell Proliferation Assay,Transwell Assay,TUNEL Assay for Cell Apoptosis,RNA-FISH,RNA Pull-Down Assay,RIP,Statistical Analysis	 tissue samples of foot ulcer,C57BL/6J mice,Mesenchymal stem cells 	down-regulated 	MSC-derived exosomal lncRNA H19 prevented the apoptosis and inflammation of fibroblasts by impairing miR-152-3p-mediated PTEN inhibition, leading to the stimulated wound-healing process in DFU.	31958697	2020	The MSC-Derived Exosomal lncRNA H19 Promotes Wound Healing in Diabetic Foot Ulcers by Upregulating PTEN via MicroRNA-152-3p	NA	NA	pubmed	Foot
928	Diabetic foot	H19	NA	NA	NA	4713	NA	NA	NA	-	1558	chr11:1,995,176-1,997,875	1	0	1	0	Ethics statement,Study subjects,Isolation and culture of fibroblasts,DFU rat model establishment and treatment,Construction and transfection of lentiviral vectors,RT-qPCR,Western blot analysis,Fluorescent in situ hybridization (FISH) assay,RNA binding protein immunoprecipitation  (RIP) assay,Chromatin immunoprecipitation (ChIP)-PCR,Dual-luciferase reporter gene assay,5-Ethynyl-2′-deoxyuridine (EdU) assay,Terminal deoxynucleotidyl transferase-mediated  dUTP-biotin nick end labeling (TUNEL) staining,Hematoxylin–eosin (HE) and Masson’s  trichrome staining,Immunohistochemistry,Statistical analysis	 foot  ulcer  tissues,fibroblasts,rats	down-regulated 	lncRNA H19 accelerated wound healing in DFU through elevation of CTGF and activation of the MAPK signaling pathway.	32698141	2020	Long non-coding RNA H19 contributes to wound healing of diabetic foot ulcer	NA	NA	pubmed	Foot
929	Diabetic foot	H19	NA	NA	NA	4713	NA	NA	NA	-	1558	chr11:1,995,176-1,997,875	1	0	1	0	Ethics statement,Microarray data analysis,Study subjects,Immunohistochemistry,Isolation, culture, and grouping of fibroblasts,Reverse transcription quantitative  polymerase chain reaction,estern blot analysis,Fluorescent in situ hybridization (FISH),Dual luciferase reporter gene assay,RNA pull-down assay,RNA binding protein immunoprecipitation (RIP) assay,Scratch test,5-Ethynyl-2ʹ-deoxyuridine (EdU) assay,Flow cytometry,Preparation of cerium dioxide nanoparticles-plasmid complexes,Establishment of DM model in mice,Establishment of DFU models in DM mice,ound healing assay,Masson staining,HE staining,Electron microscope observation,Statistical analysis	patients,tissue mass of foot, DM  mouse 	down-regulated 	upregulation of lncRNA H19 can elevate the expression of FBN1 through competitively binding to miR-29b, which enhances the proliferation, migration, and inhibits apoptosis of fibroblasts, thus facilitating the wound healing of DFU.	33174326	2021	Long noncoding RNA H19 acts as a miR-29b sponge to promote wound healing in diabetic foot ulcer	NA	NA	pubmed	Foot
930	Diabetic foot	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Human skin tissue specimens,Cell culture and treatments,Cell transfection,CCK-8 assay,5-Ethynyl-2′-deoxyuridine (EdU) assay,Flow cytometry,Wound healing assay,Tube formation assay,qPCR,Western blot,Fluorescence in situ hybridization (FISH) assay,RNA pull-down assay,RNA immunoprecipitation (RIP) assay,Luciferase assay and chromatin immunoprecipitation (ChIP) assay,DFU model,Mouse crawling assessment,Histological analysis of the skin,Statistical analysis	Human skin tissue,Human umbilical vein endothelial cells,mice 	down-regulated 	Long noncoding RNAs GAS5 activates the HIF1A/VEGF pathway by binding to TAF15 (a component of RNA polymerase II), resulting in accelerated wound healing in diabetic foot ulcers.	33875793	2021	LncRNA GAS5 activates the HIF1A/VEGF pathway by binding to TAF15 to promote wound healing in diabetic foot ulcers	NA	NA	pubmed	Foot
931	Diabetic foot	GAS5	TCONS_00000087	NA	NA	16355	ENSMUST00000161229.5	mouse	NONMMUT003417.3	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Animal studies,Human samples,Cell culture and reagents,Dermal fibroblast and wound macrophage isolation and analysis,GAS5 overexpression and transfection,Real-time qPCR,Western blot analysis,Flow cytometry,Statistical analysis	mice,Human skin samples	down-regulated 	Reductions in the levels of GAS5 in wounds appeared to enhance healing by promoting transition of M1 macrophages to M2 macrophages. 	32004569	2020	Long Noncoding RNA GAS5 Regulates Macrophage Polarization and Diabetic Wound Healing	NA	NA	pubmed	Foot
932	Diabetic foot	GAS5	TCONS_00000088	NA	NA	16355	ENSMUST00000161229.5	NA	NONMMUT003417.4	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Cell Culture and Wound Scratch Assay,Human ex vivo wound models,Western  blot,Cortisol  ELISA,RNA isolation and RT-PCR,Plasmids and Transient Transfection,Experimental Animals, Wounding and  Treatments,Evaluation  of  Wound  Epithelialization,Evaluation of Wound Angiogenesis,Statistics	Primary human epidermal keratinocytes,skin  samples, pig,	 	Gas5 plays a role in regulating cell proliferation and survival (28). Gas5 can function as a glucocorticoid response element (GRE) decoy to inhibit GR-mediated gene expression.  	29158265	2018	Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the glucocorticoid receptor and the long non-coding RNA Gas5	NA	NA	pubmed	Foot
933	Diabetic nephropathy	NR_038323	NA	NA	NA	NA	 ENST00000519692.1	NA	NONHSAT125560.2	+	4387	chr8:23,336,208-23,366,125	1	0	1	0	Antibodies and Reagents,Cell Culture and Treatments,Luciferase Reporter Assays,Animal Models,Analysis of Physiological Parameters,Histology and Immunohistochemistry,Real-Time qPCR,Immunoblot Analysis,FISH,Human Samples,Statistical Analyses	HK-2 cells,Wistar rats,Human kidney biopsy sample	up-regulated 	overexpression of lncRNA NR_038323 directly interacts with miR-324-3p to upregulate DUSP1 expression to inactive p38MAPK and ERK1/2 pathways, leading to the suppression of renal fibrosis.	31430717	2019	lncRNA NR_038323 Suppresses Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-324-3p/DUSP1 Axis	NA	NA	pubmed	Kidney
934	Diabetic foot	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Isolation and characterization of EPCs,Cell treatment,Immunofluorescence,Wound scratch assay,Transwell assay,Tube formation assay,Ischemic hind limb model construction,Dual-luciferase reporter assay,qRT-PCR,Western blot analysis,Statistical analysis	C57BL/6 J mice,endothelial progenitor cells	down-regulated 	TUG1 restores high glucose-treated EPC function by regulating miR-29c-3p/PDGF-BB/Wnt signaling.	33059750	2020	TUG1 enhances high glucose-impaired endothelial progenitor cell function via miR-29c-3p/PDGF-BB/Wnt signaling	NA	NA	pubmed	Foot
935	Diabetic nephropathy	TUG1	TCONS_00025133	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Tissue culture,Animal  studies,Transgenic  mice,CRISPR/Cas9-mediated targeting,RNA IP,ChIRP,Mitochondria  functional  assays,ChIRP-seq,Statistics	mouse podocytes,mice,	down-regulated 	the interaction between Tug1 and PGC-1α promotes the binding of PGC-1α to its own promoter. 	27760051	2016	Tug1 interacts with PGC-1α at its promoter,resulting in elevated Ppargc1a transcriptional output.	NA	NA	pubmed	Kidney
936	Diabetic nephropathy	TUG1	TCONS_00025133	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	establishment of Dn rats,cell culture and transfection,elisa,qrT-Pcr,Western blot,rna pull-down,rna precipitation,TUnel assay,Ubiquitination assay,statistical analysis	rats,mouse podocytes	down-regulated 	astragaloside IV attenuated podocyte apoptosis and protected diabetic rats from DN via the lncRNA-TUG1/TRAF5 pathway.t TUG1 could target TRAF5,a molecule that could induce mice podocytes apoptosis, and AS-IV could suppress TRAF5 via regulating TUG1. 	30233141	2018	Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats	NA	NA	pubmed	Kidney
937	Diabetic nephropathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr9:21,802,636-22,049,597	1	0	1	0	Tissue Samples,Cell Culture,Cell Treatment,Cell Transfection,qRT-PCR,3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assay,Western Blot Assay,Cell Apoptosis Analysis,Dual-Luciferase Reporter Assay,Statistical Analysis	Blood  samples,Mouse  mesangial  cells	up-regulated 	miR-23c as a direct target of lncRNA NEAT1  and  lncRNA  NEAT1  facilitated proliferation, fibrosis and EMT through sponging miR-23c in DN.	32096162	2020	LncRNA NEAT1 accelerates the occurrence and development of diabetic nephropathy by sponging miR-23c	NA	NA	pubmed	Kidney
938	Diabetic nephropathy	TUG1	TCONS_00025133	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Animal model,Cell culture,Protein extraction,Western blot,Masson staining,Target prediction and luciferase assay,RNA extraction and qRT-PCR,RNA immunoprecipitation (RIP),Statistical analysis	mice,Rat proximal tubular epithelial cells 	down-regulated 	lncRNA TUG1 could indirectly regulated the expression of TIMP3 by targeting miR-21. LncRNA TUG1 inhibited high glucose-stimulated NRK-52E cell fibrosis and renal fibrosis in DN mice.	31933879	2019	LncRNA TUG1 ameliorates diabetic nephropathy by inhibiting miR-21 to promote TIMP3-expression	NA	NA	pubmed	Kidney
939	Diabetic nephropathy	Smad3 	TCONS_00013049	NA	NA	6769	NA	human	NONHSAT046837.2	+	1784	chr15:67,065,602-67,195,169	1	0	1	0	Animals,Real-time polymerase chain reaction (PCR) analysis,Western blot analysis,Renal function,Histology and immunohistochemistry,Statistical analysis  	C57BL/6J mice  	up-regulated 	 Decreased  pro-inflammatory  cytokine  production  and inhibited NF-κB/p65 signaling resulted in reduced inflammation  injury in Smad3  KO db/db  mice,inhibition of  Smad3-Erbb4-IR-miR-29b axis  may be  a  mechanism  by  which  Smad3  deficiency  attenuates  renal  fibrosis  in  db/db  mice. 	31734275	2020	Deletion of Smad3 prevents renal fibrosis and inflammation in type 2 diabetic nephropathy	NA	NA	pubmed	Kidney
940	Diabetic nephropathy	OIP5-AS1	TCONS_00011868	NA	NA	43563	ENST00000500949.5	NA	NONHSAT041920.2	+	8865	chr15:41,284,032-41,309,737	NA	NA	NA	NA	NA	NA	NA	NA	32519534	2020	LncRNA OIP5-AS1 induces epithelial-to-mesenchymal transition and renal fibrosis in diabetic nephropathy via binding to miR-30c-5p	NA	NA	pubmed	Kidney
941	Diabetic nephropathy	CLYBL-AS2 	NA	NA	NA	39894	NA	NA	NA	NA	NA	chr13:99,690,081-99,690,971	1	0	1	0	Animal procedure,Cell culture,Clinical Specimens,RNA sequencing,Quantitative real-time reverse transcription PCR (qRT-PCR),Plasmid construction and transfection,Western blot,Transwell Invasion assays,Luciferase assay,Statistical analysis 	KK-Ay mouse,human  tubule  epithelial  cell  line  HK-2  cells,Human  serum	up-regulated 	lncCLYBL-AS2 was negatively correlated with miR-204-4p with a positive correlation with SNAI1, eventually CLYBL-AS2 regulated SNAI1 by binding to miR-204-5p,  which  accounted  for  the  inhibition  of  epithelial–mesenchymal  transition  (EMT)  and fibrogenesis. 	32310009	2020	Coptis inhibited epithelial-mesenchymal transition and fibrogenesis of diabetic nephropathy through lncRNA CLYBL-AS2-miR-204-5p-SNAI1 axis	NA	NA	pubmed	Kidney
942	Diabetic nephropathy	MIAT	NA	NA	NA	33425	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,646,452-26,669,655	1	0	1	0	patients,Cell culture,Cell transfection,eparation of nuclear and cytoplasmic fractions,RNA Fish assay,CCK-8 proliferation assay,EdU proliferation assay,Cycle analysis,Quantitative real-time PCR,Immunofluorescence,Western blot,Luciferase reporter assay,RNA immunoprecipitation assaY,Statistical analysis	renal biopsy samples,human mesangial cells  	up-regulated 	MIAT induced mesangial cell proliferation and fibrosis via sponging miR-147a and regulating E2F3.	33009725	2020	Loss of lncRNA MIAT ameliorates proliferation and fibrosis of diabetic nephropathy through reducing E2F3 expression	NA	NA	pubmed	Kidney
943	Diabetic nephropathy	SNHG16 	NA	NA	NA	NA	NA	human	NONHSAT056037.2	+	2439	chr17:76,557,766-76,565,338	1	0	1	0	Animals,Blood and urine examination,HE and IHC staining,Cell culture,Lentivirus construction,Transfection,CCK-8 assay,EdU incorporation assay,TUNEL assay,Cell apoptosis by flow cytometry,Cycle analysis,RNA extraction and quantitative real-time PCR(qPCR),Western blot analysis,Dual-luciferase assay,RIP assay,Statistical analysis	mice, urine,Kidney tissues,Mice mesangial cell 	up-regulated 	SNHG16 induced proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathy.	32504027	2020	LncRNA SNHG16 induces proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathy	NA	NA	pubmed	Kidney
944	Diabetic nephropathy	SNHG16	NA	NA	NA	NA	NA	human	NONHSAT056037.2	+	2439	chr17:76,557,766-76,565,338	1	0	1	0	Cell Culture and Treatment,Collection of Serum,Cell Viability Assessment,TUNEL Staining,RT-qPCR,Western Blotting,Measurement of Reactive Oxygen Species (ROS),Dual-Luciferase Assay,Statistical Analysis	murine podocyte cell line MPC5,serum of patients	up-regulated 	LncRNA SNHG16 could promote HG-stimulated podocytes injury via targeting miR-106a to enhance KLF9 expression.The level of miR-106a was decreased by SNHG16 overexpression and miR-106a overexpression reduced KLF9 expression. Furthermore, overexpression of KLF9 or SNHG16 blunted the protective effects of miR-106a on HG-induced MPC5 injury.	33116706	2020	LncRNA SNHG16 Aggravates High Glucose-Induced Podocytes Injury in Diabetic Nephropathy Through Targeting miR-106a and Thereby Up-Regulating KLF9	NA	NA	pubmed	Kidney
945	Diabetic nephropathy	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Cell culture,Flow cytometry analysis,Cell proliferation assay,Reverse transcription PCR and quantitative real-time PCR,Fluorescence in site hybridization,RNA extraction, lentivirus production, and cell transfection,Nuclear and cytoplasmic RNA extraction,Dual-luciferase reporter assay,RNA immunoprecipitation assays,Western blot,Immunofluorescence assay,Bioinformatics analysis,Animal models,Statistical analysis     	Mesangial  cells,Sprague-Dawley  rats 	down-regulated 	SIRT1  was  confirmed  as  a  target  gene  of  miR-221.  lncRNA GAS5  upregulated  SIRT1  expression  and  inhibited  MCs  proliferation  and  fibrosis  by  acting  as  an  miR-221 sponge. 	31631065	2019	Long noncoding RNA GAS5 inhibits cell proliferation and fibrosis in diabetic nephropathy by sponging miR-221 and modulating SIRT1 expression	NA	NA	pubmed	Kidney
946	Diabetic nephropathy	LINC00968	NA	NA	NA	48727	ENST00000499425.1	human	NONHSAT126708.2	-	2520	chr8:56,518,321-56,559,671	1	0	1	0	 Animals，Cell lines and culture, Interfering RNA transfection, Real-time qPCTR, Western blot analysis, CCK-8 proliferative assay, Cycle analysis by flow cytometry, Subcellular fractionation analysis, RNA immunoprecipitation (RIP), Chromatin immunoprecipitation (ChIP) assay, Statistical analysis	mice，mesangial cell	up-regulated 	The overexpression of lncRNA LINC00968 facilitated the mesangial cells proliferation and fibrosis-related protein secretion. Mechanically, the LINC00968 ectopic expression inhibits the p21 protein expression via recruiting EZH2.	30197001	2018	LncRNA LINC00968 accelerates the proliferation and fibrosis of diabetic nephropathy by epigenetically repressing p21 via recruiting EZH2	NA	NA	pubmed	Kidney
947	Diabetic nephropathy	MEG8	TCONS_00010635	NA	NA	14574	ENST00000553584.4	human	NONHSAT039802.2	+	498	chr14:100,897,922-100,986,938	1	0	1	0	Patients and Healthy Controls,Blood Extraction and Preparation of Plasma Samples,Podocytes,Cell Transfection,RNA Preparations,RT-qPCR,Cell Apoptosis Assayv,Methylation Specific PCR (MSP),Statistical Analysis	patients,Plasma Samples,Human podocyte cell line CIHP-1	up-regulated 	miR-770-5p and MEG8 are both upregulated in DN and they may induce glucose-induced apoptosis of podocytes to participate in DN.MEG8 may upregulate miR-770-5p by reducing the methylation of miR-770-5p gene.	32765026	2020	lncRNA MEG8 Upregulates miR-770-5p Through Methylation and Promotes Cell Apoptosis in Diabetic Nephropathy	NA	NA	pubmed	Kidney
948	Diabetic nephropathy	ZEB1-AS1	TCONS_00003851	NA	NA	42354	ENST00000441257.1	human	NONHSAT012611.2	-	2213	chr10:31,307,717-31,319,035	1	0	1	0	Tissue samples,Cell culture,Cell transfection,Quantitative polymerase chain reaction (qRT-PCR),Western blot assay,RNA isolation of nuclear and cytoplasmic fractions,Luciferase reporter assay,Statistical analysis	Kidney tissue samples,Human kidney-2 cells	down-regulated 	lncRNA ZEB1-AS1 inhibited high glucose-induced EMT and fibrogenesis via regulating miR-216a-5p/BMP7 axis in diabetic nephropathy.	32294702	2020	lncRNA ZEB1-AS1 inhibits high glucose-induced EMT and fibrogenesis by regulating the miR-216a-5p/BMP7 axis in diabetic nephropathy	NA	NA	pubmed	Kidney
949	Diabetic nephropathy	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	Cell culture and high glucose model,Lentivirus infection,MTT,Quantitative real-time PCR,Western blot,Flow cytometry,Luciferase assay,Immunofluorescence experiment,Statistical analysis	Podocytes	down-regulated 	XIST acts as a ceRNA sponging miR-30, which targets AVEN, thus modulating AVEN.XIST significantly elevated the expression of Bcl-2 and inhibited the levels of pro-apoptotic proteins Bax and the cleaved caspases-9 and caspases-3, which indicates that XIST might regulate the apoptosis of podocytes through the miR30/AVEN axis.	33332155	2020	LncRNA XIST protects podocyte from high glucose-induced cell injury in diabetic nephropathy by sponging miR-30 and regulating AVEN expression	NA	NA	pubmed	Kidney
950	Diabetic nephropathy	UCA1	TCONS_00018226	NA	NA	37126	ENST00000397381.4	human	NONHSAT061515.2	+	2314	chr19:15,828,206-15,836,136	1	0	1	0	Reagents，Instruments,Animals,Establishment of the Rat Model of DN,Detection of Serum Levels of BUN, Scr, and UP in Rats Using Biochemical Method,Detection of Serum TNF-α and IL-6 Content in Rats via ELISA,Detection of mRNA Levels of PI3K and Akt in Kidney Tissues via RT-PCR,Detection of Protein Levels of PI3K and Akt in Kidney Tissues via Western Blotting,Statistical Analysis	Sprague-Daw-ley (SD) rats,rats serum,rats kidney tissues 	down-regulated 	lncRNA  UCA1  inhibitor  could  improve  the  pathological  damage  of  kidney  tissues  and  the  renal  function  in  DN  rats,it could also inhibit the inflammatory response, whose mechanism might be related to the inhibition of the PI3K-Akt signaling  pathway.	31799676	2019	Influence of LncRNA UCA1 on glucose metabolism in rats with diabetic nephropathy through PI3K-Akt signaling pathway	NA	NA	pubmed	Kidney
951	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	Ethical statement,Study subjects,Model establishment,Periodic acid-Schiff staining,Culture of primary podocytes,Culture of podocytes,Cell transfection,Dual-luciferase reporter gene assay,Reverse transcription-quantitative PCR,Western blot analysis,Methylation-specific PCR,RNA FISH,RIP assay,Chromatin immunoprecipitation,Immunofluorescence assay,Flow cytometry,Statistical analysis	patients,C57BL/6 mice,renal tissues,mouse glomeruli,mouse podocyte clone 5	up-regulated 	PVT1 promotes the recruitment of H3K27me3 in the FOXA1 promoter region by recruiting EZH2 and thus inhibits the expression of FOXA1 to promote the apoptosis and damage of podocytes in DN.	31371698	2019	Silencing of long noncoding RNA PVT1 inhibits podocyte damage and apoptosis in diabetic nephropathy by upregulating FOXA1	NA	NA	pubmed	Kidney
952	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Establishment of DM Model in Rats,Cell Culture,RNA Extraction and Quantitative RealTime-Polymerase Chain Reaction (qRT-PCR),Western Blotting,5-Ethynyl-2’-Deoxyuridine (EdU) Assay,Cell Transfection,Cell Counting Kit-8 (CCK-8),Statistical Analysis	Sprague Dawley (SD) rats,Mouse-derived  mesangial  cells	down-regulated 	The  overex-pression of TUG1 could suppress the proliferation and ECM accumulation of mesangial cells via in-hibiting the PI3K/AKT pathway. 	31539141	2019	LncRNA TUG1 inhibits the proliferation and fibrosis of mesangial cells in diabetic nephropathy via inhibiting the PI3K/AKT pathway	NA	NA	pubmed	Kidney
953	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Animal studies,Renal tissue staining,Collection of renal tubules,Cell culture and treatment,Quantitative real-time PCR,Western blot,Dual-luciferase activity assay,RNA pull-down assay,RNA immunoprecipitation,Chromatin immunoprecipitation assay,Statistical analysis	C57BL/6 mice,human renal tubular epithelial cell line HK-2,mouse renal tissue,mouse renal cortex 	down-regulated	TUG1 restrains the ERS and apoptosis of renal tubular epithelial cells and ameliorates DN through inhibition of transcription factor PU.1.	34062006	2021	LncRNA TUG1 ameliorates diabetic nephropathy via inhibition of PU.1/RTN1 signaling pathway	NA	NA	pubmed	Kidney
954	Diabetic nephropathy	SPAG5-AS1	TCONS_00015380	NA	NA	41140	ENST00000554154.1	human	NONHSAT052593.2	+	1365	chr17:28,599,646-28,617,347	1	0	1	0	cell culture and treatment,NA extraction and real-time quantitative PCR (RT-qPCR),Western blotting,mmunofluorescence (IF) staining,lasmid transfection,Cell apoptosis analysis,Fluorescence in situ hybridization (FISH),GFP-mRFP-LC3 adenoviral transfection,Nucleus-cytoplasm separation,Dual-luciferase reporter analysis,Stability assay,Pull-down assay,hromatin immunoprecipitation (ChIP),RNA immunoprecipitation (RIP),Co-immunoprecipitation (Co-IP), Statistical analyses	 	up-regulated 	SPAG5 is positively  regulated  by  and  its  neighbour  gene  SPAG5-AS1.Mechanistically, YY1 induced transactivation of SPAG5-AS1/SPAG5.SPAG5-AS1/miR-769-5p/YY1 formed a positive feedback loop to induce SPAG5 transcription and SPAG5-AS1 stabilized SPAG5 protein through USP14, so that SPAG5-AS1 activated SPAG5/AKT/mTOR signalling and inhibited autophagy in HPCs.	31957155	2020	SPAG5-AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway	NA	NA	pubmed	Kidney
955	Diabetic nephropathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	Serum samples,Cell culture,qRT‑PCR,Western Blot Analysis,Cell viability,Cell transfection,3‑(4,5‑dimethyl‑2‑thiazolyl)‑2,5‑diphenyl‑2‑H‑tetrazolium bromide (MTT),Flow cytometry assay,Dual‑luciferase reporter assay,Statistical analysis	Blood samples,Human glomerular mesangial cells (HGMCs)	up-regulated 	KCNQ1OT1 promoted proliferation  and  restrained  apoptosis  via  miR-18b-5p/SORBS2 axis in high glucose-induced HGMCs and HRGECs.Moreover,  KCNQ1OT1  knockdown  inhibited  EMT  and  NF-κB  pathway.	32905431	2020	LncRNA KCNQ1OT1 affects cell proliferation, apoptosis and fibrosis through regulating miR-18b-5p/SORBS2 axis and NF-ĸB pathway in diabetic nephropathy	NA	NA	pubmed	Kidney
956	Diabetic nephropathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	Cell culture and transfection,qRT‑PCR,Cell proliferation assay,Flow cytometry,Western blot assay,Bioinformatics analysis and dual‑luciferase reporter assay,RNA immunoprecipitation (RIP) assay,Statistical analysis	Blood samples,human glomerular mesangial cells,human renal glomerular endothelial cells	up-regulated 	KCNQ1OT1 knockdown inhibited cell proliferation and fibrosis and induced apoptosis in DN by regulating miR-93-5p/ROCK2 axis, providing potential value for the treatment of DN.	34654473	2021	LncRNA KCNQ1OT1 promotes the development of diabetic nephropathy by regulating miR-93-5p/ROCK2 axis	NA	NA	pubmed	Kidney
957	Diabetic nephropathy	ZEB1-AS1	TCONS_00003851	NA	NA	42354	ENST00000441257.1	human	NONHSAT012611.2	-	2213	chr10:31,307,717-31,319,035	1	0	1	0	Antibodies and Reagents,Animals,Human Samples,Animal Models,Cell Culture and Treatments,Analysis of Renal Function and Physiological Parameters,Histology,Immunohistochemistry, and Immunoblot Analyses,Real-Time PCR Analysis of lncRNA-ZEB1-AS1,RNA Immunoprecipitation,ChIP Analysis,Statistical Analyses	mices,Human Samples,human kidney 2 (HK-2) cells,Kidney tissues	down-regulated 	ZEB1-AS1 bound directly to H3K4 methyltransferase myeloid and lymphoid or mixed-lineage leukemia 1 (MLL1) and promoted H3K4me3 histone modification on ZEB1 promoter, which was reduced by HG treatment.	30121551	2018	lncRNA ZEB1-AS1 Was Suppressed by p53 for Renal Fibrosis in Diabetic Nephropathy	NA	NA	pubmed	Kidney
958	Diabetic nephropathy	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Cell Culture and HG Induction,Cell Transfection,RT-qPCR Analysis,Enzyme-Linked Immunosorbent Assay(ELISA),Detection of ROS, MDA and SOD Activity,Western Blot Analysis,Immunofluorescence,Dual-Luciferase Reporter Assay,Statistical Analysis	Human renal tubular cells	down-regulated 	GAS5 overexpression inhibited the inflammation, oxidative stress and pyroptosis of HG-induced renal tubular cells by downregulating the expression of miR-452-5	31849505	2019	lncRNA GAS5/miR-452-5p Reduces Oxidative Stress and Pyroptosis of High-Glucose-Stimulated Renal Tubular Cells	NA	NA	pubmed	Kidney
959	Diabetic nephropathy	CASC2	TCONS_00003725	NA	NA	22933	ENST00000454781.4	human	NONHSAT016552.2	+	2396	chr10:118,046,824-118,210,153	1	0	1	0	Animals,Cell Culture and High Glucose Treatment,Histology and PAS Staining,Cell Transfection and Plasmid Construction,Quantitative Real-Time PCR,Flow Cytometry Analysis,Western Blot,Dual-Luciferase Reporter Assay,Statistical Analysis	mice,human renal mesangial cells 	down-regulated 	CASC2 could alleviate the degree and process of apoptosis, inflammation, and fibrosis in diabetic nephropathic models by regulating the miR-144/SOCS2 axis.CASC2  acts  as  a  ceRNA  to  regulate  SOCS2 expression  by  competitively  sponging  miR-144,  thereby  regulating  the  progression  of  DN.  	33227790	2020	LncRNA CASC2 Alleviates the Progression of Diabetic Nephropathy by Regulating the miR-144/SOCS2 Signalling Axis	NA	NA	pubmed	Kidney
960	Diabetic nephropathy	CASC2	TCONS_00003725	NA	NA	22933	ENST00000454781.4	human	NONHSAT016552.2	+	2396	chr10:118,046,824-118,210,153	1	0	1	0	Subjects,Preparation of serum samples,Cell culture and transfection,MTT assay,Real-time quantitative PCR,Western-blot,Statistical analysis	patients,serum samples,Mouse podocyte cells 	down-regulated 	CASC2 overexpression inhibited apoptosis of podocyte cells and reduced phosphorylation level of JNK1 in them. 	29890555	2019	Long Non-Coding RNA CASC2 Improves Diabetic Nephropathy by Inhibiting JNK Pathway	NA	NA	pubmed	Kidney
961	Diabetic nephropathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr9:21,802,636-22,049,597	1	0	1	0	Cells source,Cells culture,Measurement of lnc-NEAT1 expression in SV40 MES13 cells under HG condition,Construction and transfection of lnc-NEAT1 interference plasmids,Measurement of cell proliferation,Measurement of apoptosis,Measurement of cell fibrosis,Measurement of inflammatory cytokines,Western blot,qPCR,Statistics	SV40 MES13 cells	up-regulated 	Lnc-NEAT1 is overexpressed, and its downregulation inhibits cell proliferation, fibrosis, and inflammation but promotes cell apoptosis in HG-induced MMCs DN cellular model.	31933932	2019	Downregulation of lncRNA NEAT1 inhibits mouse mesangial cell proliferation, fibrosis, and inflammation but promotes apoptosis in diabetic nephropathy	NA	NA	pubmed	Kidney
962	Diabetic nephropathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr9:21,802,636-22,049,597	1	0	1	0	Animal models,Biochemical analysis,Cell culture,Lentiviral vector infection,Bioinformatics analysis,Quantitative real‐time polymerase chain reaction (qRT‐PCR),Western blot analysis,Luciferase activity assay,RNA immunoprecipitation assay,Statistical analysis	rats,Blood samples,Mice mesangial cells	up-regulated 	Inhibition of NEAT1 restrained DN progression through regulating miR‐27b‐3p and ZEB1.These revealed that NEAT1 might serve as an effective biomarker and therapeutic target for DN. 	30549040	2019	LncRNA NEAT1 promotes extracellular matrix accumulation and epithelial-to-mesenchymal transition by targeting miR-27b-3p and ZEB1 in diabetic nephropathy	NA	NA	pubmed	Kidney
963	Diabetic nephropathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr9:21,802,636-22,049,597	1	0	1	0	Animals,Cell Culture and Treatment,MTT Assay,Flow Cytometry,Quantitative Real-Time PCR,Western Blotting ,Luciferase Reporter Assay,Statistical Analysis 	Rats,rat glomerular mesangial cell line (HBZY-1)	up-regulated 	NEAT1/miR-34c regulated the expression of NLRP3 and cell pyroptosis and revealed a potential regulating pathway of pyroptosis in DN. 	32721950	2020	Long Non-Coding RNA NEAT1 Regulates Pyroptosis in Diabetic Nephropathy via Mediating the miR-34c/NLRP3 Axis	NA	NA	pubmed	Kidney
964	Diabetic nephropathy	H19	NA	NA	NA	4713	NA	NA	NA	-	1558	chr11:1,995,176-1,997,875	1	0	1	0	Animal Model and Treatment,Cell Culture,Transfection,Immunofluorescence,Histology,RNA Isolation and Quantitative Real Time PCR,Western Blotting,Wound Healing Assay,Cell Migration Boyden Chamber Assay,Assessment of Urinary Albumin and Creatinine Concentrations,Assessment of Serum Creatinine,Glomerular Filtration Rate,Statistical Analysis	 mice,Human dermal microvascular endothelial cells	up-regulated 	H19, miR-29a, and EndMT contribute to a regulatory network involved in kidney fibrosis, and are associated with regulation of the TGF-β/SMAD3 singling pathway. 	33324218	2020	Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT	NA	NA	pubmed	Kidney
965	Diabetic nephropathy	TCF7	NA	NA	NA	11639	NA	NA	NA	NA	NA	chr5:134,114,681-134,148,210	1	0	1	0	Patient Samples,Cell Culture and Cell Transfection,RNA Extraction and Quantitative Real-Time PCR,Protein Extraction and Western Blot,Luciferase Reporter Gene Assay,Statistical Analysis	Patient Samples,human  podocyte  cell  line  (CIHP)  	up-regulated 	LncRNA  TCF7  promoted  the  pathogenesis  and  ER  stress  by  regulating  with  miR-200c,  which  might  pro-vide  a  potential  biomarker  for  end-stage  DN  and  might become  a  new  therapeutic  target  for DN.	31298342	2019	LncRNA TCF7 triggered endoplasmic reticulum stress through a sponge action with miR-200c in patients with diabetic nephropathy	NA	NA	pubmed	Kidney
966	Diabetic nephropathy	NR_033515	NA	NA	NA	NA	NA	human	NONMMUT024382.2	-	671	chr22_KQ759761v1_alt:4,342-32,739	1	0	1	0	Patients and clinical specimens,Cell lines,Construction of the lentiviral interference vectors and transfection,Treatment,Quantitative real-time reverse transcription PCR(qRT-PCR),Western blot analysis, Luciferase assay,3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay,Terminal deoxynucleotidyl transferase mediated dUTP nick-end labelling (TUNEL) assay,Statistical analysis	Patients,blood samples,HEK293 T and mouse mesangial cells (MMCs) cells	up-regulated 	 NR_033515 promoted cell proliferation and regulated P38, ASK1, Fibronectin, α-SMA, E-cadherin, and Vimentin expressions by miR-743b-5p. NR_033515 may be an effective target for reducing renal fibrosis in DN.	29990842	2018	LncRNA-NR_033515 promotes proliferation, fibrogenesis and epithelial-to-mesenchymal transition by targeting miR-743b-5p in diabetic nephropathy	NA	NA	pubmed	Kidney
967	Diabetic nephropathy	ANRIL 	NA	NA	NA	34341	ENST00000428597.4	human	NONHSAT130421.2	+	3837	chr9:21,802,636-22,049,597	1	0	1	0	Human kidney specimens，Cell culture and glucose treatment,Plasmids and transfection,MTT cell proliferation assay,Lactate dehydrogenase (LDH) activity assay kit,Enzyme-linked immunosorbent assay (ELISA),Flow cytometry,Dual luciferase reporter assay,RNA extraction and qRT-PCR,Western blot,Statistical analysis   	Human kidney specimens,Human  kidney  (HK-2)  cell  line 	up-regulated 	Elevated ARNIL in DN  promotes  cell  pyroptosis  by  sponging  miR-497  to  activate  TXNIP/NLRP3/caspase-1  signaling.This axis could serve as a diagnostic or therapeutic target for DN.	33160992	2021	LncRNA-antisense non-coding RNA in the INK4 locus promotes pyroptosis via miR-497/thioredoxin-interacting protein axis in diabetic nephropathy	NA	NA	pubmed	Kidney
968	Diabetic nephropathy	NORAD	TCONS_00023526	NA	NA	44311	 ENST00000565493.1	human	NONHSAT079548.2	-	5373	chr20:36,045,618-36,051,018	1	0	1	0	 Animal procedures, Detection of biochemical indicators,Quantitative real-time polymerase chain reaction (qRT-PCR),Cell culture and treatment,Cell counting kit (CCK-8) assay, 5-Ethynyl-20- deoxyuridine (EdU) assay, Apoptosis determination, Dual-luciferase reporter gene assay,Determination of subcellular distribution,. RIP (RNA immunoprecipitation) assay,Statistical analysis	mice,Mouse glomerular mesangial cells SV40-MES-13	up-regulated 	The regulatory loop NORAD/miR-520h/TLR4 promotes the proliferative ability and inhibits apoptosis in glomerular mesangial cells, thus aggravating the progression of DN.NORAD, miR-520h and TLR4 were mainly distributed in cytoplasm, which were enriched in anti-Ago2. 	31630796	2020	NORAD affects the progression of diabetic nephropathy through targeting miR-520h to upregulate TLR4	NA	NA	pubmed	Kidney
969	Diabetic nephropathy	LINC00162	TCONS_00024641	NA	NA	19725	 ENST00000615826.1	human	NONHSAT082908.2	-	733	chr21:44,999,208-45,004,727	1	0	1	0	Human subjects and sample collection,LncRNA microarray,RNA isolation and real-time PCR,Cell culture and transfection,Vector construction, mutagenesis and luciferase assay,Western blot analysis,Immunohistochemistry,Statistical analysis	Human subjects,kidney samples, peripheral blood samples and urine samples,Human  kidney HK-2 and 293T cells 	up-regulated 	Down-regulation of LINC00162 was associated with the development of DN in T2D via the up-regulation of miR-383 expression and reduction of HDAC9 expression.	32677473	2020	LINC00162 participates in the pathogenesis of diabetic nephropathy via modulating the miR-383/HDAC9 signalling pathway	NA	NA	pubmed	Kidney
970	Diabetic nephropathy	SOX2OT	TCONS_00007597;TCONS_00020726	NA	NA	20209	ENSMUST00000197977.1	mouse	NONMMUT042524.2	+	2970	chr3:181,711,925-181,714,436	1	0	1	0	Animal model,Cell culture,Transfection,Haematoxylin and eosin (HE) staining,Masson staining,Immunohistochemistry (IHC),Cell counting kit‑8 (CCK‑8) assay,5‑Ethynyl‑2′‑deoxyuridine (EDU) assay,Immunofluorescence,Total RNA extraction, reverse transcription and real‑time quantitative PCR,Western blot,Statistical analysis	C57BL/6  mice,Mouse  mesangial  cells	down-regulated	Overexpression of SOX2OT enhanced mesangial cell autophagy and relieved DN-induced renal injury.	34238205	2021	LncRNA SOX2OT alleviates mesangial cell proliferation and fibrosis in diabetic nephropathy via Akt/mTOR-mediated autophagy	NA	NA	pubmed	Kidney
971	Diabetic nephropathy	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr14:100,779,410-100,829,185	1	0	1	0	Patients and clinical specimens,LncRNA microarray analysis,Cell culture and transfection,Cell proliferation,Cell apoptosis,Real time quantitative PCR analysis,Luciferase reporter assay,Western blotting analysis,Blood glucose and urine protein assays,Animals,Statistical analysis	Patients serum samples,Human mesangial cells (HMCs) and HEK293Tcells, rat urine samples,C57BL/6 db/db and normal db/m mice 	up-regulated 	MEG3 silencing decreased the laboratory indicators and fibrosis-related protein secretion,MEG3 may exacerbate diabetic nephropathy by promoting ECM proteins in vivo.	31737219	2019	Long non-coding RNA MEG3 impacts diabetic nephropathy progression through sponging miR-145	NA	NA	pubmed	Kidney
972	Diabetic nephropathy	ARAP1-AS1	NA	NA	NA	39993	NA	NA	NA	NA	NA	chr11:72,685,075-72,693,808	1	0	1	0	NA	NA	down-regulated	NA	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	NA	NA	pubmed	Kidney
973	Diabetic nephropathy	ARAP1-AS2	NA	NA	NA	39994	NA	NA	NA	NA	NA	chr11:72,700,474-72,705,607	1	0	1	0	NA	NA	up-regulated 	NA	31079598	2019	Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA	NA	NA	pubmed	Kidney
974	Diabetic nephropathy	LINC00462	NA	NA	NA	42811	NA	NA	NONHSAT033722.2	-	1023	chr13:48,576,974-48,578,088	1	0	1	0	Specimens collection,Cell culture,qRT‐PCR,Cell counting kit‐8 (CCK‐8) assay,Intracellular reactive oxygen species (ROS) detection,Lipid peroxidation assay,Superoxide dismutase (SOD) and catalase (CAT) assay,Flow cytometry analysis,Western blot,Statistical analysis	kidney biopsy samples,HK‐2 and HKC cells	up-regulated 	knockdown of LINC00462 inhibited HG-induced cell apoptosis and affected the expression of apoptosis-related proteins by activating the AKT pathway. 	31489995	2019	LINC00462 is involved in high glucose-induced apoptosis of renal tubular epithelial cells via AKT pathway 	NA	NA	pubmed	Kidney
975	Diabetic nephropathy	LINC01619	NA	NA	NA	27409	NA	human	NONHSAT232295.1	-	2205	chr12:91,985,090-92,142,671	1	0	1	0	Patients and specimens,Microarrays and computational analysis,Histology and in situ hybridization analysis,Cell culture and studies,Lentiviral construction and cell transfection,Transient transfection of miRNA mimics and inhibitors,Luciferase reporter assay,RNA binding protein immunoprecipitation assay (RNA-RIP),Intracellular reactive oxidative species (ROS) measurements,Calcium spectrofluorimetry,Apoptosis assay using flow cytometry,Animal experiments,TUNEL assay and immunohistochemical analysis,Transmission electron microscopy,Measurement of biochemical parameters,qRT-PCR analysis,Western blot analysis,Statistical analysis	patients,renal biopsy samples,murine podocy te cell line 	down-regulated	LINC01619 as a competing endogenous RNA (ceRNA) and regulates miR-27a/FOXO1-mediated ER stress and podocyte injury in DN.	29334763	2018	Long Noncoding RNA LINC01619 Regulates MicroRNA-27a/Forkhead Box Protein O1 and Endoplasmic Reticulum Stress-Mediated Podocyte Injury in Diabetic Nephropathy	NA	NA	pubmed	Kidney
976	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Flow cytometry;Cell transfection;real-time PCR;Western blot;Dual-luciferase reporter assay;TUNEL assay.	Human renal tubular epithelial cell line HK-2	down-regulated	lncRNA TUG1—miR-29c-3p - SIRT1 network in regulating high glucose-induced apoptosis via ERS in renal epithelial cells.	34097717	2021	LncRNA TUG1/miR-29c-3p/SIRT1 axis regulates endoplasmic reticulum stress-mediated renal epithelial cells injury in diabetic nephropathy model in vitro	NA	NA	pubmed	Kidney
977	Diabetic nephropathy	SNHG17	NA	NA	NA	48600	NA	human	NONHSAT079656.2	-	1186	chr20:38,419,638-38,435,375	1	0	1	0	Western blot;qRT-PCR;Cell culture and transfection;Assessment of ATP level;Flow cytometry;RNA pull-down;RNA immunoprecipitation (RIP);Ubiquitination assay;Mondansylcadaverine (MDC) staining.	Diabetic mice model;podocytes.	up-regulated	lncRNA SNHG17 regulated Parkin-dependent mitophagy and apoptosis of podocytes through regulating Mst1	32627655	2020	LncRNA SNHG17 knockdown promotes Parkin-dependent mitophagy and reduces apoptosis of podocytes through Mst1	NA	NA	pubmed	Kidney
978	Diabetic nephropathy	Smad3	TCONS_00013049	NA	NA	6769	NA	human	NONHSAT046837.2	+	1784	chr15:67,065,602-67,195,169	0	1	0	1	RNA sequencing;Analysis of RNA‐Seq data;Pathway and ontology analysis of differentially expressed genes;Detection and quantification of alternative splicing variants;The co‐expression network of lncRNA and protein‐coding RNA;Quantitative real‐time PCR (qPCR)	Animal models;	up-regulated	Smad3 deficiency prevents the development of type 2 diabetic nephropathy.	33369170	2021	Identification of Smad3-related transcriptomes in type-2 diabetic nephropathy by whole transcriptome RNA sequencing	NA	NA	pubmed	Kidney
979	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	0	1	0	1	Analysis of Differentially Expressed mRNAs and miRNAs;LncRNA-Target Analysis;miRNA-Target Analysis;Functional Analysis;Transcription Factor Binding Site Analysis;The Enrichment Analysis of Target Gene Sets.	GEO ArrayExpress and reported in publications.	up-regulated	Two lncRNAs (MALAT1 and NEAT1) and three TFs (NF-κB, NEF2L2, and PPARG) that cooperatively work together with miRNAs to become controllers of DN onset and progression.	33088282	2020	Identification of Cooperative Gene Regulation Among Transcription Factors, LncRNAs, and MicroRNAs in Diabetic Nephropathy Progression	NA	NA	pubmed	Kidney
980	Diabetic nephropathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	0	1	0	1	Analysis of Differentially Expressed mRNAs and miRNAs;LncRNA-Target Analysis;miRNA-Target Analysis;Functional Analysis;Transcription Factor Binding Site Analysis;The Enrichment Analysis of Target Gene Sets.	GEO ArrayExpress and reported in publications.	up-regulated	Two lncRNAs (MALAT1 and NEAT1) and three TFs (NF-κB, NEF2L2, and PPARG) that cooperatively work together with miRNAs to become controllers of DN onset and progression.	33088282	2020	Identification of Cooperative Gene Regulation Among Transcription Factors, LncRNAs, and MicroRNAs in Diabetic Nephropathy Progression	NA	NA	pubmed	Kidney
981	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	RNA isolation and miRNA microarray analysis;Cell line and plasmid construction and transfection;Luciferase assays;Real time quantitative PCR;Western blot;CCK-8 cell  proliferation assay.	Mesangial cells of db/db DN mice.	down-regulated	LncRNA TUG1 acts as an endogenous sponge of miR-377, downregulating miR-377 expression levels and  thereby  relieving  the  inhibition  of  its  target  gene  PPAR γ. lncRNA  TUG1  is  a  novel  regulator  of  MC  proliferation  and  ECM accumulation through the post-transcriptional regulation of PPAR γ. 	28137588	2017	Long noncoding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ in diabetic nephropathy	NA	NA	pubmed	Kidney
982	Diabetic nephropathy	H19	TCONS_00005659	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Cell culture and drug treatment,Cell transfection,Quantitative real-time PCR,MTT assay,Enzyme-linked immunosorbent assay,Western blot,Luciferase reporter assay,Statistical analysis	Mouse glomerular membrane epithelial cell line	up-regulated	H19 promoted proliferation, inflammation and ECM accumulation of SV40-MES-13 cells via miR-143-3p/TGF-b1 axis.	32391614	2020	Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-β1 axis	NA	NA	pubmed	Kidney
983	Diabetic nephropathy	RMRP	NA	NA	NA	10031	ENST00000602361.1	human	NONHSAT130962.2	-	268	chr9:35,657,751-35,658,018	1	0	1	0	Cell Culture;Vector Construction, Small Interfering RNA, and Cell Transfection;RNA Extraction, Nuclear-Cytoplasmic Fractionation, and qRT-PCR Assays;Immunohistochemistry;Cell Proliferation and Flow Cytometric Analysis;Western Blot;Dual-Luciferase Reporter Assay;Chromatin Immunoprecipitation Assay;RNA Immunoprecipitation Assay;FluorescenceIn SituHybridization.	DN mouse glomerular endothelial cell (MGEC), glomerular mesangial cells (MC), glomerular podocyte cells (MPC5) and renal tubular epithelial cells (TCMK-1).	up-regulated	Rmrp might sponge miR-1a-3p to release JunD expression and activate cell proliferation and fibrosis during DN. 	34512545	2021	Sp1-Induced lncRNA Rmrp Promotes Mesangial Cell Proliferation and Fibrosis in Diabetic Nephropathy by Modulating the miR-1a-3p/JunD Pathway	NA	NA	pubmed	Kidney
984	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	Materials and Reagents,Animal Studies,Cell Culture and Treatment,Cell Transfection,Cell Counting Kit-8 (CCK-8) Analysis,Western Blot Analysis,Quantitative Real-Time (qRT-PCR)  Analysis,Intracellular Reactive Oxygen Species  (ROS), Superoxide Dismutase (SOD), and  Malondialdehyde (MDA) Estimation,ELISA,Dual-Luciferase Reporter Assay,RNA Pull-Down Assay and RNA  Immunoprecipitation,Statistics Analysis	C57BL/6J mice,Mice mesangial cells 	up-regulated	lncRNA  PVT1  regulates  high  glucose-induced viability, oxidative stress, fibrosis, and inflammation in diabetic nephropathy via miR-325-3p/Snail1 axis.	33907435	2021	LncRNA PVT1 Regulates High Glucose-Induced Viability, Oxidative Stress, Fibrosis, and Inflammation in Diabetic Nephropathy via miR-325-3p/Snail1 Axis	NA	NA	pubmed	Kidney
985	Diabetic nephropathy	GAS5	NA	NA	NA	16355	NA	human	NONHSAT227355.1	-	2060	chr1:173,858,559-173,867,045	1	0	1	0	Ethics statement,Establishment of streptozocin-induced DN rat models,In vivo lentivirus infection,Kidney tissue preparation,Hematoxylin-eosin staining,Immunohistochemistry,Masson's trichrome staining,Gelatin zymographic analysis,Isolation, culture, and transfection of renal tubular epithelial cells,RNA isolation and quantitation,Western blot analysis,Fluorescence in situ hybridization,RNA-binding protein  immunoprecipitation (RIP),Chromatin immunoprecipitation,RNA pull-down assay,Statistical analysis	rats,rats Kidney tissue,Renal tubular epithelial cell	down-regulated	GAS5 exhibited decreased expression in adipocytes of type 2 DM patients and could modulate glucose uptake by binding to the insulin receptor.	31916627	2020	Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2	NA	NA	pubmed	Kidney
986	Diabetic nephropathy	MMP9 	NA	NA	NA	7176	NA	NA	NA	NA	NA	chr20:46,008,908-46,016,561	1	0	1	0	Ethics statement,Establishment of streptozocin-induced DN rat models,In vivo lentivirus infection,Kidney tissue preparation,Hematoxylin-eosin staining,Immunohistochemistry,Masson's trichrome staining,Gelatin zymographic analysis,Isolation, culture, and transfection of renal tubular epithelial cells,RNA isolation and quantitation,Western blot analysis,Fluorescence in situ hybridization,RNA-binding protein  immunoprecipitation (RIP),Chromatin immunoprecipitation,RNA pull-down assay,Statistical analysis	rats,rats Kidney tissue,Renal tubular epithelial cell	up-regulated	demethylation  of  the  MMP9  promoter  region  can  facilitate  MMP9 expression, which may be an essential factor in the occurrence  and  progression  of  DN.	31916627	2020	Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 3	NA	NA	pubmed	Kidney
987	Diabetic nephropathy	MIR503HG	NA	NA	NA	28258	ENST00000414769.1	human	NONHSAT138623.2	-	844	chrX:134,543,340-134,546,108	1	0	1	0	Cell transfection;Real-Time qPCR;Western Blotting;Cell Apoptosis Analysis.	Human proximal tubular (HK-2) cells.	up-regulated	Inhibiting MIR503HG reduced miR-503 expression, up-regulating its target geneBcl-2, inhibiting the expression levels of apoptosis-related proteins such as Bax, and reducing high-glucose-induced HK-2 cell apoptosis.	33262626	2020	LncRNA MIR503HG Promotes High-Glucose-Induced Proximal Tubular Cell Apoptosis by Targeting miR-503-5p/Bcl-2 Pathway	NA	NA	pubmed	Kidney
988	Diabetic nephropathy	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr7:108,300,190-108,302,063	1	0	1	0	qPCR;Fluorescence in situ hybridization (FISH);Immunofluorescence analysis;ELISA;Luciferase reporter assay;Western blot;	DN rat models;The supernatant of MCs	up-regulated	MEG3 functioned as an endogenous sponge for miR-181a in mesangial cells (MCs) via direct targeting and in an Ago2-dependent manner.MEG3 promotes fibrosis and inflammatory response via the miR-181a/Egr-1/TLR4 axis in vitro and in vivo. 	31195367	2019	Long non-coding RNA MEG3 promotes fibrosis and inflammatory response in diabetic nephropathy via miR-181a/Egr-1/TLR4 axis	NA	NA	pubmed	Kidney
989	Diabetic nephropathy	ANRIL	NA	NA	NA	34341	ENST00000582301.4	human	NONHSAT130416.2	+	1067	chr9:21,995,133-22,128,103	1	0	1	0	Reverse Transcription;Real-Time Quantitative PCR;Enzyme-Linked Immunosorbent Assay;Western Blot;LDH, SOD, and MDA Assays;TUNEL Assay.	The conditionally immortalized mouse podocytes(MPC5).	up-regulated	LncRNA ANRIL silencing alleviates HG-induced podocyte injury via the upregulation of MME.	32617859	2020	LncRNA ANRIL Silencing Alleviates High Glucose-Induced Inflammation, Oxidative Stress, and Apoptosis via Upregulation of MME in Podocytes	NA	NA	pubmed	Kidney
990	Diabetic nephropathy	ANRIL	NA	NA	NA	34341	ENST00000582301.4	human	NONHSAT130416.2	+	1067	chr9:21,995,133-22,128,103	1	0	1	0	Plasmid construction and transfection;Cell proliferation and cell apoptosis assessment;Fibrosis markers and inflammatory cytokines assessment;ANRIL-related pathway assessment;RT-qPCR;Western blot.	Mouse mesangial cell.	up-regulated	 Lnc-ANRIL knock-down suppresses mouse mesangial cell proliferation, fibrosis, inflammation, Wnt/β-catenin and MEK/ERK pathways in DN.	32726814	2020	Knock-Down of Long Non-Coding RNA ANRIL Suppresses Mouse Mesangial Cell Proliferation, Fibrosis, Inflammation via Regulating Wnt/β-Catenin and MEK/ERK Pathways in Diabetic Nephropathy	NA	NA	pubmed	Kidney
991	Diabetic nephropathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	Biochemical analysis;Lentiviral vector infection and siRNA transfection;Cell culture;Cell Counting Kit‐8 (CCK‐8) assay;5‐Ethynyl‐2′‐deoxyuridine (EDU)proliferation assay;Real‐time quantitative reverse‐transcription polymerase chain reaction (qRT‐PCR);western blot.	Kidney tissues of streptozotocin‐induced diabetes model (DM) of rats and glucose‐induced mouse mesangial cell models.	up-regulated	The decrease of NEAT1 repressed the proliferation and fibrosis in DN via activating the Akt/mTOR signaling pathway.	30515796	2019	Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway	NA	NA	pubmed	Kidney
992	Diabetic nephropathy	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	H&E staining;Masson staining;Lentiviral vector construction and infection;Quantitative RT-PCR;Western blot;Fluorescence in situ hybridization;Dual-luciferase reporter assay.	DN mouse models;The human proximal renal tubular epithelial cell line (HK-2 cells).	up-regulated	XIST was identified to be a lncRNA that could bind to miR-93-5p, and CDKN1A was a target of miR-93-5p. Downregulated expression of XIST led to an increase in miR-93-5p expression, thereby decreasing CDKN1A and suppressing renal interstitial fibrosis in DN.	31545928	2019	Silencing of long noncoding RNA XIST protects against renal interstitial fibrosis in diabetic nephropathy via microRNA-93-5p-mediated inhibition of CDKN1A	NA	NA	pubmed	Kidney
993	Diabetic nephropathy	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr7:108,300,190-108,302,063	1	0	1	0	Cell culture and MEG3 overexpression;Quantitative reverse-transcriptase-PCR;Cell migration assay;Immunohistochemistry;Western blot;Cell Counting Kit‐8 (CCK‐8) assay;ELISA.	MPC5;Diabetes rat models;	down-regulated	Overexpression of MEG3 attenuated HG-induced podocyte injury by reducing Wnt/β-catenin activity, repressing cell migration, reactive oxygen species production and increasing the viability of podocytes.	31799068	2019	Long noncoding RNA MEG3 suppresses podocyte injury in diabetic nephropathy by inactivating Wnt/β-catenin signaling	NA	NA	pubmed	Kidney
994	Diabetic nephropathy	CDKN2B-AS1	NA	NA	NA	34341	ENST00000582301.4	human	NONHSAT130416.2	+	1067	chr9:21,995,133-22,128,103	1	0	1	0	Quantitative real-time polymerase chain reaction;Western blot; Dual-luciferase reporter;RNA immunoprecipitation assays;3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT).	Peripheral blood cells of diabetes patients with DN and without DN;Human glomerular mesangial cells (HGMC).	up-regulated	Knockdown of CDKN2B-AS1 suppressed proliferation, ECM accumulation and PI3K/AKT signaling by increasing miR-424-5p and decreasing HMGA2 in high glucose-treated HMGC cells.	31707340	2020	LNCRNA CDKN2B-AS1 regulates mesangial cell proliferation and extracellular matrix accumulation via miR-424-5p/HMGA2 axis	NA	NA	pubmed	Kidney
995	Diabetic nephropathy	Rpph1	NA	NA	NA	19273	NA	NA	NA	-	325	chr14:20,343,048-20,343,685	1	0	1	0	RNA-sequencing;Quantitative real-time PCR (qRT-PCR);LncRNA coding-potential analysis;Fluorescence in situ hybridization;RNA pull-down and RNA immunoprecipitation assays;Immunofluorescence analysis;Immunohistochemistry;Enzyme-linked immunosorbent assay;Cell proliferation assay.	Renal tissue of db/db DN mice;Mesangial cells (MCs) cultured under high glucose conditions (H-MCs). 	up-regulated	Rpph1 regulates inflammation and proliferation of MCs by activating the Gal-3/Mek/Erk pathway in DN,and the effect of Rpph1 on the regulation of expression of pro-inflammatory cytokines and proliferation of MCs is likely to occur via the Gal-3/Mek/Erk signaling pathway.	31285427	2019	Long non-coding RNA Rpph1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3	NA	NA	pubmed	Kidney
996	Diabetic nephropathy	RP11-363E7.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr9:19,453,209-19,455,173	0	1	0	1	Differential expression analysis;Construction of protein-protein interaction (PPI) network;Functional enrichment analysis;Prediction of miRNA-mRNA target;Prediction of lncRNAs that sponge DEmiRNAs;Drug-gene interaction network;RNA isolation and PCR amplification.	National Center for Biotechnology Information (NCBI) Gene Expression Omnibus;The human miRNA microarray dataset and gene expression dataset.	NA	 Regulated PTGER3 and MMP-2.	33435900	2021	PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms	NA	NA	pubmed	Kidney
997	Diabetic nephropathy	TTN-AS1	TCONS_00022846	NA	NA	44124	ENST00000456053.4	human	NONHSAT075762.2	+	2069	chr2:178,523,215-178,539,253	0	1	0	1	Differential expression analysis;Construction of protein-protein interaction (PPI) network;Functional enrichment analysis;Prediction of miRNA-mRNA target;Prediction of lncRNAs that sponge DEmiRNAs;Drug-gene interaction network;RNA isolation and PCR amplification.	National Center for Biotechnology Information (NCBI) Gene Expression Omnibus;The human miRNA microarray dataset and gene expression dataset.	NA	 Regulated PTGER3 and MMP-2.	33435900	2021	PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms	NA	NA	pubmed	Kidney
998	Diabetic nephropathy	HOTAIRM1	NA	NA	NA	37117	ENST00000434063.3	human	NONHSAT119665.2	+	789	chr7:27,099,619-27,100,265	0	1	0	1	Differential expression analysis;Construction of protein-protein interaction (PPI) network;Functional enrichment analysis;Prediction of miRNA-mRNA target;Prediction of lncRNAs that sponge DEmiRNAs;Drug-gene interaction network;RNA isolation and PCR amplification.	National Center for Biotechnology Information (NCBI) Gene Expression Omnibus;The human miRNA microarray dataset and gene expression dataset.	NA	 Regulated PTGER3 and MMP-2.	33435900	2021	PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms	NA	NA	pubmed	Kidney
999	Diabetic nephropathy	LINC00960	NA	NA	NA	48710	NA	human	NONHSAT090548.2	+	1289	chr3:75,672,300-75,742,048	0	1	0	1	Differential expression analysis;Construction of protein-protein interaction (PPI) network;Functional enrichment analysis;Prediction of miRNA-mRNA target;Prediction of lncRNAs that sponge DEmiRNAs;Drug-gene interaction network;RNA isolation and PCR amplification.	National Center for Biotechnology Information (NCBI) Gene Expression Omnibus;The human miRNA microarray dataset and gene expression dataset.	NA	 Regulated PTGER3 and MMP-2.	33435900	2021	PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms	NA	NA	pubmed	Kidney
1000	Diabetic retinopathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	qRT-PCR (quantitative reverse-transcriptase PCR); MTT;BrdU staining;wound healing;transwell assay;western blot;cell immunofluorescence assay;dual luciferase reporter gene assay;immunohistochemistry.	Human retinal pigment epithelium (hRPE) cell.	up-regulated	NEAT1 could mediate SOX4 to regulate EMT of DR by targeting miR-204.	34386303	2021	LncRNA NEAT1 regulated diabetic retinal epithelial-mesenchymal transition through regulating miR-204/SOX4 axis	NA	8947	pubmed	Eye
1001	Diabetic nephropathy	H19	TCONS_00005659	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Quantitative reverse‐transcription polymerase chain reaction;Western blot analysis;Computational analysis;Luciferase assays.	renal tissues of DM patients with or without DN;	up-regulated	MiR‐675 is located within the chromosome segment of H19, while the increase in H19 expression also upregulated the expression of both miR‐675‐5p and miR‐675‐3p. The negative feedback loop of H19/miR‐675/EGR1 is involved in the development of DN.	30815865	2019	A negative feedback loop of H19/miR-675/EGR1 is involved in diabetic nephropathy by downregulating the expression of the vitamin D receptor	NA	NA	pubmed	Kidney
1002	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Histopathological evaluation;Enzyme-linked immunosorbent assay;Cell culture;Plasmid constructs and transfection of cell lines;qRT-PCR.	DM rat models;Paraffin sections (5μm) of the kidneys;The HK-2 human proximal tubular epithelial cell line.	up-regulated	MALA T1 is implicated in the improvement of renal function after DJB through regulation of its downstream targets SAA3, IL-6, and TNF-α.	29781038	2018	Downregulation of lncRNA MALAT1 contributes to renal functional improvement after duodenal-jejunal bypass in a diabetic rat model	NA	NA	pubmed	Kidney
1003	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Cell culture;Protein extraction;Western blot;Masson staining;Target prediction and luciferase assay;RNA extraction and qRT-PCR;RNA immunoprecipitation (RIP).	Rat proximal tubular epithelial cells (NRK-52E);diabetic model mice.	down-regulated	Overexpression of lncRNA TUG1 resulted in down-regulation of miR-21, and upregulation of TIMP3 expression in high glucose-stimulated NRK-52E cells and in DN mice,and these effects inhibited cell fibrosis through the attenuation of renal fibrosis marker genes.	31933879	2019	LncRNA TUG1 ameliorates diabetic nephropathy by inhibiting miR-21 to promote TIMP3-expression.	NA	NA	pubmed	Kidney
1004	Diabetic nephropathy	HOXA-AS2	NA	NA	NA	43745	NA	NA	NA	+	1048	chr7:27,108,005-27,122,879	1	0	1	0	Quantitative real-time polymerase chain reaction (qRT-PCR); Dual-Luciferase reporter gene assay.	Serum and kidney tissues of DN rats.	down-regulated	HOXA-AS2/miRNA-302b-3p/TIMP3 axis protects inflammatory response, proliferation suppression, and apoptosis in podocytes treated with high-level glucose, thus alleviating the deterioration of DN.	32432759	2020	Overexpression of HOXA-AS2 inhibits inflammation and apoptosis in podocytes via sponging miRNA-302b-3p to upregulate TIMP3.	NA	NA	pubmed	Kidney
1005	Diabetic nephropathy	MIAT	NA	NA	NA	33425	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,646,452-26,669,655	1	0	1	0	Cell culture;Cell transfection;RT-PCR;Western blot;Inflammatory cytokines release measurement;MTT assay;ELISA Assay Kit;Luciferase activity assay;Nucleus-cytoplasm separation;RNA immunoprecipitation (RIP).	The conditionally immortalized mouse podocytes.	up-regulated	Inhibition of MIAT function as a ceRNA by sponging miR-130a-3p to regulate TLR4 expression,thereby repressing the impaired podocytes apoptosis and inflam-matory response, eventually influencing the podocyte injury under the HG environment. 	32972755	2020	Ablation of lncRNA MIAT mitigates high glucose-stimulated inflammation and apoptosis of podocyte via miR-130a-3p/TLR4 signaling axis	NA	NA	pubmed	Kidney
1006	Diabetic nephropathy	MGC	TCONS_00015984	NA	NA	NA	ENST00000499670.2	human	NONHSAT055775.2	-	2501	chr17:74,210,012-74,213,342	1	0	1	0	Small RNA sequencing;qRT-PCR;Western blotting;Rapid amplification of 5′ complementary DNA ends (5′ RACE);Chromatin immunoprecipitation assays;TUNEL assay.	Mouse models of diabetes;Primary mesangial cells.	up-regulated	A chemically modified oligonucleotide targeting lnc-MGC inhibits cluster microRNAs, glomerular ECM and hypertrophy in diabetic mice.	27686049	2016	An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy	NA	NA	pubmed	Kidney
1007	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	RNA extraction and quantitative polymerase chain reaction;flow cytometry;Western blotting;Dual-luciferase reporter assay;Cell transfection.	HK-2 cells.	up-regulated	MALAT1 regulated HK-2 cell pyroptosis by inhibiting miR-30c targeting for NLRP3.	32391974	2020	LncRNA MALAT1 promoted high glucose-induced pyroptosis of renal tubular epithelial cell by sponging miR-30c targeting for NLRP3	NA	NA	pubmed	Kidney
1008	Diabetic nephropathy	SOX2OT	TCONS_00007597;TCONS_00020726	NA	NA	20209	ENSMUST00000197977.1	mouse	NONMMUT042524.2	+	2970	chr3:181,711,925-181,714,436	1	0	1	0	Hematoxylin-eosin and periodic Acid-Schiff staining;Transmission electron microscopy observation;Microarray analysis;Reverse transcription-quantitative polymerase chain reaction (RT-qPCR);Gene ontology (GO) and pathway enrichment analysis;Fluorescence in situ hybridization (FISH).	 Blood and tissue samples of DN mice models;Human podocytes cells (HPCs) and human mesangial cells (HMCs)；	down-regulated	SOX2OT may serve a central role in orchestrating scenarios of molecular disorder.	30320339	2018	Microarray analysis reveals long non‑coding RNA SOX2OT as a novel candidate regulator in diabetic nephropathy	NA	NA	pubmed	Kidney
1009	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	 real‐time polymerase chain reaction (RT‐PCR);Cell culture;Cell transfection;Vector construction;Cell proliferation assay;Western blot analysis;Flow cytometry;Immunohistochemistry.	Kidney biopsy samples.	up-regulated	Long noncoding RNA (lncRNA) TUG1 influenced podocytes apoptosis via mediating endoplasmic reticulum stress (ERS)–CHOP–PGC‐1αsignaling pathway in HG‐induced DN.	30671964	2019	Deregulation of long noncoding RNA (TUG1) contributes to excessive podocytes apoptosis by activating endoplasmic reticulum stress in the development of diabetic nephropathy	NA	NA	pubmed	Kidney
1010	Diabetic nephropathy	UCA1	TCONS_00018226	NA	NA	37126	ENST00000397381.4	human	NONHSAT061515.2	+	2314	chr19:15,828,206-15,836,136	1	0	1	0	Immunofluorescence;Histological staining;RNA extraction and quantification of reverse transcription PCR;Transfection of virus, plasmid, and small interference RNA;Luciferase reporter gene assay;RNA immunoprecipitation;Western blot analysis.	Male Sprague-Dawley (SD) rats;HK-2 human proximal tubular epithelial cells (ATCC).	down-regulated	UCA1 inhibits renal tubular epithelial cell apoptosis by targeting miRNA-206 in DN.	31608712	2019	Long-chain non-coding RNA UCA1 inhibits renal tubular epithelial cell apoptosis by targeting microRNA-206 in diabetic nephropathy	NA	NA	pubmed	Kidney
1011	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Cell culture;TUNEL staining;Immunohistochemistry;Immunofluorescence;Plasmid constructs;Luciferase reporter assay ;Transfection of HK-2 cells;Western blot analysis;RNA extraction and qRT-PCR.	HK-2 human proximal tubular epithelial cells;Kidney cortex sections from STZ-injected diabetic rats.	up-regulated	The expression of MALA T1 antagonized the effect of miR-23c on the downregulation of its target ELA VL1 and inhibited hyperglycemia-induced cell pyroptosis. 	27964927	2017	Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy	NA	NA	pubmed	Kidney
1012	Diabetic nephropathy	OR13C9	NA	NA	NA	15104	NA	human	NONHSAT133801.2	-	553	chr9:104,617,248-104,618,204	1	0	1	0	Oil red O staining;RT-qPCR; Western blotting;immunocytofluorescence analyses;LncRNA microarrays;Fluorescencein situhybridization (FISH);Bioinformatics analysis;Rescue assay;Dual-luciferase reporter assay.	glomerular endothelial cells (GEnCs).	up-regulated	 LncOR13C9 could regulate ABCA1 by inhibiting the action of miR-23a-5p in the LXR pathway.	33192550	2020	High Glucose Aggravates Cholesterol Accumulation in Glomerular Endothelial Cells Through the LXRs/LncRNAOR13C9/ABCA1 Regulatory Network	NA	NA	pubmed	Kidney
1013	Diabetic nephropathy	LOC100190986	NA	NA	NA	NA	NA	human	NONHSAT140989.2	-	2432	chr16:21,432,003-21,434,455	0	1	0	1	Data selected and analyzed;Functional enrichment analysis;Protein-protein interaction network analysis;Constructe integrated ceRNA network.	Online NCBI Gene Expression Omnibus (GEO) database 	up-regulated	lncRNA LOC100190986-associated ceRNA regulatory networks were involved in immune and inflammation processes of DKD.	34087849	2021	Identification and construction of lncRNA-associated ceRNA network in diabetic kidney disease	NA	NA	pubmed	Kidney
1014	Diabetic nephropathy	MAGI2-AS1	NA	NA	NA	40860	NA	NA	NA	NA	NA	chr7:78,939,850-78,940,895	0	1	0	1	Data selected and analyzed;Functional enrichment analysis;Protein-protein interaction network analysis;Constructe integrated ceRNA network.	Online NCBI Gene Expression Omnibus (GEO) database 	up-regulated	lncRNA MAGI2-AS1-associated ceRNA regulatory networks were involved in immune and inflammation processes of DKD.	34087849	2021	Identification and construction of lncRNA-associated ceRNA network in diabetic kidney disease	NA	NA	pubmed	Kidney
1015	Diabetic nephropathy	VCAN-AS1	NA	NA	NA	40163	NA	NA	NA	NA	NA	chr5:83,541,477-83,581,320	0	1	0	1	Data selected and analyzed;Functional enrichment analysis;Protein-protein interaction network analysis;Constructe integrated ceRNA network.	Online NCBI Gene Expression Omnibus (GEO) database 	up-regulated	lncRNA VCAN-AS1-associated ceRNA regulatory networks were involved in immune and inflammation processes of DKD.	34087849	2021	Identification and construction of lncRNA-associated ceRNA network in diabetic kidney disease	NA	NA	pubmed	Kidney
1016	Diabetic nephropathy	LOC100505985	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr6:50,093,389-50,099,283	0	1	0	1	Data selected and analyzed;Functional enrichment analysis;Protein-protein interaction network analysis;Constructe integrated ceRNA network.	Online NCBI Gene Expression Omnibus (GEO) database 	down-regulated	lncRNA LOC100505985-associated ceRNA regulatory networks were involved in immune and inflammation processes of DKD.	34087849	2021	Identification and construction of lncRNA-associated ceRNA network in diabetic kidney disease	NA	NA	pubmed	Kidney
1017	Diabetic nephropathy	BRE-AS1	NA	NA	NA	44171	NA	NA	NA	-	16659	chr2:27,889,456-27,891,114	0	1	0	1	Data selected and analyzed;Functional enrichment analysis;Protein-protein interaction network analysis;Constructe integrated ceRNA network.	Online NCBI Gene Expression Omnibus (GEO) database 	down-regulated	lncRNA BRE-AS1-associated ceRNA regulatory networks were involved in immune and inflammation processes of DKD.	34087849	2021	Identification and construction of lncRNA-associated ceRNA network in diabetic kidney disease	NA	NA	pubmed	Kidney
1018	Diabetic nephropathy	CASC2	TCONS_00003725	NA	NA	22933	ENST00000454781.4	human	NONHSAT016552.2	+	2396	chr10:118,046,824-118,210,153	1	0	1	0	Quantitative real-time polymerase chain reaction (qRT-PCR);Cell counting kit-8 (CCK-8) assay;Western blot analyses;Corresponding detection kit;Dual-luciferase reporter assay;RNA pull-down.	human mesangial cells (HMCs);serum from DN patients.	down-regulated	CASC2 upregulation suppressed HG-induced proliferation, ECM accumulation and oxidative stress of HMCs through miR-133b /FOXP1 regulatory axis.	32016985	2020	LncRNA CASC2 regulates high glucose-induced proliferation, extracellular matrix accumulation and oxidative stress of human mesangial cells via miR-133b/FOXP1 axis	NA	NA	pubmed	Kidney
1019	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	Cell culture;Cell Transfection;3′ UTR Luciferase Reporter Assays;RNA extraction and quantification;Quantitative real-time RT-PCR (qPCR);Protein extraction and quantification;Enzyme-linked immunosorbent assay analysis (ELISA).	human renal proximal tubule epithelial cells (RPTEC);human mesangial cells (MC).	up-regulated	PVT1 increases plasminogen activator inhibitor 1 (PAI-1) and transforming growth factor beta 1 (TGF-β1) in mesangial cells, upregulate miR-1207-5p,  increases expression of TGF-β1, PAI-1, and FN1. 	24204837	2013	Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy	NA	NA	pubmed	Kidney
1020	Diabetic nephropathy	LINC01619	NA	NA	NA	27409	NA	NA	NA	-	2205	chr12:91,985,090-92,142,671	1	0	1	0	Microarrays and computational analysis;Histology and in situ hybridization analysis;Cell culture;Lentiviral construction;Cell transfection;Luciferase reporter assay;RNA binding protein immunoprecipitation assay (RNA-RIP);Flow cytometry;TUNEL assay;Immunohistochemical analysis;Transmission electron microscopy;qRT-PCR;Western blot.	Renal biopsy samples from type 2 diabetic patients;Normal human renal tissues;murine  podocyte  cell  line;Blood samples from the DN patients and rats;kidneys of DN rats.	down-regulated	LINC01619 functions as a competing endogenous RNA and regulates miR-27a/FOXO1-mediated ER stress and podocyte injury in DN.	29334763	2018	Long Noncoding RNA LINC01619 Regulates MicroRNA-27a/Forkhead Box Protein O1 and Endoplasmic Reticulum Stress-Mediated Podocyte Injury in Diabetic Nephropathy	NA	NA	pubmed	Kidney
1021	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	Quantitative real-time polymerase chain reaction (qRT-PCR);Western blot;3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetr-azolium (MTS) assay;Dual-luciferase reporter assay.	human mesangial cells (MCs).	up-regulated	PVT1 modulated WT1 expression through acting as a molecular sponge of miR-23b-3p.	32322310	2020	Knockdown of lncRNA PVT1 alleviates high glucose-induced proliferation and fibrosis in human mesangial cells by miR-23b-3p/WT1 axis	NA	NA	pubmed	Kidney
1022	Diabetic nephropathy	GAS5	NA	NA	NA	16355	NA	human	NONHSAT227355.1	-	2060	chr1:173,858,559-173,867,045	1	0	1	0	Cell culture and transfection;WST-1 assay;Western blot;Quantitative real-time PCR;RNA pull-down;Enzyme-linked immunosorbent assay(ELISA);Luciferase assays.	Mice serum;Mouse renal mesangial cells	down-regulated	GAS5 regulated the proliferation of HG-induced mesangial cells and accumulation of extracellular matrix through NF-κB pathway	31481528	2019	Danggui buxue tang inhibited mesangial cell proliferation and extracellular matrix accumulation through GAS5/NF-κB pathway	NA	NA	pubmed	Kidney
1023	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	qRT-PCR;EdU and Colony formation; Annexin V-PI staining;Muse cell cycle;Scratch;Transwell assays;Enzyme-linked immunosorbent assay (ELISA);Western blot;StarBase3.0 (an online software for analyzing the targeting relationship);Dual-luciferase reporter (DLR) assay.	mouse mesangial cells (MMCs).	up-regulated	PVT1 silencing inhibited the proliferation, migration, invasion and fibrosis, promoted the apoptosis, and blocked PI3K/Akt/mTOR pathway in HG-induced MMCs via up-regulating miR-93-5p.	32329508	2020	Silencing of LncRNA PVT1 inhibits the proliferation, migration and fibrosis of high glucose-induced mouse mesangial cells via targeting microRNA-93-5p	NA	NA	pubmed	Kidney
1024	Diabetic nephropathy	ANRIL	NA	NA	NA	34341	ENST00000582301.4	human	NONHSAT130416.2	+	1067	chr9:21,995,133-22,128,103	1	0	1	0	Cell culture and transfection;Cell Counting Kit-8 assay;Flow cytometry;Western blot;RNA extraction;RT-qPCR.	Human mesangial cells (HMCs)	up-regulated	UK	32256771	2020	Rhein-8-O-β-D-glucopyranoside inhibited high glucose-induced apoptosis of human mesangial cells by regulating the lincRNA ANRIL/let-7a/TGF-β1/Smad signaling pathway	NA	NA	pubmed	Kidney
1025	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	qRT-PCR;Dual luciferase reporter assays;Western blot.	db/db mouse;Human proximal tubular epithelial cells (HK-2 cells).	up-regulated	MALAT1 functions as a sponge RNA for miR-145 to derepress the expression of target gene ZEB2, thereby inducing EMT and fibrosis. 	31081103	2019	LncRNA MALAT1 facilities high glucose induced endothelial to mesenchymal transition and fibrosis via targeting miR-145/ZEB2 axis	NA	NA	pubmed	Kidney
1026	Diabetic nephropathy	PEA15	NA	NA	NA	8822	NA	human	NONHSAT149933.1	+	2315	chr1:160,205,384-160,215,372	0	1	0	1	Chip re‐annotation;Identification of the differentially expressed genes;Functional analysis.	gene chip datasets GSE30528 and GSE30529  downloaded from Gene Expression Omnibus (GEO, https://www.ncbi.nlm. Nih. Gov /geo/) database. 	down-regulated	PEA15 regulated by the transcription factor ATF3 and STAT4 may play an important role during the development of DKD.	30317603	2019	EA15, MIR22, LINC00472 as diagnostic markers for diabetic kidney disease	NA	NA	pubmed	Kidney
1027	Diabetic nephropathy	MIR22	NA	NA	NA	31599	NA	NA	NA	NA	NA	chr17:1,713,903-1,713,987	0	1	0	1	Chip re‐annotation;Identification of the differentially expressed genes;Functional analysis.	gene chip datasets GSE30528 and GSE30529  downloaded from Gene Expression Omnibus (GEO, https://www.ncbi.nlm. Nih. Gov /geo/) database. 	down-regulated	MIR22 regulated by the transcription factor ATF3 and STAT4 may play an important role during the development of DKD.	30317603	2019	EA15, MIR22, LINC00472 as diagnostic markers for diabetic kidney disease	NA	NA	pubmed	Kidney
1028	Diabetic nephropathy	LINC00472	NA	NA	NA	21380	ENST00000426635.5	human	NONHSAT113508.2	-	9515	chr6:71,343,427-71,420,130	0	1	0	1	Chip re‐annotation;Identification of the differentially expressed genes;Functional analysis.	gene chip datasets GSE30528 and GSE30529  downloaded from Gene Expression Omnibus (GEO, https://www.ncbi.nlm. Nih. Gov /geo/) database. 	down-regulated	LINC00472 regulated by the transcription factor ATF3 and STAT4 may play an important role during the development of DKD.	30317603	2019	EA15, MIR22, LINC00472 as diagnostic markers for diabetic kidney disease	NA	NA	pubmed	Kidney
1029	Diabetic nephropathy	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr7:108,300,190-108,302,063	1	0	1	0	LncRNA microarray analysis;Cell culture and transfection;Real time quantitative PCR analysis;Luciferase reporter assay;Western blot;Enzyme-linked immunosorbent assay (ELISA);Flow cytometry.	serums of healthy and DN patients;Human mesangial cells (HMCs);HEK293Tcells;DN mouse models.	up-regulated	MEG3 serves as an important role in DN progression targeted by miR-145.	31737219	2019	Long non-coding RNA MEG3 impacts diabetic nephropathy progression through sponging miR-145	NA	NA	pubmed	Kidney
1030	Diabetic nephropathy	GAS5	NA	NA	NA	16355	NA	human	NONHSAT227355.1	-	2060	chr1:173,858,559-173,867,045	1	0	1	0	Cell culture;Flow cytometry analysis;CCK-8 and EDU assays;Reverse transcription PCR;quantitative real-time PCR;Fluorescence in site hybridization;cell transfection;Dual-luciferase reporter assay;RNA immunoprecipitation assays;Western blot;Immunofluorescence assay;Bioinformatics analysis.	Mesangial cells;DN rat models.	down-regulated	lncRNA GAS5 upregulated SIRT1 expression and inhibited MCs proliferation and fibrosis by acting as an miR-221 sponge. 	31631065	2019	Long noncoding RNA GAS5 inhibits cell proliferation and fibrosis in diabetic nephropathy by sponging miR-221 and modulating SIRT1 expression	NA	NA	pubmed	Kidney
1031	Diabetic nephropathy	GAS5	NA	NA	NA	16355	NA	human	NONHSAT227355.1	-	2060	chr1:173,858,559-173,867,045	1	0	1	0	RT-qPCR;Western blot;RNA-binding protein immunoprecipitation (RIP);RNA pull-down;ChIP assays;Immunohistochemistry;Gelatin zymographic analysis;Cell culture;Cell transfection;Fluorescence in situ hybridization.	DN rat models;Renal tubular epithelial cells of DN rats.	down-regulated	GAS5 downregulates MMP9 expression through recruiting EZH2 to MMP9 promoter region and alleviates the progression of renal fibrosis in DN rats.	31916627	2020	Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2	NA	NA	pubmed	Kidney
1032	Diabetic nephropathy	MMP9	NA	NA	NA	7176	NA	NA	NA	NA	NA	chr20:46,008,908-46,016,561	1	0	1	0	RT-qPCR;Western blot;RNA-binding protein immunoprecipitation (RIP);RNA pull-down;ChIP assays;Immunohistochemistry;Gelatin zymographic analysis;Cell culture;Cell transfection;Fluorescence in situ hybridization.	DN rat models;Renal tubular epithelial cells of DN rats.	up-regulated	MMP9 silencing impedes the progression of renal fibrosis in DN	31916627	2020	Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2	NA	NA	pubmed	Kidney
1033	Diabetic nephropathy	MGC	TCONS_00015984	NA	NA	NA	ENST00000499670.2	human	NONHSAT055775.2	-	2501	chr17:74,210,012-74,213,342	1	0	1	0	Real-time qPCR;Western blot;Chromatin immunoprecipitation assays;hybridization;Histology and immunohistochemistry;Electron microscopy.	DN mice models;mouse mesangial cells (MMCs);Human nephrectomy samples.	up-regulated	lncRNA MGC and its component miRNAs target regulators of ER stress and protein synthesis resulting in hypertrophy and fibrosis related to DN.	27686049	2016	An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy.	NA	NA	pubmed	Kidney
1034	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	RNA IP (RIP);Quantitative real time-PCR (qRT-PCR);ChIRP-seq;ChIRP experiments.	Mouse podocytesouse podocytes;DN mice models.	down-regulated	Tug1 interacts with PGC-1α at its promoter, resulting in elevatedPpargc1atranscriptional output.	27760051	2016	Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy	NA	NA	pubmed	Kidney
1035	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	siRNA transfection and lentiviral vector transduction;Real‐time reverse transcriptase‐PCR;Western blot;Gelatin zymography;Immunofluorescence;hybridization;RNA‐binding protein immunoprecipitation;Chromatin immunoprecipitation assay;Dual‐luciferase reporter assay.	Mouse podocytesouse podocytes;DN mice models.	up-regulated	A potential feedback loop between MALAT1 and β‐catenin playing a role in high glucose‐associated podocyte impairment.	28444861	2017	LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose-induced podocyte injury via its interplay with β-catenin.	NA	NA	pubmed	Kidney
1036	Diabetic nephropathy	CDKN2B-AS1	NA	NA	NA	34341	ENST00000582301.4	human	NONHSAT130416.2	+	1067	chr9:21,995,133-22,128,103	1	0	1	0	quantitative real-time polymerase chain reaction (qRT-PCR);Cell Counting Kit-8 (CCK-8);flow cytometry assays;western blot;enzyme-linked immunosorbent assay (ELISA);dual-luciferase reporter assay.	human mesangial cells (HMCs)	up-regulated	CDKN2B-AS1 regulated HG-induced HMC viability, cell cycle progression, ECM accumulation, and inflammation response via regulating the miR-15b-5p/WNT2B axis.	33298110	2020	Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis	NA	NA	pubmed	Kidney
1037	Diabetic nephropathy	SOX2OT	TCONS_00007597;TCONS_00020726	NA	NA	20209	ENSMUST00000197977.1	mouse	NONMMUT042524.2	+	2970	chr3:181,711,925-181,714,436	1	0	1	0	flow cytometry assay;western blot;luciferaseactivity assay.	human podocytes cells (HPCs).	down-regulated	SOX2OT overexpression alleviates the HG-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis.	31301307	2019	LncRNA SOX2OT alleviates the high glucose-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis	NA	NA	pubmed	Kidney
1038	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	Mesangial cell culture;RNeasy Plus Mini Kit;Quantitative real-time RT-PCR (qPCR);BCA Protein Assay kit;Enzyme-linked immunosorbent assay analysis (ELISA).	human mesangial cells (MC) 	up-regulated	PVT1 is regulated by hyperglycemia, and may mediate susceptibility to diabetic kidney disease through effects involving ECM accumulation.	21526116	2011	Functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy	NA	NA	pubmed	Kidney
1039	Diabetic nephropathy	HOTAIR	TCONS_00007755	NA	NA	33510	ENST00000439545.1	human	NONHSAT028509.2	-	2337	chr12:53,962,308-53,974,956	1	0	1	0	Digoxigenin-labelled in situ hybridisation and RNAscope in situ hybridisation;Immunofluorescence microscopy;Transmission electron microscopy;Quantitative reverse transcription-PCR;Immunoblotting;Immunohistochemistry;Bioinformatics;	human kidney tissue;DN mices;mouse podocytes.	up-regulated	Exposure to high glucose increases Hotair expression by mouse podocytes in a p65-dependent manner and Hotair knockout from podocytes does not affect the development of glomerular injury in diabetic mice.	31399844	2019	Dysregulated expression but redundant function of the long non-coding RNA HOTAIR in diabetic kidney disease	NA	NA	pubmed	Kidney
1040	Type 2 diabetes combined with chronic renal failure	CASC2	TCONS_00003725	NA	NA	22933	ENST00000454781.4	human	NONHSAT016552.2	+	2396	chr10:118,046,824-118,210,153	1	0	1	0	qRT-PCR;ROC curve analysis.	Blood samples and renal tissues from patients with type 2 diabetes combined with chronic renal failure/patients with diabetic retinopathy, diabetic ketoacidosis, diabetic foot infections or diabetic cardiomyopathy/diabetic patients without any obvious complication/healthy controls.	down-regulated	NA	30171178	2018	Clinical Significance of Serum lncRNA Cancer Susceptibility Candidate 2 (CASC2) for Chronic Renal Failure in Patients with Type 2 Diabetes	NA	NA	pubmed	Kidney
1041	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Real-time-quantitative polymerase chain reaction(qRT-PCR)	 	up-regulated	MALAT1over-expression that was associated to some extent with MIR-499A down-regulation that might be involved in DN-related ESRD.	30270667	2020	Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis	NA	NA	pubmed	Kidney
1042	Diabetic nephropathy	HOTTIP	NA	NA	NA	37461	NA	human	NONHSAT211845.1	+	4665	chr7:27,201,844-27,207,259	1	0	1	0	qRT-PCR;Ellisa;Western blot;MTT assay,;luciferase reporter assay.	DN mice;mouse mesangial cells (MMCs). 	up-regulated	lncRNA Hottip/miR-455-3p/Wnt2B axis plays an important role in cell proliferation, inflammation, and extracellular matrix (ECM) accumulation in diabetic nephropathy.	31934070	2019	Long non-coding RNA Hottip modulates high-glucose-induced inflammation and ECM accumulation through miR-455-3p/WNT2B in mouse mesangial cells	NA	NA	pubmed	Kidney
1043	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Real-Time Quantitative PCR (RT-qPCR);Western Blot;Immunohistochemistry;Cell culture;Plasmid Construction and Cell Transfection;Enzyme-Linked Immunosorbent Assay;In Situ Cell Death Detection Kit;MTT method;RNA Pull-Down Assay;Chromatin Immunoprecipitation Assay;Methylation Specific PCR.	human renal glomerular endothelial cells (HRGECs)	up-regulated	MALAT recruits methyltransferase G9a to epigenetically inhibit klotho expression, and thus mediates HG-induced glomerular endothelial cell injury. 	30762931	2019	Long noncoding RNA MALAT1 mediates high glucose-induced glomerular endothelial cell injury by epigenetically inhibiting klotho via methyltransferase G9a	NA	NA	pubmed	Kidney
1044	Diabetic nephropathy	ANRIL	NA	NA	NA	34341	ENST00000582301.4	human	NONHSAT130416.2	+	1067	chr9:21,995,133-22,128,103	1	0	1	0	Echocardiography;Enzyme-linked immunosorbent assay analysis (ELISA);Real-Time Quantitative PCR (RT-qPCR);Luminex assay;Urine albumin assay;Histology and immunohistochemistry.	DN mice model;DCM mice model.	up-regulated	ANRIL regulates functional and structural alterations in the kidneys and hearts in diabetes through controlling the expressions of ECM proteins and VEGF.	29118015	2018	ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications	NA	NA	pubmed	Kidney
1045	Diabetic nephropathy	SNHG17	NA	NA	NA	48600	NA	human	NONHSAT079656.2	-	1186	chr20:38,419,638-38,435,375	1	0	1	0	Cell culture, grouping and transfection;Quantitative reverse-transcription PCR (qRT-PCR);MTT assay;Enzyme-linked immunosorbent assay (ELISA);Dual luciferase reporter (DLR) assay;Western blot.	The pathological kidney tissues of the DN patients and the normal kidney tissues of the healthy children;Human glomerular mesangial cells (HGMCs).	up-regulated	silencing of SNHG15 ameliorated the malignant behaviors of pediatric DN via modulating the miR-141/ICAM-1 axis	33506255	2021	SNHG15 knockdown inhibits diabetic nephropathy progression in pediatric patients by regulating the miR-141/ICAM-1 axis in vitro	NA	NA	pubmed	Kidney
1046	Diabetic nephropathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	quantitative reverse transcription polymerase chain reaction;western blot;3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide;dual-luciferase reporter analysis; RNA immunoprecipitation;RNA pull-down;levels of reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD), and SOD2;levels of fibronectin (FN), collagen I (Col I), and Col IV.	Serum samples;human mesangial cells (HMCs).	up-regulated	KCNQ1OT1 knockdown attenuated HG-induced proliferation, oxidative stress, and ECM accumulation of HMCs by regulating miR-18b/HMGA2 axis.	32989627	2021	KCNQ1OT1/miR-18b/HMGA2 axis regulates high glucose-induced proliferation, oxidative stress, and extracellular matrix accumulation in mesangial cells	NA	NA	pubmed	Kidney
1047	Diabetic nephropathy	KCNQ1OT1	TCONS_00006990	NA	NA	6295	ENST00000597346.1	human	NONHSAT017523.2	-	91671	chr11:2,608,328-2,699,994	1	0	1	0	RT-qPCR analysis;Western blot;ELISA assay;ROS assay kit (containing DCFH-DA).	HK-2 cells;Serum samples.	up-regulated	Downregulation of KCNQ1OT1 inhibited the inflammation, oxidative stress and pyroptosis of HG-induced HK-2 cells by up-regulating the expression of miR-506-3p.	32104033	2020	Silencing of KCNQ1OT1 Decreases Oxidative Stress and Pyroptosis of Renal Tubular Epithelial Cells	NA	NA	pubmed	Kidney
1048	Diabetic nephropathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	Cell culture and transfection;quantitative real-time polymerase chain reaction (qRT-PCR);Western blot;Immunofluorescence;fluorescence in situ hybridization (FISH);RNA immunoprecipitation (RIP).	DN mouse kidney tissues;The human proximal tubular cell line (HK-2)	up-regulated	NEAT1 is involved in the protective effect of Klotho against renal tubulointerstitial fibrosis and EMT in renal tubular epithelial cells through the ERK1/2 signaling pathway in diabetic kidney disease. 	32054986	2020	Long noncoding RNA NEAT1 is involved in the protective effect of Klotho on renal tubular epithelial cells in diabetic kidney disease through the ERK1/2 signaling pathway	NA	NA	pubmed	Kidney
1049	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	qRT-PCR;western blot;enzyme linked immunosorbent assay (ELISA);RIP;RNA pull-down assay;Dualluciferasereporter assay.	The human proximal tubular cell line (HK-2);DN mice models;	up-regulated	LncRNA MALAT1 interacts with transcription factor Foxo1 to represses SIRT1 transcription in high glucose incubated HK-2 cells, which promotes high glucose-induced HK-2 cells injury.	29928873	2018	Long non-coding RNA MALAT1 interacts with transcription factor Foxo1 to regulate SIRT1 transcription in high glucose-induced HK-2 cells injury	NA	NA	pubmed	Kidney
1050	Diabetic nephropathy	ARAP1-AS2	NA	NA	NA	39994	NA	NA	NA	NA	NA	chr11:72,700,474-72,705,607	1	0	1	0	Cell culture;Cell transfection;Real‐time PCR;Western blot;Cdc42 activation assay;Phalloidin fluorescent staining;Cell counting kit‐8 assay;Wound healing analysis;Transwell assay.	Human renal tubular epithelial cells (HK‐2);	up-regulated	ARAP1‐AS2 may play a pathogenic role in DN by regulating the expression of ARAP1. In addition, inhibition of ARAP1 expression can reduce cytoskeleton rearrangement and EMT process in HK‐2 cells and improve renal fibrosis.	31975379	2020	The effect of lncRNA-ARAP1-AS2/ARAP1 on high glucose-induced cytoskeleton rearrangement and epithelial-mesenchymal transition in human renal tubular epithelial cells	NA	NA	pubmed	Kidney
1051	Diabetic nephropathy	ARAP1	NA	NA	NA	16925	NA	NA	NA	NA	NA	chr11:72,685,069-72,752,408	1	0	1	0	Cell culture;Cell transfection;Real‐time PCR;Western blot;Cdc42 activation assay;Phalloidin fluorescent staining;Cell counting kit‐8 assay;Wound healing analysis;Transwell assay.	Human renal tubular epithelial cells (HK‐2);	up-regulated	ARAP1‐AS2 may play a pathogenic role in DN by regulating the expression of ARAP1. In addition, inhibition of ARAP1 expression can reduce cytoskeleton rearrangement and EMT process in HK‐2 cells and improve renal fibrosis.	31975379	2020	The effect of lncRNA-ARAP1-AS2/ARAP1 on high glucose-induced cytoskeleton rearrangement and epithelial-mesenchymal transition in human renal tubular epithelial cells	NA	NA	pubmed	Kidney
1052	Diabetic nephropathy	MIAT	NA	NA	NA	33425	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,646,452-26,669,655	1	0	1	0	 Cell Counting Kit-8 (CCK-8);colony formation assay;caspase-3 detection;flow cytometry;Enzyme-linked immunosorbent assay (ELISA);western blot;reverse transcription-quantitative polymerase chain reaction (RT-qPCR);dual-luciferase reporter;RNA immunoprecipitation (RIP);RNA pull-down assays.	 human renal tubular epithelial cells (HK-2);	down-regulated	MIAT functioned as an inhibitory factor in the pathogenesis to impede the development of DN and inactivate the NF-κB pathway via regulating the miR-182-5p/GPRC5A axis.	34553078	2021	Long noncoding RNA MIAT inhibits the progression of diabetic nephropathy and the activation of NF-κB pathway in high glucose-treated renal tubular epithelial cells by the miR-182-5p/GPRC5A axis	NA	NA	pubmed	Kidney
1053	Diabetic retinopathy	HOTTIP	NA	NA	NA	37461	NA	human	NONHSAT211845.1	+	4665	chr7:27,201,844-27,207,259	1	0	1	0	reverse transcriptase-polymerase chain reaction (RT-PCR),electrophysiology,Western blot,MTT,Cell apoptosis	rats,cell	up-regulated	HOTTIP improves diabetic retinal microangiopathy through the p38-MAPK pathway	29863235	2018	LncRNA HOTTIP improves diabetic retinopathy by regulating the p38-MAPK pathway	NA	8947	pubmed	Eye
1054	Diabetic nephropathy	LINC00462	NA	NA	NA	42811	NA	NA	NA	-	1023	chr13:48,576,974-48,578,088	1	0	1	0	quantitative reverse-transcription polymerase chain reaction (qRT-PCR);Cell culture;Cell counting kit‐8 (CCK‐8) assay;Intracellular reactive oxygen species (ROS) detection;Lipid peroxidation assay;Superoxide dismutase (SOD) and catalase (CAT) assay;Flow cytometry analysis;Western blot.	renal tubular epithelial cells (RTEC);human kidney (HK-2 and HKC) cells.	up-regulated	knockdown of LINC00462 can ameliorate oxidative stress and apoptosis in HG-induced RTEC by activating the AKT pathway.	31489995	2019	LINC00462 is involved in high glucose-induced apoptosis of renal tubular epithelial cells via AKT pathway	NA	NA	pubmed	Kidney
1055	Diabetic nephropathy	GAS5	NA	NA	NA	16355	NA	human	NONHSAT227355.1	-	2060	chr1:173,858,559-173,867,045	1	0	1	0	Cell culture;Cell transfection;qRT-PCR;Cell viability assay;Cell apoptosis assay;Western blot.	human renal tubular epithelial HK-2.	up-regulated	Silence of GAS5 alleviated high glucose toxicity to human renal tubular epithelial HK-2 cells might be via down-regulating miR-27a and BNIP3, and then inactivating JNK pathway. 	31159592	2019	Silence of lncRNA GAS5 alleviates high glucose toxicity to human renal tubular epithelial HK-2 cells through regulation of miR-27a.	NA	NA	pubmed	Kidney
1056	Type 2 diabetes mellitus	DNM3OS	DNM3 Opposite Strand/Antisense RNA	NA	NA	41228	ENST00000417354.2	human	NONHSAT007597.2	-	4358	chr1:172,138,397-172,144,840	1	0	1	0	LRLSLDA-LNCSIM1	NA	NA	NA	NA	NA	NA	NA	NA	LncRNADisease v2.0	NA
1057	Diabetic nephropathy	CASC2	TCONS_00003725	NA	NA	22933	ENST00000454781.4	human	NONHSAT016552.2	+	2396	chr10:118,046,824-118,210,153	1	0	1	0	Cell culture;MTT assay;Real-time quantitative PCR;Western-blot.	serum samples from DN patients;Mouse podocyte cells.	down-regulated	long non-coding RNA CASC2 may improve diabetic nephropathy by inhibiting JNK pathway.	29890555	2019	Long Non-Coding RNA CASC2 improves diabetic nephropathy by inhibiting JNK pathway	NA	NA	pubmed	Kidney
1058	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	0	1	0	1	Analysis of SNP microarray data;Pool construction;SNP detection;SNP genotyping in individuals.	Patients with DM or DN.	up-regulated	PVT1may contribute to ESRD susceptibility in diabetes.	17395743	2007	Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study.	NA	NA	pubmed	Kidney
1059	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	direct sequencing;quantitative PCR.	mesangial cortical epithelial;epithelial;proximal tubule cells;Patients with T1DM duration of at least 10 years and severe DN.	up-regulated	PVT1 play a role in mediating susceptibility to ESRD attributable to diabetes.	17881614	2007	Variants in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes.	NA	NA	pubmed	Kidney
1060	Type 2 diabetes mellitus	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Real time quantitative PCR;ELISA assay;SiRNA transfection;Intracellular ROS measurement.	Human umbilical vein endothelial cells (HUVECs);T2DM mice model.	up-regulated	 lncRNA MALAT1 is induced following short-term hyperglycaemia which turns on early inflammatory events in the endothelium through SAA3. 	25787249	2015	Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells.	E11	9352	pubmed	NA
1061	Diabetic nephropathy	MIAT	NA	NA	NA	33425	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,646,452-26,669,655	1	0	1	0	Cell culture;Quantitative real-time-PCR;Western blot;RNA interference;MTT assay;RNA pull-down;RIP (RNA binding protein immunoprecipitation).	DN rat models;human renal tubular epithelial cell line (HK-2).	down-regulated	MIAT/Nrf2 served as an important signaling pathway for high glucose induced renal tubular epithelial injury.	26551455	2015	Long non-coding MIAT mediates high glucose-induced renal tubular epithelial injury.	NA	NA	pubmed	Kidney
1062	Diabetic nephropathy	ZEB1-AS1	TCONS_00003851	NA	NA	42354	ENST00000441257.1	human	NONHSAT012611.2	-	2213	chr10:31,307,717-31,319,035	1	0	1	0	Cell Culture;Histology;immunohistochemistry;Immunoblot Analyses;Real-Time PCR;RNA Immunoprecipitation;ChIP Analysis.	DN mice models;HK-2 cells.	down-regulated	lnc ZEB1-AS1 bound directly to H3K4 methyltransferase myeloid and lymphoid or mixed-lineage leukemia 1 (MLL1) and promoted H3K4me3 histone modification on ZEB1 promoter	30121551	2018	lncRNA ZEB1-AS1 was suppressed by p53 for renal fibrosis in diabetic nephropathy.Mol	NA	NA	pubmed	Kidney
1063	Diabetic nephropathy	ZEB1-AS1	TCONS_00003851	NA	NA	42354	ENST00000441257.1	human	NONHSAT012611.2	-	2213	chr10:31,307,717-31,319,035	1	0	1	0	Cell culture;Cell transfection;Quantitative polymerase chain reaction (qRT-PCR);Western blot;Luciferase reporter assay.	Human Kidney tissues;HK-2 cells.	down-regulated	lncRNA ZEB1-AS1 inhibited high glucose-induced EMT and fibrogenesis via regulating miR-216a-5p/BMP7 axis in diabetic nephropathy	32294702	2020	lncRNA ZEB1-AS1 inhibits high glucose-induced EMT and fibrogenesis by regulating the miR-216a-5p/BMP7 axis in diabetic nephropathy.	NA	NA	pubmed	Kidney
1064	Diabetic nephropathy	NR_038323	NA	NA	NA	NA	ENST00000519692.1	NA	NA	+	4387	chr8:23,336,208-23,366,125	1	0	1	0	Cell culture;Luciferase reporter assay;Histology and Immunohistochemistry;Real-Time qPCR;Immunoblot Analysis;FISH.	HK-2 cells;DN rat models;Human kidney biopsy samples.	up-regulated	overexpression of lncRNANR_038323may suppress HG-induced renal fibrosis via the miR-324-3p/DUSP1/p38MAPK and ERK1/2 axis.	31430717	2019	lncRNA NR_038323 Suppresses Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-324-3p/DUSP1 Axis	NA	NA	pubmed	Kidney
1065	Diabetic nephropathy	OIP5-AS1	TCONS_00011868	NA	NA	43563	ENST00000500949.5	human	NONHSAT041920.2	+	8865	chr15:41,284,032-41,309,737	1	0	1	0	Cell culture;RT-qPCR.;Western blot;dual luciferase reporter assay.	db/db DN mice kidney tissue;HK2 cells.	up-regulated	lncRNA OIP5-AS1 induces EMT and renal fibrosis in DN via binding to miR-30c-5p.	32519534	2020	LncRNA OIP5-AS1 induces epithelial-to-mesenchymal transition and renal fibrosis in diabetic nephropathy via binding to miR-30c-5p	NA	NA	pubmed	Kidney
1066	Diabetic nephropathy	LINC00968	NA	NA	NA	48727	ENST00000499425.1	NA	NA	-	2520	chr8:56,518,321-56,559,671	1	0	1	0	Qrt-pcr;RNA immunoprecipitation (RIP);chromatin immunoprecipitation (ChIP) assay.	diabetic db/db mouse tissue;mesangial cells.	up-regulated	lncRNA LINC00968 accelerates the proliferation and fibrosis of mesangial cells by epigenetically repressing p21 via recruiting EZH2	30197001	2018	LncRNA LINC00968 accelerates the proliferation and fibrosis of diabetic nephropathy by epigenetically repressing p21 via recruiting EZH2.Biochem. Biophys	NA	NA	pubmed	Kidney
1067	Diabetic nephropathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	RT-qPCR;MTT assay;commercial kits;Western blot;dual-luciferase reporter assay;RNA immunoprecipitation assay.	HK-2 cells	up-regulated	NEAT1 facilitates high glucose-induced damage in HK-2 cells by suppressing mitophagy via the miR-150-5p–DRP 1 axis	33914383	2021	LncRNA NEAT1 accelerates renal tubular epithelial cell damage by modulating mitophagy via miR-150-5p-DRP1 axis in diabetic nephropathy	NA	NA	pubmed	Kidney
1068	Diabetic nephropathy	MGC	TCONS_00015984	NA	NA	NA	ENST00000499670.2	human	NONHSAT055775.2	-	2501	chr17:74,210,012-74,213,342	1	0	1	0	Small RNA sequencing;Real-time qPCR;Western blot;Chromatin immunoprecipitation assays;Serum toxicity analyses;hybridization;Histology and immunohistochemistry;Electron microscopy;Quantification of miRNAs from human renal biopsies.	DN mice model;Primary mesangial cells.	up-regulated	A single oligonucleotide (GapmeR) targeting a lncRNA which hosts a cluster of miRNAs can control the expression of the host lncRNA, component miRNAs, their targets, profibrotic genes and symptoms of DN in mice, and in human MC.	27686049	2016	An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy	NA	NA	pubmed	Kidney
1069	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	real-time RT-PCR;luciferase assay;Immunoprecipitation; biotinylated oligonucleotide pulldown assay;ChIP-qPCR.	Conditionally immortalized mouse podocytes.	down-regulated	under HG conditions, binding of the ChREBP/MLX heterodimer to ChoRE triggers the formation of a multisubunit complex, composed of at least MXD1, HDAC1, and SIN3A, to repress the transcription of Tug1 in podocytes.	32467232	2020	Role for carbohydrate response element-binding protein (ChREBP) in high glucose-mediated repression of long noncoding RNA Tug1	NA	NA	pubmed	Kidney
1070	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	3′ UTR Luciferase Reporter Assays;Quantitative real-time RT-PCR (qPCR);Protein extraction and quantification;Enzyme-linked immunosorbent assay analysis (ELISA).	Primary cultures of MC and RPTEC.	up-regulated	The plasmacytoma variant translocation 1 (PVT1) increases plasminogen activator inhibitor 1 (PAI-1) and transforming growth factor beta 1 (TGF-β1) in mesangial cells.	24204837	2013	Role of MicroRNA 1207-5P and Its Host Gene, the Long Non-Coding RNA Pvt1, as Mediators of Extracellular Matrix Accumulation in the Kidney: Implications for Diabetic Nephropathy	NA	NA	pubmed	Kidney
1071	Diabetic retinopathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	Real-time PCR;flow cytometry;Western blot;RNA immunoprecipitation;chromatin immunoprecipitation assay. 	Human mesangial cells.	up-regulated	 Long noncoding RNA (lncRNA) NEAT1 regulates the progression of mesangial cell hypertrophy via a competing endogenous RNA (ceRNA) mechanism.	33585566	2021	LncRNA NEAT1 Promotes High Glucose-Induced Mesangial Cell Hypertrophy by Targeting miR-222-3p/CDKN1B Axis	NA	NA	pubmed	Eye
1072	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	quantitative real-time polymerase chain reaction (qRT-PCR);Cell Counting-8 (CCK-8) assay;Western blot assay;dual luciferase reporter assay;corresponding kits. 	 serum samples of DN patients and HG-induced HRMCs.	up-regulated	PVT1 knockdown suppressed DN progression though functioning as ceRNA of miR-23b-3p to regulate EGR1 expression in vitro.	33408314	2021	Knockdown of plasmacytoma variant translocation 1 (PVT1) inhibits high glucose-induced proliferation and renal fibrosis in HRMCs by regulating miR-23b-3p/early growth response factor 1 (EGR1)	NA	NA	pubmed	Kidney
1073	Diabetic nephropathy	MIAT	NA	NA	NA	33425	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,646,452-26,669,655	1	0	1	0	Cell culture;Quantitative real-time-PCR;Western blot;RNA interference;MTT assay;RNA pull-down;RIP (RNA binding protein immunoprecipitation).	DN rat models;human renal tubular epithelial cell line (HK-2).	down-regulated	MIAT/Nrf2 served as an important signaling pathway for high glucose induced renal tubular epithelial injury.	26551455	2015	Long non-coding MIAT mediates high glucose-induced renal tubular epithelial injury.	NA	NA	pubmed	Kidney
1074	Diabetic nephropathy	ANKRD10-IT1	NA	NA	NA	39891	NA	NA	NA	NA	NA	chr13:110,894,639-110,899,172	0	1	0	1	Transmission electron microscopy (TEM);Nanoparticle tracking analysis (NTA);Western blot analysis;Differential expression analysis.	 human renal tubular epithelial cells	down-regulated	participate in the progression of diabetic nephropathy,but it's specific functions have not been investigated or verified.	33714195	2021	Determining the influence of high glucose on exosomal lncRNAs, mRNAs, circRNAs and miRNAs derived from human renal tubular epithelial cells	NA	NA	pubmed	Kidney
1075	Diabetic nephropathy	RN7SL870P	NA	NA	NA	46886	NA	NA	NA	NA	NA	chr3:47,560,229-47,560,524	0	1	0	1	Transmission electron microscopy (TEM);Nanoparticle tracking analysis (NTA);Western blot analysis;Differential expression analysis.	 human renal tubular epithelial cells	down-regulated	participate in the progression of diabetic nephropathy,but it's specific functions have not been investigated or verified.	33714195	2021	Determining the influence of high glucose on exosomal lncRNAs, mRNAs, circRNAs and miRNAs derived from human renal tubular epithelial cells	NA	NA	pubmed	Kidney
1076	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	0	1	0	1	Western blotting;immunofluorescenc;qRT-PCR;CCK-8;flow cytometry;spectrophotomete.	MPC-5	up-regulated	MALAT1/miR-200c/NRF2 was involved in the regulation of pyroptosis and OS in podocytes.	33880049	2021	Atorvastatin Regulates MALAT1/miR-200c/NRF2 Activity to Protect Against Podocyte Pyroptosis Induced by High Glucose	NA	NA	pubmed	Kidney
1077	Diabetic nephropathy	CASC2	TCONS_00003725	NA	NA	22933	ENST00000454781.4	human	NONHSAT016552.2	+	2396	chr10:118,046,824-118,210,153	1	0	1	0	real-time quantitative polymerase chain reaction (RT-qPCR);Cell Counting Kit-8 (CCK8) assay;5-ethynyl-29-deoxyuridine (EDU) assay;Enzyme-linked immunosorbent assay (ELISA);Western blot assay;Dual-luciferase reporter assay;RNA immunoprecipitation (RIP) assay.	Human glomerular mesangial cells (HMCs) and 293T cells.	down-regulated	CASC2 alleviated proliferation, inflammation and fibrosis in DN cell model by sponging miR-135a-5p to induce TIMP3 expression.	34446088	2021	Long non-coding RNA CASC2 restrains high glucose-induced proliferation, inflammation and fibrosis in human glomerular mesangial cells through mediating miR-135a-5p/TIMP3 axis and JNK signaling	NA	NA	pubmed	Kidney
1078	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	ELISA assay;qRT-PCR;western blotting;MTT assay.	HBZY-1, rat glomerular mesangial cell line	up-regulated	PVT1 overexpression significantly enhanced cell viability and promoted the expression levels of TGF-β1 and c-myc.	28861164	2017	Danggui buxue tang suppresses high glucose-induced proliferation and extracellular matrix accumulation of mesangial cells via inhibiting lncRNA PVT1	NA	NA	pubmed	Kidney
1079	Diabetic nephropathy	TTC28-AS1	TCONS_00025385	NA	NA	29336	ENST00000437713.4	human	NONHSAT084607.2	+	948	chr22:27,994,560-28,002,602	1	0	1	0	Cell Counting-8 Kit (CCK-8) assa;flow cytometry;quantitative real-time polymerase chain reaction (qRT-PCR);western blot;enzyme-linked immunosorbent assay (ELISA);dual-luciferase reporter;RNA immunoprecipitation (RIP) assays.	HK-2 cells	down-regulated	TTC28-AS1 attenuates HG-induced damage in HK-2 cells at least partially by targeting the miR-320a/CD2AP axis.	34623609	2021	Long non-coding RNA TTC28-AS1 attenuates high glucose-induced damage in HK-2 cells depending on the regulation of miR-320a/CD2AP axis	NA	NA	pubmed	Kidney
1080	Diabetic nephropathy	CDKN2B-AS1	NA	NA	NA	34341	ENST00000582301.4	human	NONHSAT130416.2	+	1067	chr9:21,995,133-22,128,103	1	0	1	0	Quantitative real-time polymerase chain reaction (qRT-PCR);3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT);flow cytometry assays;western blotting;dual-luciferase reporter assay.	The serum of DN patients;human podocytes (HPCs);human renal tubular cells (HK-2)	up-regulated	High glucose-induced CDKN2B-AS1 promoted apoptosis and fibrosis via the TGF-β1 signaling mediated by the miR-98-5p/NOTCH2 axis in HPCs and HK-2 cells.	34649592	2021	CDKN2B-AS1 participates in high glucose-induced apoptosis and fibrosis via NOTCH2 through functioning as a miR-98-5p decoy in human podocytes and renal tubular cells	NA	NA	pubmed	Kidney
1081	Diabetic nephropathy	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	PCR;miRNA and lncRNA assessment;Laboratory assessments.	The serum and urinary specimens of DM patients and controls utilized.	up-regulated	LncRNA MALAT1 are upregulated in early DKD and inhibit miRNA 93 and miRNA 29a function, while enhancing miRNA 21 and miRNA 124 activities	33859515	2021	Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients	NA	NA	pubmed	Kidney
1082	Diabetic retinopathy	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	PCR;miRNA and lncRNA assessment;Laboratory assessments.	The serum and urinary specimens of DM patients and controls utilized.	up-regulated	LncRNA NEAT1 are upregulated in early DKD and inhibit miRNA 93 and miRNA 29a function, while enhancing miRNA 21 and miRNA 124 activities	33859515	2021	Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients	NA	NA	pubmed	Eye
1083	Diabetic nephropathy	MIAT	NA	NA	NA	33425	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,646,452-26,669,655	1	0	1	0	PCR;miRNA and lncRNA assessment;Laboratory assessments.	The serum and urinary specimens of DM patients and controls utilized.	down-regulated	LncRNA MIAT are downregulated and enhance miRNA 93 and miRNA 29a expression in DKD patients, and suppress miRNA 21 and miRNA 124 activities	33859515	2021	Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients	NA	NA	pubmed	Kidney
1084	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	PCR;miRNA and lncRNA assessment;Laboratory assessments.	The serum and urinary specimens of DM patients and controls utilized.	down-regulated	LncRNA TUG1 are downregulated and enhance miRNA 93 and miRNA 29a expression in DKD patients, and suppress miRNA 21 and miRNA 124 activities	33859515	2021	Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients	NA	NA	pubmed	Kidney
1085	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	0	1	0	1	Analysis of SNP microarray data;Pool construction;SNP detection;SNP genotyping in individuals.	Patients with DM or DN.	up-regulated	PVT1may contribute to ESRD susceptibility in diabetes.	17395743	2007	Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study.	NA	NA	pubmed	Kidney
1086	Diabetic nephropathy	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NONHSAT129063.2	+	1706	chr8:127,795,799-128,101,256	1	0	1	0	direct sequencing;quantitative PCR.	mesangial cortical epithelial;epithelial;proximal tubule cells;Patients with T1DM duration of at least 10 years and severe DN.	up-regulated	PVT1 play a role in mediating susceptibility to ESRD attributable to diabetes.	17881614	2007	Variants in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes.	NA	NA	pubmed	Kidney
1087	Diabetic nephropathy	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Immunofluorescence;Western blot analysis;RT-qPCR;Transmission electron microscopy;ultra–high resolution mass spectrometry (HRMS).	conditionally immortalized mouse podocytes (MPC5);mice.	 	PGC1α is required for the protective effects of lncRNA Tug1 on mitochondrial function in podocytes and progression of diabetic nephropathyin vivo.	34380028	2021	PGC1α is required for the renoprotective effect of lncRNA Tug1 in vivo and links Tug1 with urea cycle metabolites	NA	NA	pubmed	Kidney
1088	Diabetic nephropathy	NNT-AS1	NA	NA	NA	49005	ENST00000513560.5	human	NONHSAT101321.2	-	5892	chr5:43,571,594-43,603,138	1	0	1	0	Bioinformatics analysis;luciferase reporter assay;quantitative real-time PCR;WB analysis;CCK-8 assay;ELISA;qRT-PCR;western blot analysis.	human glomerular mesangial cells (HGMCs)	up-regulated	NNT-AS1 can be positively used as a potential biomarker and indicator of DN and causes extracellular matrix (ECM) accumulation and inflammation of human mesangial cells.	34742256	2021	LncRNA NNT-AS1 regulates proliferation, ECM accumulation and inflammation of human mesangial cells induced by high glucose through miR-214-5p/smad4	NA	NA	pubmed	Kidney
1089	Diabetic nephropathy	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	quantitative real-time PCR (qRT-PCR);western blot;3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT);flow cytometry assays.	human kidney (HK) cells;human glomerular mesangial cells (HMCs);human kidney-2 (HK-2) cells.	up-regulated	XIST depletion suppressed proliferation and promoted apoptosis via miR-423-5p/HMGA2 axis in HG-treated HK cells.	34532814	2021	Long non-cording RNA XIST promoted cell proliferation and suppressed apoptosis by miR-423-5p/HMGA2 axis in diabetic nephropathy	NA	NA	pubmed	Kidney
1090	Diabetic nephropathy	GAS5	NA	NA	NA	16355	NA	human	NONHSAT227355.1	-	2060	chr1:173,858,559-173,867,045	1	0	1	0	Cell Culture;Cell Transfection;HE, PAS Staining, and Immunohistochemical Detection of Renal Tissue;RNA FluorescenceIn SituHybridization;qRT-PCR;Mitochondrial ATP Determination;Mitochondrial ROS Determination;Western Blot;Chromatin Immunoprecipitation-qPCR Assay;Double Luciferase Reporter Gene Analysis;RNA Immunoprecipitation Assay;flow cytometry assays.	HK-2 cells;DN rat model.	down-regulated	Gas5 could further promote the C/EBPβ expression by inhibiting the miR-18a-5p expression through the ceRNA effect. 	34526965	2021	Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells	NA	NA	pubmed	Kidney
1091	Diabetic nephropathy	NORAD	TCONS_00023526	NA	NA	44311	ENST00000565493.1	human	NONHSAT079548.2	-	5373	chr20:36,045,618-36,051,018	1	0	1	0	Reverse transcription-quantitative polymerase chain reaction (RT-qPCR);MTT assay;ELISA;dual-luciferase reporter assay;Western blot.	human mesangial cells (HMCs)	up-regulated	NORAD knockdown inhibited HG-induced HMC proliferation, inflammation and fibrosis by regulating miR-485/NRF1.	34194552	2021	Knockdown of lncRNA NORAD inhibits the proliferation, inflammation and fibrosis of human mesangial cells under high-glucose conditions by regulating the miR-485/NRF1 axis	NA	NA	pubmed	Kidney
1092	Diabetic nephropathy	HCP5	NA	NA	NA	21659	NA	human	NONHSAT252185.1	-	1168	chr6:31,463,170-31,472,408	1	0	1	0	quantitative polymerase chain reaction (QPCR);cell counting kit-8 (CCK-8) assay;flow cytometry assay;western blot;enzyme-linked immunosorbent assay (ELISA);dual-luciferase reporter assay,;pull-down assay;RNA immunoprecipitation (RIP) assay.	Human glomerular mesangial cells (HGMCs).	up-regulated	HCP5 was implicated in DN progression by modulating the miR-93-5p/HMGA2 axis.	34187448	2021	LncRNA HCP5 knockdown inhibits high glucose-induced excessive proliferation, fibrosis and inflammation of human glomerular mesangial cells by regulating the miR-93-5p/HMGA2 axis	NA	NA	pubmed	Kidney
1093	Type 2 diabetes mellitus	HOTAIR	TCONS_00007755	NA	NA	33510	ENST00000439545.1	human	NONHSAT028509.2	-	2337	chr12:53,962,308-53,974,956	1	0	1	0	qRT-PCR;ROC curve;K-M curve;COX multivariate analysis.	serum of T2DM patients with T2DM and healthy controls.	up-regulated	the augment of HOTAIR expression was a character of T2DM. 	34496971	2021	Diagnostic significance of serum lncRNA HOTAIR and its predictive value for the development of chronic complications in patients with type 2 diabetes mellitus	E11	9352	pubmed	NA
1094	Hypoglycemia	H19	TCONS_00005659	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	DNA Extraction;Polymerase Chain Reaction (PCR)-Single-Strand Conformation Polymorphism (SSCP) and Sequence Analysis;LOH Study;Quantification of Paternal Allele;Reverse Transcriptase (RT)-PCR.	DNA samples	up-regulated	UK	11395395	2001	Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11	NA	NA	pubmed	Pancreas
1095	Insulin resistance	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229877.1	+	8841	chr11:65,497,688-65,506,431	1	0	1	0	Ethics Statement,Study Subjects,RNA Isolation and Quantitation,IR Mouse Model Establishment,Biochemical Analysis,ELISA,Cell Culture and Transfection,Western Blot Analysis,Detection of Glucose Uptake,Transwell Assay,Dual-Luciferase Reporter Assay,RNA Binding Protein Immunoprecipitation Assay,Statistical Analysis	patients with T2DM,C57BL/6J mice,human umbilical vein endothelial cells 	up-regulated 	Inhibition of MALAT1 elevates miR-382-3p to repress resistin, which consequently underlies the mechanism of exercise protecting against IR, highlighting a direction for T2DM therapy development.	31479923	2019	Exercise Reduces Insulin Resistance in Type 2 Diabetes Mellitus via Mediating the lncRNA MALAT1/MicroRNA-382-3p/Resistin Axis	NA	NA	pubmed	NA
1096	Insulin resistance	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229877.1	+	8841	chr11:65,497,688-65,506,431	1	0	1	0	Reagents,Cell culture,Primary isolation and culture of hepatocytes,Animal studies,Measurement of intracellular cholesterol and triglyceride,Small  interfering  RNA,Real-time PCR assay,Western blot analysis,RNA immunoprecipitation (RIP),RNA  pull-down  assay,Ubiquitination Assay,Expression plasmids construction,Histological analysis,Intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance test (ITT),Statistical analysis	Mice,Hepatocytes,HepG2 cells 	up-regulated 	MALAT1 induced hepatic lipid accumulation and insulin resistance by increasing SREBP-1c and target genes expression,inhibition of MALAT1 has potential for the treatment of obesity and type 2 diabetes.	26935028	2016	Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability	NA	NA	pubmed	NA
1097	Insulin resistance	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229877.1	+	8841	chr11:65,497,688-65,506,431	1	0	1	0	Reagents,Animals, drug treatment and metabolic parameters,isolation of mouse primary hepatocytes,Immunohistochemistry,ROS measurement,Western blot and immunoprecipitation,Pancreatic Islet Cell Isolation,RNA Pulldown Assay	mice,liver tissues,mouse  primary  hepatocytes,Islets	up-regulated 	MALAT1 plays  an  important role  in regulating  insulin sensitivity  and  has  the  potential asa  therapeutic  target  for  the  treatment  of  diabetes  as  well  as  other diseases caused by excessive exposure to ROS. 	29577871	2018	Long noncoding RNA MALAT1 regulates generation of reactive oxygen species and the insulin responses in male mice	NA	NA	pubmed	NA
1098	Type 2 diabetes mellitus	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229877.1	+	8841	chr11:65,497,688-65,506,431	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 3 diabetes,blood,peripheral blood mononuclear cells	up-regulated 	upregulated expression of lncRNA MALAT1 was linked to hyperglycemia-induced inflammation and endothelial dysfunction, diabetic nephropathy, and gestational diabetes mellitus. 	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 3 diabetes	NA	NA	pubmed	NA
1099	Insulin resistance	MALAT1	TCONS_00006031	NA	NA	29665	ENSMUST00000172812.2	mouse	NONMMUT033600.2	-	6983	chr11:65,497,688-65,506,431	1	0	1	0	Animals,RAP-PCR,qPCR,Dual energy X-ray absorptiometry(DEXA) scan,Indirect calorimetry(oxygenconsumption),Histology,Plasma bioassays,Glucose and insulin tolerance tests,Statistical analysis	C57BL/6J mice,Blood	down-regulated	The overall metabolic impactof the absence of Malat1 on adipose tissue accretion and glucose intolerance is either physiologically not relevant upon aging and obesity.	29746487	2018	Loss of Malat1 does not modify age- or diet-induced adipose tissue accretion and insulin resistance in mice	NA	NA	pubmed	NA
1100	Insulin resistance	NONMMUT008655.2	NA	NA	NA	NA	NA	NA	NONMMUT008655.2	+	3480	chr11:65,497,688-65,506,431	1	0	1	0	Animals,Establishment of the animal model,Serum and tissue specimens,Determination of blood indicators,Haematoxylin-eosin staining,Oil Red O staining,Western blot analysis,RT-qPCR,High-throughput sequencing,Identification and expression analysis of lncRNAs and mRNAs,Establishment of cell model and analysis,Statistical analysis	C57BL/6J mice,Blood of mice,liver tissue of mice	up-regulated 	Resveratrol improves hepatic IR and controls blood sugar levels by downregulating NONMMUT008655.2,resveratrol and NONMMUT008655.2 may serve as potential therapeutic targets for IR and T2DM.	32051733	2020	Resveratrol improves high-fat diet-induced insulin resistance in mice by downregulating the lncRNA NONMMUT008655.2	NA	NA	pubmed	NA
1101	Insulin resistance	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr14:100,857,245-100,861,018	1	0	1	0	Animals and treatment,GTTs and ITTs,Plasmid construction and cell transfection,Isolation and culture of mouse primary hepatocytes,RNA extraction and RT-qPCR,Western blot analysis,Luciferase activity assay,Statistical analysis	mice,Hepatocytes 	up-regulated 	MEG3 knockdown improved impaired glucose and insulin tolerance, while down-regulating HFD-induced ATF4 expression and upregulating HFD-suppressed miR-214 expression.MEG3 promoted hepatic insulin resistance by serving as a ceRNA of miR-214 to facilitate ATF4 expression. 	30431065	2019	lncRNA MEG3 promotes hepatic insulin resistance by serving as a competing endogenous RNA of miR-214 to regulate ATF4 expression	NA	NA	pubmed	NA
1102	Type 2 diabetes mellitus	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr14:100,857,245-100,861,018	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 2 diabetes,blood,peripheral blood mononuclear cells	up-regulated 	knockdown of Meg3 in vivo led to the impaired glucose tolerance and decreased insulin secretion, consisted with the reduction of insulin positive cells areas by immunochemistry assays.Meg3 may function as a new regulator of maintaining beta cells identity via affecting insulin production and cell apoptosis. 	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes	NA	NA	pubmed	NA
1103	Insulin resistance	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr14:100,857,245-100,861,018	1	0	1	0	Animals and chemicals,Isolation and Culture of Primary Hepatocytes,Real-time PCR analysis,Western blot analysis,Hepatocyte gluconeogenesis and glycogen accumulation,easurement of triglyceride (TG), glycogen contents and body weight,Statistic	mice, Primary Hepatocytes	up-regulated 	Upregulation of lncRNA MEG3 in the liver would  lead  to  elevated  hepatic  insulin  resistance  via  increasing  FoxO1expression,thereby  provides  a  new insight into the molecular mechanism of hepatic insulin resistance in liver and novel targets and strategies for the treatment of T2DM. 	26603935	2016	Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression	NA	NA	pubmed	NA
1104	Insulin resistance	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr14:100,857,245-100,861,018	1	0	1	0	Ethical declaration,Microarray data archives,Microarray data and DEG identification,GO and pathway enrichment analyses,PPI network creation and hub gene identification,Target miRNA prediction of Meg3 and corresponding target mRNA prediction,Construction of Meg3 ceRNA regulatory network,Statistical analysis	 	up-regulated 	The network of Meg3 as a ceRNA was constructed, which demonstrated that Meg3 modulated five hub DE mRNAs via competitive binding to microRNAs.	32614631	2020	Identification of differentially expressed mRNA and the Hub mRNAs modulated by lncRNA Meg3 as a competing endogenous RNA in brown adipose tissue of mice on a high-fat diet	NA	NA	pubmed	NA
1105	Insulin resistance	RPL13p5	NA	NA	NA	30363	NA	NA	NA	NA	NA	chr12:6,883,996-6,884,613	1	0	1	0	Data collection,Maternal characteristics,xtraction and qPCR,Correlation analysis between lncRNA level and insulin resistance,Statistical analysis of lncRNA	patient,pregnant women	up-regulated 	LncRNA RPL13P5 forms a co-expression chain with the TSC2 gene through the PI3K-Akt signaling pathway and becomes part of the process of insulin resistance in GDM.	34763465	2021	LncRNA RPL13p5 gene expression promotes insulin resistance in patients with gestational diabetes	NA	NA	pubmed	NA
1106	Insulin resistance	H19	TCONS_00005659	NA	NA	4713	 ENST00000428066	human	NONHSAT017473.2	-	736	chr11:1,995,171-1,997,875	1	0	1	0	Experimental animals,Overexpression of H19 in db/db mice,Isolation of satellite cells and cell culture,Differentiated primary satellite cells transfection and infection,RNA extraction and RT-qPCR analysis,Western blot analysis,Differentiated primary satellite cells lipid measurements,Nile red staining,Immunohistochemical staining,Mitochondrial respiration analysis,Transmission electron microscopy,RNA immunoprecipitation (RIP),RNA pull-down assay and mass spectrometry,Statistical analysis	mice,Primary satellite cells	down-regulated	Overexpression of lncRNAH19 promotes fatty acids oxidation via targeting of hnRNPA1,overexpression of H19 ameliorates insulin resistance by reducing ectopic lipid accumulation in skeletal muscle. 	33115498	2020	LncRNAH19 improves insulin resistance in skeletal muscle by regulating heterogeneous nuclear ribonucleoprotein A1	NA	NA	pubmed	NA
1107	Insulin resistance	H19	TCONS_00005659	NA	NA	4713	 ENST00000428066	human	NONHSAT017473.2	-	736	chr11:1,995,171-1,997,875	1	0	1	0	Animals,Body Composition and Glucose and Insulin Tolerance Tests,Hyperinsulinemic-Euglycemic Clamp and Measurement of Muscle 2-[14C]deoxy-d-glucose Uptake,Plasmid Construction,RNA Extraction and Real-time Quantitative PCR,Western Blot Analysis,Myotube Culture and Transfection,Glucose Uptake Assay,RNA-Seq and Data Analysis,Immunoprecipitation,Immunofluorescence,In Vitro Pulldown Assays,Quantitative Methylation-Specific PCR,Statistical Analysis	mice,soleus muscle tissues from WT mice	down-regulated	Consistent with decreased H19 expression in the muscle of insulin-resistant human subjects and rodents, mice with genetic H19 ablation exhibit muscle insulin resistance.highly expressed lncRNA as an important regulator of muscle insulin sensitivity.	30201684	2018	H19 lncRNA Promotes Skeletal Muscle Insulin Sensitivity in Part by Targeting AMPK	NA	NA	pubmed	NA
1108	Insulin resistance	H19	TCONS_00005659	NA	NA	4713	 ENST00000428066	human	NONHSAT017473.2	-	736	chr11:1,995,171-1,997,875	1	0	1	0	Isolation and identification of rat ovarian granulosa cells,Enzyme-linked immunosorbent assay (ELISA),Cell apoptosis assay,Western blot,RNA extraction and quantitative real-time PCR (qRT-PCR),Stable expression of H19,Immunofluorescence,Animal experiments,Biochemical analysis,Histopathological evaluation,Statistical analysis	Rat ovarian granulosa cells,SD rats	down-regulated	co-treatment with metformin and sitagliptin induced H19 expression via suppressing the PI3K/AKT-DNMT1 pathway.	31405334	2019	Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19	NA	NA	pubmed	NA
1109	Insulin resistance	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	NA	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Construction of obesity mouse model,Detection of associated indices in obesity mouse,Hematoxylin & eosin (H&E) staining,Cell culture and transfection,Dual‑luciferase reporter activity assay,Quantitative real‑time PCR (RT‑qPCR),Western blotting,Statistical analyses	C57 BL/6 J mice,blood and fatty tissue,3T3-L1 cells 	down-regulated	LncRNA TUG1 could negatively regulate miR-204 to alleviate inflammation and insulin tolerance via promoting SIRT1/GLUT4/PPARγ/AKT pathway	32888158	2020	LncRNA TUG1 reduces inflammation and enhances insulin sensitivity in white adipose tissue by regulating miR-204/SIRT1 axis in obesity mice	NA	NA	pubmed	NA
1110	Type 2 diabetes mellitus	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 5 diabetes,blood,peripheral blood mononuclear cells	up-regulated 	Decreased GAS5 levels in serum were associated with diabetes in a cohort of US military veterans,lncRNA GAS5 levels are correlated to prevalence of T2DM.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 5 diabetes	NA	NA	pubmed	NA
1111	Insulin resistance	GAS5	TCONS_00000086	NA	NA	16355	ENSMUST00000161229.4	mouse	NONMMUT003417.2	+	2556	chr1:173,858,559-173,867,045	0	1	0	1	Patients,Data collection,RNA extraction, reverse transcription, and quantitative real-time PCR (qRT-PCR),Statistical analysis	Patients,serum samples	down-regulated	 lncRNA GAS5 was validated to be involved in the cellcycle arrest in several types of diseases,Downregulation of GAS5 in serums might contribute to IR in PCOS patients.	29648472	2018	Downregulation of serum long noncoding RNA GAS5 may contribute to insulin resistance in PCOS patients	NA	NA	pubmed	NA
1112	Insulin resistance	Gomafu	NA	NA	NA	33425	 ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,657,566-26,657,648	1	0	1	0	Reagents,Cell culture,Primary isolation and culture of hepatocytes,Animal studies,Small interfering RNA,Vector construction,Cytosolic/nuclear fractionation isolation and real-time PCRassay,Western blot analysis,Quantitative chromatin immunoprecipitation (qChIP) assay,Pulldown assay with biotinylated lncRNA-Gomafu DNA probe,Pulldown assay with biotinylated miR-139,Luciferase reporter assays,Glucose tolerance test (GTT), insulin tolerance test (ITT),and pyruvate tolerance test (PTT),Statistical analysis	The mouse hepatocyte cell line AML-12,Hepatocytes,mice	down-regulated	Silenced Foxo1 expression abolished the effect of Gomafuoverexpression on gluconeogenesis and glucose production in hepatocytes,the increase in Gomafu expression contributed to hepatic IR in obese mice.	29459686	2018	Long noncoding RNA Gomafu upregulates Foxo1 expression to promote hepatic insulin resistance by sponging miR-139-5p	NA	NA	pubmed	NA
1113	Insulin resistance	Mirt2	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr8:144,011,372-144,012,736	1	0	1	0	Cell culture,Experimental animals,Adenovirus and plasmid construction,Western blot,Oil Red O staining and histological analysis,Serum analysis, hepatic lipid analysis, and glucose production analysis,Lipolysis of adipose tissue,Real-time PCR,Luciferase reporter assays,2.10. Statistical analysis	AML-12 cells,mice,livers of mice,Epididymal adipose tissue	down-regulated	The decrease of Mirt2 expression contributed to hepatic insulin resistance and steatosis in obese mice, andMirt2/miR-34a-5p/USP10was involved in NAFLD development. Overexpression ofMirt2 might be a promising strategyfor treatment of NAFLD.	30898698	2019	Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p	NA	NA	pubmed	NA
1114	Insulin resistance	LOC157273	NA	NA	NA	NA	ENST00000520390.1	human	NONHSAT124942.2	+	3442	chr8:9,325,051-9,335,080	1	0	1	0	SNP Genotyping,Cellular Localization of LOC157273 With Stellaris RNA Fluorescentin situ Hybridization,TaqMan Quantitative Reverse-Transcriptase PCR to Measurethe Expression Levels of Two Isoforms of PPP1R3B mRNA and a Single Isoform of LOC157273 lncRNA,Small Interfering RNA Knockdown of LOC157273,Transcriptome-Wide Effects of LOC157273 Knockdown Using RNASequencing,Glycogen Deposition Assay in Responseto Insulin or Glucagon,Allelic Imbalance of LOC157273 Transcription in Primary Human Hepatocytes	primary   human   hepatocytes	down-regulated	lncRNALOC157273 is a negative regulator ofPPP1R3B expression and glycogen deposition in human hepatocytes and a causal transcript at an insulin-resistant T2D risk locus.	32754192	2020	A Long Non-coding RNA, LOC157273, Is an Effector Transcript at the Chromosome 8p23.1- PPP1R3B Metabolic Traits and Type 2 Diabetes Risk Locus	NA	NA	pubmed	NA
1115	Insulin resistance	GM44502	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr22:50,568,948-50,582,791	1	0	1	0	Bioinformatics passage,Animals,Prediabetic model induction,Diabetic model induction,Exercise training simultaneous with HF diet,Dissected liver samples and histological analysis,HbA2c, Glucose, insulin, triglyceride, and HOMA‐IR,RT‑qPCR analyses for mRNA level assessment,Statistical analysis	 	down-regulated	The  high‑fat liver  HML  network,  including  GM44502  associ-ated  with  Cpt1b,  is  downregulated,  indicating  that  the  lipolysis pathway is decreased. 	34284789	2021	Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice	NA	NA	pubmed	NA
1116	Insulin resistance	HOTAIR	TCONS_00007755	NA	NA	33510	ENST00000439545.1	human	NONHSAT028509.2	-	2337	chr12:53,962,308-53,974,956	1	0	1	0	Sample Collection,Experimental Animal,Cell Culture and Transfection,Western Blot,RNA Extraction and Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR),Determination of Glucose and Hepatic Glycogen,Statistical Analysis	2D patients,57BL/6J and db/db mice,HepG2 cells	up-regulated 	Upregulated HOTAIR promotes hepatic insulin resistance by inhibiting SIRT1 expression and AKT/GSK pathway.	30536334	2018	HOTAIR participates in hepatic insulin resistance via regulating SIRT1	NA	NA	pubmed	NA
1117	Diabetic cardiomyopathy	HOTAIR	TCONS_00007755	NA	NA	33510	ENST00000439545.1	human	NONHSAT028509.2	-	2337	chr12:53,962,308-53,974,956	1	0	1	0	Animal and model,Echocardiography and hemodynamic evaluations,Histological analysis, immunohistochemistry,and TUNEL staining,Detection of total superoxide dismutase activity, nicotinamide adenine dinucleotide phosphate oxidase activity,Detection of reactive oxygen species and cell viability,Cell culture and treatment,Real‐time polymerase chain reaction,Western blot analysis,Luciferase reporter assay,RNA‐binding protein immunoprecipitation assay,RNA pull‐down assay,Statistical analyses	C57/B6 mice,The fresh mice hearts,cardiomyocytes,H9c2 cells	down-regulated	HOTAIR functioned as a molecular sponge of miR‐34a in H9c2 and SIRT1was identified as a target of miR‐34a,the protective effects of HOTAIRon DCM was abolished in SIRT1 deficiency mice in vivo.HOTAIR protected againstDCM via activation of the SIRT1 expression by sponging miR‐34a.	30216438	2019	LncRNA HOTAIR functions as a competing endogenous RNA to upregulate SIRT1 by sponging miR-34a in diabetic cardiomyopathy 	NA	NA	pubmed	Heart
1118	Diabetic cardiomyopathy	HOTAIR	TCONS_00007755	NA	NA	33510	ENST00000439545.1	human	NONHSAT028509.2	-	2337	chr12:53,962,308-53,974,956	1	0	1	0	Subjects,Specimen collection,Cell line and cell culture,Cell transfection,MTT assay,RT-qPCR,Western blot analysis,Statistical analysis	patients with diabetic cardiomyopathy,Human cardiomyocyte cell line AC16	down-regulated	LncRNA HOTAIR may improve diabetic cardiomyopathy by increasing the viability of cardiomyocytes through activation of the PI3K/Akt pathway.	30542437	2018	LncRNA HOTAIR improves diabetic cardiomyopathy by increasing viability of cardiomyocytes through activation of the PI3K/Akt pathway	NA	NA	pubmed	Heart
1119	Type 2 diabetes mellitus	PLUTO	TCONS_00009403	NA	NA	43698	NA	human	NONHSAT032675.2	-	2002	chr13:27,819,376-27,917,298	1	0	1	0	Pancreatic Islets,Glucose-Stimulated Insulin Release,RNA Analysis,amiRNA and CRISPRi Experiments,Gene Expression Array Analysis,Differential Expression in IGT and T2D Islets,3C,Annotation of Islet lncRNAs,Network Analysis	Human islets	down-regulated	Decreased levels of the lncRNA, PLUTO in islets of T2D or impaired glucose tolerant sub-jects affect the 3D chromatin structure and transcription of Pdx-1, a key β cell transcription factor implicating its role in insulin synthesis and β cell-specific regulatory network.	28041957	2017	Human Pancreatic β Cell lncRNAs Control Cell-Specific Regulatory Networks	E11	9352	pubmed	NA
1120	Type 2 diabetes mellitus	PANDA	NA	NA	NA	44048	ENST00000629595.1	human	NONHSAT209051.1	-	1506	chr6:36,673,621-36,675,126	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 4 diabetes,blood,peripheral blood mononuclear cells	up-regulated 	PANDA confines cells to their existing proliferative state and that modulating its level of expression can cause entry or exit from senescence.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 4 diabetes	NA	NA	pubmed	NA
1121	Type 2 diabetes mellitus	LINC-P21	NA	NA	NA	43652	NA	NA	NA	NA	NA	chr6:36,663,392-36,667,296	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 6 diabetes,blood,peripheral blood mononuclear cells	up-regulated 	lincRNA-p21 enhanced PTEN expression by competitively binding miR-181b,lincRNA-p21 as a promising molecular target for antifibrosis therapy.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 6 diabetes	NA	NA	pubmed	NA
1122	Type 2 diabetes mellitus	ENST00000550337.1	TCONS_00007704	NA	NA	53329	ENST00000550337.1	human	NONHSAT027784.2	-	1212	chr12:42,615,221-42,646,508	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 7 diabetes,blood,peripheral blood mononuclear cells	up-regulated 	LncRNA ENST00000550337.1 is a potential diagnostic biomarker for pre-diabetes and T2DM.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 7 diabetes	NA	NA	pubmed	NA
1123	Type 2 diabetes mellitus	NBR2	NA	NA	NA	20691	NA	human	NONHSAT053813.2	+	1366	chr17:43,125,551-43,153,649	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 8 diabetes,blood,peripheral blood mononuclear cells	up-regulated 	NBR2-GLUT1 axis may serve as an adaptive response in cancer cells to survive in response to phenformin treatment, and identify a novel mechanism coupling lncRNA to biguanide-mediated biology.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 8 diabetes	NA	NA	pubmed	NA
1124	Type 2 diabetes mellitus	THRIL	NA	NA	NA	49503	 ENST00000627370.1	human	NONHSAT164169.1	-	1981	chr12:125,025,434-125,027,410	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 9 diabetes,blood,peripheral blood mononuclear cells	down-regulated	THRIL was shown to regulate TNF-α expression through an epigenetic mechanism, and TNF-α can also reduce THRIL expression via a negative feedback action.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 9 diabetes	NA	NA	pubmed	NA
1125	Type 2 diabetes mellitus	SALRNA1	NA	NA	NA	49001	NA	NA	NA	NA	NA	chr14:60,639,216-60,642,589	1	0	1	0	Recruitment of the study subjects,Anthropometric measurements,Biochemical and clinical investigations,Blood collection and isolation of peripheral blood mononuclear cells (PBMCs),RNA extraction and cDNA synthesis,lncRNA/mRNA expression by Q-PCR,DNA isolation and measurement of telomere length,Statistical analysis	participants and patients with type 10 diabetes,blood,peripheral blood mononuclear cells	down-regulated	SAL-RNA1 was earlier identified as putative age-delaying lncRNA, since its reduction with small inhibitory RNAs (siRNA) induced rapid aging changes of the fibroblasts, such as large cell morphology, positive β-galactosidase activity, and upregulation of p53.	30139387	2018	Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 10 diabetes	NA	NA	pubmed	NA
1126	Insulin resistance	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Collection of epidemiological dataCollection of epidemiological data,Anthropometric index and risk variables,Reagents and cell culture,Preparation of CSE,Glucose‐stimulated insulin secretion assay,RNA extraction and real‐time PCR analyses,Cell transfection,Protein extraction and western blot assays	MIN6 cells were obtained from the American Type Culture Collection (Manassas)	up-regulated	In the sera of patients with diabetes who smoked, there were higher MALAT1 levels and lower miR-17 levels than in the sera of nonsmokers. Thus, CSE inhibits insulin production by upregulating TXNIP via MALAT1-mediated downregulation of miR-17, which provides an understanding of the processes involved in the reduced 尾-cells function caused by cigarette smoke	29856480	2018	MALAT1 via microRNA-17 regulation of insulin transcription is involved in the dysfunction of pancreatic β-cells induced by cigarette smoke extract	NA	NA	pubmed	NA
1127	Insulin resistance	MEG3	TCONS_00010614	NA	NA	NA	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr14:100,779,410-100,829,185	1	0	1	0	Human Islets,Transcription Activator-Like Effector Experiments,DNA Methylation Analysis,Gene Expression by Quantitative RT-PCR,Cell Death Assays,Dual Luciferase Reporter Assay: Enhancer Activity,Allele-Specific Chromatin Immunoprecipitation PCR,Circular Chromosome Conformation Capture Sequencing	βTC6 cells	up-regulated	our results demonstrate that targeted methylation of the MEG3-DMR is sufficient to repress the locus and increase β-cell susceptibility to cytokines and provide evidence for the role of a novel enhancer in the regulation of imprinting at the DLK1-MEG3 locus in human cells	30084829	2018	The Dysregulation of the DLK1-MEG3 Locus in Islets From Patients With Type 2 Diabetes Is Mimicked by Targeted Epimutation of Its Promoter With TALE-DNMT Constructs	NA	NA	pubmed	NA
1128	Prader-Willi syndrome	116HG	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr7:66,442,030-67,294,872	1	0	1	0	Animal care,Human tissue,Mouse tissue,RNA FISH and DNA FISH,RNA/DNA FISH,Immunofluorescence and laser scanning cytometry,Microscopy,Oligo purification of RNA-bound proteins,In vitro biotinylated RNA pull-down of proteins,Antibodies,Chromatin isolation by RNA purification,RNA-sequencing,Next-generation sequencing,ChIRP-sequencing data analysis,RNA-sequencing data analysis,Metabolic chamber analysis,Body weight and percent fat,qPCR	Human tissue and Mouse tissue	up-regulated	These novel molecular insights into the energy imbalance in PWS should lead to improved therapies and understanding of lncRNA roles in complex neurodevelopmental and metabolic disorders.	23771028	2013	A Prader-Willi locus lncRNA cloud modulates diurnal genes and energy expenditure	NA	NA	pubmed	NA
1129	Prader-Willi syndrome	Fox2	TCONS_00025563	NA	NA	9906	NA	human	NONHSAT085067.2	-	594	chr22:35,744,148-35,840,284	0	1	0	1	NA	NA	NA	In this issue of Molecular Cell, Yin et al. (2012) identify a class of long noncoding RNAs (lncRNAs) and propose a new mechanism as to how they contribute to the pathogenesis of Prader-Willi syndrome.	23102265	2012	Long noncoding RNAs as sinks in Prader-Willi syndrome	NA	NA	pubmed	NA
1130	Prader-Willi syndrome	HG116	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr7:66,442,030-67,294,872	1	0	1	0	Animals,Genomic DNA extraction,RRBS library construction and sequencing,Sequence alignment and data analysis,Locus-specific sodium bisulfite genomic sequencing,	DNA was purified from frozen tissue using standard methods 41 with modifications	NA	These results suggest that the PWS-IC may affect DNA methylation at these loci by directly interacting with them, or may affect methylation at these loci through indirect downstream effects due to PWS-IC deletion. They further suggest the PWS-IC may have a previously uncharacterized function outside of the imprinted AS/PWS domain	25482058	2014	Influence of the Prader-Willi syndrome imprinting center on the DNA methylation landscape in the mouse brain	NA	NA	pubmed	NA
1131	Hyperlipidemia	LASER	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr6:127,266,883-127,288,362	1	0	1	0	Study subjects,Bioinformatic analysis,Cell culture,RNA isolation and qRT-PCR analysis,RNA library preparation and pathway analysis,Filipin labeling of membrane cholesterol,Cholesterol assay,ELISA detection of PCSK9,Western blot,Subcellular fractionation,RNA fluorescence in situ hybridization (FISH) and immunofluorescence,RNA immunoprecipitation,Chromatin immunoprecipitation analysis	Human hepatocellular carcinoma cell lines (HepG2)	up-regulated	we identified a novel lncRNA in lipid associated single nucleotide polymorphism locus (LASER) near SNP rs486394 in chromosome 11q12 region. Knock-down of LASER leads to reduction of cholesterol in HepG2 cells. LASER could bind to LSD1 directly; then regulate HNF-1a and proprotein convertase subtilisin/kexin 9 (PCSK9) expressions through REST/CoREST protein complex. LASER inhibition further reduced the intracellular cholesterol level caused by statin. We also found that the intracellular cholesterol regulated LASER expression. Taken together, the results from the current investigation revealed a mechanism in which LASER acts a feedback regulator of HNF-1伪/PCSK9 and LXR dependent pathway to maintain cholesterol homeostasis in hepatocytes.	31118464	2019	Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER	NA	NA	pubmed	NA
1132	Hyperlipidemia	lncARSR	NA	NA	NA	NA	NA	NA	NA	NA	NA	chr9:79,517,873-79,567,777	1	0	1	0	Mice model,Cell culture,Intracellular and hepatic TC determination, RNA isolation and real-time PCR,Total, nuclear and cytoplasmic protein extraction, Western blotting,Measurement of de novo cholesterol biosynthesis	The human HepG2 hepatocellular carcinoma cell line was obtained from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai	up-regulated	we found that upregulated lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathway. Our data suggested that lncARSR would be a potential therapeutic target for cholesterol disorder.	29678744	2018	Long noncoding RNA lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathway	NA	NA	pubmed	NA
1133	Hyperlipidemia	ANRIL	NA	NA	NA	34341	ENST00000428597.4	human	NONHSAT130421.2	+	3837	chr9:21,802,636-22,049,597	1	0	1	0	Ethics declaration,Selection criteria and sample collection,Genotyping,	DNA isolation and lipid profile determination of the 611 individuals were performed as described previously	up-regulated	We conclude from the present study that the SNP rs1333049:C>G at the ANRIL locus could be used as a genetic marker for the screening of MI in the general Pakistani population. In addition genotyping of individuals can be potentially useful from a pharmacogenomics point of view	23266621	2013	Association of ANRIL polymorphism (rs1333049:C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia	NA	NA	pubmed	NA
1134	Hyperlipidemia	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Animal protocol,Serum analysis,Atherosclerotic lesion analysis,Cell culture,Cell transfection and treatment,RNA isolation and qRT-PCR,Western blot analysis,RNA immunoprecipitation (RIP),Luciferase reporter assay,Cell counting Kit-8 (CCK-8) assay,Trypan blue dye exclusion method,Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay,ELISA analysis	Mouse macrophage cell line RAW264.7 and mouse VSMC line MOVAS were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA)	up-regulated	To summarize, our study demonstrated that TUG1 knockdown abated atherosclerotic lesion in HFD-treated ApoE−/− mice. Moreover, TUG1 down-regulation alleviated ox-LDL-induced dysfunction by inhibiting cell growth and inflammation, and promoting apoptosis of VSMCs and macrophages. Mechanistic analysis further indicated that TUG1 exerted its function by sponging miR-133a to regulate its target FGF1 expression. Our findings may provide valuable insight into the potential application of TUG1 as a therapeutic target for preventing atherosclerosis	29268138	2018	TUG1 knockdown ameliorates atherosclerosis via up-regulating the expression of miR-133a target gene FGF1	NA	NA	pubmed	NA
1135	Hyperlipidemia	MALAT1	NA	NA	NA	54476	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Patients and controls,Isolation of serum exosomes,Transmission electron microscopy (TEM),Nanoparticle tracking analysis (NTA),Cell culture and treatment,Neutrophils isolation and co-cultured with exosomes,Cell transfection,In vivo experiments,RNA extraction and qRT-PCR analysis,Western blotting,ELISA,Immunofluorescence staining,Measurement of intracellular ROS,Determination of serum TC, TG and LDL,Oil red O staining	Human umbilical vein endothelial cells (HUVECs) purchased from American Type Culture Collection (ATCC, Manassas, VA, USA)	up-regulated	our study demonstrated that ox-LDL-induced endothelial inflammation was involved in the pathogenesis of AS partly due to the released exosomes, which induced NETs formation via MALAT1-mediated p38/AKT pathway	31318684	2020	Exosomal MALAT1 derived from ox-LDL-treated endothelial cells induce neutrophil extracellular traps to aggravate atherosclerosis	NA	NA	pubmed	NA
1136	Hyperlipidemia	ANRIL	NA	NA	NA	34341	ENST00000428597.4	human	NONHSAT130421.2	+	3837	chr9:21,802,636-22,049,597	1	0	1	0	Inclusion of subjects,Establishment of mice models and sample collection,Determination of cardiac function,Cell culture,Conduction of ELISA,Quantitative real‐time polymerase chain reaction (qRT‐PCR),Cell transfection,Colony formation assay,Cell proliferation assay,Cell apoptosis assay,Western blotting,Dual luciferase reporter gene assay	Human coronary endothelial cells (HCAECs) and human umbilical vein endothelial cells (HUVECs) were purchased from the American Type Culture Collection (ATCC).	up-regulated	this investigation elucidated that ANRIL could target miR‐181b to control proliferation and apoptosis of CAD cells, thereby inducing activation of NF‐κB signalling and release of inflammatory biomarkers, including IL‐6, IL‐8, NF‐κB, TNF‐α, iNOS, ICAM‐1, VCAM‐1 and COX‐2	30079603	2018	The interplay of LncRNA ANRIL and miR-181b on the inflammation-relevant coronary artery disease through mediating NF-κB signalling pathway	NA	NA	pubmed	NA
1137	Obesity	EDF1	NA	NA	NA	3164	NA	human	NONHSAT135605.2	-	2746	chr9:136,862,119-136,866,308	1	0	1	0	Mice,Cell culture,Metabolic analyses,Gene expression analyses,Immunoblotting analysis,RNA-seq data analysis,In vitro lipogenesis assay,RNA-protein interaction assays,Luciferase reporter and ChIP assays	Primary hepatocytes were isolated from C57BL/6J mice, as previously described,	up-regulated	In this study, we demonstrate that Blnc1 is a component of the LXR transcriptional complex that is required for SREBP1c induction and hepatic lipogenic activation in obesity. CRISPR/Cas9-mediated liver-specific inactivation of Blnc1 abrogates HFD-induced hepatic steatosis and insulin resistance and protects mice from diet-induced NASH.	30061575	2018	Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis	NA	NA	pubmed	NA
1138	Obesity	H19	TCONS_00005659	NA	NA	NA	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Plasmid construction,Animals,Cell culture and treatment,Cell apoptosis,Serum analysis,Histology,Quantitative real-time PCR,Western blotting,Western blotting,Bioinformatics analysis	The HCM (human cardiac myocyte) cell line was purchased from ATCC	up-regulated	our study demonstrates that ghrelin protects against obesity-induced myocardial injury via regulating the lncRNA H19/miR29a/IGF-1 signalling pathway, which provides new insights into understanding the molecular mechanisms of ghrelin in cardiovascular protection and presents further evidence for the clinical application of ghrelin.	32084395	2020	Ghrelin protects against obesity-induced myocardial injury by regulating the lncRNA H19/miR-29a/IGF-1 signalling axis	NA	NA	pubmed	NA
1139	Obesity	FLG-AS1	TCONS_00003034	NA	NA	27913	ENST00000445097.2	human	NONHSAT006483.2	+	2857	chr1:152,189,344-152,405,050	0	1	0	1	Collection of RNA-seq Datasets,Identification of Differentially Expressed mRNAs and lncRNAs,Gene Ontology and Kyoto Encyclopedia of Genes and Genomes Analysis of DEmRNAs,lncRNA-miRNA-mRNA Network,KEGG Analysis for the Target miRNAs,Gene Set Enrichment Analysis	NA	up-regulated	In this paper, we constructed a ceRNA network consisting of lncRNAs, miRNAs, and mRNAs, identifying four obesity- and T2DM-related lncRNAs that have not been reported in metabolic diseases. 	32337289	2020	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity	NA	NA	pubmed	NA
1140	Obesity	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Construction of obesity mouse model,Detection of associated indices in obesity mouse,Hematoxylin & eosin (H&E) staining,Cell culture and transfection,Dual‑luciferase reporter activity assay,Quantitative real‑time PCR (RT‑qPCR),Western blotting	3T3-L1 cells were purchased from the Chinese Center of Type Culture Collection	up-regulated	, miR-204 was abnormally upregulated in obesity, but TUG1 and SIRT1 were signifcantly downregulated in obesity. Overexpression of TUG1 could signifcantly alleviate infammation and promote insulin sensitivity in obesity via downregulating miR-204 and increasing SIRT1/ GLUT4/PPAR款/AKT pathway	32888158	2020	LncRNA TUG1 reduces inflammation and enhances insulin sensitivity in white adipose tissue by regulating miR-204/SIRT1 axis in obesity mice	NA	NA	pubmed	NA
1141	Obesity	MAFG	TCONS_00015599	NA	NA	6781	ENST00000582106.1	human	NONHSAT056598.2	+	2538	chr17:81,918,270-81,927,735	1	0	1	0	Animal care and research diets,RNA isolation and total RNA-Sequencing,RNA-Sequencing data processing,Gene overlap analysis,Ingenuity pathway analysis,Promoter analyses and motif enrichment analysis,Chromatin-immunoprecipitation (ChIP) sequencing analysis,In vivo RNAi using LNAs,In vivo RNAi using antisense oligonucleotides (ASO),Generation of LincIRS2∆/∆ knockout mice using CRISPR/Cas9,Adeno-associated virus (AAV)-mediated MAFG overexpression,Isolation of primary hepatocytes and liver fractionation,Subcellular fractionation of primary hepatocytes,LNA-mediated gene knockdown of primary hepatocytes,Quantification of glucose production,Adenoviral overexpression of metabolic TF in hepatocytes,Immunoblot analysis,Glucose, insulin, and PTT,Indirect calorimetry (PhenoMaster),Tissue collection,Enzyme-linked immunosorbent assay,Histological staining,RNA isolation and quantitative RT-PCR (qPCR) analysis,	Liver samples used for total RNA-Sequencing (RNA-Seq) were from male, 36-week-old C57BL/6N mice exposed to CD (n鈥=鈥3) or HFD (n鈥=鈥3) feeding for 30 weeks, starting at 6 weeks of age.	up-regulated	We find that obesity-repressed LincIRS2 is controlled by MAFG and observe that genetic and RNAi-mediated LincIRS2 loss causes elevated blood glucose, insulin resistance and aberrant glucose output in lean mice. Taken together, we identify a MAFG-lncRNA axis controlling hepatic glucose metabolism in health and metabolic disease.	32005828	2020	A MAFG-lncRNA axis links systemic nutrient abundance to hepatic glucose metabolism	NA	NA	pubmed	NA
1142	Obesity	MAP7	NA	NA	NA	6869	NA	human	NONHSAT136444.2	NA	1664	chr6:136,342,734-136,550,422	1	0	1	0	Sample information description,DNA extraction and sequencing,Bioinformatics analysis,Screening of mutation site, Mutation site harmful classification,Copy number variations (CNV) analysis,DNA and RNA conjoint analyses,	DNA samples were evaluated by agarose gel electrophoresis and Qubit analysis. 	 	 	31957265	2020	Combined analysis of whole-exon sequencing and lncRNA sequencing in type 2 diabetes mellitus patients with obesity	NA	NA	pubmed	NA
1143	Obesity	Gomafu	NA	NA	NA	NA	ENST00000613780.3	human	NONHSAT192181.1	+	10184	chr22:26,657,566-26,657,648	1	0	1	0	Animals,Cell culture,Cell treatments,Cell transfection,Quantitative real-time reverse transcription PCR (qRT-PCR),Determination of plasma triglyceride and glucose levels,Western blot, Flow cytometry,Immunofluorescence staining,Hemotoxylin and eosin (H&E) staining,	RAW264.7 macrophages and 3T3-L1 preadipocytes were purchased from ATCC	up-regulated	Berberine improves obesity-induced chronic inflammation by alleviating endoplasmic reticulum stress and consequently promoting macrophage M2 polarization. And these protective effects were mediated at least partly by the suppression of lncRNA Gomafu.	32650294	2020	Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu	NA	NA	pubmed	NA
1144	Obesity	H19	TCONS_00005653	NA	NA	NA	ENST00000414790.4	human	NONHSAT017465.2	-	2361	chr11:1,995,176-1,997,875	1	0	1	0	Clinical sample,Patient plasma preparation and exosomes isolation,Animals,Induction of obesity and fracture,Cell culture,Isolation and identification of exosomes from BMSCs,Osteogenic differentiation,Quantitative real‐time PCR (QRT‐PCR), Western blot (WB),Dual luciferase reporter assay,Ribonucleoprotein immunoprecipitation assay,Immunofluorescence staining,Bone mineral density detection of fracture areas,Bone mechanical testing,	The BMSCs were extracted and passaged according to the previous operation methods of our research group	up-regulated 	this study further found that H19 plays an important role in the poor healing of fractures caused by obesity by combining with previous studies	33471953	2021	Obesity regulates miR-467/HoxA10 axis on osteogenic differentiation and fracture healing by BMSC-derived exosome LncRNA H19	NA	NA	pubmed	NA
1145	Obesity	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	human	NONHSAT039746.2	+	1478	chr7:108,300,190-108,302,063	0	1	0	1	Microarray data archives，Microarray data and DEG identification，GO and pathway enrichment analyses，PPI network creation and hub gene identification，Target miRNA prediction of Meg3 and corresponding target mRNA prediction，Construction of Meg3 ceRNA regulatory network，	GEO database	up-regulated	 lncRNA Meg3 might modulate several mRNAs via binding to microRNAs competitively	32614631	2020	Identification of differentially expressed mRNA and the Hub mRNAs modulated by lncRNA Meg3 as a competing endogenous RNA in brown adipose tissue of mice on a high-fat diet	E66.902	9970	pubmed	NA
1146	Obesity	H19	TCONS_00005659	NA	NA	4713	ENST00000412509	mouse，human	 NONCELT003346.2	-	1558	chr11:1,995,176-1,997,875	1	0	1	0	Synthesis of H19-Rgof mimics, AGR-H19-Rgof mimics, and pharmacokinetics (PK) studies,Tissue collection,Run-to-exhaustion test,Forelimb grip strength test,Echocardiography,Induced pluripotent stem cells (iPSC) maintenance and differentiation and cell cultures,RNA pull-down and liquid chromatography–mass spectrometry (LC-MS) analysis, in vitro RNA-protein binding assay, and dot-blot assay，Glucose and insulin tolerance tests，Blood analyses，Metabolic studies，RNAscope, immunohistochemistry image analysis, and quantification，Determination of Kd value using alpha assay，RNA electrophoretic mobility shift assay (EMSA)，UV-crosslinking and immunoprecipitation (CLIP) and RNA immunoprecipitation (RIP) assay，Mouse L308 array，Plasmid construction, recombinant protein expression,and transfection，DNA and RNA isolation, quantitative real-time PCR，	C57BL/6 J or LepOb/Ob mice,fresh-frozen human skeletal muscle tissues 	 	H19 GOF mutant in enhancing muscle performance and anti-obesity effects.	34454586	2021	Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects	E66.902	9970	pubmed	NA
1147	Obesity	H19	TCONS_00005659	NA	NA	4713	ENST00000412509	mouse	 NONCELT003346.2	-	1558	chr11:1,995,176-1,997,875	1	0	1	0	Animal care and research diets，Mouse RNA isolation，Deep RNA-sequencing procedure，Deep RNA-sequencing data processing，Gene set enrichment analysis，Cultivation of PIBA cell lines，Generation of stable PIBA cell lines，Isolation stromal-vascular fraction derived 1° adipocytes，Induction of SVF adipogenesis，LNA-mediated gene knockdown of primary adipocytes，siRNA-mediated gene knockdown of primary adipocytes，Immunoblot analysis，Oil Red O Staining，Oxygen consumption rates and glycolytic activity，Glucose tolerance test & insulin tolerance test，Indirect calorimetry (PhenoMaster)，mRNA isolation and quantitative RT-PCR (qPCR) analysis，Immunohistochemistry，Automated adipocyte quantification，Electron microscopy and mitochondrial morphometry，Analysis of H19 expression，CHART-MS，Sample preparation for MS，Mass spectrometry，Bioinformatic analysis of MS data，Ingenuity pathway analysis and AMIGO2 GO Term Analysis，Analyses of public datasets，Serum analyses，Pyrosequencing	C57BL/6	down-regulated	H19 acts as PEG gatekeeper in brown adipocytes, potentially acting via MBD1-dependent alterations of H3K9me3 KMTs recruitment are in line with previous reports demonstating that H19 regulates fine-tuned regulation of embryonic growth mediated by the H19 gene.	30190464	2018	LincRNA H19 protects from dietary obesity by constraining expression of monoallelic genes in brown fat	E66.902	9970	pubmed	NA
1148	Obesity	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30969210-30979394	1	0	1	0	Biochemical and laboratory measurements,Adipose tissue samples,Real‑time quantitative polymerase chain reaction (PCR)	obese patients subcutaneous fat	down-regulated	TUG1 with distinct expression pattern in VAT and SAT are involved in the regulation of lipogenic and adipogenic genes and obesity-related parameters.	32368256	2020	Adipose tissue gene expression of long non-coding RNAs; MALAT1, TUG1 in obesity: is it associated with metabolic profile and lipid homeostasis-related genes expression?	E66.902	9970	pubmed	NA
1149	Obesity	H19	TCONS_00005659	NA	NA	4713	ENST00000412509	mouse	NONCELT003346.2	-	1558	chr11:1,995,176-1,997,875	1	0	1	0	Cell culture, transfection, and adeno-associated virus/lentivirus construction，Flow cytometry analysis，Fluorescence detection，Transmission electron microscopy detection，Seahorse experiments，Western blotting and quantitative reverse transcription polymerase chain reaction，RNA antisense purification, RNA-binding protein immunoprecipitation, and chromatin immunoprecipitation assays	H9c2 cell and Lep−/− mice	down-regulated	H19-mediated Pink1 regulation is critically involved in obesityinduced mitochondrial suppression and cardiac dysfunction.	34050133	2021	LncRNA H19 governs mitophagy and restores mitochondrial respiration in the heart through Pink1/Parkin signaling during obesity	E66.902	9970	pubmed	NA
1150	Obesity	MEG3	TCONS_00010614	NA	NA	14575	ENST00000521404.4	mouse，human	NONHSAT039746.2	+	1478	chr7:108,300,190-108,302,063	1	0	1	0	Glucose tolerance and insulin tolerance tests，Cell culture，Endothelial cell isolation，Senescence-associated β-gal staining，MitoSOX staining，Electron paramagnetic resonance (EPR) spectroscopy，Assessment of mitochondrial bioenergetics，RNA sequencing and analysis，RNA sequencing and analysis，Quantitative real-time PCR (qPCR)，Western blot analysis，Live cell imaging，ELISA	p53fl/fl-Cre mice，Human liver specimens，Human Umbilical Vein Cells (HUVECs) 	up-regulated	Meg3 expression in the vascular endothelium maintains glucose homeostasis and insulin signaling by protecting the hepatic endothelium against cellular senescence in obesity	33508742	2021	Long non-coding RNA Meg3 deficiency impairs glucose homeostasis and insulin signaling by inducing cellular senescence of hepatic endothelium in obesity	E66.902	9970	pubmed	NA
1151	Obesity	ZFAS1	WD Repeat Containing Antisense To TP53	NA	NA	33101	ENST00000441722.4	human	NONHSAT080209.2	+	946	chr20:49,278,642-49,299,600	1	0	1	0	RNA isolation and cDNA synthesis，Statistical analysis	 breast tissues	down-regulated	This finding of our study is also supported by the correlation between the lower expression level of ZFAS1 and increased BMI in women	29690801	2018	A link between expression level of long-non-coding RNA ZFAS1 in breast tissue of healthy women and obesity	E66.902	9970	pubmed	NA
1152	Obesity	PVT1	NA	NA	NA	9709	ENST00000513868.5	human	NA	+	1706	chr8:127890620-128101253	1	0	1	0	RNA preparation,Reverse-transcription quantitative polymerase chain reaction (RT-qPCR)	Parathyroid tissue samples	up-regulated	PVT1 expression were associated with increased serum calcium level after water ingestion and PC risk	33910638	2021	Role of LncRNA score and PVT1 in primary hyperparathyroidism-- a preliminary study	E66.902	9970	pubmed	NA
1153	Obesity	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Western blot analysis，Fluorescent labeling and transfer of exosomes，Alkaline phosphatase (ALP) staining and alizarin red staining，Cell counting kit-8 (CCK-8) assay，Dual luciferase reporter gene assay，RNA pull-down assay，RNA-immunoprecipitation (RIP)，RT-qPCR，Establishment of an OVX mouse model，Treatment of the OVX mouse model，Micro-computed tomography (micro-CT)，Micro-computed tomography (micro-CT)	Bone marrow-derived mesenchymal stem cells (BMSCs)，Extraction of exosomes from human BMSCs(hBMSCs)	up-regulated	BMSCs-derived exosomal MALAT1 enhances osteoblast activity in osteoporotic mice by mediating the miR-34c/SATB2 axis. 	31659145	2019	LncRNA MALAT1 shuttled by bone marrow-derived mesenchymal stem cells-secreted exosomes alleviates osteoporosis through mediating microRNA-34c/SATB2 axis	E66.902	9970	pubmed	NA
1154	osteoporosis	TUG1	TCONS_00013049	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,211-30,979,395(GRCh38/hg38)	1	0	1	0	Real-time quantitative PCR;Vectors, siRNAs, and cell transfection;In vitro cell proliferation assay;Cell apoptosis assay	Primary marrow–derived osteoclasts	up-regulated	TUG1 can sponge miR-204-5p to promote osteoblast differentiation	31815638	2019	LncRNA TUG1 was upregulated in osteoporosis and regulates the proliferation and apoptosis of osteoclasts	M81.991	11476	pubmed	Bone
1155	osteoporosis	MSC-AS1	NA	NA	NA	48724	ENST00000522519.4	human 	NONHSAG050493.2	+	4802	chr8:71,828,166-72,118,393(GRCh38/hg38)	1	0	1	0	Cell culture and osteogenic differentiation;Cell transfection;Quantitative real-time polymerase chain reaction (qRT-PCR);Western blot assay;ALP staining;Alizarin red staining;Dual-luciferase reporter gene assay	Bone marrow-derived MSCs 	up-regulated	MSC-AS1 might promote the osteogenic differentiation of BMSCs through sponging microRNA-140e5p to up-regulate BMP2, thus alleviating the progression of osteoporosis.	31551149	2019	LncRNA MSC-AS1 promotes osteogenic differentiation and alleviates osteoporosis through sponging microRNA-140–5p to upregulate BMP2	M81.991	11476	pubmed	Bone
1156	osteoporosis	ANCR	NA	NA	NA	482	NA	human	NONHSAG052510.2	-	722	chr15:-(GRCh38/hg38)	1	0	1	0	PMOP model construction;Primary cell culture;Intracellular calcium ions measurement;Primary cell culture;LncRNA-ANCR siRNA transfection;The qRT-PCR detection;Western blot;MTT assay;Apoptosis detection by flow cytometry;ALP staining assay;Alizarin red staining assay;RNA pull-down assay;Osteogenesis model construction;Morphological observation;	osteoblast cells from mice models of  postmenopausal osteoporosis (PMOP)	down-regulated	specific binding of lncRNA-ANCR with EZH2 inhibits the expression of RUNX2, thus inhibiting the osteogenesis of osteoblast cells in PMOP	31347330	2019	Silencing of LncRNA-ANCR Promotes the Osteogenesis of Osteoblast Cells in Postmenopausal Osteoporosis via Targeting EZH2 and RUNX2	M81.991	11476	pubmed	Bone
1157	osteoporosis	GAS5	NA	NA	NA	16355	NA	human	NONHSAG003504.3	-	2060	chr1:173,851,284-173,869,006(GRCh38/hg38)	1	0	1	0	Cell isolation and culture;Osteoblast differentiation and identification;RNA isolation, reverse transcription, and qRT-PCR analyses;Western blot and antibodies;Nuclear and cytoplasmic fractionation and agarose gel electrophoresis;RNA pull-down assay and mass spectrometry;RNA immunoprecipitation (RIP);Plasmid, lentivirus construction, and infection;Bone formation of BMSCs in vivo;Collection of human bone samples;Fluorescent in situ hybridization (FISH);Osteoporosis mouse model construction and treatment;Cranial defect experiment;Enzyme-linked immunosorbent assay (ELISA);Microcomputed tomography (micro-CT) and histomorphometric analyses;H and E, Masson, and immunohistochemical staining	Human BMSCs	down-regulated	he increased expression of GAS5 combined with UPF1 strengthened the binding of UPF1 and SMAD7, leading to the accelerated degradation of SMAD7 and activation of the SMAD1/5/8 pathway, ultimately promoting osteoblast differentiation.	33006314	2020	GAS5 protects against osteoporosis by targeting UPF1/SMAD7 axis in osteoblast differentiation	M81.991	11476	pubmed	Bone
1158	osteoporosis	NEF	NA	NA	NA	7737	NA	human	NONHSAG098702.1	+	1630	chr21:46,598,604-46,605,243(GRCh38/hg38)	1	0	1	0	Patients and specimen collection;Treatment and follow-up;Cells and cell transfections;ELISA;RT-qPCR;	Human bone marrow mesenchymal stem cells 	down-regulated	lncRNA-NEF may interact with IL-6 to participate in postmenopausal osteoporosis	31220986	2019	LncRNA-NEF is downregulated in postmenopausal osteoporosis and is related to course of treatment and recurrence	M81.991	11476	pubmed	Bone
1159	osteoporosis	H19	TCONS_00005659	NA	NA	4713	ENST00000428066.4	human	NONHSAG007409.2	-	736	chr11:1,995,129-2,001,710(GRCh38/hg38)	1	0	1	0	qRT-PCR;Luciferase reporter assay;RNA immunoprecipitation assay;Overexpression and knockdown;Cell proliferation assay；Flow cytometric analysis；	 Bone marrow samples and blood samples from patients with or without OP, bone marrow cells from 4- to 6-wk-old C57BL/6 mice	up-regulated	lncRNA H19/miR-29a-3p axis contributes to the development of osteoporosis via modulating the expression of proinflammatory factors, proliferation and apoptosis. 	33207859	2020	An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis	M81.991	11476	pubmed	Bone
1160	osteoporosis	GAS5	NA	NA	NA	16355	NA	human	NONHSAG003504.3	-	2060	chr1:173,851,284-173,869,006(GRCh38/hg38)	1	0	1	0	Osteoclasts and Transient Transfections;Qrt-Pcr;Cell Apoptosis Assay	plasma of both osteoporosis patients and healthy controls;	up-regulated	GAS5 was upregulated in osteoporosis patients and it could downregulate miR-21 to promote the apoptosis of osteoclasts	32764903	2020	lncRNA GAS5 Is Upregulated in Osteoporosis and Downregulates miR-21 to Promote Apoptosis of Osteoclasts	M81.991	11476	pubmed	Bone
1161	osteoporosis	ZBTB40	NA	NA	NA	41493	NA	NA	NA	NA	NA	chr1:22,517,473-22,519,708(GRCh38/hg38)	1	0	1	0	NA	NA	up-regulated	lncRNA ZBTB40-IT1 is able to suppress osteogenesis and promote osteoclastogenesis by regulating the expression of WNT4, RUNX2, OSX, ALP, COL1A1, OPG and RANKL in U-2OS and hFOB1.19 cell lines	30661131	2019	LncRNA ZBTB40-IT1 modulated by osteoporosis GWAS risk SNPs suppresses osteogenesis	M81.991	11476	pubmed	Bone
1162	osteoporosis	SNHG1	LINC00057	NA	NA	32688	NA	human	NONHSAG008552.3	-	1118	chr11:62,851,873-62,856,011(GRCh38/hg38)	1	0	1	0	RNA preparation and RT-qPCR	Blood from healthy postmenopausal females and postmenopausal osteoporosis patients	down-regulated	plasma levels of SNHG1 were reduced with menopause and the development of osteoporosis	31693735	2019	LncRNA SNHG1 was down-regulated after menopause and participates in postmenopausal osteoporosis	M81.991	11476	pubmed	Bone
1163	osteoporosis	Bmncr	NA	NA	NA	54188	NA	NA	NA	NA	NA	chr1:203,404,221-203,407,625(GRCh38/hg38)	1	0	1	0	Establishment of Osteoporosis Model in Mice;BMMs Extraction and Osteoclast Differentiation;Lentivirus Transfection;Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR); TRAP Staining ;MicroCT Analyses	Bone marrow mesenchymal stem cells from female C57BL/6J mice with eight-week-old	down-regulated	LncRNA Bmncr inhibits RANKL-induced osteoclast differentiation, thus alleviating the progression of osteoporosis.	31773670	2019	LncRNA Bmncr alleviates the progression of osteoporosis by inhibiting RANML-induced osteoclast differentiation	M81.991	11476	pubmed	Bone
1164	osteoporosis	BCAR4	NA	NA	NA	22170	ENST00000574028.1	human	NONHSAG018621.3	-	480	chr16:11,808,312-11,828,905(GRCh38/hg38)	1	0	1	0	Cell Culture；Induction of Osteogenic Differentiation ；Cell Transfection；Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)；Western Blot；ALP Activity Determination；ALP and ARS Staining；Animal Procedures；Enzyme-Linked Immunosorbent Assay (ELISA)；Determination of Bone Density and Biomechanics；	bone marrow mesenchymal stem cells	up-regulated	 BCAR4 is involved in the osteogenic differentiation of BMSCs. The knockdown of BCAR4 can alleviate the progression of osteoporosis.	32572903	2020	Silence of lncRNA BCAR4 alleviates the deterioration of osteoporosis	M81.991	11476	pubmed	Bone
1165	osteoporosis	AK023948	NA	NA	NA	37127	NA	human	NONHSAG051327.2	+	2809	chr8:133,054,958-133,057,767(GRCh38/hg38)	1	1	1	0	Cell Culture；Calcium Concentration Analysis；Phosphorus Concentration Analysis；ALP Activity Analysis；XTT Analysis；Plasmid Construction；Transfection；Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR)；Western Blotting；	Osteoblasts from the postmenopausal osteoporosis rat model	down-regulated	LncRNA AK0 can regulate the phosphorylation level of AKT in osteoblasts of rats with estrogen deficiency-related osteoporosis through the PI3K/AKT signaling pathway, thus regulating the proliferation of osteoblasts. 	32196569	2020	Effect of lncRNA AK023948 on rats with postmenopausal osteoporosis via PI3K/AKT signaling pathway	M81.991	11476	pubmed	Bone
1166	osteoporosis	CASC11	NA	NA	NA	48939	ENST00000518376.1	human	NONHSAG051255.3	-	872	chr8:127,673,882-127,738,987(GRCh38/hg38)	1	0	1	0	Total RNA extraction and real-time quantitative PCR (RT-qPCR)；Enzyme-linked immunosorbent assay (ELISA)；Cell transfection；Western blot；	Human primary osteoblasts；Fasting blood (5 mL) was extracted from 67 patients with POP and healthy controls 	up-regulated	CASC11 is upregulated in POP and may upregulate TNF-伪 to promote disease development.	31571846	2019	LncRNA CASC11 is upregulated in postmenopausal osteoporosis and is correlated with TNF-α	M81.991	11476	pubmed	Bone
1167	osteoporosis	DANCR	TCONS_00029804	NA	NA	28964	ENST00000411630.5	human	NONHSAG037936.3	+	1224	chr4:52,712,257-52,723,623(GRCh38/hg38)	1	0	1	0	Isolation and culture of human BMSCs；Human BMSC osteogenic differentiation induction；Cell transfection；Luciferase reporter assay；Animal models and grouping；Histological analysis by H&E and Alcian Blue staining；Alkaline phosphatase (ALP) staining and activity detection；Mineral nodule quantification using Alizarin Red dye staining；RNA extraction and qPCR detection；Western blot analysis；	human and mouse BMSCs	up-regulated	osteogenic differentiation in BMSCs was regulated by a novel genetic network that consisted of DANCR, miR-320a, and CTNNB1 through the Wnt/尾-catenin signaling pathway	32778797	2020	LncRNA DANCR and miR-320a suppressed osteogenic differentiation in osteoporosis by directly inhibiting the Wnt/β-catenin signaling pathway	M81.991	11476	pubmed	Bone
1168	osteoporosis	TERC	Telomerase RNA Component 	NA	NA	11727	NA	NA	NA	-	599 	chr3:169,764,462-169,765,060(GRCh38/hg38)	1	0	1	0	Cell Culture and Osteogenesis；Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR)；Cell Transfection；Alkaline Phosphatase (ALP) Activity Determination ；Alizarin Red Staining；Dual-Luciferase Reporter Gene Assay；Western Blot	MC3T3-E1 cells and hMSCs	down-regulated	TERC influences hMSCs osteogenesis by absorbing miRNA-217 to upregulate RUNX2, thus alleviating the progression of OP.	32016954	2020	LncRNA TERC alleviates the progression of osteoporosis by absorbing miRNA-217 to upregulate RUNX2	M81.991	11476	pubmed	Bone
1169	osteoporosis	GAS5	NA	NA	NA	16355	NA	human	NONHSAG003504.3	-	2060	chr1:173,851,284-173,869,006(GRCh38/hg38)	1	0	1	0	Quantitative Real-time polymerase chain reaction;Western blot;alkaline phosphatase (ALP) activity assay;ALP staining	Human multipotential mesenchymal stem cells 	up-regulated	 Overexpression of GAS5 promotes osteogenic differentiation of hMSCs through regulating microRNA-498 to up-regulate RUNX2 expression, thus alleviating the development of osteoporosis.	31599401	2019	LncRNA GAS5 overexpression alleviates the development of osteoporosis through promoting osteogenic differentiation of MSCs via targeting microRNA-498 to regulate RUNX2	M81.991	11476	pubmed	Bone
1170	osteoporosis	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	BMSC Culture and Transfection；Microcomputed Tomography Analysis；Osteogenic Differentiation；qRT-PCR Analysis；Western Blot；Dual Luciferase Reporter Assay；RNA Immunoprecipitation (RIP) Assay；RNA Pull-down Assay； 	The BMSCs from mouse and human	up-regulated	 lncRNA Xist was participated in osteoblast differentiation via miR-19a-3p/Hoxa5 pathway.	33014522	2020	lncRNA Xist Regulates Osteoblast Differentiation by Sponging miR-19a-3p in Aging-induced Osteoporosis	M81.991	11476	pubmed	Bone
1171	osteoporosis	MALAT1	TCONS_00006031	NA	NA	29665	ENSMUST00000172812.2	mouse	NONMMUG020671.2	-	6983	chr11:65,496,266-65,509,085(GRCh38/hg38)	1	0	1	0	Grouping of Laboratory Rats and Establishment of OP Rat Model；Real Time-Polymerase Chain Reaction (RT-PCR)；Cell Transfection；Apoptosis Assay；Western Blotting ；Osteogenic Induction and Alkaline Phosphatase (ALP) Staining；	BMSCs from OP rats and normal rats	down-regulated	 LncRNA MALAT1 was lowly expressed in OP rats. Moreover, it inhibited osteogenic differentiation of BMSCs by enhancing the activation of the MAPK signaling pathway, thereby promoting OP progression.	31210287	2019	LncRNA MALAT1 inhibits osteogenic differentiation of mesenchymal stem cells in osteoporosis rats through MAPK signaling pathway	M81.991	11476	pubmed	Bone
1172	osteoporosis	LOXL1-AS1	TCONS_00012378	NA	NA	44169	ENST00000566675.4	human	NONHSAG070857.2	-	2179	chr15:73,898,711-73,947,224(GRCh38/hg38)	1	0	1	0	 RT-qPCR；ALP, ARS staining assays and oil red O staining assay	hBMMSCs；peripheral blood from postmenopausal osteoporosis patients 	up-regulated	LOXL1-AS1/miR-196a-5p/Hmga2 axis regulated hBMMSCs differentiation through controlling C/EBPβ-mediated PPARγ expression	32651705	2020	LncRNA LOXL1-AS1 controls osteogenic and adipocytic differentiation of bone marrow mesenchymal stem cells in postmenopausal osteoporosis through regulating the miR-196a-5p/Hmga2 axis	M81.991	11476	pubmed	Bone
1173	osteoporosis	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	NA	NA	NA	 IA regulated osteoblast apoptosis through XIST/miR-758-3p/caspase 3 axis,	33336851	2021	Iron accumulation regulates osteoblast apoptosis through lncRNA XIST/miR-758-3p/caspase 3 axis leading to osteoporosis	M81.991	11476	pubmed	Bone
1174	osteoporosis	WT1-AS	TCONS_00005344	NA	NA	18135	ENST00000395900.1	human	NONHSAG007984.3	+	26101 	chr11:32,434,075-32,460,175(GRCh38/hg38)	1	0	1	0	Transient transfection of osteoblasts;ELISA;RNA extraction and reverse transcription-quantitative PCR (RT-qPCR);Western blot analysis;Cell apoptosis analysis	Blood from healthy volunteer and patient;primary osteoblasts	up-regulated	WT1-AS was demonstrated to be upregulated in osteoporosis and promoted the apoptosis of osteoblasts by upregulating p53	34055051	2021	lncRNA WT1-AS is upregulated in osteoporosis and regulates the apoptosis of osteoblasts by interacting with p53	M81.991	11476	pubmed	Bone
1175	osteoporosis	GAS5	NA	NA	NA	16355	NA	human	NONHSAG003504.3	-	2060	chr1:173,851,284-173,869,006(GRCh38/hg38)	1	0	1	0	reverse transcription‑quantitative PCR;ELISA and western blotting ;Matrigel angiogenesis test;	 	up-regulated	GAS5 overexpression increased angiogenesis by inhibiting miR‑10a‑3p, promoting the expression of VEGFA	34396445	2021	lncRNA GAS5 regulates angiogenesis by targeting miR‑10a‑3p/VEGFA in osteoporosis	M81.991	11476	pubmed	Bone
1176	osteoporosis	LINC00052	TCONS_00012080	NA	NA	26455	ENST00000560153.2	human	NONHSAG017783.2	+	1966	chr15:87,576,920-87,579,866(GRCh38/hg38)	1	0	1	0	High-throughput sequencing analysis；RNA extraction and quantitation；Western blot analysis；Transfection of BMSCs；Immunofluorescence assay；Dual-luciferase reporter gene assay；Cell proliferation assay；Cell migration assay；Apoptosis and cell cycle assays；BMSC transplantation in OVX rats；Osteogenic differentiation and staining assay；Serum ALP and histological analysis	BMSCs from mouse	up-regulated	LNC_000052 knockdown promoted BMSC proliferation, migration, and osteogenesis and inhibited apoptosis.	32968049	2020	A novel lncRNA LNC_000052 leads to the dysfunction of osteoporotic BMSCs via the miR-96-5p-PIK3R1 axis	M81.991	11476	pubmed	Bone
1177	osteoporosis	MIR22HG	NA	NA	NA	28219	 ENST00000575626.4	human	NONHSAG020474.3	-	1847	chr17:1,710,719-1,717,276(GRCh38/hg38)	1	0	1	0	Cell cultivation；Transfection；Alkaline phosphatase (ALP) staining and activity；Alizarin red S staining and quantification；RNA isolation and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis；Western blot analysis；Establishment of ovariectomized mouse model；Micro CT analyses of mice；Ectopic bone formation in vivo；RNA sequencing；Fluorescent in situ hybridization (FISH)；Subcellular fractionation；Colocalization of MIR22HG and PTEN；Tartrate resistant acid phosphatase (TRAP) staining	Primary hBMSCs, human adipose-derived stem cells (hASCs) and RAW264.7 cells	down-regulated	MIR22HG promoted osteogenic differentiation of hBMSCs via PTEN/AKT signaling	32732881	2020	Long non-coding RNA MIR22HG promotes osteogenic differentiation of bone marrow mesenchymal stem cells via PTEN/ AKT pathway	M81.991	11476	pubmed	Bone
1178	osteoporosis	HOTAIR	TCONS_00007755	NA	NA	33510	ENST00000439545.1	human	NONHSAG011264.3	-	2337	chr12:53,962,307-53,974,957(GRCh38/hg38)	1	0	1	0	qRT-PCR；Alkaline Phosphatase (ALP), Alizarin Red S (ARS) staining,；	BMSCs derived from human or rats 	up-regulated	HOTAIR inhibits osteoblast differentiation of rat BMSCs. The underlying mechanism of which may be related to the mediation of Wnt/β-catenin pathway.	31539110	2019	LncRNA HOTAIR inhibited osteogenic differentiation of BMSCs by regulating Wnt/β-catenin pathway	M81.991	11476	pubmed	Bone
1179	Klinefelters syndrome	GAS5	NA	NA	NA	16355	ENST00000442067	human	NONHSAT227355.1	-	2060	chr1:173,858,559-173,867,045	1	0	1	0	RNA sequencing,Data analysis,Availability of data and materials,Validation whit qRT-PCR	peripheral blood mononuclear cells	up-regulationin	In conclusion, the results of this study showed a significant over-expression of lncRNA GAS5 in patients with non-mosaic KS compared to controls.	30612561	2019	Evidence for long noncoding RNA GAS5 up-regulationin patients with Klinefelter syndrome	NA	1921	pubmed	Testis
1180	Turner syndrome	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	0	1	0	1	Cell Maintenance,RNA Sequencing and Data Generation,Data Analysis,Functional Analysis of Differentially Expressed Genes,Quantitative Real Time PCR (qRT-PCR) Assay	Human fibroblast cell lines of white population	down-regulationin	XIST was found to be down-regulated and had almost no expression in the 45,X cell line as compared to 46,XX fibroblasts.	24932682	2014	Human 45,X fibroblast transcriptome reveals distinct differentially expressed genes including long noncoding RNAs potentially associated with the pathophysiology of Turner syndrome	NA	3491	pubmed	Ovary
1181	Polycystic ovary syndrome	SRA	NA	NA	NA	11281	ENST00000507279	human	NONHSAT250486.1	-	576	chr5:140,550,068-140,557,473	1	0	1	0	H&E staining was used to examine the histological changes of ovaries. ELISA was used to assess serum insulin level and proinflammatory cytokines and angiogenetic factors contents in ovary tissue. The expression levels of LncRNA SRA and proteins involved in the NF-κB signaling pathway were detected through Quantitative real-time PCR and Western blot. The nuclear translocation of NF-κB was observed by immunofluorescence and the activity of NF-κB-DNA binding was detected using EMSA.	Granulosa cell 	up-regulationin	Silencing of lncRNA Steroid Receptor RNA Activator (SRA) attenuates polycystic ovary syndrome (PCOS) in mice. 	30391287	2019	Silencing of LncRNA steroid receptor RNA activator attenuates polycystic ovary syndrome in mice	E28.253	11612	pubmed	Ovary
1182	Polycystic ovary syndrome	GAS5	NA	NA	NA	16355	ENST00000442067	human	NONHSAT227355.1	-	2060	chr1:173,858,559-173,867,045	1	0	1	0	Plasma preparation,Cells and transfections,RNA preparation and qPCR assays,ELISA,Western-blot,Cell apoptosis assay,Statistical analysis	human granulosa-like tumor cell	up-regulationin	GAS5 is upregulated in PCOS and regulates cell apoptosis and the expression of IL-6.	33308258	2020	LncRNA GAS5 is upregulated in polycystic ovary syndrome and regulates cell apoptosis and the expression of IL-6	E28.253	11612	pubmed	Ovary
1183	Polycystic ovary syndrome	XIST	WD Repeat Containing Antisense To TP53	NA	NA	12810	ENST00000429829.4	human	NONHSAT137541.2	-	19280	chrX:73,817,774-73,852,754(GRCh38/hg38)	1	0	1	0	Follow-up,Specimen collection,Observation indictors,Real-time quantitative PCR (QRT-PCR),Statistical analysis	Fasting antecubital intravenous blood 	down-regulationin	 the downregulation of Xist expression might be involved in PCOS and is correlated with adverse pregnant outcomes in PCOS.	32416882	2020	Expression of serum lncRNA-Xist in patients with polycystic ovary syndrome and its relationship with pregnancy outcome	E28.253	11612	pubmed	Ovary
1184	Polycystic ovary syndrome	 MMP‐2	NA	NA	NA	7166	NA	NA	NA	NA	NA	chr16:55,479,198-55,506,691	1	0	1	0	RNA isolation and real‐time PCR,Cell culture and transfection,Vector construction, mutagenesis, and luciferase assay,Western blot analysis,Gelatin zymography,Statistical analysis	peripheral blood samples and aortic blood samples	up-regulationin	MET inhibited the pathogenesis of PCOS by decreasing the expression of MMP‐2 and MMP‐9 via the H19/miR‐29b‐3p and AKT/mTOR/autophagy pathways.	30989649	2019	Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP‐2 and MMP‐9 via H19/ miR‐29b‐3p and AKT/mTOR/autophagy signaling pathways	E28.253	11612	pubmed	Ovary
1185	Polycystic ovary syndrome	MMP9	NA	NA	NA	7176	NA	NA	NA	NA	NA	chr20:46,008,908-46,016,561	1	0	1	0	RNA isolation and real‐time PCR,Cell culture and transfection,Vector construction, mutagenesis, and luciferase assay,Western blot analysis,Gelatin zymography,Statistical analysis	peripheral blood samples and aortic blood samples	up-regulationin	MET inhibited the pathogenesis of PCOS by decreasing the expression of MMP‐2 and MMP‐9 via the H19/miR‐29b‐3p and AKT/mTOR/autophagy pathways.	30989649	2019	Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP‐2 and MMP‐9 via H19/ miR‐29b‐3p and AKT/mTOR/autophagy signaling pathways	E28.253	11612	pubmed	Ovary
1186	Polycystic ovary syndrome	H19	TCONS_00005659	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Cell recovery and culture，Real-time PCR，Cell transfection，Cell proliferation，Apoptosis，Luciferase reporter assay，Statistical analysis	KGN cells 	up-regulationin	this experiment confirmed the role of lncRNA H19 as a ceRNA in KGN cells, which regulated the expression of CTGF through the lncRNA H19/miR-19b/CTGF regulatory axis, and finally played an important role in the pathogenesis of PCOS	33053114	2020	lncRNA H19 acts as a ceRNA to regulate the expression of CTGF by targeting miR-19b in polycystic ovary syndrome	E28.253	11612	pubmed	Ovary
1187	Polycystic ovary syndrome	H19	TCONS_00005659	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Isolation and identification of rat ovarian granulosa cells,Enzyme-linked immunosorbent assay (ELISA),Cell apoptosis assay,Western blot,RNA extraction and quantitative real-time PCR (qRT-PCR),Stable expression of H19,Immunofluorescence,Animal experiments,Biochemical analysis,Histopathological evaluation,Statistical analysis	Rat ovarian granulosa cells	down-regulationin	DMBG and TECOS combination therapy ameliorates PCOS with IR, at least partially, through upregulation of lncRNA H19. Furthermore, co-treatment with TECOS and DMBG induces H19 expression via inhibiting the PI3K/AKT-DNMT1 pathway.	31405334	2019	Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19	E28.253	11612	pubmed	Ovary
1188	Polycystic ovary syndrome	SRA1	NA	NA	NA	11281	ENST00000507279	human	NONHSAT250486.1	-	576	chr5:140,550,068-140,557,473	1	0	1	0	Genotype analysis,Quantitative real-time PCR (qRT-PCR),Statistical analysis,	peripheral blood leukocytes	up-regulationin	From this study, we found that the lncRNA SRA1 gene rs10463297 SNP is associated with PCOS susceptibility	32783135	2020	Association between long-chain non-coding RNA SRA1 gene single-nucleotide polymorphism and polycystic ovary syndrome susceptibility	E28.253	11612	pubmed	Ovary
1189	Polycystic ovary syndrome	TUG1	TCONS_00025132	NA	NA	26066	ENST00000521091.5	human	NONHSAT084833.2	+	7597	chr22:30,969,270-30,979,395	1	0	1	0	Cell culture,Cell transfection,Nuclear and cytoplasmic RNA fractionation,RNA extraction and qRT-PCR,RNA fluorescence in situ hybridization,Ethynyl-2-deoxyuridine assays, Cell Counting Kit-8 assays, western blotting, and flow cytometry,Transient transfection and identification of autophagy,Measurement of E2 concentration,Statistical analyses	granulosa cells 	up-regulationin	TUG1 expression was markedly increased in PCOS GCs compared with that of controls; this increase in TUG1 expression was related to increased AFC	32559120	2020	Long non-coding RNA TUG1 and its molecular mechanisms in polycystic ovary syndrome	E28.253	11612	pubmed	Ovary
1190	Polycystic ovary syndrome	ZFAS1	WD Repeat Containing Antisense To TP53	NA	NA	33101	ENST00000441722	human	NONHSAT080209.2	+	946	chr20:49,278,642-49,299,600	1	0	1	0	Detection of sex hormone levels and biochemical indicators,Sample collection,Extraction and primary culture of ovarian granulosa cells,Identification of ovarian granulosa cells,Grouping and treatment of ovarian granulosa cells, Enzyme-linked immunosorbent (ELISA),5-ethynyl-2′-deoxyuridine (EdU) and 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) assays,Immunofluorescence assay,Flow cytometry,Reverse transcription quantitative polymerase chain reaction (RT- qPCR),Western blot assay,Dual-luciferase reporter gene assay,RNA-pull down assay, Statistical analysis	Ovarian granulosa cells	down-regulationin	down-regulation of lncRNA ZFAS1 and up-regulation of miR-129 inhibit endocrine disturbance, increase proliferation and inhibit apoptosis of ovarian granulosa cells in PCOS by decreasing HMGB1	32320818	2020	Downregulation of lncRNA ZFAS1 and upregulation of microRNA-129 repress endocrine disturbance, increase proliferation and inhibit apoptosis of ovarian granulosa cells in polycystic ovarian syndrome by downregulating HMGB1	E28.253	11612	pubmed	Ovary
1191	Polycystic ovary syndrome	H19	TCONS_00005659	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Data collection,Isolation of peripheral blood leukocytes,RNA isolation and RT-PCR,Quantitative real-time polymerase chain reaction,Statistical analysis	peripheral blood leukocytes	up-regulationin	the expression levels of lncRNA H19 are associated with PCOS and estab- lished the possibility that abnormal H19 expression may represent a risk factor for PCOS in the Chinese popula- tion.	30982795	2019	Long non-coding RNA H19 is associated with polycystic ovary syndrome in Chinese women: a preliminary study	E28.253	11612	pubmed	Ovary
1192	Polycystic ovary syndrome	SRA	NA	NA	NA	11281	ENST00000507279	human	NONHSAT250486.1	-	576	chr5:140,550,068-140,557,473	1	0	1	0	Clinical and hormone assays，Isolation of peripheral blood leukocytes，RNA isolation and RT-PCR，Quantitative real time-polymerase chain reaction，Statistical analysis	 peripheral blood leukocytes	up-regulationin	data demonstrated a significant association of obesity in PCOS women with the expression of lncRNA SRA.	25609053	2015	Peripheral blood leukocyte expression level of lncRNA steroid receptor RNA activator (SRA) and its association with polycystic ovary syndrome: a case control study	E28.253	11612	pubmed	Ovary
1193	Polycystic ovary syndrome	H19	TCONS_00005659	NA	NA	4713	ENST00000428066.4	human	NONHSAT017473.2	-	736	chr11:1,995,176-1,997,875	1	0	1	0	Participants and sample collection,DNA extraction and genotyping,Statistical analysis,silico analysis	5 ml of the peripheral blood sample	up-regulationin	 rs2067051 located in the first exon of the H19 gene is associated with an increased risk of PCOS in the study population. The findings also show that rs3741219 polymorphism plays a protective role in PCOS.	32720692	2020	An association study of polymorphisms in the H19 imprinted gene in an Iranian population with the risk of polycystic ovary syndrome	E28.253	11612	pubmed	Ovary
1194	Polycystic ovary syndrome	TMPO-AS1	TCONS_00009179	NA	NA	44158	ENST00000548760.2	human	NONHSAT030138.2	-	3389	chr12:98,512,973-98,516,422	1	0	1	0	Participants and follicular fluid extraction,Granulosa-like tumor cells and primary granulosa cells,Cell transfections,RNA preparation,RT-qPCRs,Nuclear fractionation assay,RNA pull-down assay,BrdU assay,Statistical analysis	KGN cell	up-regulationin	TMPO-AS1 is overexpressed in PCOS and may suppress miR-335-5p maturation by directly interacting with premature miR-335-5p, thereby increasing cell proliferation to participate in PCOS.	34330309	2021	LncRNA TMPO-AS1 suppresses the maturation of miR-335-5p to participate in polycystic ovary syndrome	E28.253	11612	pubmed	Ovary
1195	Polycystic ovary syndrome	CTBP1-AS	NA	NA	NA	48337	ENST00000625256.1	human	NONHSAT094684.2	+	3886	chr4:1,210,120-1,218,591	1	0	1	0	Study Patients,Hormone Assays,Isolation of Peripheral Blood Leukocytes,RNA Isolation and Real-Time Polymerase Chain Reaction,Measurement of CTBP1-AS Gene Expression,Statistical Analysis	 peripheral blood leukocytes	up-regulationin	CTBP1-AS expression is a risk factor for PCOS in the Chinese population, and it is a predictor of serum TT level variability in Chinese women with PCOS.	25552498	2015	Androgen Receptor Coregulator CTBP1-AS Is Associated With Polycystic Ovary Syndrome in Chinese Women: A Preliminary Study	E28.253	11612	pubmed	Ovary
1196	Polycystic ovary syndrome	SRA	NA	NA	NA	11281	ENST00000507279	human	NONHSAT250486.1	-	576	chr5:140,550,068-140,557,473	1	0	1	0	Isolation and culture of ovarian granular cells,Cell transfection,Immunofluorescence,Real-time PCR,CCK-8 assay,Flow cytometry detection of cell cycle,Flow cytometry detection of cell apoptosis,Hoechst stain,Western blot,Detection of E2 and PG,Statistical analysis.	ovarian granular cells	up-regulationin	 LncRNA SRA can facilitate cell growth, change distribution of cell cycle phases, restrain cell apoptosis, and stimulate E2 and PG secretions, which indicates that it may be a potential risk factor for PCOS.	29674607	2018	Up-Regulation of Long Noncoding RNA SRA Promotes Cell Growth, Inhibits Cell Apoptosis, and Induces Secretion of Estradiol and Progesterone in Ovarian Granular Cells of Mice	E28.253	11612	pubmed	Ovary
1197	Polycystic ovary syndrome	LINC-ROR	TCONS_00017519	NA	NA	43773	ENST00000553704.2	human	NONHSAT059436.2	-	2603	chr18:57,054,558-57,072,119	1	0	1	0	Study population and serum collection,Cell culture,Cell transfection,RNA extraction and qRT-PCR,Cell viability assay,Cell apoptosis assay,Luciferase reporter gene assay,Statistical analysis	KGN cells	up-regulationin	Highly expressed lncROR indirectly up-regulated the expression of VEGF by down-regulating the expression of miR-206, thereby promoting the proliferation of KGN cells and inhibiting apoptosis, and further promoting the development of PCOS	34148561	2021	Differential expression of long non-coding RNA Regulator of reprogramming and its molecular mechanisms in polycystic ovary syndrome	E28.253	11612	pubmed	Ovary
1198	Polycystic ovary syndrome	lnc-CCNL1-3:1	NA	NA	NA	20569	NA	human	NONHSAT092887.2	-	651	chr3:157,147,553-157,160,147	1	0	1	0	Isolation and culture of ovarian granulosa and KGN cells,Cell transfection and treatment,RNA extraction and quantitative real-time PCR,RNA ligase-mediated RACE (RLM-RACE),Immunoblotting assay,Subcellular fractionation,Flow cytometry analysis,TUNEL assay,Determination of ROS levels,ATP measurement,Glucose uptake assay,RIP assay,Immunofluorescence experiment,Luciferase reporter assay,Statistical analysis and reproducibility.	The human granulosa cell	up-regulationin	These findings thus identify lnc-CCNL1-3:1 as a potential therapeutic target for PCOS and provide a new perspective regarding the molecular mechanisms underlying the pathogenesis of this disorder.	33552682	2020	Long non-coding RNA lnc-CCNL1-3:1 promotes granulosa cell apoptosis and suppresses glucose uptake in women with polycystic ovary syndrome	E28.253	11612	pubmed	Ovary
1199	Thyroid hormone insensitivity syndrome	NEAT1	TCONS_00005427	NA	NA	30815	ENST00000501122.2	human	NONHSAT022112.2	+	22744	chr11:65,423,096-65,426,513	1	0	1	0	Cell transfections,Cell proliferation assay,Apoptosis assay,Nitric oxide production assay,Mitochondrial membrane potential (MMP) assay,Quantitative RT‐PCR,Western blotting,Measurement of plasma thyroid hormones,Measurement of vascular reactivity,Dual‐luciferase reporter assay,Animal experiments,Statistical analysis.	Primary aortic endothelial cells	up-regulationin	dysregulation of the NEAT1/miR-126/ TRAF7 axis is responsible for impaired endothelial func- tions in SCH. Targeting this axis might become a promis- ing treatment strategy for improving endothelial functions in SCH.	33677813	2021	Long non-coding RNA NEAT1 regulates endothelial functions in subclinical hypothyroidism through miR-126/TRAF7 pathway	E07.803	NA	pubmed	Thyroid
1200	Autoimmune thyroid disease	MALAT1	NA	NA	NA	29665	NA	human	NONHSAT229865.1	+	2448	chr11:65,497,688-65,506,431	1	0	1	0	Bioinformatics analysis,The stimulation of Nthy-ori 3-1 cells,Cell treatment,RNA extraction and quantitative real-time PCR (qRT- PCR),Western blot,Cell proliferation assay,Cell apoptosis detection,Dual luciferase assay,Enzyme-linked immunosorbent assay (ELISA) for de- tection of TNF-α, IL-8, and IL-10,Statistical analysis	Human thyroid follicular epithelial cells	up-regulationin	UA treatment significantly relieved the injury of Nthy-ori 3-1 cells via inhibiting the ceRNA mechanism of MALAT1/miR-206/PTGS1 and inflammatory pathways, insinuating that UA may be helpful for the treatment of AIT.	33452572	2021	Ursolic acid ameliorates Nthy-ori 3-1 cells injury induced by IL-1β through limiting MALAT1/miR-206/PTGS1 ceRNA network and NF-κB signaling pathway	NA	7188	pubmed	Thyroid